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Effect of Dynamization of a Static
Interlocking Nail in Promoting Fracture
Healing
James P. Waddell, MD, FRCSC
Director, Trauma Program, St. Michael's Hospital, Toronto, Ont. Member, Editorial Board,

Canadian Journal of Surgery

n this issue of the journal (pages
302 to 306) Wu and Shih report
on the use of routine dynamization
of locked nails to promote fracture
healing in cases of delayed union of
femoral and tibial shaft fractures.
The introduction of static locked
intramedullary nails for the routine
treatment of tibial and femoral shaft
fractures has greatly broadened the
indications for intramedullary nail
ing in patients who have comminut
ed displaced unstable diaphyseal
fractures of long bones.
Originally promoted as a method
by which length and rotation could
be maintained with intramedullary
nailing, it was feared that the po
tential for distraction due to the use
of cross-screws at the proximal and
distal ends of the nail would result
in an unacceptably high incidence
of delayed union or nonunion in
fractures so treated.
As familiarity with the technique
increased it became evident that the
rate of delayed and nonunion was, if
anything, diminished with this tech
nique of nailing, and the initial

I
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recommendation for routine remov
al of proximal or distal cross-screws
to allow dynamic compression of
the fracture site by weight bearing
was abandoned. However, it was felt
that in cases of delayed union “dy
namization” of the nail (removal of
the cross-screws) would actively
promote fracture union by allowing
physiologic compression of the frac
ture site through weight bearing.
Wu and Shih are the first to
report on the outcome of a policy of
routine dynamization for ununited
fractures of long bones. Twenty-two
patients with fractures evenly divid
ed between femur and tibia were
diagnosed as having delayed union
by radiographic and clinical parame
ters at 7 months or longer after
initial treatment. The patients were
treated routinely by dynamization
of the previously static locked nail
by removal of cross-screws at either
the proximal or distal end of the
nail. The patients were then allowed
weight bearing as tolerated.
The authors report disappointing
results with this technique. Only

half of the fractures united; the
other half required onlay cancellous
bone grafting.
Wu and Shih suggest that rou
tine dynamization, although possi
bly beneficial, will not consistently
result in healing after delayed
union. It seems sensible to continue
this practice as the initial treatment
of such nonunions or delayed
unions because dynamization is
simple and readily accomplished as
a minor surgical procedure, and it
may avoid a major operation of
bone grafting in one-half of the
patients so treated. The patients
should be warned, however, that
there is a substantial chance that
this small operation will not result
in union of their fracture and that
they should be prepared for the
more extensive and difficult opera
tion of cancellous bone grafting. If
dynamization is to be effective,
some positive evidence of fracture
healing should be evident within 8
to 12 weeks; failure of healing by
that time should be sufficient to
warrant further intervention.■

QUILL ON SCALPEL

Evaluation of New Surgical Procedures
Jonathan L. Meakins, MD, FRCSC
Coeditor, Canadian Journal of Surgery. Surgeon-in-Chief, Department o f Surgery, Royal Victoria
Hospital, Montreal, Que.

V

ariations in technique for stan
dard operations are common.
Indeed, it is the nature of all surgi
cal residents to modify learned pro
cedures to suit their own needs,
operating styles or perceptions of
good technique — leading to the
ubiquitous comment, "Here let me
show you how I do it . . . Voila.”
The changes imposed by laparos
copy on the two most common
procedures in general surgery re
quire evaluation, and examples are
presented in this issue of the jour
nal (pages 326 to 336). The princi
ple that surgeons know their re
sults is a sound one, implying eval
uation and, possibly, improvement.
From the beginning, questions
were raised about how laparoscopic
cholecystectomy (LC) was going to
be evaluated. Indeed, it was stated
in 1990 that a randomized con
trolled trial was not possible and
might even be unethical.1 In a large
multicentre series, the Southern
Surgeons’ Club2 defined a standard
of care but provided no reference
point with respect to other tech
niques. As the paper by Sanabria
and colleagues (pages 330 to 336)
was being reviewed and prepared
for publication, a small randomized
controlled trial3 was published in
the Lancet on open versus closed
LC, demonstrating the efficacy of
the laparoscopic technique, with
shortened hospital stay, faster re
turn of the patient to normal activi
ties and reduced requirement for
pain medication. A key point was

the importance of independent
third-party assessment. When sur
geons administer the intervention
and measure the outcome, their
evaluation tends to be optimistic. In
the Lancet trial, although both sur
geon and research nurse agreed
that the patient’s return to full
activities was faster after LC, the
research nurse’s estimate was 11.9
days compared with 7.8 days for
the surgeon’s estimate (p < 0.008).
As stated in their paper, Sanabria
and colleagues, in a single-surgeon
series from the University of Toron
to, elected not to do a randomized
controlled trial but to study three
sequential groups of 121 patients
over 3 years. The first was of OC
only, the second was a mixture of
OC and LC and the third was LC
only. This is a novel approach to
the assessment of a change in a
surgical procedure and lends itself
to a single-surgeon or single-service
study. Their results are consistent
with the literature: LC is better but
is associated with some potentially
serious complications. They also
showed a “Hawthorne effect” in
their open cholecystectomy results,
with a more rapid return to normal
activities and to work, issues of
which insurance companies, work
er’s compensation boards and un
employment insurance payers must
take cognizance.
The second paper in this issue,
evaluating outcome, is that of Mor
rison from the James Paton Memo
rial Hospital in Gander, Nfld. (pages

326 to 329). He studied laparoscop
ic hernia repair. In recent years, an
abundance of new repairs for ingui
nal hernias have been promulgated:
preperitoneal; with mesh; without
mesh; sutureless; and tensionless
repairs. Many have strong anatomi
cal studies, always with excellent
results, to support their use. Gener
ally speaking, there is not a multi
tude of good therapies for a single
disease. Into this field comes lapa
roscopic hernia repair to compete at
two important levels of efficacy and
outcome: short term (hospitaliza
tion, costs, pain relief, return to
work and full activity) and long
term (what is the recurrence rate
and efficacy of its repair?) Clearly,
at present, we are examining only
short-term outcome with variables
similar to those of the cholecystec
tomy experience. This is fair to a
point. However, the gallbladder is
gone and late sequelae are rare.
Proper evaluation of hernia repair
will require at least a 2-year follow
up by the same surgeon. The per
formance of a randomized trial of
hernia repair presents all the diffi
culties of any randomized con
trolled trial of surgical technique,
including the biases and preferences
of the surgeon and patient. Morri
son’s single-surgeon series is open
to many observations and ques
tions: Why the roll of Marlex? Is
Cooper’s ligament seen? Is the ileopubic tract noted? The repair de
scribed is for indirect hernias —
what real modifications are made
CJS, VOL. 36, NO. 4, AUGUST 1993
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for direct hernias? The nature of
follow-up is acknowledged to be
brief. The advantages appear sig
nificant yet are not compared
against modern hernia surgery done
under local or regional anesthesia
as a day case with return to work
within a week. Dr. Morrison is to be
congratulated in his initial assess
ment, but the next level of evalua
tion must go further.
There is a myth that valuable
clinical studies and new clinical
knowledge can only be developed in
university centres. This, of course,
is nonsense. Turner’s presidential

address to the Canadian Association
of General Surgeons4 makes this
point. Sanabria and colleagues pro
vide a framework that is suitable to
the high-volume practice. The Ca
nadian Journal o f Surgery would
like to encourage studies evaluating
new procedures. However, to be
credible and to maintain this jour
nal’s credibility, such studies must
be well-designed, likely to answer
the questions posed and subjected
to evaluation that takes into ac
count both the short- and long-term
benefits or harms of the surgical
procedures.

References

10 years have seen a small explosion in
the publication of texts on selected
topics in colorectal surgery, and there
are several excellent comprehensive
texts now available.
Marvin Corman’s Colon and Rectal
Surgery, in its third edition in 10 years,
is one of these comprehensive texts. I
could quibble about some aspects of the
organization of information and some
of Dr. Corman’s opinions, but there can
be little argument that this edition is
truly comprehensive. It is one-third lon
ger than its predecessor and contains
copious drawings and photographs. In
deed, there are sufficient illustrations to
justify Dr. Corman’s description of the
book as a “text-atlas,” and the illustra
tions of operative technique are particu
larly well done. The references are up to
date, including 1991, and are very
extensive — the chapter on colonic
cancer alone has 699 references.
Colon and Rectal Surgery is a single
author work. I have not been impressed
that the single-author versus multipleauthor argument is very important in
assessing reference tests. If the infor
mation is clearly and comprehensively
presented with few gaps, if the illustra
tions are good and the bibliography is
current, and if I can quickly find an

swers to questions or a cogent discus
sion of the relevant issue then I am a
happy customer. Not only does this
volume meet these criteria, but it also
stands out owing to Dr. Corman’s con
sistent, personal, readable style. With
the exception of a chapter on pediatric
surgical problems by Dr. Alberto Pena
and a section on laparoscopic tech
niques by Dr. Robert Beart, the book is
all Marvin Corman. Dr. Corman cannot
be accused of presenting only his side
of the story. Although he leaves no
doubt about his stand on clinical con
troversies, he regularly reviews the cur
rently available data in a complete and
unbiased fashion.
The organization of the text is gener
ally good and is definitely better than
the last edition. Ulcerative colitis and
Crohn’s disease are now dealt with in
separate chapters, the latter including a
discussion of indeterminate colitis. A
third chapter deals with infectious and
noninfectious colitides. Also, there is a
new chapter on the difficult topic of
defecation disorders. However, Dr.
Beart’s excellent discussion of laparo
scopic techniques appears in the chap
ter on carcinoma of the colon, where it
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The following books are also re
viewed in this issue: Bone Grafts
and Bone Substitutes (page 320);
Osteoarthritis. Diagnosis and Med ical/Surgical Management 2nd
edition (page 379); Pediatric Sinus
itis (page 379)

COLON AND RECTAL SURGERY.
3rd edition. Marvin L. Corman. 1221
pp. Illust. J.B. Lippincott Company,
Philadelphia. 1993. Price not stated.
0 -3 9 7 -5 1 1 7 8 -7

As recently as a decade ago the decision
regarding which colorectal reference
text to purchase was easy. There was
Professor John Goligher’s Surgery o f
the Anus, Rectum and Colon and little
else. For those who wanted more about
less, the was Essentials o f Anorectal
Surgery by Goldberg, Gordon and Nivatvongs. Fortunately these were, and
still are, outstanding books. Now, the
decision as to which reference text to
buy is not as straightforward. The past
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continued on page 320

CORRESPONDANCE

Stenosis of Stapled
Colorectal Anastomosis
To the editors. We read with inter
est the article entitled ”An unusual
intraoperative complication of sta
pled colorectal anastomosis: report
of a case and review of the litera
ture” by Bard, Cohen and Ross
(Can J Surg 1993; 36: 165-168),
because within the last 2 years at
our 160-bed community hospital we
have encountered five cases of de
layed stenosis of anastomoses sta
pled with the end-to-end anastomot
ic (EEA) stapler. Two patients (A
and B) had undergone anterior re
section for malignant disease. Three
had undergone a Hartmann take
down for benign disease: patient C
had a perforated fecaloma; patient
D had perforated diverticulitis; and
patient E had undergone a revision
of an operation done for inconti
nence. All cases were otherwise
uncomplicated. The largest diame
ter EEA stapler had been used, and
in patients C, D and E the stapling

had been done through the middle
of the anterior wall of the rectal
stump, more than 2 cm away from
the previous TA linear stapling.
All patients presented with small
stools or obstructive symptoms and
had stenoses of 5 mm to 7 mm.
Management of these five patients
was as follows. Patient A, an elderly
women, got by with liquid stools.
Patient B underwent dilatation of
the stenosis in the morning and
laparotomy and a revision for perfo
ration in the evening. He subse
quently died of metastatic disease a
few months later. Patient C, who
had a perforated fecaloma was ma
naged with a laparotomy and GIA
stapling (staples that divide and
staple at the same time); when
stenosis recurred he was operated
on with sutured enlargement and is
doing well. In patient D the stenosis
was managed with GIA stapling
through the rectum with simulta
neous laparotomy from above to
ensure the small bowel was not
caught between the anterior wall of

the rectal stump and the end colon.
For patient E we plan to use a
laparoscopic GIA stapler from below
with a laparoscopic view above.
We searched the literature and
made inquiries at our university
centre in Halifax, the Mayo Clinic,
the Swiss gastrointestinal surgery
course in Davos and the stapler
manufacturer, and we have not
found a convincing explanation for
this complication. Some of our col
leagues have said it is common and
some have said it is rare, but they
have all had some cases. We believe
that there must be more unreported
cases and that the problem is not
being addressed. We would appreci
ate any comments others might
have concerning the frequency of
this problem and how it may be
prevented.
J.P. Schaefer, MD, FRCSC, FACS
W.L. Walker, MD, FRCSC
W. Thurlow, MD, FRCSC, FACS
Prince County Hospital
Summerside, PEI
C1N 2A9
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Consensus Conference
on Well-Differentiated Thyroid Cancer:
a Summary
Janice L. Pasieka, MD, FRCSC; Lome E. Rotstein, MD, FRCSC
Objective: To update recommendations for the surgical treatment of
well-differentiated thyroid cancer.
Data Sources: Literature reviews and personal files.
Study Selection: Panelists selected relevant articles to make arguments for and
against current recommendations for the surgical treatment of well-differentiated
thyroid cancer.
Outcomes: Four aspects of surgical treatment were considered: (a) the extent of
surgical resection, (b) the definition and utilization of high- and low-risk patient
groups, (c) who should perform thyroid surgery and (d) the use of radioactive
iodine.
Recommendations: Total thyroidectomy is not the treatment of choice for all
well-differentiated thyroid cancers. The use of risk factors help select those patients
in whom a total thyroidectomy would be of benefit. High-risk patients are those who
are considered at high risk according to the AGES and AMES classifications or who
have lymph-node metastases, aggressive variants of their disease, multifocal cancer
or disease in the contralateral thyroid lobe and a history of radiation to the neck.
Those at low-risk are those previously described as being at low risk according to
the AGES and AMES classifications. General surgery training programs across
Canada need to ensure that their residents obtain enough experience in thyroid
surgery that as general surgeons they can perform this type of surgery with low
morbidity.
Conclusions: The findings of this consensus conference were supported by those of
several review articles and by the arguments put forward by the panelists. These
findings are only guidelines as to the surgical approach to well-differentiated
thyroid cancer.

Objectif: Mettre a jour les recommandations relatives au traitement chirurgical du
cancer bien differencie de la thyroi'de.
Sources de donnees : Recensions des ecrits et dossiers personnels.
Selection d'etudes : Les panelistes ont choisi des articles pertinents afin d’invoquer
des arguments pour et contre les recommandations actuelles relatives au traitement
chirurgical du cancer bien differencie de la thyroi'de.
Resultats : On a examine quatre aspects du traitement chirurgical : a) l’importance
de la resection chirurgicale, b) la definition et [’utilisation de groupes de patients a

The Consensus Conference on Well-Differentiated Thyroid Cancer was held at a meeting o f the Canadian Society o f Surgical Oncology, Montreal,
Que., A p ril 1993. The moderator was Dr. Janice L. Pasieka, MD, FRCSC and the panelists were Dr. Claude P. Potvin, MD, FRCSC, FACS, associate
professor o f surgery, Department o f Surgery, Universite de Montreal, and Dr. Lome E. Rotstein, MD, FRCSC, associate professor, Department o f
Surgery, University o f Toronto
Accepted fo r publication June 29, 1993
Reprint requests to: Dr. Janice L. Pasieka, Assistant professor, Department o f Surgery, Foothills Hospital, University o f Calgary,
1403 - 29th St NW, Calgary, A B T2N 2T9
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risque eleve et faible, c) qui devrait pratiquer la chirurgie thyroidienne et d)
l’utilisation d’iode radioactif.
Recommandations : La thyroidectomie totale n’est pas le traitement de choix pour
tous les cancers bien differencies de la thyrolde. Le recours aux facteurs de risque
facilite la selection des patients chez qui une thyroidectomie totale serait
avantageuse. Les patients a risque eleve sont ceux que Ton considere comme tels en
vertu des classifications AGES et AMES ou qui ont des metastases ganglionnaires,
des variantes agressives de la maladie, un cancer multifocal ou une maladie du lobe
contralateral de la thyroi'de et des antecedents d’irradiation du cou. Les patients a
faible risque sont ceux que Ton a precedemment decrits comme tels en vertu des
classifications AGES et AMES. Dans l’ensemble du Canada, les programmes de
formation en chirurgie generate doivent veiller a ce que leurs residents acquierent
suffisamment d’experience en chirurgie thyroidienne pour etre en mesure, a titre de
chirurgiens generaux, de pratiquer ce type de chirurgie en maintenant un faible
taux de morbidity.
Conclusions : Les constatations de cette conference consensuelle sont appuyees par
celles de plusieurs comptes rendus critiques et par les arguments avances par les
panelistes. Ces constatations ne sont que des lignes directrices sur l’approche
chirurgicale du cancer bien differencie de la thyroi'de.

A

t this conference arguments
were put forward that recent
retrospective reviews1' 4 demonstrat
ed that near-total or total thyroidec
tomy and iodine-131 ablation im
proved survival and decreased re
currence rates in patients with welldifferentiated thyroid cancer. Sever
al of these series demonstrated a
low morbidity with near-total or
total thyroidectomy.1'2'4 However,
permanent hypoparathyroidism and
recurrent laryngeal nerve injury,
which can be found in 1% to 12% of
patients, are still problems for the
general surgeon.5-6 This unaccepta
bly high morbidity during thyroid
surgery was used as an argument
that aggressive surgical interven
tion for well-differentiated thyroid
carcinoma is not necessary in all
cases. The overall mortality from
well-differentiated thyroid cancer
has not changed over the years,
despite the trend to more aggres
sive surgical intervention in the last
2 decades. It was argued that pa
tients who are at low risk for recur
rent thyroid cancer or death from
this disease had no improvement in
survival with more aggressive surgi
cal intervention.6' 8 Therefore, the
added potential danger to the para
thyroid glands and the possibility of

recurrent laryngeal nerve injury
make a bilateral surgical procedure
in these low-risk patients possibly
unnecessary.
The consensus on surgical inter
vention for well-differentiated thy
roid cancer was as follows:
la. Total thyroidectomy is not
the treatment of choice for all welldifferentiated thyroid cancers.
lb. Total thyroidectomy is the
treatment of choice for patients
who are at high risk for recurrent
thyroid cancer or death from the
disease. Total thyroidectomy can be
achieved in several ways: by bilater
al total thyroid lobectomies or uni
lateral thyroid lobectomy plus sub
total thyroid lobectomy followed by
ablation of the remaining thyroid
tissue.
lc. Minimal surgery for welldifferentiated thyroid cancer is a
total thyroid lobectomy and isthmusectomy.
ld. Low-risk patients — those
with small tumours confined to the
thyroid — can be treated with lo
bectomy and isthmusectomy only.
The second point of discussion
was an attempt to identify patients
who are at high risk for recurrence
or metastases. Various age-risk
classifications have been described.

The AGES classification from the
Mayo Clinic9 and the AMES classifi
cation from the Lahey Clinic7 are
the most widely known. These two
classifications take into account the
age of the patient, the presence of
distant metastases, the size of the
tumour and its extent beyond the
thyroid itself. Patients with distant
metastases or older patients with
either large tumours (greater than 5
cm in dimension) or extension be
yond the thyroid are considered to
be at high risk according to these
classifications. Although the AGES
and AMES classifications are con
sidered to be helpful in defining the
prognosis of high- and low-risk pa
tients, other factors such as the
DNA content of the tumour,10' 12 the
presence of grossly involved lymph
nodes, histologic variants of the
well-differentiated thyroid cancers,
such as tall-cell variant of thyroid
cancer13' 15 and Hurthle cell carcino
ma,16 previous head and neck irradi
ation and the technical feasibility of
removing all grossly abnormal tis
sue all play a role in defining the
risk to the patient of having a
recurrence or dying of the disease.
The following consensus was
achieved on the use of a risk classi
fication in defining high- and lowCJS, VOL. 36, NO. 4, AUGUST 1993
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risk patients and as a means of
assessing the degree of surgical
interventions:
2a. Although agreement was not
unanimous, each member of the
group considered various factors in
assessing the high-risk patients.
High-risk patients can be defined as
those who are at high risk accord
ing to AGES or AMES classification
or who have lymph-node metastases, aggressive variants of well-dif
ferentiated thyroid cancer, multifo
cal cancer or disease in the contra
lateral lobe and a history of radia
tion to the neck.
2b. Low-risk patients were unani
mously agreed to be those with
small tumours localized to one lobe
of the thyroid who fell into the
previously described AMES or
AGES low-risk classification.
The question of whether thyroid
surgery should be performed by all
general surgeons across Canada, or
whether it should be restricted to
those with specialized training and
expertise was debated. Several fac
tors were brought out.
The consensus as to who should
perform thyroid surgery was as fol
lows:
3a. Surgeons performing thyroid
surgery should not undertake a
thyroid lobectomy unless they are
capable of safely performing a total
thyroidectomy with a low morbidity
and mortality, because the need for
total thyroidectomy may develop intraoperatively. It is up to each sur
geon to monitor his or her results
and to ensure that they are in
keeping with those reported in the
recent literature.
3b. There was a general consen
sus that as general surgeons in
training programs across this coun
try we make a firm commitment to
improve and develop the experience
of thyroid surgery at the resident
and fellow level to train general
surgeons across Canada to perform
this operation with little morbidity.
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Finally, the routine use of 131I for
ablation of remaining thyroid tissue
was discussed. Several studies dem
onstrated that 131I ablation com
bined with aggressive surgical inter
vention decreases local and regional
recurrence rates.417 However, sur
vival to date has not been proven to
be superior after 131I ablation.
Some authors18 have advocated
the use of 131I ablation of an entire
thyroid lobe when the need for a
total thyroidectomy was not recog
nized at the initial operation. The
rationale for this is to minimize the
morbidity of performing a surgical
completion thyroidectomy. Howev
er, it has been observed that there
appears to be an increase in the
development of parathyroid disease
on the side of the ablated gland
years later.19 Others have found it
difficult to ablate a large amount of
thyroid tissue, and multiple high
doses of 13II are usually required.20
The question of increased morbidity
with surgical completion thyroidec
tomy was debated. Several recent
series have demonstrated that sur
gical completion thyroidectomy can
be performed safely with no added
morbidity to the patient when done
by surgeons with experience in this
procedure.21-23
The overall consensus on the
routine use of radioactive ablation
of thyroid tissue was as follows:
4a. There is no such thing as
routine use of 131I after thyroid sur
gery for well-differentiated thyroid
cancer. 131I ablation should be used
selectively. Indications for use are
as follows:
i. Significant uptake, demonstrat
ing substantial thyroid tissue re
maining in the neck, after a total or
near-total thyroidectomy or when a
total lobectomy with contralateral
subtotal thyroidectomy is per
formed and ablation is used to com
plete the total thyroidectomy.
ii. Extrathyroidal uptake indicat
ing regional disease.

iii.
Metastatic disease demonstrat
ed either preoperatively or postoperatively.
4b. If an entire lobe is left in situ
and total thyroidectomy is required,
surgical completion thyroidectomy
should first be considered, not 131I
ablation of the remaining lobe.
Overall, the mortality from welldifferentiated thyroid cancer re
mains stable. The biologic behavi
our of the majority of well-differen
tiated thyroid cancers makes it diffi
cult to study this disease in a
randomized, controlled trial. As cli
nicians, we need to continue to look
for and develop risk factors that
predict those patients at high risk
for recurrence or death so as to
identify the patients in whom more
aggressive surgical intervention
may be beneficial. These overall
consensuses are broad definitions of
how one should approach well-dif
ferentiated thyroid cancer. Each
case must be individualized preoper
atively, intraoperatively and perioperatively. The overall feeling was
that not all patients require total
thyroidectomy or 131I ablation for
well-differentiated thyroid cancer.
Total thyroidectomy, when neces
sary, should be done by surgeons
capable of performing this proce
dure with little morbidity.
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SESAP VII Question / Question SESAP VII
Item 52
Which of the following statements about radionuclide biliary scans in the diagnosis of acute cholecystitis is
TRUE?

(A) These scans are not accurate when serum bilirubin exceeds 5 m g/d L
(B) Adverse reactions are more likely in patients with iodine allergies
(C) A normal gallbladder will usually fill within 30 minutes after injection of the radionuclide material
(D) The test has a specificity of 97% in detecting acalculous cholecystitis
(E) The examination can reliably distinguish acute cholecystitis from acute pancreatitis

For the five answers given above select the one that is best.
For the critique of Item 52 see page 336.
(Reproduced by permission from SESAP ’9 2 - ’93 Syllabus; Surgical Education and Self-Assessment Program
No. 7. For enrolment in the Surgical Education and Self-Assessment No. 7, please apply to the American College
of Surgeons, 55 E Erie St., Chicago, IL 60611.)
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Effect of Dynamization of a Static
Interlocking Nail on Fracture Healing
Chi-Chuan Wu, MD; Chun-Hsiung Shih, MD
A retrospective study was done of 22 patients with complex femoral (11) and tibial
(11) shaft fractures treated with static interlocking nailing followed by
dynamization, which was carried out on average 7.8 months later. The success rate
was 54% with no significant difference between the healing of femoral and tibial
fractures. The follow-up was at least 2 years. The interval from nailing to
dynamization did not correlate with the success rate; the longest interval associated
with successful healing was 20 months. The authors found that static interlocking
nailing without dynamization can still produce a high union rate, and if there is
sparse callus formation during the healing process, indicating low osteogenesis,
dynamization will result in fracture union in only half the cases. To improve the
union rate, cancellous bone grafting may be necessary.
Une etude retrospective a porte sur 22 patients qui ont subi des fractures complexes
du corps du femur (11) et du tibia (11) traitees par enclouage emboitant statique
suivi d’une dynamisation effectuee en moyenne 7,8 mois plus tard. Le taux de
reussite etait de 54 %, sans difference significative entre la reparation des fractures
du femur et du tibia. Le suivi a dure au moins deux annees. II n’y a aucune
correlation entre l’intervalle qui s’est ecoule entre l’enclouage a la dynamisation et
le taux de reussite; l’intervalle le plus long lie a la reussite de la reparation est de 20
mois. Les auteurs ont constate que l’enclouage emboitant statique sans
dynamisation peut quand meme produire un taux eleve de consolidation et, advenant
la formation peu abondante de cal pendant le processus de reparation, ce qui
temoigne d’une faible osteogenese, la dynamisation ne provoquera la consolidation
des fractures que dans la moitie des cas. Pour ameliorer le taux de consolidation,
une greffe d’os spongieux sera peut-etre necessaire.
immobilization in a
A lthough
cast is still favoured worldwide

for treating tibial shaft fractures,1'2
reamed intramedullary nailing has
been the treatment of choice for
femoral shaft fractures.3-6 The in
troduction of interlocking nails has
widened the indications for reamed
intramedullary nailing,78 so that
this technique is widely used for the

treatment of complex femoral and
tibial shaft fractures.
A static interlocking nail is load
bearing910 and is usually used in
segmental or severe comminuted
(Winquist types III and IV) frac
tures.11 Initially, the static inter
locking nail was thought to be
associated with delayed union or
nonunion because of the lack of

weight sharing,12 so routine dynam
ization 3 months after nailing was
commonly performed.91314 (In this
procedure, the screws at one or
both ends of the nail are removed,
allowing the fracture surface to
make contact on weight bearing.)
However, interlocking nailing has
proven to have a high union rate,
so that dynamization is not rou-

From the Department o f Orthopedic Surgery, Chang Cung Memorial Hospital, Chang Cung Medical College, Taiwan, ROC
Accepted fo r publication Aug. 19, 1992
Reprint requests to: Dr. Chi-Chuan Wu, Department o f Orthopedic Surgery, Chang Cung Memorial Hospital, No. 5, Fu-Hsin St 33333 Kweishan
Taoyuan, Taiwan, ROC
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tine.15 It has been suggested that
the procedure be used only when
there is sparse callus formation 4
months after nailing.16 To our
knowledge, there are no reports of
the clinical effects of dynamization.

Patients and Methods
From December 1986 to May
1989, 421 consecutive fractures
(276 femoral, 145 tibial), were
treated with Grosse-Kempf inter
locking nails (Howmedica Inc., Kiel,
Germany) at the authors’ institu
tion. The patients ranged in age
from 16 to 85 years (average, 37
years) with a male-to-female ratio of
5:1. The commonest cause of the
fractures was motor vehicle acci
dents. Of the 421 fractures, 218
(148 femoral and 70 tibial) were
treated initially with static inter
locking nailing.
In all but 22 fractures, the static
assembly of interlocking nails was
preserved without routine dynami

zation. The indication for dynamiza
tion was sparse callus formation 4
months after nailing or nonunion
with less bony gap. For dynamiza
tion the screws most distal from the
fracture site were removed. Then
partial weight bearing was permit
ted. Patients were followed up as
outpatients regularly at 4- to
6-week intervals. The clinical and
radiologic progress of healing was
recorded. Knee and ankle range-ofmotion exercises were encouraged.
Bony union was defined as fol
lows: clinically, there was no pain
or tenderness, and the patient
walked without aids; radiologically,
solid bridging callus had connected
the fracture fragments.13'17 A state
of nonunion was considered to exist
when the fracture was still ununited
after 1 year of follow-up.18 Delayed
union was not defined to avoid
misrepresenting the union rate.
Of the 218 nails inserted, 22
were dynamized during the treat
ment course, 11 nails in the femur
and 11 nails in the tibia (Table I).

The interval from nailing to dynami
zation was noted, and the results of
dynamization were analysed and
compared.

Findings
The interval from nailing to dy
namization ranged from 4 to 20
months (average 7.8 months). In
four cases (three femoral nails, one
tibial nail), dynamization took place
more than 1 year after nailing.
Twelve (54%) of the 22 fractures
had healed at a mean (± SD) of 4.3
± 2.8 months after dynamization; 5
(46%) of 11 femoral fractures unit
ed at a mean (± SD) of 3.2 ± 1.3
months and 7 (64%) of 11 tibial
fractures united at a mean (± SD)
of 5.1 ± 3.3 months after dynami
zation (Figs. 1 and 2).
In the 10 cases in which there
was nonunion despite dynamiza
tion, the mean (± SD) interval from
nailing to dynamization was 8.4 ±
2.8 months.

Table I. Clinical Courses of 22 Patients With Femoral and Tibial Shaft Fractures Treated by Static interlocking Nailing Followed by Dynamization of the
Nails
Fracture

Case

Age,
yr

Sex

Level

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

35
25
64
28
61
26
20
32
26
41
50
23
55
40
25
53
24
30
32
29
21
30

M
M
F
M
M
M
F
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M

T, U
F, M
T, M
F, M
F, L
T, M
F, M
T, M
T, M
F, L
T
F, L
F
T, M
F, M
T, U
T, M
F, M
T
T, L
F, M
F, M

Type

Operative
method

Interval from
nailing to
dynamization,
mo

Comminuted
Comminuted
Nonunion
Comminuted
Comminuted
Comminuted
Comminuted
Comminuted
Comminuted
Comminuted
Segmental
Comminuted
Segmental
Comminuted
Comminuted
Comminuted
Comminuted
Comminuted
Segmental
Comminuted
Comminuted
Comminuted

Closed
Closed
Open
Closed
Closed
Closed
Closed
Closed
Closed
Closed
Closed
Closed
Closed
Closed
Closed
Closed
Closed
Closed
Closed
Closed
Closed
Closed

4
4
5
10
20
4
4
12
4
12
10
5
7
6
6
10
8
10
6
8
12
6

Outcome (time
to union,
mo*)

Follow
up, mo

Union (3)
Union (3)
Union (2)
Nonunion
Union (2)
Nonunion
Union (2)
Nonunion
Union (11)
Nonunion
Nonunion
Nonunion
Nonunion
Union (3)
Union (4)
Union (3)
Union (8)
Nonunion
Union (6)
Nonunion
Union (5)
Nonunion

46
42
42
41
38
38
37
36
36
34
32
32
28
28
28
27
27
26
26
25
25
24

* Months from dynamization to union
T = tibia, F = femur, U = upper third of shaft, M = middle third of shaft, L = lower third of shaft
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After dynamization, there was no
superficial or deep infection, and no
leg-length discrepancy of more than
2 cm was noted. Nevertheless, one
patient had deep infection of the
tibia soon after nailing. Local drain
age was followed by dynamization 4
months after nailing. The tibial
fracture healed at 11 months with
out a flare-up of infection (Fig. 3).

Discussion
In spite of the objections of Rig
gins and colleagues over the con
cept of weight bearing to promote
fracture healing,19 the majority of
orthopedists still support the con
cept. Theoretically, the piezoelectric
effect and Wolff’s law have ap
proved the concept,20"22 and clinical
ly, tibial shaft fractures treated with

cast immobilization and early
weight bearing also favour the heal
ing process.23 24 Thus, weight shar
ing over the fracture site to pro
mote fracture healing seems reason
able.2526
An interlocking nail can be a
static or dynamic assembly, and
each has different indications. After
all, a static assembly is a a loadbearing device, and weight stress
does not pass through the fracture
site.10 Theoretically, the healing
process should be hindered, but
fortunately the bending and rotato
ry micromovement are not com
pletely blocked.1627 Clinically, a
high union rate with copious callus
formation has been reported in nu
merous articles.1628 Until now, dy
namization to promote healing has
rarely been advised.
The factors favouring fracture

healing are a small gap between the
fracture surfaces and adequate me
chanical stability and nutrition.29 A
static interlocking nail can provide
adequate stability and produce a
high union rate. Nevertheless, in
high energy trauma, severe softtissue injury combined with perios
teal vascularity may impede fracture
healing. Even though partial fibulectomy may be used to treat tibial
shaft nonunion,3031 nail dynamiza
tion in cases of sparse callus forma
tion may be ineffective. Reports of
the effect of dynamization in the
literature and the results in our
series demonstrate a success rate of
about 50%. It can be inferred that
dynamization plays an auxiliary but
not a major role in fracture healing.
Because of the high union rate in
the majority of cases of static inter
locking nailing without dynamiza-

FIG. 1. Case 5. (A) Left femoral shaft fracture (lower third, comminuted, open type IHb) in 61-year-old man. (B) Open reduction,
wiring and Hoffmann external fixation was performed. After wound healing, closed static interlocking nail was inserted. (C)
Hypovascular nonunion at 20 months. (D) Distal dynamization produced bony union 2 months later.
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DYNAMIZATION IN FRACTURE HEALING

tion, the major consideration is the
characteristic of adequate mechani
cal stability in the static interlock
ing assembly.
Although the success rate of dynamization was only 55% in the
present series, this simple proce
dure can be successful (as in our
case 5) when the degree of os
teogenesis is just below the critical
point. If osteogenesis can be en
couraged by dynamization of the
nail, the fracture may unite.
For a segmental fracture caused
by high energy trauma, the healing
process is prolonged. Usually the
intermediate-distal fragment junc
tion is the site of nonunion, and the
fracture is classified as avascular.32
Dynamization produces union in
33% of cases. Practically, local can
cellous bone grafting with dynami
zation should be more effective.

Conclusions
Theoretically and clinically, static
interlocking nailing is successful in
the majority of cases of complex
femoral and tibial shaft fractures.
When osteogenesis is poor, nail
dynamization will result in a suc
cess rate of about 55%. The interval
between nailing and dynamization
does not affect the success rate.
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Double Stress Fracture of the Tibia
in the Presence of Arthritis of the Knee
Hugh U. Cameron, MB, ChB, FRCSC
Two cases of double stress fracture of the tibia are described. Both patients had
severe medial compartment arthritis of the knee and some varus bowing of the tibia
prior to the stress fractures. The deformities were corrected by tibial osteotomies.
Total knee replacement was not required.

On decrit deux cas de double fracture de stress du tibia. Prealablement a la fracture
de stress, les deux patients presentaient une arthrite severe du compartiment
interne du genou et une courbure du tibia. Les desformites furent corrigees par
osteotomie tibiale. II ne fut pas necessaire de pratiquer une arthroplastie du genou.

tress fractures o f bone are well
recognized and, except for fem
oral neck fractures, are usually
treated with benign neglect.1-4 Re
cently, two cases o f unrecognized
stress fracture of the tibia were seen
in elderly patients with arthritis of
the knee and resulted in significant
deformity o f the tibia.

S

more distal stress fracture was
found, which became unstable (Fig.
1). The bone removed at the site o f
the attempted osteotomy was re
placed, and the opportunity was
taken to correct the tibial deformity
through the distal stress fracture
(Fig. 2). The “ hardware” was re
moved 18 months later. Two years
later the condition o f her knee is
satisfactory with good alignment.

Case Report
Case 2

with a severely deformed limb (Fig.
3). When seen 3 years later, the
tibia was severely deformed and
required a dome-type osteotomy.
The bone was so soft that two
plates were bolted together to pro
vide internal fixation (Fig. 4). The
plates were removed 18 months
later. The result was satisfactory
with good alignment o f the knee. A
knee replacement was planned as a
second stage but has not yet been
required.

Case 1

A 59-year-old East African, Asian
woman presented with pain in and
distal to the knee. She spoke no
English so communication was diffi
cult. Radiologically, she appeared to
have a stress fracture of the proxi
mal part of the tibia. An osteotomy
through the stress fracture was
scheduled to correct the tibial de
formity. During the operation, a

A 64-year-old East African, Asian
woman with an arthritic knee and a
severely deformed tibia gave a his
tory o f tibial pain o f spontaneous
onset in 1981 at the mid-shaft level
o f the tibia. The pain resolved with
in a few months, but the leg seemed
deformed. She had another, similar
episode in 1987, but the pain was
more acute. This, too, resolved
within a few months but left her

Discussion
Although double stress fractures
o f the tibia are rare, these being the
only two cases ever seen by the
author, isolated tibial stress frac
tures are not uncommon. They
occur mainly in people with rheu
matoid arthritis or those w ho are
extremely inactive, suggesting that
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osteoporosis plays an important
role. Osteomalacia may be an addi
tional factor, but bone biopsies were
not done in these patients to con
firm this.
The eight patients I have treated
with stress fractures of the tibia all
had significant varus deformity of
the tibia in both legs, predating the
knee arthritis. This deformity cou
pled with severe medial compart
ment osteoarthritis would give rise
to significantly eccentric tibial load
ing.
Failure to recognize these stress
fractures usually results in accentu
ation of the varus bowing of the
tibia or, rarely, in nonunion. If
these fractures are recognized early,
there is an opportunity to overcor
rect the tibia to restore the mechan
ical axis of the knee. Not only will
this result in amelioration of symp
toms in the knee, thus delaying the
FIG. 1. Case 1: Patient was initially
operated on for proximal tibial stress
fracture, but during osteotomy to cor
rect deformity, another stress fracture
was found (arrows) at junction of
upper and middle thirds of tibia.

FIG. 2. Case 1: Bone already removed
at site of proposed osteotomy was
replaced and fracture fixation plate was
contoured to allow correction of tibial
deformity through distal stress frac
ture.

FIG. 3. Case 2: (Left) anteroposterior and (right) lateral views showing double
stress fractures (arrows) of tibia. One occurred in 1981 and one in 1987. Patient’s
deformity increased considerably after each event.
308
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FIG. 4. Case 2: Extra-articular deformi
ty was corrected by dome osteotomy to
prevent loss of limb length. Bone was
so soft that double plates bolted to
gether were necessary to provide sta
bility.

TIBIAL FRACTURES AND ARTHRITIS

inevitable total knee replacement,
but it will also make subsequent
total knee replacement considerably
easier.
Almost any intra-articular defor
mity can be corrected by ligament
releases at the time o f total knee
replacement, but it is difficult to

correct more than 15° o f extraarticular deformity.5 Therefore,
when a knee is severely deformed,
long x-ray films are required be
cause of the possibility o f a tibial
stress fracture with consequent ex
tra-articular deformity. Correction
o f this deformity before total knee

replacement simplifies the proce
dure greatly.
In hip replacement surgery, it is
common to do a femoral diaphyseal
osteotomy, if required, at the same
time as the replacement.67 For this,
a long-stem prosthesis must be
used. Distal fluting for rotational
stability at the site o f the osteotomy
greatly simplifies the procedure. In
knee replacement surgery, it has
been more common to correct the
deformity first and then to carry out
total knee replacement. The reason
for this is that the only stems long
enough to allow combined diaphy
seal osteotomy with total knee re
placement were stems attached to
constrained knees (Figs. 5 and 6).

FIG. 5. Nonunion of supracondylar fracture above very stiff knee was handled by
bypassing nonunion with long-stem, cemented, hinge prosthesis.

FIG. 6. Nonunion of tibia below failed total knee prosthesis. Ten years ago only
implant with stems long enough to handle this problem was long-stem, cemented,
hinge prosthesis.

FIG. 7. Newer modular condylar type
knees allow long-stem extensions to be
attached to primary stem, making onestage tibial osteotomy in total knee
replacement possible. This particular
stem extension is split to reduce bend
ing stiffness in sagittal plane.
C'JS, VOL. 36, NO. 4, AUGUST 1993
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Considerable fear of implant loosen
ing still exists with the use of
constrained implants because of in
creased stress at the implant-bone
interface.
Now, modular stems are becom
ing available, which can be attached
to a primary implant (Fig. 7), and
the concept of diaphyseal osteoto
my combined with total knee re
placement as a single-stage proce
dure is becoming more attractive.
Concern still does exist, however,
about the poor soft tissue coverage
of the tibia. The tibial cortex, espe
cially in elderly osteoporotic pa
tients, is very thin and allows little
reaming to give press-fit stability.
Even with the introduction of flexi
ble stems to decrease the metal
stem-bone elastic modulus mis

match, total press-fit contact might
result in “ end-of-stem pain.”
Should supplementary side plates
and bone grafting be required, the
paucity of soft tissue coverage
might pose a problem.
The advantage of a two-stage
procedure in the knee is demon
strated in the two cases reported
here. Overcorrection of the deformi
ty by realignment of the knee to
shift the mechanical axis of the
knee to the better side, leaving a
horizontal joint line, will often re
sult in considerable alleviation of
symptoms, often enough to delay
the inevitable total knee replace
ment by several years. This offers a
considerable advantage because the
design of knee prostheses is im
proving all the time.
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Osteomyelitis of the Spine
Due to Salmonella: Case Report, Review
of Clinical Aspects, Pathogenesis
and Treatment
Cyril R. D’Souza, MD, FRCSC, FACS; Philip G. Hopp, MD, FRCSC;
Surendar Kilam, MD, FRCSC, FACS
Osteomyelitis of the spine caused by Salmonella is rare. The authors describe a case
in which the patient had fusion of the LI and L2 vertebrae, which were affected by
osteomyelitis. The infecting organism was Salmonella typhim urium . The authors
describe the relationship of the vascular anatomy to the development of
osteomyelitis of the spine. They discuss the clinical features, diagnosis,
pathogenesis and treatment of the disease. Although the association of osteomyelitis
due to Salmonella and sickle cell disease has long been known, this patient did not
have sickle cell disease or any other condition that would compromise the immune
system.

II est rare de rencontrer une osteomyelite de la colonne vertebrate due aux
salmonelles. Les auteurs decrivent le cas d’un patient presentant une fusion des
vertebres LI et L2 avec osteomyelite due a Salmonella typhim urium . Ils font le lien
entre l’anatomie vasculaire et le developpement de l’osteomyelite de la colonne, et
commentent le tableau clinique, le diagnostic, la pathogenese et le traitement de
cette maladie. Bien qu’un lien entre l’osteomyelite a Salmonella et l’anemie a
hematies falciformes soit connu de longue date, le patient ne souffrait pas de cette
maladie ni d’aucune autre qui aurait pu affaiblir son systeme immunitaire.

steomyelitis of the spine
caused by Salmonella is rare,
with an incidence of 0.45% of all
cases of osteomyelitis.1 We describe
a case of osteomyelitis in a patient
with congenital blocked vertebrae;
the infecting organism was Salmo
nella typhimurium. The association
between infections of the bone due
to Salmonella and sickle cell anemia
has long been known; its awareness
predates the use of stereotyping
schema for the former disease as
well as the clinical description of
the latter.2 Our patient, however,
did not have sickle cell anemia or

O

any disease affecting the immune
system. This is the first case in the
literature in which osteomyelitis has
been described in blocked vertebrae.

Case R eport

A 49-year-old man was admitted
through the emergency department
with a 2-day history of left lowerquadrant pain radiating from the
flank, associated with fever, chills
and rigors. In the past he had
complained of vague back pains,
and radiography had shown con

genital fusion of the LI and L2
vertebrae. Two years previously, the
patient had had gastroenteritis last
ing for 4 days while he was on
holiday in Tahiti.
The patient was in some discom
fort and had a tender mass in the
left lower quadrant, extending into
the left flank. His temperature was
38.7°C. He kept his left hip in
flexion, and any attempt at extend
ing it caused severe pain in the area
of the swelling. He had no neuro
logic deficit.
Investigation showed an in
creased leukocyte count with a shift
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to the left and a markedly elevated
erythrocyte sedimentation rate. In
travenous pyelography gave normal
results. A barium enema showed a
soft-tissue mass displacing the de
scending colon medially. Lateral
views of the lumbar vertebrae
showed a punched-out area in the
LI and L2 blocked vertebrae
(Fig. 1). A computed tomography
(CT) scan showed edema and swel
ling of the left psoas sheath and
muscle (Fig. 2).
A diagnosis of left psoas abscess
as a result of vertebral osteomyelitis
was made. The patient was started
on therapy with cephalosporin and
tobramycin and prepared for opera
tion. A large abscess extending
down the sheath of the left psoas
muscle and containing 1200 mL of
creamy pus was drained through a
left-flank incision. The bodies of the
LI and L2 vertebrae were exposed
and found to be fused; drill holes
were made in each and the cavities
curetted. The necrotic granulation
tissue present was sent for histolog
ic examination and for culture. Irri
gation catheters were placed in the

cavities of the vertebral bodies, and
suction irrigation was instituted
with a solution of normal saline
containing chloramphenicol, 4 g
daily. In addition, the patient re
ceived 1 g of chloramphenicol four
times a day intravenously.
Postoperatively, serum protein
and hemoglobin electrophoresis
showed a normal pattern. Aggluti
nin titres for Salmonella showed an
elevated level of group 0 and group
H titres. Cultures of the pus grew
S. typhimurium. Stool cultures
were negative for Salmonella sp.
Postoperative studies showed nor
mal leukocyte morphologic fea
tures, normal levels of immuno
globulins IgG, IgA and IgM and
normal levels of complements C3
and C4.
The patient made a smooth re
covery and continued taking chlor
amphenicol 1 g daily in divided
doses for 2 months.

Clinical Aspects
The signs and symptoms of os

teomyelitis due to Salmonella are
usually acute in onset, with high
fever, chills, severe bone pain, leu
kocytosis and an increased erythro
cyte sedimentation rate.
In osteomyelitis of the vertebral
bodies, the suppuration may break
out and track down into the retropharynx, mediastinum or the psoas
sheath, depending on the level of
vertebral involvement. Of patients
with spinal osteomyelitis, 17% have
neurologic symptoms, and at least
as many have inflammation involv
ing the epidural space.3 Inflammato
ry swelling that exerts direct pres
sure on the spinal cord might some
times be the cause of neurologic
deficit, but the most severe damage
is a result of thrombosis of the
spinal arteries.4
Radiography of the vertebra
shows an osteolytic lesion of the
body, and this can be confirmed on
CT scan and bone scans.
In a patient with sickle cell dis
ease there is no certain way of
distinguishing a sickle cell crisis
resulting in bone infarction from
Salmonella septicemia and osteo-

9
i
FIG. 1. Lateral view of lumbar verte
brae showing congenital “blocked” LI
and L2 verterbrae and osteolytic lesion
involving them.
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FIG. 2. Computed tomography scan of lumbar region showing swelling of left psoas
sheath and muscle (arrowhead), suggestive of abscess, and erosive lesion involving
body of vertebra (arrow).

SALMONELLA SPINAL OSTEOMYELITIS

myelitis: both of these usually pres
ent with similar symptoms and
signs, except that in osteomyelitis
the symptoms persist beyond the
usual duration of a sickle cell cri
sis.5 In patients with sickle cell
disease, the erythrocyte sedimenta
tion rate may not be increased, even
in severe sepsis, presumably be
cause the sickling interferes with
rouleaux formation.6 There is a
fourfold or greater increase of ag
glutinins against somatic (0) anti
gens for Salmonella, but these ag
glutinins appear 1 week after the
onset of symptoms and reach a
peak in 5 to 6 weeks. At the onset,
nonspecific agglutinins against fla
gellar (H) antigens, which represent
old immunologic challenge, are ele
vated.5

Treatment
The treatment for osteomyelitis
due to Salmonella is surgery, with
adequate drainage of the abscess
cavity and institution of suctionirrigation drainage with antibiotic
solution7 for about 1 week after the
cultures from the outflow give re
peatedly negative results. Although
in-vitro sensitivity to other antibiot
ics has been shown, only ampicillin
150 m g/kg daily in six divided
doses, chloramphenicol 30 to 50
m g/kg daily in four divided doses
or trimethoprim 160 mg and sul
famethoxazole 800 mg twice a day
have been used clinically with any
success. Of the three, ampicillin,
being bactericidal, appears theoreti
cally to be the drug of choice in an
immunologically compromised host
with defective phagocytosis. How
ever, chloramphenicol is the most
frequently used antibiotic in such
infections, and ampicillin is reserved
for patients in whom bone-marrow
toxicity develops due to chloram
phenicol. Treatment should be con
tinued for at least 2 months.

Third-generation cephalosporins,
such as cefotaxime, ceftriaxone and
cefoperazone, are equally effective
and are acceptable alternative anti
biotics for the treatment of multiresistant Salmonella organisms.8

Vascular Anatomy
of the Vertebral Column
The pathologic process of spinal
osteomyelitis is best understood by
a look at the anatomic features and
vascular supply of the spine. Each
vertebra is separated from the next
by an intervertebral disc, which
loses its vascular supply very early
in life and from that time onward
depends for its nutrition on diffu
sion through the cartilaginous plate
present between it and the vertebral
body. The segmental arteries, which
are branches from the vertebral,
intercostal, lumbar and sacral arter
ies, enter the intervertebral foramen
and form longitudinal channels (two
posterolateral and one anteromedi
al), around the spinal cord, supply
ing it and also sending nutrient
branches to the vertebral bodies
through the nutrient foramen ante
riorly. It has been shown that these
three channels, with their free anas
tomoses, permit reversal of blood
flow and alteration in the volume of
blood flow in response to the meta
bolic demands of the spinal cord.9
The nutrient arteries end in a
rich capillary network at the carti
laginous plate, the nutrition to the
disc diffusing out from this point.
In fused vertebrae, when the fusion
is complete, there is no interverte
bral disc between the two vertebrae.
Although work on the vascular
anatomy of fused vertebrae is
sparse and not readily available, one
might speculate that the nutrient
arteries in such instances have a
similar distribution as in normal
vertebrae — that is, one supplying
the upper half and the other the

lower half of a fused vertebra, form
ing a watershed at the middle with
no vascular anastomosis across.
Because mobility is lost due to
the fusion, one could also speculate
that there are extra shearing forces
at the centre of the fused vertebrae
and that the “end arteries’’ could
easily be damaged; the resulting
hematoma might be the nidus for a
hematogenous bacterial infection.
Another factor that might lead to
the development of a septic embo
lus is the reversal of blood flow in
the arteries of the spine causing
sluggish flow and a pooling of
blood.
The venous drainage of the spi
nal column is equally important in
the establishment of infections or
metastasis in the vertebrae. The
venous drainage consists of three
systems of veins, all of which are
without valves. The first is the
interosseous vertebral vein, which
drains the centre of each vertebral
body. This in turn communicates
with an internal venous plexus,
which lies in the spinal canal and
forms four longitudinal channels
that communicate freely with one
another and, in turn, with the exter
nal vertebral plexus. As its name
implies, this lies outside the verte
bral canal and communicates with
the segmental veins — the verte
bral, intercostal, ascending lumbar
and lateral sacral veins — forming
the “Batson plexus.” 10 It has been
shown that during episodes of
raised intra-abdominal pressure,
blood from the veins in the pelvis
flows in a retrograde fashion into
the Batson plexus of veins instead
of draining into the inferior vena
cava. Tumour cells injected into the
pelvic veins of experimental animals
gain a foothold in the metaphyseal
area of the vertebrae.11
Thus, the lumbar paravertebral
veins communicate freely with the
pelvic veins, and sepsis introduced
through procedures on the bladder
CJS, VOL. 36, NO. 4, AUGUST 1993
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can spread directly to the lumbar
vertebrae through the avalvular ve
nous plexus.
“True hematogenous” spread
through the spinal nutrient artery
occurs as well, as already men
tioned, as a result of bloodstream
infection.12

Pathogenesis
Osteomyelitis due to Salmonella
is rare in people with normal hemo
globin.13 However, the risk in
creases several hundredfold in those
with sickle cell disease.14 Although
more than 75% of hematogenous
osteomyelitis in the normal popula
tion is staphylococcal,15 over 70%
seen in sickle cell disease is due to
Salmonella sp.16 Hodges and col
leagues17 were the first to call atten
tion to the relation between sickle
cell disease and Salmonella infec
tions.
Osteomyelitis due to Salmonella
is usually seen when the patient is
immunologically compromised. In
addition to sickle cell disease such
conditions are chronic alcoholism,18
chronic lymphocytic leukemia, sys
tematic lupus erythematosus, neo
plastic disease, long-term steroid
intake19 and possibly acquired im
munodeficiency syndrome. S. typhimurium is the common oppor
tunist in these situations.20
Occasionally Salmonella may
cause osteomyelitis in an otherwise
normal person, as was the case in
our patient. Salmonella typhi, Sal
monella paratyphi B and Salmonella
choleraesuis account for most of
these infections.
Although the susceptibility of pa
tients with sickle cell disease to
Salmonella osteomyelitis has not
been completely explained, three
factors are worth mentioning.21
First, repeated episodes of sickling
and microemboli formation devital
ize the gut wall, leading to seeding
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of Salmonella organisms in the
bloodstream.22 The circulating or
ganisms then lodge in areas of
devitalized infarcted bone. Second,
chronic hemolysis results in satura
tion of the reticuloendothelial sys
tem with the breakdown products
of erythrocytes and impaired ability
of the macrophages to phagocytose
bacteria.23 Finally, the chronic over
load of Kupffer’s cells with the
breakdown products of erythrocytes
as well as the increased incidence of
cirrhosis in patients with sickle cell
disease neutralize the role of the
liver as the primary site of clearance
of opsonized blood-borne bacteria.
In our patient, the episode of
gasteroenteritis 2 years before was
most probably a result of Salmonel
la infection, and this may have been
the cause of the osteomyelitis either
immediately or as a result of the
patient becoming a chronic carrier
with recurrent episodes of Salmo
nella bacteremia.
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Arm Problems and Psychological Distress
After Surgery for Breast Cancer
Elizabeth Maunsell, PhD;* Jacques Brisson, MD, ScD;* Luc Deschenes, MD, FRCSCt

The frequency of problems in the arm affected by surgery for breast cancer and the
association of these problems with psychological distress were assessed among 223
women with newly diagnosed breast cancer 3 months after operation and again 15
months later among 201 of these same women. At 3 months after operation, 182
(82%) of the 223 patients reported at least one arm problem. Specific problems
reported were swelling (24%), weakness (26%), some limitation in range of
movement (32%), stiffness (40%), pain (55%) and numbness (58%), and these
percentages had changed little 15 months later. Regardless of the type of
mastectomy, women who underwent axillary dissection had more arm problems.
Compared with women reporting no arm problems, the adjusted odds ratios of
having psychological distress at 3 months for women reporting one to two, three to
four and five to six arm problems were 1.2, 2.3 and 3.1 respectively (x2 for trend =
9.5, p = 0.002).
Arm problems are frequent after operation for breast cancer, and these problems
appear to increase the likelihood of psychological distress. Women should be
informed that arm problems are expected but nonthreatening sequelae of initial
surgical treatment for breast cancer.
La frequence des problemes au bras affecte par la chirurgie pour cancer du sein, et
la relation de ces problemes avec la detresse psychologique ont ete evaluees chez
223 femmes ayant un nouveau diagnostic 3 mois apres l’operation et ensuite chez
201 des memes femmes 15 mois plus tard. Trois mois apres l’operation, 182 (82 %)
des 223 patientes ont signale au moins un probleme de bras. Specifiquement, les
femmes ont rapporte les problemes suivants : endure (24 %), faiblesse (26 %), une
certaine limitation de mouvement (32 %), raideur (40 %), douleur (55 %) et
engourdissement (58 %). Apres 15 mois, les pourcentages signalant la presence de
ces problemes n’avaient pas change de fa?on importante. Les femmes qui avaient
subi une dissection axillaire ont eu plus de problemes de bras, independamment du
type de mastectomie. Comparativement aux femmes qui n’ont declare aucun
probleme de bras, les rapports des cotes ajustes de detresse psychologique chez les
femmes qui signalaient un ou deux, trois ou quatre et cinq ou six problemes de bras,
respectivement, etaient de 1,2, 2,3 et 3,1 (x2 de tendance = 9,5. p = 0.002).
Les problemes de bras sont frequents apres une operation pour le cancer du sein
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et ces problemes semblent augmenter la probability de detresse psychologique. Les
femmes devraient etre informees que des problemes de bras peuvent etre anticipes
mais que ceux-ci sont une sequelle des operations pour le cancer du sein dont il ne
faut pas s’inquieter.

rm problems are frequent after
surgery to the breast and axil
la.1-3 They include weakness, stiff
ness, pain, edema, loss or change in
sensation and restricted range of
movement.45 Since the advent of
conservative breast surgery as ini
tial treatment for many women with
primary breast cancer, there has
been little discussion of the frequen
cy o f arm problems. Furthermore,
the impact of arm problems on
patient quality of life has not been
quantitatively assessed.
The objectives o f this study were
threefold: to describe the frequency
o f perceived problems in the arm on
the operated side in the first 18
months after initial surgical treat
ment for breast cancer; to examine
their frequency in relation to type of
mastectomy and axillary dissection;
and to assess the association of
perceived problems in the arm with
high levels of psychological distress
during this 18-month period.

A

Patients and Methods
The study population comprised
patients with newly diagnosed
breast cancer first treated in one of
seven Quebec hospitals between
Jan. 1, 1984, and Dec. 31, 1984.
Eligible women were those who had
undergone surgery for unilateral
disease, did not have distant metas
tasis at the time o f diagnosis, could
be interviewed within the study time
frame and for whom permission to
contact was obtained from the
treating physician.
Information on age, type of mas
tectomy (partial or total), axillary
dissection, extent of disease at the
time o f diagnosis and use o f radio
therapy was taken from patients’
316
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hospital records. Information was
available on the number o f axillary
lymph nodes examined at the time
of initial treatment. Extent of dis
ease was defined as localized or
regional according to the SEER
classification.6
Two home interviews were con
ducted approximately 3 and 18
months after initial surgical treat
ment. All interviews were carried
out by the same specially trained
nurse. The interviews included
questions on personal characterist
ics of patients, interpersonal rela
tions, perceptions o f social and pro
fessional support, daily activities,
work outside the home, stressful
life events7 and a history o f depres
sion evaluated by questions taken
from the Diagnostic Interview
Schedule (DIS)8. Information on
chemotherapy was also obtained.
The perception o f problems in
the arm on the operated side was
assessed during each interview. At
the first interview, these problems
were also assessed for the other
arm. Women were asked whether
they had experienced weakness,
stiffness, pain, numbness or swell
ing in the 2 weeks preceding the
interview and, if so, whether it
predated their breast operation. If
the problem in the affected arm was
a pre-existing one, it was not con
sidered to be related to breast sur
gery and was disregarded in the
analysis. Patients were also asked
to characterize the range of move
ment of both arms. Women de
scribed this by choosing from five
images representing the capacity to
lift each arm through a 180° range
(0°, 45°, 90°, 135° and 180°).9
Patients unable to lift the arm to
180° were considered to have some
limitation o f movement. For each

patient, a score representing the
total number o f perceived arm prob
lems was calculated and could vary
between 0 and 6.
Psychological distress was one of
the principal measures o f outcome
in this study10-12 and was asses
sed at both interviews by means
of the Psychiatric Symptom Index
(PSI).1314 The PSI provides a quan
titative measure o f the severity of
29 symptoms o f emotional distress
in the 7 days immediately preceding
the interview. Both presence and
intensity of symptoms were record
ed. PSI scores were expressed as a
percentage of the maximum rating.
Thus, scores could vary from 0 to
100, with higher scores indicating
greater distress. Cronbach’s alphas
for the PSI were 0.91 and 0.92 at 3
and 18 months respectively. The
PSI was designed and validated for
use with the general population and
takes 3 to 5 minutes to adminis
ter.1314 The PSI and the DIS were
translated from English into French
for use in a population-based study
of mental health in the province of
Quebec.1516 In this study, women
with PSI scores in the upper third
of the observed distribution (scores
of 32 or greater) were considered to
have high levels o f distress. With
this cutoff point, the sensitivity
(86%) and specificity (79%) of the
PSI for detecting serious distress,
as determined by the DIS, with the
criteria o f the Diagnostic and Statis
tical Manual for mental disorders
(third edition), appeared adequate.
The proportions o f patients re
porting different arm problems ac
cording to type o f mastectomy and
axillary dissection were compared
by means of the x 2 statistic. The
mean number of problems reported
were compared by Student’s t-test.17
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The possible confounding effects of
several factors on these associations
were examined by stratified analy
sis. Factors assessed included age,
educational level, side of operation
(dominant or not) and radiotherapy.
The results from these stratified
analyses did not differ substantially
from the crude results presented
later.
The proportions of patients with
high PSI scores at 3 and 18 months
postoperatively were compared on
the basis of number of arm prob
lems reported at those times. The
odds ratio used to quantify these
associations is the ratio of the odds
of high psychological distress
among patients who reported one
or two, three or four, or five or six
arm problems to the corresponding
figure among women who reported
no arm problems. At 3 months,
these odds ratios were assessed
using multiple logistic regression
with type of mastectomy, duration
of initial hospitalization, number of
stressful life events in the 5 years
before diagnosis and the patient’s
evaluation of her relationship with
her spouse included simultaneously
in the model.18 Partial mastectomy
was included because it was associ
ated with higher levels of psy
chologic distress at 3 months after
initial treatment in this group.10
The other variables were included
because each had a slight con
founding effect in stratified analy
ses. At 18 months, the logistic
regression model assessing the as
sociation of arm problems with dis
tress also included history of de
pression and stage at diagnosis,
because both variables are known
to be associated with the level of
psychological distress in these da
ta.10 The x2 test for trend was also
based on logistic regression. This
test assessed linear increase in the
logarithm of the odds ratio per unit
increase in the number of reported
arm problems.

Findings
Of the 286 patients treated dur
ing the study period, 235 were
considered eligible for the study.
Three months after initial treat
ment, 227 of these 235 patients
participated in the first interview.
At 18 months, 13 of the 227 pa
tients had died, and 3 more were
judged too ill to be interviewed
again. Of the remaining 211 partici
pants, 205 (97%) agreed to be inter
viewed again. In all, 205 (87%) of
all eligible women participated in
both interviews. However, four
women who had bilateral mastecto
my were subsequently excluded,
and these analyses are thus based
on 223 and 201 patients at 3 and
18 months respectively.
At the 3-month interview, 82% of
patients reported at least one prob
lem in the operated arm (Table I).
Specific problems reported most fre
quently were loss of sensation
(54%) and pain (55%). Swelling, the
least frequent problem, was still
reported by 24% of patients. Al
though some limitation in range of
movement was reported, this was
marked (90° or less) in only 9
(13%) of the 71 women with some
limitation. When the frequency of
problems in the affected arm was
examined separately for dominant
and nondominant arms, no consis
tent or large differences were noted.

Problems were infrequent in the
arm on the nonoperated side com
pared with those in the arm on the
operated side (Table I). Overall, only
14% of women reported at least one
problem. Taken individually, such
problems were perceived by no
more than 10% of patients and in
the cases of weakness, stiffness,
loss of sensation and swelling, by
even fewer women.
Eighteen months after operation,
the percentage of women reporting
at least one problem in the affected
arm was almost unchanged (Table
I). Only limitation in the range of
movement and loss of sensation had
decreased by 10% or more at 18
months. Even then, loss of sensa
tion was still reported by almost
50% of women. The mean number
of problems was still 2.0 per patient
at 18 months compared with 2.3
per patient at 3 months.
The presence of problems in the
affected arm did not appear to de
pend on the type of mastectomy
(Table II). In general, the percent
ages of women reporting problems
and the mean number of problems
were similar for those who under
went partial or total mastectomy.
Significant differences were noted
in the numbers of women reporting
weakness and stiffness, but the di
rection of the differences varied.
In contrast, from 24% to 64% of
women who had axillary dissection

Table I. Perceived Problems in Arms on Operated and Nonoperated Side Among Breast Cancer
Patients, 3 and 18 Months After Initial Treatment
3-mo follow-up
(n = 223)
Perceived problem
At least one arm problem, %
Perception of, %
Weakness
Stiffness
Pain
Loss of sensation
Swelling
Some limitation of
movement
Mean no. (range) of perceived
problems reported/patient

Operated side
82

18-mo follow-up
(n = 201)

Nonoperated side
14

Operated side
79

26
40
55
58
24

3
4
9
3
0.4

18
37
51
49
27

32

9

16

2.3 (0 - 6)

0.3 (0 - 4)

2.0 (0 - 6)
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reported specific arm problems,
compared with 0% to 33% among
women who did not. A significantly
higher mean number of arm prob
lems were reported by women who
underwent axillary dissection (2.5
problems) than by women who did
not (0.9 problems) (p = 0.0001)
(Table II).
The proportion of women with
high PSI scores increased with the
number of problems in the affected
arm as reported at 3 months (Table
III). Compared with women report
ing no problem in the affected arm,
the adjusted odds ratios for having
substantial psychological distress in
women reporting one to two, three
to four and five to six arm problems
were 1.3, 2.3 and 3.1, respectively
(x2 for trend = 9.5, p = 0.002).

This association was also observed
18 months after initial treatment.
By this time, the odds ratios of
having high distress according to
the number of arm problems report
ed at 18 months were 1.9, 4.4 and
6.0, respectively (x2 for trend =
14.0, p = 0.0002).
Finally at the 18-month inter
view, patients were asked whether
they had received information about
arm problems, exercises and pre
cautions to avoid swelling in the
arm on the operated side: 83%
recalled being told and having a
demonstration of exercises to re
gain and maintain arm mobility, and
80% carried out these exercises for
some time after their operation.
However, almost 60% reported not
being told how long to carry out

this exercise regimen. Apart from
arm mobility, 60% of these women
reported receiving no information
about the type, severity and possi
ble duration of arm problems that
they might experience postoperatively or about the precautions to
be taken to avoid the development
of swelling in the arm.

Discussion
Our results show that problems
in the arm on the operated side are
frequent, remain so even 18 months
postoperatively and have a negative
effect on the overall quality of life
of breast cancer patients. The fre
quency of problems is not affected
by the type of mastectomy, but

Table II. Perceived Problems in the Arm Affected by Operation in Relation to Type of Mastectomy and Axillary Dissection Among Breast Cancer Patients
3 Months After Initial Treatment
Type of mastectomy
Total
(n = 144)

Perceived problem
At least one arm problem, %
Perception of, %
Weakness
Stiffness
Pain
Loss of sensation
Swelling
Some limitation of movement
Mean no. (range)
of perceived
problems reported/patient

Axillary dissection

Partial
(» = 79)

No
(/» = 1 5 )

P
value

Yes
(n = 208)

P
value

81

84

0.58

53

84

0.009

22
44
58
61
24
33

34
32
49
53
23
30

0.04
0.06
0.24
0.25
0.80
0.73

20
7
33
13
0
13

26
42
56
62
25
33

0.58
0.006
0.09
0.000
0.03
0.11

0.37

0.9
(0 -3 )

2.5
(0 -6 )

0.0001

2.4
(0 -6 )

2.2
(0 -6 )

Table III. Patients With High Psychiatric Symptom Index (PSI) Scores and Crude Odds Ratios (0RC) and Adjusted Odds Ratios (ORA) of High Distress 3
and 18 Months After Initial Treatment According to Number of Problems Reported in the Arm on t he Operated Side 3 and 18 Months After Operation
3-mo follow-up
Arm prob
lems, no.*
0
1-2
3 -4
5 -6
x 2 trend
p value

18-mo follow-up

Patients,
no.

High
distress,
%

ORC

30
92
77
24

17
27
34
50

1.0
1.9
2.5
5.0
9.5
0.002

ORAt

Patients,
no.

High
distress,
%

ORC

ORAJ

1.0
1.3
2.3
3.1

35
91
65
10

17
25
54
70

1.0
1.6
5.6
11.3

1.0
1.9
4.4
6.1
14.0
0.0002

'Based on reports of perception of weakness, stiffness, pain, loss of sensation, swelling and some limitation of movement.
tAdjusted for type of mastectomy, duration of initial hospitalization, number of stressful life events in the 5 years before diagnosis and the patient’s
evaluation of relationship with spouse.
tAdjusted for history of depression and stage of disease at diagnosis.
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women who had axillary dissection
reported significantly more arm
problems.
This study was community based
and comprised a consecutive series
of women who underwent partial or
total mastectomy as initial treat
ment. Previous reports on the fre
quency of arm problems have been
based mainly on women who under
went radical or modified radical
mastectomy or on selected groups
of patients who participated in ran
domized trials evaluating immediate
versus delayed arm movements in
the rehabilitation of breast cancer
patients. Nevertheless, the results
are relatively consistent. In three
studies1’19-20 in which arm circum
ference was measured before and
after surgery, 11%, 36% and 46% of
patients had some swelling 4 to 18
months later. Similarly, in other
studies,219 21' 23 20% to 44% of pa
tients were unable to lift the arm
beyond 120° to 150°, and 19% and
33%, respectively, experienced a
loss of 20° to 30° of arm move
ment during the 18 months after
operation.20’23
The frequency of pain was as
sessed in a randomized trial of
counselling on physical and social
outcomes in breast cancer pa
tients.19 Among control women in
that study, almost 25% of patients
reported mild to intense pain in the
affected arm persisting for the 12 to
18 months after initial treatment.
The frequency of pain postoperatively (persistent or not) was 61%
among the same women. In another
study, 56% of women who had
undergone mastectomy reported
pain 4 months postoperatively.24
Problems in the arm on the oper
ated side increase the likelihood of
psychological distress. To our
knowledge, this is the first study to
consider such an association. Arm
problems may serve as reminders of
cancer diagnosis and be feared as
symptoms of disease progression

rather than sequelae of initial surgi
cal treatment.5
Our findings have several impli
cations.
• Women undergoing initial
treatment may need to be better
informed about the type and severi
ty of possible arm problems, that
these are expected but nonthreaten
ing sequelae of their initial surgical
treatment for breast cancer and that
some problems may take a year or
more to resolve.
• The physical impact of conser
vative breast surgery should not be
underestimated. Arm problems are
strongly associated with axillary
dissection, a procedure performed
in about 90% of women in our
series who had either partial or
total mastectomy. Not surprisingly,
arm problems after partial mastec
tomy are as frequent as those after
total mastectomy. Some health pro
fessionals and lay personnel per
ceive partial mastectomy as a minor
operation compared with total mas
tectomy. These results should alert
people working with breast cancer
patients to the fact that psychologi
cal distress10’25-27 and some physical
sequelae28 of conservative breast
surgery can be as serious as those
of surgery resulting in breast loss.
• Axillary dissection is currently
the best available method for dis
ease staging. Controversy exists
about the usefulness and appropri
ateness of axillary dissection in
staging and initial treatment of
breast cancer.2930 Our findings sug
gest that if axillary dissection could
be avoided, the quality of life of
breast cancer patients would be
improved.
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almost gets lost. Although issues relat
ed to the management o f patients with
acquired immunodeficiency syndrome
and human immunodeficiency virus
positive patients are reviewed, they are
not collected into a single section or
chapter. Similarly, Dr. Corman has
elected not to present an overview o f
anatomy and physiology, nor is there a
separate section on local anesthetic
techniques or on the pharmacology o f
anorectal preparations, although this
information can be found.
Despite these criticisms, Colon and
RectaI Surgery is an excellent book. It
easily fulfils the requirement o f a colo
rectal reference text for general sur
geons, colorectal surgeons and trainees
in either specialty.

Marcus Burnstein, MD, MSc, FRCSC
Associate professor
Department o f Surgery
University o f Toronto
St. Michael’s Hospital
Suite 504
38 Shuter St.
T oron to, ON
M5B 1A6
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BONE GRAFTS AND BONE SUBSTI
TUTES. Mutaz B. Habal and A. Hari
Reddi. 461 pp. Illust. W.B. Saunders
Company/Harcourt Brace Jovanovich,
Inc., Philadelphia. 1992. Price not
stated. ISBN 0 -7 2 1 6 -2 8 0 9 -5
This textbook represents the proceed
ings o f three unidentified bone sympo
sia. As frequently happens in such a
text, the editing does not produce uni
formity, and the result is lack o f uni
form style, contents and illustrations.
The text is organized into three
parts: part I is on the basic science of
bone graft healing: part II covers bone
substitutes; and part III describes clini
cal applications. Unfortunately this has
resulted in a very uneven distribution of
chapters, and remarkably little is writ
ten about bone graft substitutes —
possibly the most exciting aspect of
bone graft surgery.
The section on basic science is well
balanced with particularly good chap
ters on biologic principles o f bone in
duction and transforming growth fac
tor. There is also an excellent chapter

on the acquisition and banking o f allo
grafts and their role in clinical practice.
The clinical application section is
poorly done. Both the clinical photo
graphs and radiographs tend to be
small, dark and poorly defined. Old
bone grafting and trauma surgery are
restricted to examples o f craniofacial
bone loss, and the use o f bone grafting
in the treatment o f post-traumatic non
union or the management o f segmental
defects o f long bones is ignored.
The science o f bone grafting is based
upon extensive clinical experience with
this earliest method o f autogenous tis
sue transplantation and the extensive
use ot bone allografts in clinical prac
tice. Exciting research is under way in
bone graft substitutes, bone induction
and bone transportation. All o f these
areas o f innovation are inadequately
served by this text.
This book may find a place in large
institutional libraries or in selected indi
vidual libraries o f those particularly
interested in the basic science o f bone
continued on page 379
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Acalculous Cholecystitis Associated
With Cytomegalovirus and Sclerosing
Cholangitis in a Patient With Acquired
Immunodeficiency Syndrome
Shafique H. Keshavjee, MD, MSc, FRCSC;* Laura A. Magee, MD;t Brendan J. Mullen, MD, FRCPC;$
David L. Baron, MD, FRCPC;t James L. Brunton, MD, FRCPC;t Steven Gallinger, MD, MSc, FRCSC*
Intra- and extrahepatic bile-duct strictures, papillary stenosis and acalculous
cholecystitis have all been described in ill patients with acquired immunodeficiency
syndrome (AIDS). Acalculous cholecystitis associated with cytomegalovirus (CMV),
Cryptosporidium or Campylobacter organisms has typically been described in
critically ill or moribund patients.
The authors report a case of acute acalculous CMV cholecystitis in a 28-year-old
man who presented with abdominal pain. The patient was infected with the human
immunodeficiency virus (HIV) but was ambulatory and had had no AIDS-defining
illness. The patient did not have any well-recognized risk factors for acalculous
cholecystitis, showing that this entity can occur in relatively healthy HIV-infected
patients as well as in the terminal stages of AIDS. The diagnosis should be
considered when such a patient presents with abdominal pain. Furthermore, this
patient had sclerosing cholangitis of the intra- and extrahepatic bile ducts as well as
papillary stenosis. The cause of the acalculous cholecystitis was presumed to be
CMV, but the disease progressed despite therapy with foscarnet.

Des retrecissements des voies biliaires intra et extrahepatiques, des stenoses
papiliaires et des cholecystites acalculeuses ont ete signales chez des patients
souffrant du syndrome d’immunodeficience acquise (SIDA). Des cholecystites
acalculeuses reliees a des infections a cytomegalovirus (CMV), a Cryptosporidium ou
a Campylobacter ont couramment ete decrites chez des patients parvenus au stade
terminal d’une maladie.
Les auteurs decrivent un cas de cholecystite acalculeuse aigue a CMV chez un
homme de 28 ans qui se plaignait de douleurs abdominales. Le patient etait porteur
du virus d’immunodeficience humaine (HIV) mais il etait sur pied et n’avait eu
aucune maladie caracteristique du SIDA. Le patient ne presentait aucun facteur de
risque reconnu pour la cholecystite acalculeuse, ce qui demontre que cette
complication peut survenir chez un patient infecte par HIV en bonne sante relative,
aussi bien qu’au stade terminal du SIDA. Ce diagnostic doit etre envisage quand un
tel patient consulte pour des douleurs abdominales. Ce patient presentait, de
surcroit, une angiocholite sclerosante des canaux biliaires intra et extrahepatiques,
de meme qu’une stenose papillaire.
La cause presumee de la cholecystite acalculeuse est le CMV, meme si la maladie
s’est aggravee malgre l’utilisation de foscarnet.

From the *Department o f Surgery, fDepartment o f Medicine and fDepartm ent o f Pathology, M ount Sinai Hospital and the University o f Toronto,
Toronto, Ont.
Accepted fo r publication June 19, 1992
Reprint requests to: Dr. Steven Gallinger, Suite 1225, Mount Sinai Hospital, 600 University Ave., Toronto, ON M5G 1X5
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I

t is now well recognized that in
patients with acquired im
munodeficiency syndrome (AIDS)
there may be a number of patholog
ic processes involving the biliary
tract.1-4 Acalculous cholecystitis as
sociated with cytomegalovirus
(CMV),2'3'5 Cryptosporidium26 and
Campylobacter1 has been described
in this group of immunosuppressed
patients; also reported have been
stenosis of the ampulla of Vater4
and benign strictures of the intraand extrahepatic bile ducts resem
bling idiopathic sclerosing cholan
gitis.1-48-11 Acalculous cholecystitis
is usually seen in seriously ill hospi
talized patients; acalculous chole
cystitis associated with CMV has
been described in patients with
AIDS. This report of acute acalcu
lous CMV cholecystitis in a patient
infected with the human im
munodeficiency virus (HIV) but
with no history of an AIDS-defining
illness emphasizes that the condi
tion can occur in the early stages of
HIV infection. We report the devel
opment of sclerosing cholangitis in
this patient and its lack of response
to medical therapy.

he had had several minor opportu
nistic infections, he did not have an
AIDS-defining illness at the time of
presentation. For 2 years he had
been taking zidovudine intermit
tently; therapy had been started
because of low CD4 counts (less
than 0.2 X 109/L).
There was marked tenderness to
palpation in the right upper quad
rant as well as diffuse shotty lymphadenopathy and oral thrush. The
patient’s hemoglobin level was 138
g /L and his leukocyte count 3.1 X
109/ L (62% granulocytes, 26% lym
phocytes, 12% monocytes). Serum
levels of electrolytes, urea, creati
nine, albumin, total protein, lipase
and amylase were all within the
normal range, as were the pro
thrombin and partial thromboplas
tin times. Liver enzymes values
were as follows: gamma glutamyl
transferase (GGT) 339 U /L (nor

mally 8 to 80 U/L), alkaline phos
phatase (ALP) 183 U /L (normally
40 to 125 U/L), aspartate amino
transferase (AST) 78 U /L (normally
less than 35 U/L), alanine amino
transferase (ALT) 113 U/L (nor
mally less than 55 U/L), unconju
gated bilirubin (Bu) 7 pm ol/L (nor
mally less than 18 jumol/L) and
conjugated bilirubin (Be) less than
2 jumol/L (normally less than 5
^tmol/L). Hepatitis B surface anti
gen was absent, and hepatitis B
surface antibody was present.
Abdominal ultrasonography dem
onstrated a markedly distended gall
bladder, which was thick-walled and
tender. No stones were seen. The
liver appeared normal. Biliary scan
ning with technetium-HIDA gave
normal results except for slightly
delayed (40 minutes) gallbladder
filling. The patient was treated with
cefotetan and discharged in good

Case Report
A 28-year-old man presented to
the emergency department com
plaining of right upper-quadrant ab
dominal pain, which he had experi
enced for the first time 2 months
earlier. He described one to two
attacks per week. There was associ
ated nausea and occasional vomit
ing but no fever, chills, jaundice,
dark urine or pale stools. On
screening in 1987 the patient had
been found to be HIV positive. He
had a history of oral candidiasis,
oral hairy leukoplakia, pneumococ
cal pneumonia in 1988 and giardia
sis, confirmed by culture, in 1990
(this condition had responded to a
course of metronidazole). Although
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FIG. 1. Endoscopic retrograde cholangiopancreatogram, showing multiple intraand extrahepatic bile-duct strictures and nonfilling of gallbladder.

CMV ACALCULOUS CHOLECYSTITIS AND AIDS

condition after 6 days with only
mild residual pain.
Five weeks later the patient un
derwent endoscopic retrograde cho
langiopancreatography (ERCP) be
cause of recurrent pain and in
creased levels of liver enzymes:
GGT was 2820 U/L, ALP was
1010 U/L, AST was 166 U/L,
ALT was 134 U/L, Bu was 8
n mol/L and Be was less than 2
^tmol/L. The procedure revealed
multiple intra- and extrahepatic
bile-duct strictures and a nonfilling
gallbladder (Fig. 1). The patient
began to experience increased right
upper-quadrant pain. Abdominal ul
trasonography revealed a tender,
distended, thick-walled gallbladder.
A biliary scan demonstrated good
hepatic uptake and emptying into
the bowel but nonfilling of the
gallbladder up to 4.5 hours after
injection. The patient’s temperature
increased to 39 °C, and he was
started on antibiotics. His hemoglo
bin level was 143 g/L , the leuko
cyte count was 3.4 X 109/L , the
level of GGT was 1110 U/L, of
ALP was 595 U/L, of AST was 667
U/L, of ALT was 781 U/L, of Bu
was 10 /^mol/L and of Be was 11
junol/L. He failed to improve on
antibiotics administered over 48
hours and was taken to the operat
ing room for cholecystectomy and
liver biopsy. The gallbladder was
thick-walled and acutely inflamed;
there were no gallstones. The pa
tient tolerated cholecystectomy and
wedge biopsy of the liver without
complications. He was discharged
home feeling well on the 7th day
after surgery.
On microscopic examination, the
gallbladder wall was edematous,
and a mild, predominantly chronic,
inflammatory infiltrate was present
superficially (Fig. 2). Rare endothe
lial cells were enlarged and demon
strated large dark-purple intranu
clear inclusions (Figs. 2 and 3).
These reacted positively to a bi

otinylated CMV-DNA probe (Pathogene; Enzo Diagnostics, New
York), which was detected by an
avidin-alkaline phosphatase conju
gate (Fig. 3).
The liver biopsy showed mild
chronic inflammatory infiltrates in

the portal triads with focal bile
plugs. Some of the terminal hepatic
venules demonstrated mild perivenular fibrosis. The results of immunohistochemical staining for
hepatitis B surface and core anti
gens were negative.

FIG. 2. Gallbladder wall, infiltrated by chronic inflammatory cells. Cytomegaloviral
(CMV) intranuclear inclusions are present in two endothelial cells (hematoxylineosin, original magnification X 125).

FIG. 3. (Left) Intranuclear CMV inclusion in mucosal endothelial cell (hematoxylineosin, original magnification X 500). (Right) In-situ hybridization with use of
CMV-DNA probe shows positive reaction localized to nucleus of endothelial cell
(original magnification X 500).
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Four months postoperatively the
patient returned to hospital with a
1-week history of abdominal pain
associated with fever, weight loss
and diarrhea. The levels of liver
enzymes had increased: GGT 2640
U /L, ALP 676 U/L, AST 194
U /L, ALT 152 U/L, Bu 8 Mmol/L
and Be 2 ^mol/L. The results of
biopsies of the small and large
bowel and the results of stool cul
tures were negative for CMV; those
of urine culture were positive. Cryp
tosporidium oocysts were isolated
from a stool specimen. The patient
was treated with spiramycin, which
failed to improve his diarrhea. In
addition, he received a 2-week
course of foscarnet, but there was
no clinical response. Repeat ERCP
revealed papillary stenosis with a
dilated common bile duct (1.4 cm)
in addition to strictures of the distal
common bile duct and left hepatic
duct. A 1-cm papillotomy was per
formed. Because the patient failed
to improve clinically or radiologically a stent was placed in the common
bile duct, but this did not change
his status. He was discharged to a
chronic care institution on symp
tomatic therapy only.

Discussion
In previous reports of acalculous
cholecystitis associated with CMV
in patients with AIDS, the patients
were severely ill with multisystem
disease and infection leading to ano
rexia, dehydration and cachexia.5
This type of clinical picture is not
dissimilar from that in which acal
culous cholecystitis develops in pa
tients without AIDS. Severe illness,
hypoxia and episodes of hypoten
sion may lead to gallbladder stasis
or ischemia. Thus, in the previously
reported cases it was not clear
whether CMV was primarily respon
sible for the cholecystitis or was
merely associated with AIDS.
324
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The case described here illus
trates a distinct presentation of
acalculous cholecystitis. The patient
was known to be HIV positive and
had a CD4 count below 0.2 X
109/L , but he had not suffered
from any AIDS-defining illness.
Right upper-quadrant pain devel
oped, and he was subsequently
found to have acalculous CMV
cholecystitis, for which there were
no well-recognized risk factors.
CMV was clearly identified in the
gallbladder wall from the character
istic intranuclear inclusions as well
as by DNA hybridization.
In addition to CMV, Crypto
sporidium ,2*-* Campylobacter,7
Candida albicans and Klebsiella
pneumoniae12 have all been impli
cated in acalculous cholecystitis and
sclerosing cholangitis in patients
with AIDS. Cryptosporidium oo
cysts were isolated from stool later
in the course of this patient’s ill
ness, but there was no evidence of
involvement of the gallbladder or
biliary tree on pathological exami
nation.
Many infectious causes have been
proposed to account for the biliary
tract disease found in AIDS pa
tients, and the agents most fre
quently isolated have been CMV
and Cryptosporidium. However, the
pathogenesis of the disease remains
speculative, and there are still a
substantial number of patients in
whom no organism can be identi
fied.13 To our knowledge, this is the
first reported case in which DNA
hybridization was used to identify
CMV in the gallbladder wall; the
liver biopsy was negative. Although
Cryptosporidium oocysts were iso
lated from the patient’s stool, they
were never identified in the gallblad
der or liver tissue, and their role in
this patient’s biliary disease remains
uncertain.
The patient exhibited other ab
normalities of the hepatobiliary sys
tem that have been described in

patients with AIDS. ERCP revealed
multiple intra- and extrahepatic
bile-duct strictures. Stenotic biliary
tract disease has been reported as
yet another complication of
AIDS.18-10 Interestingly, CMV was
associated with many of the cases
reported, and other authors have
speculated that the pathophysio
logic process mimicking idiopathic
sclerosing cholangitis may be CMVinduced vasculitis and ischemia.111
Typically, these patients have ab
normalities of the proximal intrahepatic ducts with focal stric
tures, beading and "pruning” of the
terminal branches.4 Papillary steno
sis and obstruction of the common
bile duct may also develop.49
Asymptomatic elevations of pan
creatic amylase have been previous
ly described in AIDS patients in
association with sclerosing cholan
gitis and normal pancreatograms.13
Recently, CMV has been suggested
as a cause of AIDS-related pan
creatitis.14 Our patient showed fluc
tuating lipase values, but his pan
creatic duct could not be visualized
on ERCP.
The optimal therapy for acalcu
lous cholecystitis is surgery. Chole
cystectomy is well tolerated in these
patients and is the treatment of
choice. With recent refinements in
minimally invasive surgical tech
niques, laparoscopy and laparoscop
ic cholecystectomy may be useful in
the diagnosis and management of
this condition in the future.15 Ther
apy for sclerosing cholangitis in
HIV-infected patients has been less
satisfying. Papillotomy often pro
duces symptomatic (although not
biochemical) improvement; it was
unfortunately of no benefit to our
patient. Furthermore, there was no
clinical, biochemical or cholangiographic improvement after therapy
with foscarnet, one of the most
effective medical therapies available
for CMV infection. Although our
patient was quite well at the time of

CMV ACALCULOUS CHOLECYSTITIS AND AIDS

his initial presentation, the develop
ment of acute acalculous cholecysti
tis and sclerosing cholangitis ap
peared to herald the onset of clini
cal deterioration. Therefore, these
hepatobiliary complications of HIV
infection may be poor prognostic
features, although additional cases
such as ours will need to be evalu
ated to validate this claim.
In summary, a number of hepato
biliary pathologic processes have
been associated with HIV infection,
usually in the advanced stages of
AIDS. However, this case empha
sizes that these biliary tract
changes may appear before any
AIDS-defining illness occurs. Acal
culous cholecystitis should be con
sidered in the differential diagnosis
of right upper-quadrant pain in this
group of patients.
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Laparoscopic Inguinal Herniorrhaphy
John A. Morrison, MD, FRCSC, FICS, FACS
Between September 1991 and April 1992, 30 patients were admitted for repair of an
inguinal hernia. Four elderly patients were excluded because of other medical
conditions. Of the remaining 26 patients laparoscopic hernia repair was carried out
successfully in 24; the procedure was abandoned in 2 because of dense adhesions in
the pelvis from inflammatory disease. Nineteen of the 24 patients were discharged
within 24 hours of operation; the other 5 were treated as outpatients. All patients
returned to their normal employment within 7 days of operation. There were no
wound infections and no evidence of recurrence at follow-up of up to 10 months.
The authors believe that laparoscopic repair may usher in a new era of hernia
management.

De septembre 1991 a avril 1992, 30 patients furent accueillis en vue de subir une
reparation d’une hernie inguinale. Quatre patients ages furent exclus en raison de
maladies concomitantes. Des 26 autres patients, 24 subirent avec succes une
reparation de l’hernie par voie laparoscopique; l’intervention fut interrompue chez
les 2 autres en raison de la densite des adherences au bassin causees par une
maladie inflammatoire. Dix-neuf des 24 patients refurent leur conge moins de 24
heures apres l’operation; les 5 autres furent traites en clinique externe. Tous les
patients etaient retournes a leurs occupations habituelles, moins de 7 jours apres
l’intervention. On n’a constate aucune infection de plaie, ni recidive a l’examen de
controle pratique jusqu’a 10 mois plus tard. Les auteurs croient que la reparation
par voie laparoscopique inaugure probablement une nouvelle ere dans le traitement
des hernies.
ven today the repair of inguinal
hernia is a major point of de
bate. The literature is replete with
descriptions of various anatomic
anomalies that may result in, or be
due to, an inguinal hernia. Howev
er, the exact cause of the problem
— if one exists — remains a mys
tery. Despite the numerous meth
ods of repair used, economic non
productivity, social cost and misery

E

still result from the condition itself,
its treatment and the patient’s con
valescence. The aim of any repair
should be to minimize discomfort,
recurrence and convalescence time,
and to maximize patient satisfac
tion. Laparoscopic repair may fulfil
these criteria.
I present a series of 30 consecu
tive patients admitted with an ingui
nal hernia, of whom 24 underwent

laparoscopic hernia repair, and
demonstrate that this method of
repair can satisfy the criteria of lack
of patient discomfort, outpatient
management and early return to
work. However, the long-term re
currence rate cannot be commented
on, because many recurrences
occur 5 years or more after repair
and the follow-up in this series did
not exceed 10 months.
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LAPAROSCOPIC INGUINAL HERNIORRHAPHY

Patients and Methods
Between September 1991 and
April 1992, 30 consecutive patients
were admitted with a diagnosis of
an inguinal hernia. (Children were
excluded.) Four elderly patients
were found to be unfit for general
anesthesia and were dropped from
the study, leaving 26 patients (27
inguinal hernias) for study. Of the
27 hernias, 21 were classified as
indirect and 6 as direct inguinal
hernias. Two patients had incarcer
ation of an indirect hernia, one
patient had a recurrent indirect her
nia and one patient had bilateral
indirect hernias.
The patients were admitted to
hospital the evening before surgery
and underwent our routine admis
sion screening, consisting of blood
work, urinalysis and chest radiogra
phy. Those over 40 years of age
also had electrocardiography. Later,
as experience was gained, this pro
tocol was modified to admit fit
patients as day surgery cases. The
inpatients were all discharged from
hospital within 24 hours of surgery.
The last five patients of the group
were all treated as outpatients.

The Procedure
Under general anesthesia a pneu
moperitoneum is created and lapa
roscopy carried out. The inguinal
hernia is readily visible as a round
opening in the peritoneum, lateral
to the epigastric vessels in the case
of the indirect hernia, and between
these vessels and the median umbil
ical ligament in the case of the
direct inguinal hernia. The laparo
scope can be easily inserted and the
entire length of the sac examined.
The hernia can be confirmed by
transcutaneous illumination and its
position checked with finger palpa
tion. An 11-mm trocar is inserted
on the side of the hernia, lateral to

the umbilicus, and just lateral to
the rectus sheath. A 5-mm trocar is
inserted in a similar position on the
opposite side. Incarcerated bowel
may be withdrawn back into the
abdominal cavity by gentle traction
and by placing the patient in the
Trendelenburg position.
The peritoneum proximal to the
neck of the sac is incised along the
border of the defect, allowing a
bridge of intact peritoneum to re
main at the base. This bridge is
important as it will form the base of
a flap of peritoneum shaped from
the sac, to reperitonealize the de
fect.
The sac is approached from
above (preperitoneally) and traced
distally until the apex is reached.
This is usually done with sharp
dissection and cautery or with the
yttrium-aluminum-garnet laser at
10 W of power. Once the apex is
reached, the sac is drawn back into
the abdominal cavity while dissect
ing free the cord structures. Should
any portion of the bowel or bladder
be adherent to the wall of the sac,
this is reduced also. Once the sac is
back in the abdominal cavity it can
be trimmed to allow a flap to be
attached to the superior cut edge of
peritoneum.
One or two rolled-up Marlex
(Bard Inc., Cardiosurgery Division,
Billerica, Mass.) pledgets are then
inserted into the inguinal canal as
described by Schultz.1 These rolls
buttress the weakened posterior
wall and help fill the void where the
sac has been. Finally, an oval piece
of Marlex mesh, measuring 6 to 8
cm X 4 to 6 cm, clipped to prevent
buckling, is placed preperitoneally
to completely occlude both the di
rect and indirect spaces. Usually,
this mesh is on the anterior abdomi
nal wall side of the superficial epi
gastric vessels. However, there is
no reason why this should always
be so, and its location depends on
the difficulty in exposing the ves

sels and the ease with which the
mesh is placed either on the anteri
or abdominal wall side or the perito
neal side of these vessels. When
fitted snugly this mesh need not be
anchored in place.1 No attempt is
made to adjust the size of the
abdominal wall defect with sutures.
The mesh is reperitonealized, and
the remaining peritoneal sac is
tacked superiorly with clips. With
this method there is no need to
reduce the pneumoperitoneum to
achieve approximation. The pneu
moperitoneum is then released and
Steri-Strips or clips are applied to
the puncture sites.

Findings
The patients ranged in age from
17 to 74 years (mean 50 years).
Operating time ranged from 110 to
25 minutes (mean 40 minutes). As
experience was gained, the operat
ing time was greatly reduced and is
now approximately 35 minutes.
In all, 26 patients underwent la
paroscopy with a view to repair.
However, the procedure was aban
doned in two patients: because of
the presence of dense adhesions
secondary to a previously perforat
ed appendix (one patient) and previ
ous diverticulitis (one patient),
which resulted in inadequate visual
ization of the inguinal area.
The most striking result of this
surgery was the patients’ lack of
pain. All patients were completely
mobile soon after returning from
the operating room. The first 20
patients in the study were given one
dose of Demerol intramuscularly if
necessary. However, most were ma
naged successfully with Talwin, 50
mg orally. There was no wound
infection. On follow-up, ranging
from 2 to 10 months, there was no
evidence of recurrence, and no pa
tient complained of discomfort. The
Marlex pledgets could not be palCJS, VOL. 36. NO. 4. AUGUST 1993
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pated, and there were no complaints
of recurrent bulging. All patients
who were employed returned to
their work activity within 1 week.
Some patients in sedentary occupa
tions admitted to returning to work
within 3 days.

Discussion
With a laparoscopic approach to
the repair of inguinal hernias, pa
tients suffer much less discomfort
than those treated by more conven
tional means, and they resume nor
mal activities earlier. Thus, they can
become productive members of soci
ety earlier than those who undergo
more conventional repairs, who may
require up to 6 weeks of convales
cence.
With this particular technique,
the posterior inguinal wall is both
buttressed and strengthened by
Marlex mesh. One would expect the
Marlex to be incorporated into a
layer of fibrosis, thus preventing
further herniation. By avoiding su
tures approximating tissues that
have become spread apart due to
anatomical failure or the recurrent
dilatational effect of the hernia and
sac, the surgeon can provide more
comfort for the patient.
The use of prosthetic mesh in the
repair of hernias in the inguinal
region may be controversial.2 How
ever, in a large series, Lichtenstein,
Shulman and Amid3 used mesh ex
clusively without any serious reper
cussions, as in our series. Mesh has
also been used by Gerr4 and Popp5
without significant problems.
In this series, inguinal hernias
were classified only as indirect or
direct. The treatment for both was
essentially the same because we
believe that the insertion of a large
enough mesh covers both areas of
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potential weakness. No attempt was
made to suture the mesh.
Very few series of laparoscopic
inguinal herniorrhaphy have been
reported to date, and this study
represents an early series of unse
lected consecutive cases. With re
spect to recurrence, the follow-up
time in this series, as in others, is
short, so the procedure must be
considered to be in a state of devel
opment. However, none of our pa
tients have had recurrent hernias so
far.
We believe that laparoscopy is
the approach of the future for the
treatment of this common condi
tion. With the almost total lack of
patient discomfort, a low infection
rate and possibly an acceptable re
currence rate, this procedure or a
modification of it may well become
the operation of choice for inguinal
hernia. We believe that as experi
ence is gained and patient numbers
increase, this operation will join
that of laparoscopic cholecystecto
my in patient demand.
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INDICATIONS AND CLINICAL USE
VASOTEC® is indicated in the treatment of essential or renovascular
hypertension; usually administered in association with other drugs,
particularly thiazide diuretics. Consider the risk of angioedema (see
WARNINGS). Normally used when a diuretic or beta-blocker was ineffective
or associated with unacceptable adverse effects. Can also be tried as initial
agent where a diuretic and/or beta-blocker is contraindicated or could
cause serious adverse effects.
Oral enalapril is also indicated in the treatment of congestive heart failure,
as adjunctive therapy in patients not responding adequately to digitalis and
diuretics.

Use of ACE inhibitors during the second and third trimesters of
pregnancy can cause injury or death of a developing fetus.
When pregnancy is detected, discontinue VASOTEC® as soon as
possible (see WARNINGS; Use in Pregnancy).
VASOTEC® I.V. (enalaprilat) is an active metabolite of enalapril; the onset
of action after administration occurs within 15 minutes, with the maximum
effect within 1 to 4 hours.
VASOTEC® I.V. is indicated for the treatment of hypertension when oral
therapy is not practical. VASOTEC® I.V. has been studied with only one
other antihypertensive agent, furosemide, which showed additive effects on
blood pressure. Due to insufficient experience in the treatment of acceler
ated or malignant hypertension, VASOTEC® I.V. is not recommended in
such situations (see DOSAGE and ADMINISTRATION).

CONTRAINDICATIONS
Hypersensitivity to any component; history of angioneurotic edema related
to ACE inhibitor therapy.

WARNINGS
Angioedema, with laryngeal edema and/or shock, have been reported
and may be fatal. In such cases, discontinue drug promptly and observe
patient until swelling subsides. Swelling confined to the face, lips, and
mouth usually resolves without treatment, although antihistamines may be
useful in relieving symptoms. However, where there is involvement of the
tongue, glottis and larynx, likely to cause airway obstruction, prompt
administration of subcutaneous adrenaline (0.5 mL 1:1000) may be
indicated. Patients with a history of angioedema, unrelated to ACE inhibitor
use, may be at increased risk (see CONTRAINDICATIONS).
Symptomatic hypotension has occurred, usually during initial therapy
or when the dose was increased, and is more likely in patients who are
volume-depleted. In patients with severe congestive heart failure, excessive
hypotension may be associated with oliguria and/or progressive azotemia.
For patients in whom the excessive hypotension could result in severe or
fatal complications, i.e. those with severe congestive heart failure, ischemic
heart or cerebrovascular disease - start therapy under close medical
supervision, usually in a hospital. Such patients should be followed closely
for the potential fall in blood pressure during first two weeks of therapy or
when enalapril or a diuretic is increased. If hypotension occurs, place
patient in supine position and if needed, administer IV infusion of normal
saline. A transient hypotensive response is not a contraindication to further
doses of enalapril or enalaprilat.

Neutropenia/agranulocytosis and bone marrow depression have been
caused by ACE inhibitors. Current experience with enalapril shows
incidence to be rare. Consider periodic monitoring of white blood cell
counts in patients with collagen vascular disease and renal disease.
Use of ACE inhibitors in pregnancy can cause fetal and neonatal
m orbidity and m ortality. When pregnancy is detected, discontinue
VASOTEC® as soon as possible. Rarely, no alternatives to an ACE inhibitor
will be found and mothers should be apprised to the potential hazards to
the fetus. Ultrasound should be performed to assess fetal development,
well-being and volume of amniotic fluid. If oligohydramnios is observed,
discontinue VASOTEC® unless lifesaving for the mother. A non-stress test
and/or a biophysical profiling may be appropriate however, if concerns
persist, a contraction stress testing should be considered. O ligo
hydramnios may only appear after fetus has sustained irreversible injury.
Closely observe infants exposed in uteroio ACE inhibitors for hypotension,
oliguria and hyperkalemia, and initiate appropriate corrective medical
procedures.
Human Data: Exposure to ACE inhibitors during second and third
trim esters has been associated w ith hypotension, neonatal skull
hypoplasia, anuria, reversible or irreversible renal failure and death of the
fetus. O ligohvdram nios, associated w ith fetal lim b contractures,
craniofacial deformation, and hypoplastic lung development also has been
reported. Prematurity and patent ductus arteriosus also reported but
unknown if due to ACE inhibitor use. It is not known whether exposure
limited to the first trimester can adversely affect fetal outcome.

PRECAUTIONS
Impaired renal function: Renal function should be assessed before
initia tin g therapy w ith enalapril or enalaprilat. Patients w ith renal
insufficiency may require reduced or less frequent doses, and their renal
function must be monitored appropriately (see DOSAGE). Renal failure,
which has been reported mainly in patients with severe congestive heart
failure or underlying renal disease including renal artery stenosis, is
usually reversible when treated promptly.
Some hypertensive patients with no apparent renal disease have developed
increases in BUN and creatinine while on concurrent diuretic/ enalapril
therapy. Dosage reduction or discontinuation of one or both drugs may be
required.
®Trademark Merck & Co.. Inc./Merck Frosst Canada Inc., R.U.

H yp e rkalem ia: In clinical trials, hyperkalemia (>5.7 m m ol/L) was
observed in approximately 1% of hypertensive patients, and caused
discontinuation of therapy in 0.28% of such patients. Risk factors for
hyperkalemia development may include renal insufficiency, diabetes
m ellitus, and concomitant use of agents to treat hypokalemia (see
ADVERSE REACTIONS).
Valvular Stenosis: Theoretically, patients with aortic stenosis, who do
not develop as much afterload reduction, might be at risk of decreased
coronary perfusion when treated with vasodilators.
S urgery/A naesthesia: During major surgery or anaesthesia with
hypotensive agents, enalapril blocks angiotensin II formation secondary to
compensatory renin release. Hypotension that develops due to this
mechanism can be corrected by volume expansion.
Im paired liver function: Hepatitis, jaundice (hepatocellular and/or
cholestatic),elevation of liver enzymes and/or serum bilirubin, which have
occurred in patients with or without pre-existing liver abnormalities, were
usually reversed on discontinuation of enalapril or enalaprilat. For any
unexplained symptoms, particularly within the first months of treatment, a
full set of liver function tests and other necessary investigations are recom
mended. Consider discontinuation of enalapril or enalaprilat when
appropriate. Use enalapril or enalaprilat with particular caution in patients
with pre-existing liver abnormalities. Obtain baseline liver function tests
before initiating drug and monitor response and metabolic effects closely.
Cough: A dry, persistent cough has been reported, which usually
disappears after withdrawal or lowering the dose of enalapril or enalaprilat.
Nursing mothers: Enalapril and enalaprilat are secreted in human milk in
trace amounts therefore, nursing should be interrupted.
Pediatric use: This use is not recommended because enalapril and
enalaprilat have not been studied in children.
Hemodialysis patients: Anaphylactoid reactions have been reported
w ith high-flux membranes (eg. polyacrylonitrile [PAN]) and treated
concomitantly with an ACE inhibitor. If symptoms such as nausea,
abdominal cramps, burning, angioedema, shortness of breath and severe
hypotension occur, stop dialysis immediately. The symptoms are not
relieved by antihistamines and the use of a different type of dialysis
membrane or class of antihypertensive agent should be considered.
Drug Interactions
Hypotension - Patients on Diuretic Therapy: Particularly when
diuretics recently initiated, patients occasionally experience hypotension
after initiating therapy with enalapril or enalaprilat. To minim ize the
hypotensive effects, discontinue the diuretic or increase the salt intake prior
to starting the drug. If the diuretic cannot be discontinued, patients should
be placed under close medical supervision for at least one hour after the
initial dose of enalaprilat (see WARNINGS).
Agents Increasing Serum Potassium: Since enalapril and enalaprilat
decrease aldosterone production, elevation of serum potassium may occur.
Diuretics such as spironolactone, triamterene or amiloride, or potassium
supplements should be given cautiously for documented hypokalemia only
and should be monitored frequently. Potassium containing salt substitutes
should be used with caution.
Agents Causing Renin Release: Diuretics, for example, augment the
antihypertensive effect of enalapril and enalaprilat.
Agents Affecting Sympathetic Activity: Ganglionic blocking agents
or adrenergic neuron blocking agents, for example, may be used with
caution. Beta-adrenergic blockers add some further antihypertensive effect
to enalapril.
Lithium Salts: Lithium clearance may be reduced: therefore, monitor
serum lithium levels carefully if they are administered.

ADVERSE REACTIONS
VASOTEC®: In controlled clinical trials involving 2314 hypertensive
patients and 363 heart failure patients, the most severe adverse reactions
were: angioedema (0.2%), hypotension (2.3%) and renal failure (5 cases).
In hypertensive patients, hypotension occurred in 0.9% and syncope in
0.5% , with a discontinuation rate of 0.1% . In heart failure patients,
hypotension occurred in 4.4% and syncope in 0.8% , with a discon
tinuation rate of 2.5%. The most frequent clinical adverse reactions in
controlled clinical trials were: headache (4.8%), dizziness (4.6%) and
fatigue (2.8%). Discontinuation of therapy was required in 6.0% of the
2677 patients.
Hypertension
%

%

(2314 Patients)

(3 6 3 P a tie n ts )

CARDIOVASCULAR
Hypotension
Chest Pain
Palpitations
Myocardial Infarction, Acute
Myocardial Infarction, Recurrent
GASTROINTESTINAL
Nausea
Vomiting
Dysphagia
Diarrhea
Abdominal pain
RENAL
Renal failure
Oliguria
Proteinuriat
DERMATOLOGIC
Rash
Pruritus
NERVOUS SYSTEM
Headache
Dizziness
Insomnia
Nervousness
Somnolence
Paresthesia
ALLERGIC
Cough
Angioedema
HEMATOLOGIC
Anemia
Leukopenia
MISCELLANEOUS
Muscle cramps
Dyspnea

Heart Failure

0.9
0.9
0.6
0.2
—

4.4
1.7
0.3
0.6
0.3

1.4
0.8
0.1
1.4
0.7

1.1
1.7

0.1
1 case
0.1

—

3.0
1.4

MISCELLANEOUS (cont'd)
0.7
Hyperhidrosis
0.4
0.3
Impotence
1.4
3.0
Fatigue
0.4
0.3
Taste disturbance
t Defined as >1 g/24h or >0.5 g/12h on two consecutive measurements,
at least one month apart.
ABNORMAL LABORATORY FINDINGS
Hyperkalemia: (see PRECAUTIONS).
Creatinine, Blood Urea Nitrogen: Increases were reported in about
20% of patients with renovascular hypertension and about 0.2% of patients
with essential hypertension on enalapril alone. Increases, which usually
were reversible upon discontinuation of enalapril or concomitant therapy,
were reported in 9.7% of heart failure patients who were receiving diuretics
and/or digitalis.
Hem oglobin and Hematocrit: Decreases (mean approximately 0.34
g% and 1.0 vol% , respectively) occurred frequently, but were rarely of
c lin ic a l im portance. In clin ic a l tria ls , less than 0.1% of patients
discontinued therapy due to anemia.
Hepatic: Elevations of liver enzymes and/or serum bilirubin have occurred
(see PRECAUTIONS).
ADVERSE REACTIONS REPORTED IN UNCONTROLLED TRIALS
AND/OR MARKETING EXPERIENCE
W ith an in cid en ce of 0 .5 to 1 % : Insomnia, im potence, renal
dysfunction, renal failure and oliguria.
W ith an incidence < 0.5% :
Cardiovascular: Myocardial infarction or cerebrovascular accident,
possibly secondary to excessive hypotension in high risk patients (see
WARNINGS); cardiac arrest; pulmonary embolism; rhythm disturbances;
angina pectoris. G a s tro in te s tin a l: Anorexia; ileus; pancreatitis;
dyspepsia; constipation. Hemopoeitic: Neutropenia; thrombocytopenia;
bone marrow depression. Hepatic: Liver function abnormalities; hepatitis;
jaundice (hepatocellular and/or cholestatic). N erv o u s S y s te m /
Psychiatric: Vertigo; depression; confusion; ataxia. R esp irato ry:
Bronchospasm/asthma; rhinorrhea. O ther: Erythema m ultiform e;
exfoliative dermatitis; Stevens-Johnson syndrome; toxic epidermal
necrosis; urticaria; photosensitivity; alopecia; flushing; tinnitus; hearing
impairment; glossitis; blurred vision. A symptom complex has been
reported w hich may include fever, serositis, v a sc u litis, m yalgia,
arthralgia/arthritis, a positive ANA, elevated erythrocyte sedimentation rate,
e o s in o p h ilia and leuko cytosis. Rash, p h o to se n sitiv ity or othe r
dermatologic manifestations may occur. These symptoms have disap
peared after discontinuation of therapy.
LABORATORY TEST FINDINGS: Hyponatremia
VASOTEC® I.V .: Since enalapril is converted to enalaprilat, those
adverse reactions associated with VASOTEC® tablets might also be
expected to occur with VASOTEC® I.V. The incidence of symptomatic
hypotension is 3.4% with VASOTEC® I.V. Other adverse experiences
occurring in greater than 1 % of patients were headache (2.9%) and nausea
(1.1 %). Adverse reactions occurring in 0.5 to 1.0% of patients in controlled
clinical trials include myocardial infarct, fatigue, dizziness, fever, rash and
constipation.
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SYMPTOMS AND TREATMENT OF OVERDOSAGE
Limited human data are available. The most likely manifestation of
overdosage would be hypotension, which can be treated by I.V. infusion of
normal saline solution. Enalaprilat may be removed from the general
circulation by hemodialysis.

DOSAGE AND ADMINISTRATION
VASOTEC® FOR ORAL ADMINISTRATION ONLY
Dosage must be individualized. The absorption of enalapril maleate is not
affected by food.
HYPERTENSION
Initiation of enalapril requires consideration of extent of blood pressure
elevation, salt restriction and recently used antihypertensive agents, the
dosage of which may need to be adjusted.
The recommended initial dose of enalapril maleate in patients not on
diuretics is 5 mg once a day. Adjust dosage according to blood pressure
response; the usual range is 10 to 40 mg daily, in a single dose or divided
in two doses. Some patients on once-daily dosage may have diminished
antihypertensive effect toward the end of dosing interval and require an
increase in dosage, or twice daily administration. If blood pressure is not
controlled, a diuretic may be added. Raising the daily dose above 40 mg is
not recommended because adverse reactions may be increased.
Occasionally symptomatic hypotension may occur following the initial
dose, more likely in patients currently taking a diuretic. Therefore, if
possible, discontinue the diuretic two to three days before initiating
enalapril therapy (see WARNINGS). If the diuretic cannot be discontinued,
use an initial dose of 2.5 mg.
In the absence of sufficient experience in the treatment of accelerated or
malignant hypertension, enalapril is not recommended in such situations.
Dosage in the Elderly (over 65 years): Start at 2.5 mg daily. Some
elderly patients may be more responsive than younger patients.
Dosage Adjustment in Renal Im pairm ent: (see PRECAUTIONS Hemodialysis patients)
Guidelines for reducing doses in hypertensive patients:

0.6
—

—
Renal Status

1.4
0.4

1.9
1.4

5.2
4.3
0.5
0.6
0.6
0.6

2.2
6.6
0.3

1.3
0.2

14
—

0.1
1 case

—

0.6
0.6

—
—

—

—
0.3
1.1

Normal renal
function
Mild impairment
Moderate to
severe impairment
Dialysis patients

Creatinine
Clearance
m L/m in(m L/s)
> 80m L/m in
(>1.33 mlVs)
£80> 3 0 m L /m in
(<1.33 >0.50 mL/s)
< 30m L/m in
(<0.50 mL/s)

Initial Dose
mg/day

When in itia tin g enalapril consider the recent d iu re tic therapy and
possibility of severe salt/ volume depletion. Before beginning enalapril
reduce diuretic therapy if possible.
The recom mended in itia l d a ily dose is 2.5 mg. W h ile m anaging
sym ptom atic hypotension, increase dose gradually, depending on
individual response, to the usual maintenance dose of 10-20 mg daily,
given in a single dose or divided in two doses. This dose titration may be
performed over a two- to four-week period, or more rapidly if indicated by
residual signs and symptoms of heart failure. The maximum daily dose is
40 mg.
VASOTEC® I.V . FOR INTRAVENOUS ADM IN ISTRATION ONLY
VASOTEC® I.V. vials should be inspected visually and should not be used
if particulate matter or discoloration is observed.
VASOTEC® I.V. may be administered intravenously as supplied, or mixed
with up to 50 mL of one of the following diluents:
5% Dextrose Injection
0.9% Sodium Chloride Injection
0.9% Sodium Chloride Injection in 5% Dextrose
5% Dextrose in Lactated Ringer’s Injection
Diluted solutions should be used within 24 hours.
The dose is 1.25 mg every 6 hours administered intravenously over at least
5 minutes. A clinical response is usually seen within 15 minutes. Peak
effects after the first dose may not occur for up to four hours after dosing.
The peak effects of the second and subsequent doses may exceed those of
the first.
No dosage regimen for VASOTEC® I.V. has been clearly demonstrated to
be more effective in treating hypertension than 1.25 mg every 6 hours.
However, in controlled clinical studies in hypertension, doses as high as 5
mg every 6 hours were well tolerated for up to 36 hours. There has been
inadequate experience with doses greater than 20 mg per day.
In studies of patients with hypertension, VASOTEC® I.V. has not been
administered for periods longer than 48 hours. In other studies, patients
have received VASOTEC® I.V. for as long as 7 days.
The dose for patients being converted to VASOTEC® I.V. from oral therapy
for hypertension w ith enalapril maleate is 1.25 mg every 6 hours
administered intravenously over at least 5 minutes. For conversion from
intravenous to oral therapy, the recommended initial dose of VASOTEC®
tablets is 5 mg once a day w ith subsequent dosage adjustm ents as
necessary.
Patients on Diuretic Therapy
For patients on diuretic therapy, the recommended starting dose for
hypertension is 0.625 mg adm inistered intravenously over at least
5 minutes. A clinical response is usually seen within 15 minutes. Peak
effects after the first dose may not occur for up to 4 hours after dosing,
although most of the effect is usually apparent within the first hour. If after
1 hour there is an inadequate clinical response, the 0.625 mg dose may
be repeated. Additional doses of 1.25 mg may be administered at 6 hour
intervals.
For conversion from intravenous to oral therapy, the recommended initial
dose of VASOTEC® tablets for patients who have responded to 0.625 mg of
enalaprilat every 6 hours is 2.5 mg once a day with subsequent dosage
adjustment as necessary.
Dosage Adjustment in Renal Im pairm ent
The usual dose of 1.25 mg of enalaprilat every 6 hours is recommended for
patients with a creatinine clearance >30 m l/m in [> 0.50 m L/s] (serum
creatinine up to approximately 3 mg/dL [265.2 pmol/L]). For patients with
creatinine clearance <30 m L/m m [< 0 .5 0 m L/s] (serum creatinine
>3 mg/dL [£ 265.2 pmol/L]), the initial dose is 0.625 mg (see WARNINGS).
If after 1 hour, there is an adequate clinical response, the 0.625 mg dose
may be repeated. Additional doses of 1.25 mg may be administered at
6 hour intervals.
For dialysis patients, the initial dose should be 0.625 mg every 6 hours,
(see PRECAUTIONS - Hemodialysis patients).
For conversion from intravenous to oral therapy, the recommended initial
dose of VASOTEC® is 5 mg once a day for patients w ith creatinine
clearance >30 mL/min [>0.50 mL/s] and 2.5 mg once daily for patients with
creatinine clearance <30 mL/min [<0.50 mL/s], Dosage should then be
adjusted according to blood pressure response.

AVAILABILITY OF DOSAGE FORMS
Barrel-shaped, biconvex tablets, engraved with code number on one side
and VASOTEC on other.
VASOTEC® 2.5 mg - yellow, scored, engraved 14.
VASOTEC® 5 mg - white, scored, engraved 712.
VASOTEC® 10 mg - rust-red, engraved 713.
VASOTEC® 20 mg - peach, engraved 714.
All strengths available in bottles of 100 tablets.
VASOTEC® I.V. 1.25 mg per mL, is a clear, colourless solution and is
supplied in vials containing 2 mL.
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Laparoscopic Versus Open
Cholecystectomy: a Matched Study
Juan R. Sanabria, MD; Pierre A. Clavien, MD; Robert Cywes, MD; Steven M. Strasberg, MD, FRCS
To determine the efficacy of laparoscopic cholecystectomy (LC) in the treatment of
gallstone disease, all patients who underwent elective surgery for cholelithiasis
during three consecutive periods (1989, 1990 and 1991) were studied. There were
121 patients in each period. All patients in the first period underwent open
cholecystectomy (OC), whereas 70 (58%) patients underwent laparoscopic
procedures in the second period (OC-LC). LC was the treatment of choice in the
third period. Multiple factors, including sex, age, clinical and biochemical
presentation of the disease and modified Apache II score were comparable among
the three groups. The authors found significant differences in length of
hospitalization (6.4 ± 4.2 days in the OC group, 3.6 ± 2.4 days in the OC-LC group
and 2.4 ± 1 .7 days in the LC group, p < 0.01 when compared with the OC group)
and return to work after surgery (5.8 ± 2.8 weeks, 2.8 ± 1 .2 weeks and 1.3 ± 1.8
weeks respectively, p < 0.01 when compared with the OC group). There was no
significant difference in postoperative complications among the groups, but
complications in the OC patients were more severe. Although operative time
increased significantly after the introduction of LC, it returned to the range of OC
after 36 procedures. Nine patients (5%) with LC required conversion to OC. Benefits
of LC include a shorter hospital stay and a shorter recovery period. There were no
deaths, very low morbidity, a substantial decrease in overall cost and a high degree
of patient satisfaction with LC.

Dans le but de mesurer l’efficacite de la cholecystectomie laparoscopique (CL) dans
le traitement de la lithiase biliaire, on a etudie tous Ies patients qui subirent une
intervention chirurgicale non urgente pour des calculs au cours de trois periodes
consecutives (1989, 1990,1991). Cent vingt-et-un patients furent operes au cours
de chaque periode. Tous les patients de la premiere periode subirent une
cholecystectomie ouverte (groupe CO), alors que 70 % des patients de la seconde
periode subissaient une operation par voie laparoscopique (groupe CO-CL). La CL
etait devenue le traitement de premier choix au cours de la troisieme periode
(groupe CL). De multiples facteurs tels que le sexe, l’age, le tableau clinique et
biochimique et la cote a l’echelle Apache II modifiee etaient comparables entre les
trois groupes. Les auteurs ont constate des differences significatives entre les
groupes en ce qui a trait a la duree de l’hospitalisation (6,4 ± 4,2 jours pour le
groupe CO, 3,6 ± 2,4 jours pour le groupe CO-CL et 2,4 ± 1 ,7 jours pour le groupe
CL, p < 0,01 comparativement au groupe CO) et au retour au travail apres
l’operation (respectivement, 5,8 ± 2,8 semaines, 2,8 ± 1,2 semaines et 1,3 ± 1,8
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semaines, p < 0,01). II n’y a eu aucune difference significative entre les groupes en
ce qui concerne l’incidence des complications postoperatoires, bien que les
complications dans le groupe CO aient ete plus graves. Meme si la duree des
interventions s’est accrue sensiblement apres l’introduction de la CL, elle est
revenue a l’interieur des ecarts de la CO apres 36 operations. Neuf patients du
groupe Cl necessiterent un changement pour une CO. Les avantages de la CL
comprennent une hospitalisation plus breve et une convalescence plus courte. Avec
la CL, aucun deces n’a ete enregistre, la morbidity fut tres faible, les couts
sensiblement diminues et le degre de satisfaction des malades tres eleve.

L

aparoscopic cholecystectomy
(LC) has revolutionized the
treatment of cholelithiasis. Reports
of pioneering surgeons in this
area1-4 have provided evidence of
the benefit of this technique and
have led to its widespread adoption.
However, no randomized studies
comparing the new technique to
open cholecystectomy (OC) have
been published. Thus, the extent of
improvement in patients requiring
cholecystectomy can only be rough
ly estimated.
A standard study design requir
ing randomization to compare LC
to OC is particularly difficult at
present because patients are ex
tremely reluctant to have OC once
they are aware of the potential
benefits of LC.5 To obtain the most
conclusive approach in comparing
these treatments, we have compared
three populations with the same
number of patients who underwent
elective cholecystectomy during
three consecutive time periods, that
is the year before the introduction
of LC in our institution, the year of
the introduction of LC, including
both OC and LC, and the year after
the introduction of LC, in which LC
was the elective treatment of choice
for cholelithiasis. For such a com
parison to be meaningful and to be
able to attribute differences in the
results to the use of LC in some of
the groups, it is first necessary to
demonstrate that the three groups
were well matched at the time of
treatment.
The purpose of this study was to
determine the benefits and disad
vantages of LC over OC in our

study population, to report the ex
perience of LC in our institution
and to estimate the possible dura
tion of the learning curve of LC in
our group.

Patients and Methods
For several years we have pro
spectively collected detailed data on
all patients having elective chole
cystectomy on our service as part of
ongoing studies on gallstone patho
genesis. Preoperative and postoper
ative protocols as well as interpreta
tion of clinical, biochemical and
radiologic data were completed or
reviewed by one surgeon (S.M.S.).
The three groups of patients were
formed as follows. LC was intro
duced in our institution in May
1990, and in that year 70 LCs were
performed. In 1990, all patients
who had elective cholecystectomy
by either method from the date that
LC was initiated until the end of the
year were included. This group
comprised 121 patients, 70 LC and
51 OC. To obtain a potentially
comparable group from patients op
erated on in 1989, a consecutive
group of patients having elective
OC were gathered beginning at the
end of the year and moving back
ward in the protocols of that year
until 121 cases were obtained. The
same number of patients were ob
tained during a similar period in
1991, in which LC was the first
choice for the management of
cholelithiasis.
To demonstrate that the groups
were well matched for type of pa

tient and disease severity, compari
sons between groups were made for
numerous variables. Most criteria
used for comparison will be obvious
but some require definition. Diabet
ics were defined as patients who
were taking insulin or an oral hypo
glycemic agent or patients with a
fasting serum glucose level greater
than 11 mmol/L on one occasion
or 7.8 mmol/L on two occasions in
the same hospitalization as their
surgery, in the absence of fever,
corticosteroid therapy or intrave
nous glucose infusion.6 Obesity was
defined as a patient whose body
mass index (weight/height2 in
k g /m 2) was greater than 28 for all
ages and for both sexes.7
As a guide to the severity of
disease we used a modified Apache
II system in which only the age and
chronic disease elements of the
standard classification were used.89
Three levels are possible in this
modified classification 0 to 5, 6 to 9
and 10 and above. Since the maxi
mum score for age is 6 (75 years
and older) and the maximum score
for intercurrent disease is 5, the
maximum overall score in this scale
is 11.
Our technique of LC has been
described elsewhere10 and was simi
lar to that of Reddick and Olsen.4 In
those selected for LC, preoperative
endoscopic retrograde cholangio
pancreatography (ERCP) was done
in the presence of abnormal liver
function test results, a dilated com
mon bile duct (CBD) on ultrasonog
raphy or a history compatible with
choledocholithiasis, such as jaun
dice or pancreatitis. If bile duct
CJS, VOL. 36, NO. 4, AUGUST 1993
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stones were found at ERCP, an
endoscopic sphincterotomy and
stone extraction were done. An op
erative cholangiography was done
on a selective basis in both the OC
and LC groups, and it was attempt
ed only in patients found to have a
cystic duct greater than 2 mm at
the time of surgery or if there was a
question of anatomical variance.
An important outcome measure
is surgical complications. To evalu
ate complications we used a new
classification of surgical complica
tions that we have recently present
ed.8 Briefly, complications are grad
ed from I to IV. Grade I is a minor
complication, such as postoperative
atelectasis, that requires only bed
side treatment or can be corrected
by the patient. Grade 11 is a compli
cation requiring more extensive in
tervention, such as systemic antibi
otics or invasive therapeutic proce
dures like percutaneous drainage of
an abscess. Grade III complications
are those associated with residual
disability, such as myocardial dam
age or ductal injury. Grade IV indi
cates death from a complication of
the surgery.
Every patient was assessed at
follow-up 6 weeks after the surgical
procedure. In 40 patients chosen at
random in each group, a more
extensive assessment was done of
the patient’s quality of life and
satisfaction with the procedure.
The major outcome measures se
lected for comparing the three
groups of 121 patients were length
of hospital stay, operative time,
complications, time of return to
work, quality of life and satisfac
tion. Finally, the effect of the intro
duction of LC on the cost of health
care in Ontario was estimated.
Statistical analysis was by Stu
dent’s t-test, x2 (contingency table
analysis) or a nonparametric test
depending on the type of variable. A
probability of less than 0.05 was
taken as the limit of significance.
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Data are presented as means ± the
standard deviation.

the patients were similar in terms of
pain severity, timing of attacks and
associated symptoms such as vomit
ing, fever and jaundice. An attack
was considered “severe” when the
patient came to an emergency de
partment to obtain analgesia during
an episode of pain. Preoperative
liver function test results were simi
lar among the groups. In the LC
group, the mean duration of symp
toms before surgery was longer, but
the difference was not significant.
The trend to a longer period of
symptoms before surgery in this
group might have been caused by
some patients who were reluctant

Findings
A comparison of the three patient
groups is presented in Table I under
the headings of clinical observa
tions, findings of laboratory tests,
modified Apache score and ul
trasonographic evaluation. Patients
were found to be well matched for
age, sex, number of pregnancies
and intercurrent disease. Most pa
tients had had episodes of biliary
colic, and among the three groups

Table I. Comparison of the Patient Groups
Group
Information
Clinical observations
Sex, M/F
Age, yr
Obesity, no.
Diabetes, no.
History of biliary
colic, no.
Time from first
episode of pain to
operation, mo
Total attacks, no.
Severe attacks, no.'
Food causes pain, no.
Nausea, no.
Vomiting, no.
Fever, no.
Jaundice, no.
Laboratory results
Elevated aspartate
aminotransferase, no.
Elevated gamma glutamyl
transferase, no.
Elevated alkaline
phosphatase, no.
Risk score - modified
Apache score, no.
0 -5
6 -9
> 10
Ultrasonography
Positive for
gallstones no.
Polyps, no.
Common bile duct
exploration, no.

OC (1989)
(n = 121)

0C-LC (1990)
(/»= 121)

LC (1991)
(zr= 121)

28/93
45.3 ± 15.9
19
2

26/95
44.3 ± 14.7
18
2

18/103
46.3 ± 13.6
33
3

120

121

121

22.9 ± 28.1
10.9 ± 2 2 .7
1.89 ± 1 .9 3
57
59
39
6
5

20.7 ± 26.3
13.0 ± 2 0 .4
2.68 ± 3.43
73
75
53
8
7

32.9 ± 31.1
10.3 ± 14.4
3.01 ± 3.29
93
89
52
6
7

6

6

3

18

16

15

20

28

18

98
16
7

105
12
4

94
19
8

118
2

116
1

120
3

7

8

6t

OC = open cholecystectomy, LC = laparoscopic cholecystectomy
'Patient came to Emergency Department during an attack of pain.
flncludes four cases of preoperative endoscopic retrograde cholangiopancreatography with
papillotomy
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to have open surgery deciding to
have laparoscopic surgery.
The modified Apache II score
showed similar distribution of pa
tients in the three groups. Most
patients fell into the 0 to 5 range,
but a few in each group fell into the
two higher risk levels. In a recent
evaluation of over 1200 cases of
elective OC, patients with modified
Apache scores of 6 to 9 and 10 or
more had a much higher incidence
of grade II complications than pa
tients who had a score of 5 or
less.11 Therefore, it is important for
comparison in this study that the
Apache score distribution was simi
lar in all our groups. In summary,
the results show that our three
groups of patients were well
matched in every aspect of presen
tation and disease severity. Thus, it
is valid to compare the three groups
to determine the effect of LC on
overall outcomes.
During the collection of the data
it became clear that direct compari
son between LC and OC within the
LC-OC group would have been fal
lacious because there were statisti
cally significant differences in the
patients selected for LC versus OC
during the introduction of LC. Pa
tients selected for OC were more
likely to be male (male-to-female
ratio 1:3.55 versus 1:6.7), older
(53.9 ± 16.36 years versus 39.02 ±
10.61 years), more obese (13
[25.5%] patients versus 5 [7%] pa
tients) and to have a higher Apache
II score. Furthermore, patients with
a history of previous cholecystitis
or upper abdominal surgery were
more likely to have OC. Those
differences clearly are due to selec
tion criteria that were appropriate
at the beginning of a new surgical
procedure. This was not the case
during the following year, since
there was no difference in any pa
rameter between the LC group
(1991) and the OC group (1989).

charged within 24 hours of opera
tion.
There was a significant (p <
0.001, Student’s f-test) increase in
operative time with the introduction
of LC, from 94 ± 26 minutes in OC
group to 110 ± 39 minutes in the
OC-LC group. Operative time was
also evaluated over the study period
in the second group (Fig. 1). Inter
estingly, after the first 36 cases of
LC there was a decrease in the
operative time to one similar to that
of the OC group.
Nine (4.7%) LCs were converted

Comparison o f L C and OC

Hospital stay was considerably
shortened by the introduction of LC
(Table II). It was reduced from 6.4
± 4.2 days in the OC group to 2.4
± 1 . 7 days in the LC group (p <
0.001, Student’s f-test compared
with OC group). The difference in
hospital stay among groups was
largely due to the shorter stay after
LC (2 days). Since patients were
admitted on the day before surgery,
it is apparent that almost all pa
tients who underwent LC were dis

Table II. Length of Hospitalization, Operative Time and Postoperative Complications in the Three
Groups
Group
OC-LC (1990)

Patients, no.
Hospital stay, d
Operative time,
min
Postoperative
complications, no.
Grade 1
Grade II

OC (1989)

Total

OC

LC

LC (1991)

121
6.4 ± 4.2

121
3.7 ± 2.4*

51
5.5 ± 2.7

70
2.2 ± 0.6

121
2.4 ± 1.7

94 ± 2 6

110 ± 3 9

100 ± 3 6

119 ± 4 0

87 ± 3 0

7
4

3
10

4t
10t

1
0

10t
ot

*p < 0.01 when compared with OC group, Student's f-test
tContingency table analysis (x2 variation)

1990

1991

FIG. 1. Operative times for laparoscopic cholecystectomy (LC), expressed as mean
(by month), since its introduction. Curve has logarithmic correlation (r2). Plateau
was reached after 36 procedures. Thereafter, there were no significant changes in
operative times.
CJS, VOL. 36. NO. 4. AUGUST 1993
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to OC, four because of anatomic
uncertainty, three because on open
ing the cystic duct for cholangiog
raphy multiple small stones were
found that could not be completely
cleared, and two because of bleed
ing from the gallbladder bed. This
was easily controlled at open sur
gery, and no patient received blood
transfusion.
Four patients selected for LC had
a history of jaundice with slight
dilatation of the common bile duct
and elevated enzyme levels. Preop
erative ERCP was uncomplicated,
and sphinterotomy was done. Pa
tients then underwent LC, and their
follow-up has been uncomplicated.
The numbers of postoperative
complications were comparable
among the three groups, 11 in the
OC group, 14 in the OC-LC group
and 10 in the LC group (Table II).
However, there was a significant
difference in the severity of the
complications. They were more se
vere when OC was performed (Table
III).
There was a significant reduction
in the number of operative cholan
giographies performed during LC.
One patient in the LC group had
postoperative choledocholithiasis:
in this patient preoperative liver
function test results and the size of
the common bile duct on ul
trasonography were normal. At op
eration the gallbladder was large
and thick-walled with a very short
thick cystic duct. The gallbladder
was removed from its bed starting
at the fundus after division of the
cystic artery, and the cystic duct
was occluded with an Endoloop.
Operative cholangiography was not
attempted because of the shortness
of the cystic duct. Three months
postoperatively after a bout of pain,
a stone was removed from the CBD
by endoscopic sphincterotomy.
Quality of life and patient satis
faction were assessed in 40 patients
selected at random from each
334
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group. In the OC-LC group, there
was proportional representation of
the two procedures (Table IV). The

time at which patients returned to
work was 5.8 ± 2.8 weeks in the
OC group, 2.8 ± 1 . 2 weeks in the

Table III. Postoperative Complications in Three Groups of Patients Who Underwent
Cholecystectomy
Group
Complications

OC (1989)
(/» = 1 2 1 )

OC-LC (1990)
(o = 121)*

LC (1991)
(0 = 1 2 1 )

2
2
1
1
1
0

2
1
1t
0
0
0

2
1
1
0
5
1|

3
1

0
0

0
0

0
0
0
0
0

3
1
1
1
1

0
0
0
0
0

0
0
0

1
1
1

0
0
0

Grade 1
Fever
Urinary retention
Wound infection
Tinnitus
Ileus
Atrial fibrillation
Grade II
Pneumonia
Atrioventicular block
Premature ventricular
contractions
Atrial fibrillation
Angina
Lung embolism
Bronchospasm
Upper gastrointestinal
bleeding
Urinary tract infection
Morphine intoxication

*51 OC, 70 LC
tA subumbilical wound infection was the only complication after LC in this group.
tT his atrial fibrillation resolved after suspension of digoxin therapy without further complication.

Table IV. Follow-up of Three Groups of Patients After Cholecystectomy
Group
OC-LC (1990)
Patients, no.
Patients' concept
of operation, no.
Major
Minor
Return to work, wk
Return to normal
activities, mo
Patients' categori
zation of quality
of life after
operation, no.
Definitely better
Much better
Just better
The same
Worse
Patient would change
for another
operation, no.
Yes
No

OC (1989)

Total

OC

LC

LC (1991)

40

40

17

23

40

39
1
5.8 ± 2.8

23*
17
2.8 ± 1.2f

16
1
4.5 ± 1.7

7
16
1.6 ± 0 .7 2

8*
32
1.3 ± 1 .8 t

10.3 ± 7.3

4.8 ± 2 .2 t

7.7 ± 3.0

2.8 ± 1.6

2.97 ± 2.4t

7
19
8
5
1

11
16
10
3
0

3
6
5
3
0

8
10
5
0
0

9
20
7
4
0

27
13

14*
26

13
4

1
22

1*
39

*p < 0.01 when compared to OC group. Contingency table analysis (x 2 variation)
tStudent's f-test
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OC-LC group and 1.3 =t 1.8 weeks
in the LC group (p < 0.01, Stu
dent’s f-test compared with OC
group). Again the difference was
largely due to LC. Patients were
asked, “When did you return to
normal activity?” (i.e., starting to
drive, playing usual sports and sex
ual activity). There was considera
ble variability in the response to
this question, but there was a sig
nificant reduction in the time cited
by patients in the OC-LC and LC
groups compared with OC group
(Table IV). Similar improvements in
response in the same groups were
noted when patients were asked
about the concept of the surgery
and satisfaction with the operation.
There was no significant difference,
however, when patients were asked
if the operation had improved their
quality of life. In all groups, there
was clearly a trend to improvement
after the operation.
The effect of OC and LC on the
cost of health care (in Canadian
dollars) in our institution was esti
mated. The Ontario Health Insur
ance Plan (OHIP) covers the cost of
surgical procedures. The basic price
of a room is $663/daily. Therefore,
the basic cost of OC is $4243
(mean hospital stay for the OC
group being 6.4 days), and if the
cost of the increase in operative
time and disposables in LC during
its introduction is taken into ac
count, the cost of LC is $1941 or
$2302 less per patient than OC.
The evaluation of cost does not
include the indirect savings in
hours of labour by the patient’s
early return to work.

Discussion
Case series of LC are being
reported with increasing frequen
cy,1-5' n- 2o aji with encouraging re
sults. However, to evaluate any new
technology properly, comparison

with current therapy must be made,
in this case a comparison between
OC and LC. One approach to this
would be a prospective randomized
controlled trial. Although this may
be the most desirable method, it is
one that is difficult to institute once
patients become aware of the poten
tial advantages of LC.5 For that
reason we have attempted to exam
ine the effect of LC through the use
of matched groups in 3 consecutive
years.
The findings confirm that LC has
had a major impact on the morbidi
ty of surgery for cholelithiasis, re
ducing hospital stay and postopera
tive recovery time and resulting in
earlier return to work. There is also
improvement in patient satisfaction
with the procedure. The measures
of patient satisfaction must be inter
preted with the knowledge that
many patients who had OC were
contacted recently and were there
fore aware of the potential benefits
of LC. As a result the degree of
satisfaction of patients with OC
might have been influenced. LC
offers the patient less pain and
improved cosmetic results. Al
though patients in the LC group
tended to consider the procedure to
be minor and would not want a
different procedure, there was little
difference between groups with re
spect to improved quality of life.
Complications do occur with la
paroscopic cholecystectomy; even
deaths have been reported.1718 Di
rectly related complications of LC,
such as bile duct injury, bleeding,
bile leak, trocar injuries, subcutane
ous emphysema and spillage of
stones or bile during operation, can
be minimized by rigorous operative
techniques.21 In this setting, defini
tive identification of the structures
in the triangle of Calot is critical.
Also surgeons must convert to a
traditional OC at any time during
LC if difficulties arise.
This study was conducted from

the start of an LC program in one
hospital. Results of any new proce
dure are expected to improve with
time. Even in the short period of
this study, the operative time fell
substantially after the 36th LC to
levels comparable with the OC
group. This point is important,
since a more prolonged exposure to
anesthetics has been suggested as
one disadvantage of the LC tech
nique.16 The effects on hospital stay
and time for recuperation can be
expected to fall even further in the
total group of patients requiring
cholecystectomy as experience with
LC is gained. The psychologic ef
fect of the patient’s concept of the
procedure as being noninvasive may
also play a role in the postoperative
recovery.
We recommend selective intraop
erative cholangiography in the prac
tice of LC because it has been
shown to be effective in OC.22-26 A
meticulous evaluation of the pa
tient’s history, liver enzyme levels,
diameter of the common bile duct
on ultrasonography and diameter of
the cystic duct at surgery can iden
tify the patients at risk for having
common duct stones. Patients with
a clear history of choledocholithiasis, can be treated successfully by
preoperative endoscopic sphinc
terotomy. In the very isolated cases
of retained stones, postoperative
sphincterotomy may also be useful.
In summary, this study shows
that LC provides benefits to pa
tients requiring gallbladder surgery,
particularly in regard to length of
hospital stay, recovery time and
patient satisfaction.
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SESAP VII Critique / Critique SESAP VII
Item 52
Radionuclide scanning is the most sensitive test for the detection of acute cholecystitis. Technetium-labelled
isotopes are rapidly excreted by hepatocytes and flow is quickly seen into the common bile duct and the
duodenum. The gallbladder usually fills within 30 minutes after injection, although the test is continued for four
hours before concluding that cystic duct obstruction is present. An elevated bilirubin rarely interferes with this
technique. However, excretion of the isotope depends on functioning hepatocytes, and the scan is not useful for
patients with severe hepatic dysfunction.
Radionuclide scanning cannot reliably distinguish acute cholecystitis from a dysfunctional gallbladder
secondary to chronic cholecystitis, perforated peptic ulcer disease, acute hepatitis, or acute pancreatitis. Adverse
reactions are not more likely to occur in patients who have iodine allergies because the agents do not contain
iodine.
Radionuclide scanning has a sensitivity of 97% for detecting acute alcalculous cholecystitis, but specificity is
only 38%.
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Surgical and Postoperative Management
of Two Neonates With Necrotizing Fasciitis
C. Anthony Ryan, MB, MRCPI, MRCP(UK), FRCPC;* James Fischer, MD, FRCSC;t
Michael Gayle, MD, FRCPC;* Wanda Wenman, MD, FRCPC*
Two neonates who presented with necrotizing fasciitis (NF) secondary to omphalitis
were treated by radical excision of the anterior abdominal wall. Postoperatively,
renal failure in both children was managed by continuous arteriovenous
hemofiltration (CAVH). One child survived; the other died of sepsis. Serum lactate
levels, which were 10 to 15 times the normal levels in both infants postoperatively,
decreased rapidly in the survivor, but never approached normal levels in the infant
who died.
Although the best prospect for survival in neonatal NF remains prompt, radical,
surgical excision and is associated with a low threshold for repeat debridement,
modern supportive measures (including CAVH) may enhance survival.

Deux nouveau-nes souffrant de fasciite necrosante (FN) consecutive a une omphalite
ont ete traites par excision radicale de la paroi abdominale anterieure. En
postoperatoire, l’insuffisance renale chez les deux enfants fut traitee par
hemofiltration arterioveineuse continue (HAVC). Un enfant a survecu; l’autre est
decede de sepsie. L’acide lactique serique qui atteignait 10 a 15 fois les taux
normaux chez les deux enfants apres l’operation, a diminue rapidement chez le
survivant mais ne s’est jamais rapproche de la normale chez l’enfant qui est decede.
Meme si le meilleur espoir de survie chez le nouveau-ne souffrant de FN demeure
l’excision chirurgicale prompte et radicale et que cette intervention necessite
rarement qu’on ait a repeter le debridement, des techniques de soutien modernes
(comme l’HAVC) peuvent ameliorer la survie.

ecrotizing fasciitis (NF) is a
serious life-threatening condi
tion characterized by a rapidly
spreading necrosis of the fascia and
subcutaneous skin.1-3 It has been
recognized for over 100 years and
is associated with a death rate of
between 52%4 and 87.5%.5 How
ever, the condition is uncommon in
children.6 In adults and in children
beyond the neonatal period there is
usually an initiating injury, such as
surgery or minor trauma. By con
trast, most neonatal cases present
as omphalitis, which spreads along

N

an edematous plane above the deep
fascia and results in local necrosis
and severe systemic toxicity. We
report on two newborn infants who
had NF secondary to omphalitis,
and we describe the use of continu
ous arteriovenous hemofiltration
(CAVH) in their management.

Case Report
Case 1

A white, female infant was deliv

ered at a local hospital, at term, by
cesarean section because of mater
nal cephalopelvic disproportion.
She was discharged home after 3
days but was readmitted 4 days
later with erythema and induration
of the umbilicus and anterior ab
dominal wall. She was treated ini
tially with cloxacillin but subse
quently with vancomycin, cefotax
ime, metronidazole and tobramycin
when the omphalitis continued to
spread throughout the anterior ab
dominal wall. A needle aspirate of
the cellulitis grew Enterococcus and
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coagulase-negative Staphylococcus.
Multiorgan system failure developed
with increasing oxygen require
ments, renal failure, encephalopa
thy associated with seizures and a
diffuse intravascular coagulopathy.
She was intubated and then trans
ferred to the University of Alberta
Hospitals.
On the infant’s arrival, the anteri
or abdominal wall was indurated,
and black necrotic spots were noted
around the umbilicus. There was a
violaceous hue around the perine
um and lower abdominal wall.
There was no palpable crepitus. A
diagnosis of NF was made, and
radical excision of the anterior ab
dominal wall was performed, in
cluding a circular area of muscle 4
cm in diameter, of fascia 6 cm in
diameter and of skin 8 cm in diame
ter. The umbilical vessels to the
level of the hepatic origin and the
urachal remnant were excised. A
Vicryl patch was sutured over the
defect. The antibiotics were
changed to ampicillin, clindamycin
and cefotaxime.
Postoperatively, the infant was
anuric and had a marked lactic
acidosis (Fig. 1). Her hyperkalemia
(serum potassium level 8 mmol/L)
was treated with sodium bicarbon
ate, calcium and infusions while
emergency hemodialysis was ar
ranged. During hemodialysis, exter
nal chest wall compression and epi
nephrine were administered on six
occasions because of major hypo
tensive episodes. The serum potas
sium level was lowered to 3
mmol/L during hemodialysis; how
ever, the infant remained anuric
and acidotic and was started on
CAVH in the manner described by
Bishof and colleagues.7 The details
of CAVH are presented in Table I.
The infant was weaned from the
ventilator 8 days after surgery, at
which time CAVH was discontinued
because renal function had recov
ered. The anterior abdominal wall
338
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healed by granulation (Fig. 2), and
autologous skin grafting (75 cm2)
was performed in the 7th week with
a good cosmetic result. On patho
logical examination of the anterior
abdominal wall, the findings of in
flammation and necrosis involving
the skin and subcutaneous tissues
were consistent with NF. There was
also some muscle involvement, sug
gesting myositis or myonecrosis.
Clostridium perfringens was isolat
ed from the necrotic fascia removed
at the initial surgery.
Case 2
At 36 weeks’ gestation, a female
infant of native Canadian origin was
delivered by cesarean section be
cause of a breech presentation. At 1
week of age she presented with
periumbilical cellulitis, which was
treated with ampicillin, gentamicin
and later clindamycin. Two days
later she was transferred to the
University of Alberta Hospitals with
a diagnosis of NF (Fig. 3). A radical
dissection of the anterior abdominal
wall (3.5 X 5 cm) was performed,
and the umbilical vessels were iden

tified and excised. The defect was
closed with Vicryl mesh, which was
sutured to the fascia. An umbilical
swab grew C. perfringens, and the
antibiotics were changed to clin
damycin, metronidazole and gen
tamicin.
The postoperative period was
complicated by lactic acidosis (se
rum lactate level 14 mmol/L, nor
mal value less than 2 mmol/L;
[Fig. 1]) and a diffuse intravascular
coagulopathy (prothrombin time,
International Normalized ratio [INr]
2.6, partial thromboplastin time 53
s, fibrinogen level 1.0 g/L , platelet
count 3.0 X 109/ L and elevated
fibrinogen split products). Despite
the replacement of clotting factors
and the administration of fluids,
diuretics and low-dose dopamine,
the infant was in established renal
failure within 24 hours of surgery.
CAVH was initiated (Table I).
By the 3rd postoperative day, the
tissues around the original excision
appeared nonviable, and the level of
serum lactate remained elevated
(Fig. 1). The incision in the anterior
abdominal wall was extended to
approximately 10 cm in diameter.

FIG. 1. Comparison of serum lactate levels (normal values less than 2 mmol/L) in
case 1 (squares, survivor) and case 2 (diamonds, nonsurvivor).
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Although the perineal area also
looked necrotic, this was superficial
involvement only (Fig. 4a): the
deeper tissues were viable when the
superficial layers had been rubbed
away with a surgical scrub (Fig.
4b).
The serum creatinine level, which
was stable initially, began to in
crease 8 days after institution of
CAVH and of CAVH with countercurrent dialysis and 1.5% Dianeal
(Baxter-Travenol, Deerfield, 111.).
Nevertheless, progressive acute res
piratory distress, liver dysfunction
and encephalopathy developed, and
the infant required increasing ino
tropic support. Abdominal ul
trasonography demonstrated hypodense wedge-shaped lesions in the
spleen, possibly representing septic
emboli (Fig. 5). Subsequently, she

died of intractable respiratory and
cardiac failure. The parents refused
a request for an autopsy.

Discussion
It has been postulated that cellu
litis, NF and myonecrosis may re
flect a continuum of soft-tissue in
fection, progressing from involve
ment of the superficial skin to that
of deeper tissue areas by extension
along entry wounds or by tracking
of infection along vascular chan
nels. Antibiotic therapy in the ab
sence of surgery is likely to fail,
because of the inability of antibiot
ics to penetrate devitalized tissue
spaces. Thus, delay in surgical in
tervention is associated with a poor
outcome. However, even with sur

gery the outcome is still uncertain
in infancy. In a series of 11 cases,
four out of five infants with NF
who underwent surgery died within
24 hours from hemorrhage due to
disseminated intravascular coagula
tion and shock.1
The two infants described here
survived the immediate periopera
tive period because of the aggres
sive management of shock and coa
gulopathy. By lowering the in
creased serum potassium level, he
modialysis was immediately lifesav
ing in the first infant, although it
was associated with major hemody
namic instability. The options avail
able for the intermediate manage-

Table I. Demographic Characteristics, Clinical Course and Continuous Arteriovenous
Hemofiltration Detail in the Two Infants
Characteristics
Age, wk
Sex
Race
Predisposing factors
Interval between onset of
symptoms and surgery, d
Bacteriologic findings
Complications
Encephalopathy
Adult respiratory distress
syndrome
Cardiac dysfunction
Renal failure
Diffuse intravascular
coagulopathy (hemorrhage)
Treatment
No. of blood units
transfused daily
<6)
Gamma globulin given
intravenously
CAVH access, catheter size
Arterial
Venous
CAVH filter used
Mean ultrafiltrate rate, cm3/h
Duration of CAVH, d
Duration of CAVHD, d
Outcome

Case 1

Case 2

3
F
Caucasian
Premature rupture of membranes,
maternal endometritis

3
F
Native Canadian
None

7
Clostridium perfringens
Enterococcus, coagulasenegative Staphlococcus

4
Clostridium
perfringens

Yes

Yes

No
No
Yes

Yes
Yes
Yes

Yes

Yes

8 < 4d

4< 2d

Yes

Yes

Femoral, 4F
Femoral, 6F
Minifilter-plus*
10
7
0
Alive and well

Brachial, 3F
Femoral, 6F
Minifilter-plus*
19
8
2
Died, 11 d postop

*Amicon Division, Beverley, Mass. (0.015 m2 surface area)
CAVH = continuous arteriovenous hemofiltration; CAVHD = CAVH with counter-current dialysis

FIG. 2. Case 1: Anterior abdominalwall healing by granulation.

FIG. 3. Case 2: Necrotizing fasciitis of
periumbilical area.
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ment of anuria and acidosis and
perhaps for the removal of the
endogenous toxins produced by ne
crotic tissue in these critically ill
infants include peritoneal dialysis
and CAVH. Peritoneal dialysis was
not feasible in the presence of a
large abdominal-wall excision.
Thus, without CAVH the first in
fant would almost certainly have
died from complications of renal
failure. CAVH prolonged the clini
cal course in the second infant, who
subsequently died of sepsis and
multiorgan system failure.
The use of CAVH has now been
reported in infants and children
with acute renal failure from vari
ous causes,8 with heart failure after
open-heart surgery9 and with the
tumour lysis syndrome.10 CAVH has
been shown to improve respiratory
function in children with multiple
organ system failure.11 In adults it

has been used as an adjunct in the
treatment of sepsis.1213 In the cases
reported here, CAVH controlled the
effects of renal failure, may have
had beneficial effects on lung func
tion and endotoxin removal and
allowed sufficient fluids to be ad
ministered to meet caloric require
ments in the presence of renal fail
ure. Total parenteral nutrition was
necessary in both cases to replace
the ultrafiltrate.
Lactate levels have not previously
been reported in patients with NF.
Elevated lactate levels may repre
sent impaired metabolism and ex
cretion or increased production as a
result of postoperative oxygen debt,
sepsis or devitalized tissue.14-16 In
the first infant, the level of serum
lactate decreased to normal values
within 24 hours; this is consistent
with the findings of Waxman,
Nolan and Shoemaker,17 who

showed that lactate levels correlated
with estimated intraoperative oxy
gen debt in adults after surgery. We
measured simultaneous serum (22.5
mmol/L) and filtrate (27 mmol/L)
lactate levels, which gave a filtering
coefficient of 1.23 (27/22). Thus,
although lactate is filtered by the
Amicon hemofilter (Amicon Divi
sion, Beverley, Mass.), CAVH at a
mean ultrafiltrate rate of 10 cm3/ h
in this infant could not have ac
counted for the rapid decrease in
serum lactate level.
The elevated lactate levels in the
infant with the septic syndrome
possibly represented impairment of
the oxidative metabolism of lactate
and pyruvate in the hypermetabolic
phase of sepsis.18 Although repeat
ed blood cultures and laparotomy
did not identify any septic focus in
this infant, the low-density areas in
the spleen were suggestive of in-

FIG. 4. Case 2: (a) necrotic appearance of perineal area; (b) healthy subepidermal tissue revealed after cleansing with surgical
scrub. Fascia in right upper quadrant of abdominal excision appeared necrotic.
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farction, perhaps from septic embo
li. Septic foci to liver, lungs, spleen,
brain and pericardium have been
described in patients with NF. 19
The fundamental principles in the
diagnosis of NF include acute
awareness in cases of omphalitis or
minor skin trauma and early confir
mation through needle aspiration
and Gram’s staining, and culture of
suspicious lesions. Antibiotic man
agement should be guided by the
microbiologic findings and the
known polymicrobial nature of the
infections. Surgical excision, includ
ing the umbilical vessels and ura
chal remnants,20 should be per
formed without delay. There should
be a low threshold for further surgi
cal exploration and debridement of
necrotic tissue. Intraoperative fro
zen sections may be of help in
differentiating necrotic tissue from
healthy tissue. Postoperatively, the
aggressive management of coagulo
pathy, shock, lactic acidosis and
renal failure in a centre that has the
facilities for hemodialysis and
CAVH may enhance survival in this
potentially lethal condition. Finally,
hyperbaric oxygenation is another

adjunctive therapy that has been
used with some success in adults
with NF, 21’22 although its use in
infantile NF has yet to be report
ed.23
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SPECIAL SUPPLEMENT
SUPPLEMENT SPECIAL

Thrombolytic Therapy in Peripheral
Arterial Occlusive Disease: Mechanisms
of Action and Drugs Available
Anthony J. Comerota, MD;* Gary S. Cohen, MDt
Catheter-directed thrombolytic therapy has become an important part of the
treatment of patients with acute arterial and graft occlusion. The underlying
pharmacologic principle is the activation of plasminogen, bound to fibrin within the
thrombus. Guide-wire passage reliably predicts success of catheter-directed
thrombolysis. The underlying disease process leading to thrombosis should be
accurately identified and promptly corrected to reduce the probability of recurrent
occlusion. Streptokinase (SK), urokinase (UK) and recombinant tissue plasminogen
activator (rt-PA) are the three agents used to treat peripheral arterial occlusive
disease. The evolution from SK to UK and rt-PA and improvements in techniques
and delivery systems have led to improved success rates and lower complication
rates. Patient selection, basic technical considerations and overall results are
discussed here. The currently available thrombolytic agents, as well as those being
developed, are reviewed to provide background information for current and future
applications.

atheter-directed infusion of
thrombolytic agents has be
come an important adjunct in the
treatment of patients with acute
occlusion of arteries and grafts. The
first attempt at regional delivery of
thrombolytic agents was made over
30 years ago.1 However, only dur
ing the past decade has this form of
therapy become accepted as rou

C

tine. This evolution has occurred
because of a growing interest in
thrombolytic agents, a better under
standing of the technique of deliv
ery and continuing improvements in
catheter delivery systems and
thrombolysis techniques.
The underlying pharmacologic
principle in thrombolytic therapy is
activation of fibrin-bound plasmino

gen.2 The fibrin bond of the plas
minogen molecule, contained within
the thrombus, makes it particularly
susceptible to activation. However,
it is too optimistic to believe that
regional clot dissolution can occur
without systemic fibrinolytic activi
ty. For the most part, systemic
Fibrinolysis accompanies regional
infusion. Most patients tolerate this

This supplement o f the Canadian Journal of Surgery was developed from a satellite symposium o f the Royal College o f Physicians and Surgeons o f
Canada 1992 annual meeting in Ottawa, Ont., entitled “ Thrombolytic Therapy in Peripheral Vascular Disease. ” I t was supported by the Canadian
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The goal o f this symposium is to share clinical experiences in the use o f throm bolytic therapy in the management o f arterial and venous disease.
Each faculty member has valuable "hands-on ” experience to help practitioners identify appropriate indications and management protocols. When it
was organized, the Canadian Society fo r Vascular Surgery made the establishment o f registries to document the therapeutic management o f patients
one o f its prim e objectives. Forums like this special supplement w ill help to spur on the development o f a national registry fo r patients receiving
lytic therapy. — Allan R. Downs, Chairman.
Symposium faculty: Allan R. Downs, MD (chairman); Dennis F. Bandyk, MD; Anthony J. Comerota, MD; and Thomas F. O’Donnell Jr., MD
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MECHANISMS AND DRUGS IN THROMBOLYTIC THERAPY

modest systemic activity without
difficulty. Although intravenous in
fusions for acute arterial and graft
occlusion have been suggested,
they are minimally effective and are
no longer recommended.

Patient Selection
Appropriate patient selection is
important to the success of cathe
ter-directed thrombolysis. Vascular
surgeons and intervention radiolo
gists know that long segments of
the vascular tree can be obliterated
by acute thrombus, which can be
precipitated by severe but relatively
short segmental atherosclerotic dis
ease. Similarly, failure of a bypass
graft may be due to segmental
disease, either anastomotic or with
in the graft; the remainder of the
graft may function well as a con
duit. However, despite focal disease,
an entire graft or long segments of
the arterial tree will be angiographically obliterated. Following throm
bolysis, the underlying disease must
be accurately identified. If an under
lying lesion is not identified and
corrected, recurrent occlusion can
be expected.
The patient selection criteria for
catheter-directed thrombolytic infu
sion are listed in Table I. These
general guidelines are followed at
Temple University Hospital.

Technique
Successful results with the few
est complications are achieved by
treating intra-arterial thrombolytic
therapy as an option before arteri
ography. The arteriographic ap
proach should be made from the
contralateral femoral artery, thread
ing the catheter around the aortic
bifurcation. An ipsilateral puncture
is usually preferred if it allows ac
cess to the occluded artery or graft.
Occluded vessels considered for
fibrinolysis should be submitted to
the guide-wire test. If a guide wire
can be passed through the occlu
sion, a soft, relatively acute throm
bus exists, which will likely respond
to a fibrinolytic agent. If a guide
wire cannot be passed through the
occlusion, then atherosclerotic dis
ease, neointimal fibroplasia, or a
highly organized thrombus that will
not respond to a lytic agent should
be suspected; in this case primary
operative reconstruction is recom
mended.
Fibrinolytic agents are adminis
tered through a catheter into the
thrombus. The agent may be either
urokinase (UK) or recombinant tis
sue plasminogen activator (rt-PA).
If UK is chosen, a bolus of 250 000
units is infused into the thrombus
followed by 4000 units per minute
for 4 to 8 hours. Subsequently, the
rate of infusion is reduced to 2000

T a b le 1. P a tie n t S e le c tio n f o r In tra -a rte ria l T h ro m b o ly tic T h e ra p y
P oor c a n d id a te s

Good c a n d id a te s

P a tie n ts w ith :
E a rly p o s to p e ra tiv e th ro m b o s is o f a bypass
g ra ft
S ev e re is c h e m ia th a t th re a te n s v ia b ility w ith in
h o u rs
A cu te la rge v e s s e l e m b o li, e a s ily a cc e ssib le b y
s u rg e ry
M ild to m o d e ra te is c h e m ia w ith to le ra b le
c la u d ic a tio n , o rd in a rily n o t g iv e n a n g io g ra p h y
o r o p e ra tiv e in te rv e n tio n
A n y a b s o lu te c o n tra in d ic a tio n o r m u ltip le
re la tiv e c o n tra in d ic a tio n s s ig n ific a n tly
in c re a s in g th e ris k o f c o m p lic a tio n

A c u te th ro m b o s is o f s a p h e n o u s ve in b y p a s s
g ra ft
A c u te th ro m b o s is o f n a tiv e a rte ry
A c u te a rte ria l e m b o lu s n o t e a s ily accessed b y
s u rg e ry
T h ro m b o s is o f p o p lite a l a n e u ry s m causing
se v e re is c h e m ia
T h ro m b o tic -e m b o lic o c c lu s io n w h e n o p e ra tiv e
th ro m b e c to m y c a rrie s h ig h p o te n tia l
m o r b id ity and m o rta lity
M a s s iv e p u lm o n a ry e m b o lis m

units per minute and continued for
up to an additional 24 hours as
required. If rt-PA is chosen, 0.05
m g/kg hourly is infused for 8 to
12 hours.
All patients receive broad spec
trum antibiotics intravenously while
the catheter is in place. Routine
blood studies are performed during
treatment, including a complete co
agulation profile. All patients are
kept in bed throughout the treat
ment and most remain in the inten
sive care unit. The puncture sites
are checked constantly for bleeding;
circulation in the infused extremity
is monitored with Doppler ultra
sonography and ankle pressure is
measured every 1 or 2 hours.
Periodic arteriography is neces
sary to follow the therapeutic re
sponse and guide the adjustment of
catheter position as lysis pro
gresses. As a result, the first 2 to 4
hours of infusion are usually spent
in the radiology department. Cathe
ters are advanced into the thrombus
as required. If the catheter cannot
be positioned accurately in the
thrombus, lytic therapy should not
be continued as it will fail.
If the patient has multisegment
occlusion, infusion guide wires are
placed in the distal segment and
infusion is performed through a
coaxial system. The dose of lytic
agent is split between the two cath
eters, with relatively higher doses
delivered to the distal occlusion.
Concurrent administration of
heparin is recommended, especially
if the catheter is placed into a long,
static arterial segment or if it tra
verses a high-grade stenosis to
reach the occluding thrombus.
However, if streptokinase (SK) is
the lytic agent, heparin should be
avoided due to an excessively high
rate of hemorrhage.3 This problem
has not been observed when UK or
rt-PA is used.
Fibrinogen level, prothrombin
time, partial thromboplastin time
CJS. VOL. 36. NO. 4. AUG UST 1993
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and fibrin degradation products are
monitored during infusion to docu
ment the presence of a systemic
lytic effect. If the level of fibrinogen
falls below 100 mg/dL, the infu
sion is slowed or stopped to allow
restoration of circulating fibrinogen
and clotting factors. On rare occa
sions, fresh-frozen plasma or cryoprecipitate can be given. Although
the risk of bleeding cannot be deter
mined by titration, we have ob
served that bleeding complications
escalate when significant hypofibrinogenemia occurs. In our experi
ence over the last 10 years, five
patients have suffered major bleed
ing complications, of which two
were fatal intracranial hemorrhages.
In each case, the fibrinogen level
was less than 50 m g/dL at the time
of the hemorrhage.3

Results
As the evolution from SK to UK
and rt-PA has occurred, along with
improved techniques and develop
ment of drug delivery systems, suc
cess rates have improved and com
plication rates have diminished (Ta
ble II).4-27
After infusion is completed arteri
ography is performed and blood
studies are repeated. Following suc
cessful lysis, the underlying cause
of the occlusion is identified and
corrected using standard tech
niques. If percutaneous correction
is not appropriate, systemic anti
coagulation is continued until the
definitive operative procedure is

completed. The key to prolonging
patency following catheter-directed
thrombolysis is identification and
correction of the underlying lesion.
McNamara and Bom berger28
showed that, after thrombolysis, pa
tients who left the hospital without
a persistent stenosis had enviable
6-month patency rates compared
with those who had uncorrected
underlying disease at the time of
discharge. These observations were
further confirmed by Sullivan and
colleagues.29
Graor and associates30 compared
catheter-directed thrombolysis fol
lowed by operative thrombectomy
to repair the presumed lesion of the
thrombosed bypass graft to the
lower extremity. They found that
patency rates were significantly
higher and amputation rates signifi
cantly lower among patients who
underwent thrombolysis before op
erative revision of their bypass
graft. These data suggest that iden
tifying the underlying lesion caus
ing the thrombosis facilitates defini
tive correction. They also might
suggest that pharmacologic throm
bectomy is more effective than me
chanical thrombectomy.
However, a question remains:
should any thrombosed bypass
graft undergo thrombectomy (either
operatively or pharmacologically)
followed by appropriate operative
revision, or should the patient with
the thrombosed graft be offered an
entirely new bypass procedure? We
have observed that patients who
have early failure of femoral-distal
bypasses will have poor long-term

Table II. Short-Term Efficacy and Safety of Catheter-Directed, Intra-arterial Thrombolysis'

Agent

Patients,
no.

Average
duration of
infusion, h

SK
UK
rt-PA

542
277
144

41
28
7
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Plasminogen Activators

Plasminogen activators have
evolved from relatively impure and
highly antigenic substances to pure,
less antigenic and increasingly fi
brin-specific agents. Their continu
ing improvement in addition to our
increasing knowledge of the coagu
lation and fibrinolytic systems al
lows much safer and effective use of
these agents.
The most common plasminogen
activators used today include SK,
UK, rt-PA, prourokinase (single
chain urokinase plasminogen acti
vator) and acylated streptokinase.

Outcome, no. and % of patients
Successful
cases

Major
complications

354 (65)
222 (80)
123 (85)

112(21)
32(12)
11 (8)

'Data from representative studies have been pooled.
SK = streptokinase, UK = urokinase, rt-PA = recombinant tissue plasminogen activator
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outcomes, and reocclusion is com
mon. This most likely represents
extensive underlying disease or a
badly compromised graft. Gardiner
and associates31 also found that
most grafts that failed within 1
month of placement could be reca
nalized; however 67% of those reca
nalized reoccluded in less than 3
months.
Autogenous grafts that fail early
(in the absence of an easily demon
strable and correctable technical
problem) are probably doomed to
failure. Likewise, vein grafts occlud
ing late (1 or more years after
placement) are likely to have a focal
underlying lesion that is more easily
correctable, with the graft remain
ing an effective conduit. A large
national study evaluating surgery
versus thrombolysis for the isch
emic lower extremity (STILE study)
should further define the role of
catheter-directed thrombolysis in
patients with occluded arteries and
bypass grafts.

Streptokinase

SK was first discovered in 193332
and was the first thrombolytic
agent approved for clinical use.
This protein, which contains 415
amino acids and has a molecular
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weight of 437 daltons, is produced
by group C /3-hemolytic streptococ
ci.33 SK alone is incapable of con
verting plasminogen to plasmin di
rectly and is, therefore, not an
enzyme. Instead, it activates plas
minogen by forming a 1:1 complex
with human plasminogen. This
complex causes a conformational
change that exposes an active site
on the plasminogen molecule. The
plasminogen-SK complex can then
convert other plasminogen mole
cules to plasmin. An SK-plasmin
complex also forms, which is fur
ther capable of catalyzing the for
mation of plasmin from plasmino
gen. The various cleavage products
are SK fragments ranging in mole
cular weight from 10 000 to
40 000 daltons; all are able to form
a complex with plasminogen. These
fragments are 50% to 60% as likely
as the parent molecule to cause
allergic reactions.
Patients with recent exposure to
streptococci or those recently treat
ed with SK have a high level of
circulating antistreptococcal anti
bodies capable of neutralizing SK.
These patients may require excess
SK infusion to saturate the antibod
ies; the remaining SK is then avail
able to form the activator complex
with plasminogen. In the presence
of antibodies, SK’s half-life is about
18 minutes compared with 83 min
utes when no antibodies are pres
ent. SK must neutralize any anti
streptococcal antibodies before a
lytic state can be established. Invitro testing can determine the SK
dose needed for systemic fibrinol
ysis, although 95% of patients will
be effectively treated by the stan
dard recommended doses.
SK has various systemic effects
on the coagulation system. Circulat
ing levels of plasminogen and fi
brinogen are markedly decreased
during SK therapy. Increased me
tabolism of fibrinogen results in an
increase in fibrin-split products.

Plasmin activity causes a reduction
in clotting factors V and VIII. These
reductions alter normal hemostasis
and explain the hemorrhagic com
plications. Effective SK therapy re
sults in a plasminolytic state that
includes a decrease in plasma plas
minogen, a decrease in whole blood
clotting time, a decrease in fibrino
gen and the appearance of serum
fibrin and fibrinogen degradation
products with a slower coagulation
time. Although this state is the
general result of systemic fibrinol
ysis with any of the fibrinolytic
agents, SK appears to have a more
pronounced effect than the other
agents, perhaps with the exception
of acylated streptokinase.
SK is an effective thrombolytic
agent, but has several disadvan
tages. It is rapidly cleared from the
plasma, it requires the presence of a
co-factor, plasminogen, for its acti
vation, it has significant systemic
fibrinolytic effects and it is antigen
ic.
Interestingly, in the early days of
fibrinolytic therapy with SK, serious
bleeding complications were treated
with additional (excess) SK infu
sion. The purpose was to bind all
plasminogen, thereby not leaving
plasminogen available for activation
by the SK-plasminogen activator
complex. Because fibrin-bound plas
minogen continues to be activated
by the SK-plasminogen activator
complex and observing that the
massive systemic doses of SK now
given to patients suffering acute
myocardial infarction clearly show
that a significant systemic fibrino
lytic response occurs, it is clear that
this principle is not clinically appli
cable.
Urokinase

UK is a human plasminogen acti
vator produced by the kidney.3435
Although it is generally accepted
that urokinase is a double-chain

polypeptide with a molecular weight
of 54 000 to 57 000 daltons, sever
al investigators observed that UK
could exist in several molecular
weights of approximately 22 000,
33 000 and 54 000 daltons. The
complete primary amino acid se
quence of UK has been deter
mined.36 Plasmin and kallikrein
cleave prourokinase at position
156, which then produces UK in its
two-chain form. The two chains are
held together by a disulfide bond
that is important to the enzyme’s
fibrinolytic activity.
UK preparations for therapeutic
use were formerly extracted from
human urine, but they are now
isolated from cultures of human
fetal kidney cells. Producing UK
from urine requires large quantities
of urine; 1500 litres are required to
obtain enough enzyme to treat one
patient. The tissue culture tech
niques of Bernik and Kwaan37 dem
onstrated that improved production
of UK could be achieved, and that
the best fibrinolytic activity is ob
tained using cells taken from 26- to
32-week-old fetuses.
UK converts the inactive forms of
plasminogen to plasmin with great
er affinity for the fibrin-bound lysplasminogen. The conversion is due
to the cleavage of a single bond
(arginine 560-valine 561).38 Activa
tion of fibrin-bound plasminogen
allows fibrinolysis to occur in a
relatively inhibitor-free environ
ment, as there are no competing
substrates for fibrin-bound plasmin.
UK is rapidly cleared by the liver
and 3% to 5% is cleared by the
kidneys. Its short half-life is about
16 minutes, but might be prolonged
in patients with hepatic dysfunc
tion.
Although UK induces clotting de
fects that persist after the discontin
uation of the drug’s infusion (simi
lar to those mentioned for SK),
coagulation parameters do not dete
riorate as much and normalize more
CJS, VOL. 36. NO. 4, AUGUST 1993
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rapidly with UK than with SK.39
Because of increased production
costs, the price of UK is five to
eight times that of SK for the
treatment of an individual patient.
Tissue Plasminogen Activator
The development of fibrin-specif
ic plasminogen activators became
possible when physiologic tissue
plasminogen activator was extract
ed from human vascular endotheli
um.40 The endothelial extract was
found to induce highly specific clot
lysis compared with SK or UK.41
Tissue plasminogen activator (tPA) is a single-chain polypeptide
serine protease with a molecular
weight of approximately 68 000
daltons. It was first extracted from
Bowes melanoma cells and other
mammalian tissue but is now pre
pared by recombinant DNA tech
niques. The principal site of in-vivo
synthesis is the endothelial cell.
Structurally, t-PA exists as a sin
gle chain that is easily converted to
a double chain by cleavage of the
peptide bond arginine 275-isole
ucine 276. In the absence of fibrin,
t-PA is a weak activator of plas
minogen. The presence of fibrin
causes a 500- to 1000-fold increase
in activation.42 This effect is a result
of specific binding of t-PA with
fibrin and plasminogen with fibrin.
The half-life of t-PA is 2 to 6
minutes due to binding by the rapid
t-PA inhibitors and clearance by the
liver. The agent exists in plasma in
a free state and complexed with
plasma serine proteinase inhibitors.
Tissue plasminogen activator is
fibrin specific and can induce
thrombolysis without causing sys
temic lytic effects.4344 Local or re
gional infusions also cause more
effective lysis than systemic infu
sion.43 The first person to receive
t-PA treatment was a renal trans
plant recipient who suffered an ilio
femoral venous thrombosis.45 Effec
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tive thrombolysis was achieved
without a systemic lytic effect, al
though the t-PA used was from
melanoma cells. Early use of t-PA
in acute myocardial infarction from
acute coronary thrombosis likewise
resulted in high thrombolytic rates
without systemic fibrinogenolytic
effects.46
With the development of recom
binant DNA technology, larger
quantities of t-PA could be pro
duced from Escherichia coli cells.
The properties of this rt-PA are
similar to those of t-PA derived
from melanoma cell lines.47
Clinical trials involving rt-PA
have been enthusiastically accepted.
It is an effective lytic agent with
relative fibrin selectivity and signifi
cantly less fibrinogenolysis.4849 Al
though it has not been observed in
all trials, any agent that causes less
coagulopathy can be expected to be
associated with fewer bleeding com
plications. On the other hand,
agents with higher fibrin selectivity
may lyse hemostatic thrombi more
efficiently, leading to potentially
more bleeding from sites of vascular
injury.
Prourokinase
In 1979, a single-chain precursor
to high molecular weight uroki
nase, prourokinase, was isolated
from urine.50 Because of its config
uration it is also called single-chain
urokinase plasminogen activator
(scu-PA).
Prourokinase has been identified
in human plasma, cultures of endo
thelial cells, explants of fetal organs
and various malignant cell lines.51
The proenzyme is derived from
human urine or genetically manipu
lated E. coli and has a molecular
weight of about 54 000 daltons.
Prourokinase is converted to
high molecular weight UK by hy
drolysis of the lysine 158-isole
ucine 159 peptide bond. This cleav

age converts prourokinase into its
two-chain structure and increases
its activity 500- to 1000-fold.52
Prourokinase differs from UK in
several ways: mainly its higher fi
brin affinity, lower specific activity
and stability in plasma. In vitro,
prourokinase is nonreactive due to
circulating competitive inhibitors.
Because of these inhibitors, prouro
kinase has several hundred-fold
higher plasminogen activating
power than plasmin. The fibrin
specificity of prourokinase does not
depend on actual fibrin binding as
does that of t-PA; thus, the method
of clot lysis of the two agents
differs.51
Studies in which prourokinase
was used in rabbits, dogs and ba
boons demonstrated fibrin selective
clot lysis without fibrinogenolytic
effects or hemorrhagic complica
tions.50 Testing in dogs also re
vealed that, although prourokinase
had superior fibrin specificity, it
was equal to UK in efficacy.53
The agent was first used in hu
mans to treat acute myocardial in
farction. A pilot study followed by a
multicentre study of acute myocar
dial infarction resulted in a 60%
reperfusion rate in patients with
proven coronary artery thrombosis.
The dose given was 50 mg of
prourokinase and mean time to lysis
was about 55 minutes. Increasing
the dose to 70 to 80 mg increased
reperfusion to almost 70%, however
time to lysis was prolonged and
several patients developed systemic
fibrinogenolysis.51 No hemorrhagic
effects were noted. Combining UK
and prourokinase, as well as t-PA
and prourokinase, produces a syn
ergistic response because of com
plementary mechanisms of action.54
Acylated PlasminogenStreptokinase Activator Complex
SK has significant fibrinogenolyt
ic effects reflecting the wide rang-
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ing proteolysis resulting from its
use. Modifying its molecular struc
ture by adding an acyl group pro
duced a more efficient agent with
greater fibrin specificity. Further
more, the acyl group blocked the
binding site of antistreptococcal an
tibodies, thereby eliminating its ac
tivation in plasma by the circulating
inhibitors.55'56 The acylated strepto
kinase molecule, therefore, is essen
tially inert in the activation of plas
minogen to plasmin in vitro.
However, acylation has little, if
any, effect on the binding of the
plasminogen-streptokinase com
plex to fibrin. Because the fibrin
binding site and the functionally
active catalytic site are spatially
separate, this compound retains its
ability to bind to fibrin despite its
lack of enzymatic activity when
freely circulating. Activation occurs
by hydrolysis, in which the com
pound deacylases to give free acti
vator complex and anisic acid in
equal concentrations. Because most
of the deacylation occurs after the
fibrin binding, the result is im
proved concentration of the activa
tor complex bound to fibrin and a
relatively small amount of free acti
vator complex circulating systemically. The deacylation half-life in
plasma is 90 to 105 minutes,57 and,
because deacylation governs plasma
clearance, the compound has a true
half-life of 90 to 105 minutes, with
fibrinolytic activity persisting for 4
to 6 hours.
In trials of acylated SK in rabbits
and guinea pigs, this compound
had higher thrombolytic activity
than an equal amount of nonacylated SK complex and did not cause
systemic fibrinogenolysis.55 There
fore, specific thrombolysis without
systemic fibrinolytic side effects was
demonstrated in animal clots. A
comparison of SK with acylated SK
in a dog model of jugular venous
thrombosis and pulmonary embo
lism revealed minimal lytic response

with SK, but thrombolysis was radiologically complete with acylated
SK. There was, however, significant
fibrinogenolysis with a decrease in
the circulating fibrinogen levels to
approximately 50%.
In humans, phase I studies with
SK plasminogen complex (BRL
26921) demonstrated some allergic
manifestations with occasional in
fluenza-like symptoms, but true
systemic toxicity was not observed.
Human trials treating acute myocar
dial infarction resulted in 70% reca
nalization rates; however, these
studies showed a higher systemic
fibrinolytic effect than was expected
based on the animal experiments.
Half the treated patients had fibrin
ogen levels of 30% or less. De
creases in plasminogen levels and
a-2 plasmin inhibitor were also ob
served.58
The studies of humans showed
that higher reperfusion rates can be
achieved with acylated SK than
with high-dose SK, but a similar
systemic fibrinolytic response is ob
served. Therefore, at present, the
advantages of acylated SK are pro
longation of the thrombolysis and
the convenience of bolus adminis
tration. The predicted fibrin speci
ficity at therapeutic human dose
ranges for thrombolysis does not
seem to correlate with observations
in animal trials.
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SPECIAL SUPPLEMENT

Arterial Diagnosis and Management
of Acute Thrombosis of the Lower Extremity
Thomas F. O’Donnell Jr., MD
Acute ischemia of the lower extremity is associated with reduced blood flow to
muscle, nerve, subcutaneous tissue and skin. This condition may be caused by
thrombosis on an atherosclerotic plaque or embolus or by the occlusion of a
previously placed arterial bypass graft. The difficulties in differentiating embolic
arterial occlusion from acute thrombotic arterial occlusion are discussed. Although
balloon catheter thrombectomy has been the traditional approach to treatment of
patients with acute ischemia, this method has several disadvantages: it may not
remove all of the thrombus, the thrombus may be inaccessible, it may damage
vessels and atherosclerotic plaque and it does not identify or correct the underlying
cause of the thrombosis. The advantages of catheter-directed thrombolysis are
discussed, including its use as a diagnostic tool. Detailed techniques are presented
along with data from extensive studies.

cute ischemia of the lower ex
tremity is associated with re
duced blood flow to muscles,
nerves, subcutaneous tissue and
skin. This condition may be caused
by in-situ thrombosis on an athero
sclerotic plaque, embolus, or occlu
sion of a previously placed arterial
bypass graft. Acute thrombotic oc
clusion (ATO) develops in an artery
with preexisting atherosclerotic
plaque, and the patient usually has
preexisting symptoms of chronic
arterial insufficiency. The natural
history of atherosclerotic plaque in
the peripheral arterial circulation is
progression of the stenosis to overlying thrombus with subsequent
sudden occlusion of the vessel. Ap
proximately 30% to 40% of the
diameter of the occlusion may be
due to soft occlusive thrombus
rather than atherosclerotic plaque.1
The pathologic features of the oc
cluding lesion determine the suc
cess of the various treatments.

A

Diagnosis
The first problem confronting
surgeons in the management of
acute limb ischemia is differentiat
ing embolic arterial occlusion from
ATO. ATO should be considered
when a patient has a history of
claudication, or when a preceding
event has caused hypotension. In
contrast, arterial embolism fre
quently occurs in a patient without
preexisting symptoms of peripheral
arterial occlusive disease and often
develops in the setting of atrial
fibrillation or recent cardioversion.
With the decreased incidence of
rheumatic valvular disease, the inci
dence of mural thrombus in the
proximal aorta or in the heart as
the source of embolus has risen.
Arteriography is sometimes help
ful in differentiating between ATO
and embolism. In the patient with
ATO, well-developed collaterals may
be visualized, and atherosclerotic

stenoses or occlusion may be evi
dent in the contralateral limb o r
aorta. In contrast, arterial emboli
typically lodge at major bifurcations
or at the origins of branch vessels.
Mature collaterals are usually a b 
sent in the patient with local throm
bosis.
After reviewing criteria for differ
entiating embolism from ATO,
Cambria and Abbott2 found that the
presence of atrial fibrillation was
the only useful one. Establishing
the exact cause of acute limb isch
emia is important. Of 103 patients
thought to have arterial emboli on
the basis of preoperative criteria,
29% were misdiagnosed and actual
ly had ATO.3 In half of these pa
tients, revascularization attempts
failed, and the patients died.

Treatment
In patients with acute limb isch-
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emia, the goals of treatment are to
restore blood flow and to identify
and correct the underlying lesions.
For patients with acute limb isch
emia secondary to ATO, several
therapeutic options are available:
expectant treatment; hepariniza
tion; surgery with thrombectomy
alone or with bypass or both; and
thrombolysis.
Surgical thrombectomy has been
the traditional approach to patients
with acute ischemia. Although bal
loon catheter thrombectomy re
moves the soft thrombus, it may
leave residual thrombus on the ath
erosclerotic plaque; it also fails to
remove thrombus from the occlud
ed small-calibre branch vessels. In
addition, the balloon catheter may
produce significant damage to the
vessel wall and the atherosclerotic
plaque. Finally, balloon catheter
thromboembolectomy does not
eliminate the underlying cause of
ATO.
Two studies have cast doubt on
the role of surgical thrombectomy
in ATO (Fig. 1). Blaisdell, Steele
and Allen4 reviewed nearly 3500
limbs treated by surgery from 1963

through 1978; the overall death
rate was 27% and the amputation
rate approached 50%. At the Massa
chusetts General Hospital, Abbott
and associates5 found an insignifi
cant 4% decrease in the amputation
rate from 1937 to 1981. The death
rate was constant: 18% in the early
part of the series and 17% later.
During this period, the number of
patients referred for surgical treat
ment increased from 25% to nearly
90%. Abbott and associates criti
cized an approach where overconfi
dence in the ease of and indication
for surgical therapy may select
limbs for surgery that may have
done well with conservative thera
py. During the period studied, there
was no improvement in the limb
salvage rate with surgery (89%)
compared with the nonsurgical
group (77%).
Blaisdell, Steele and Allen4 have
advocated high-dose heparin thera
py, which lowered the death rate by
7.5% over historic surgically treated
controls (Fig. 1). This approach
indicated a delay in surgery. Highdose heparin treatment produced no
increase in the amputation rate.

50

Blaisdell’s review article on the ad
verse effects of surgical therapy in
acute limb ischemia, which stimu
lated his conservative approach,
was criticized because the data were
collected from outmoded intensive
care settings and did not reflect
contemporary surgical therapy.
In addition to thromboembolecto
my with a Fogarty balloon catheter,
arterial bypass has been attempted
in patients with acute limb isch
emia. A series from Boston, al
though small, showed a low paten
cy rate of 25% and an amputation
rate of 75%;6 the later study by
Cambria and Abbott2 showed an
improved patency rate (86%) but a
disappointing amputation rate
(33%). In a review7 of the effects of
immediate surgery for ATO in near
ly 2500 patients, from 1978 to
1984, the death rate remained ele
vated at 18% whereas amputation
rate was 16%. McPhail and col
leagues8 believed that embolism
could be differentiated from ATO in
90% of cases, so that immediate
surgery could be carried out in
limbs with acute arterial embolus;
patients with ATO were heparinized
for about 14 days before surgery
was undertaken. The result was no
difference in the death rate for
limbs with embolus (13.8%) com
pared with those with ATO (12%).
However, the amputation rate for
limbs with ATO (22%) was twice
that for limbs with embolism (10%).
Clearly a surgical approach does
not provide optimal death and am
putation rates.

Thrombolytic Therapy
Blaisdell
(A/= 3350)
1978

Jivegaard
(A/= 2495)
1984

Blaisdell
(A/=54)
1978

McPhail
(A/=50)
1983

Cambria
(A/ = 52)
1984

Reviews

FIG. 1. Mortality (first bar) and amputation rates (second bar) resulting from
surgical treatment of acute thrombotic ischemia4'7 compared with those of
subsequent studies that employed high-dose heparin4 or surgery.2'8
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Direct intra-arterial thrombolytic
therapy has several potential advan
tages in ATO: not only is the
thrombus lysed, but the ischemia is
also resolved.9 An emergent situa
tion becomes semielective; thus,
cardiorespiratory risks can be evalu-

ACUTE THROMBOSIS OF LOWER EXTREMITY

ated appropriately and subsequent
modification of these risks carried
out. In addition, following lysis of
the thrombus, a complete picture of
the underlying anatomy can be pro
vided by arteriography. As in other
areas, catheter-directed thromboly
sis is associated with a high rate of
lysis and, with certain thrombolytic
agents, a moderate degree of com
plications. Catheter-directed throm
bolysis is in essence a diagnostic
tool, and ultimate therapeutic suc
cess depends upon treatment of the
underlying anatomic cause of
ATO.10 Specific treatment of these
lesions can either be delayed or
performed as a scheduled surgical
procedure. Alternatively, if the le
sion is suitable for endovascular
treatment, this procedure can be
carried out immediately in the arte
riography department.
Balloon thromboembolectomy is
limited by the location of the
thrombus. Thrombus in the distal
arteries and smaller branches are
beyond the reach of the balloon
catheter. Of thromboembolectomies
subsequently examined by arteriog
raphy, Plecha and Poires11 found
that 30% had residual thrombus.
Angioscopic evaluation of the com
pleteness of thromboembolectomy
revealed adherent thrombus on the
vessel wall in 80% of patients stud
ied by White and colleagues.12 Re
garding preliminary evidence on the
beneficial role of lytic agents in
arterial occlusion, improved clear
ing of arterial segments following
embolectomy has been report
ed13’14 when lytic agents were ad
ministered intraoperatively. These
findings suggest an adjunctive if
not primary role for thrombolytic
therapy in acute arterial ischemia.
Thrombolytic therapy may re
move the occluding thrombus not
only from the main vessel, but also
from the collateral and distal
branch vessels. Furtherm ore,
thrombus in the microvascular beds

can be lysed, and this might im
prove muscle viability. To determine
whether intra-arterial urokinase
(UK) would improve the function of
ischemic muscle, the gracilis muscle
and its blood supply was isolated in
six dogs, so that temporary occlu
sion of the gracilis artery could be
applied.15 Following occlusion for 5
hours, the therapeutic group re
ceived a 90-minute intra-arterial in
fusion of UK; the control group
received saline solution for the
same period. Examination of muscle
samples, stained with triphenyltetrazolium chloride to determine
muscle viability, showed a nearly
threefold increase in the area of
damaged muscle of control limbs
(20.2% ± 8.1%) compared with UKtreated limbs (8.6% ± 6.2%). In
addition, the muscle samples were
weighed to determine the degree of
edema. Those from the control
group were nearly twice as heavy as
those from the UK-treated group.
These experiments suggest that UK
administration in acute ischemia
may improve the degree of muscle
viability on reperfusion, perhaps by
lysing thrombi in the microcircula
tion.
A theoretical disadvantage of
thrombolytic therapy in ATO is that
the time required to produce lysis
may exceed the interval considered
safe for retaining tissue viability.
Lysis of the clot may also cause
distal embolization that can further
jeopardize arterial ischemia. Finally,
hemorrhagic complications may
occur or coagulation factors may be
deranged for subsequent surgery.10
The vascular surgeons at New En
gland Medical Center (NEMC) be
lieve that patients without signifi
cant sensory loss or motor changes
are candidates for lytic therapy.
However, patients with absent dorsiflexion of the toes or ankle — an
indication of underlying muscle
damage — or patients with sensory
loss involving more than the toes

should be considered for alternative
forms of therapy.

Techniques
The catheter introduction site for
direct intra-arterial infusion is deter
mined by the location and extent of
thrombosis. The catheter is usually
introduced through the contralater
al femoral artery so that the guide
wire is manipulated around the aor
tic bifurcation into the affected
limb. In this way the puncture site
can be compressed vigorously, be
cause it is not proximal to a previ
ously lysed site where low flow,
produced by arterial compression,
might cause rethrombosis. In distal
ATO, where manipulation of the
catheter into various major branch
es (tibial vessels) is important, the
femoral artery of the affected limb
may be punctured for antegrade
manipulation. The guide wire test
of whether a catheter can tra
verse the lesion determines the
amount of thrombus occluding the
artery and the feasibility of throm
bolytic therapy.16 A Teflon-coated
guide wire with a small outside
diameter (less than 0.05 cm) can
pass through most occlusions in
which some degree of thrombus is
present. The failure of the guide
wire to pass through the occluding
thrombus is generally a sign of an
adverse outcome, because the oc
clusion is not thrombus rich.
Today, catheter systems provide
coaxial infusion rather than the
older method by which the lytic
agent was delivered from the distal
portion of a single catheter. The
outer sheath is positioned within
the artery, and an inner catheter,
approximately half the diameter of
the outer one, can be passed
through it. The inner catheter is
embedded in the entire thrombus,
whereas the larger outer catheter is
positioned in the more proximal
CJS, VOL. 36. NO. 4. AUGUST 1993
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thrombus. Urokinase is infused
through both catheters. Alternative
delivery systems have been devel
oped: one has multiple holes along
the catheter; the other elutes the
lytic agent from multiple microports
along the length of the catheter.
The goal of both systems is to
expose the thrombus surface area
to the maximum amount of lytic
agent.
Another variation in the delivery
of the lytic agent is the pulsedspray technique. A high-pressure
jet of the agent is sprayed through
a specialized catheter into the
thrombus.17 The clot is attacked in
much the same way as a blender
minces food, resulting in an in
creased concentration of fibrinolytic
agent within the thrombus. The
rate of lysis is increased by this
technique.
In addition to improvements in
the delivery of lytic agents, various
dosage regimens have been advocat
ed. One popular technique is to
initiate infusion with UK at a rate of
4000 IU/min for 2 to 4 hours via a
continuous infusion pump. If prog
ress in lysis is noted on an arterio
gram, the infusion rate is decreased
to 1000 IU/min. At NEMC, a highdose regimen is preferred in which
250 000 IU of UK is administered
as a bolus followed by infusion of
UK at 6000 IU/min. The progress
of lysis is monitored in the radiolo
gy department. After 1 hour, arteri
ography is used to determine the
degree of lysis.
Concomitant heparin is adminis
tered either systemically or via the
proximal catheter to achieve a par
tial thromboplastin time of at least
twice the control level. Although a
slight increase in the risk of bleed
ing complications might be associ
ated with heparin administration,
this regimen has decreased the inci
dence of pericatheter thrombosis.
Close patient monitoring is essential
in minimizing hemorrhagic compli
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cations with thrombolytic therapy.
Excess patient movement should be
minimized so that the infusion cath
eter remains stable.10 The patients
should be able to cooperate with
the physician during thrombolytic
therapy. Indeed, back pain is one of
the most common complaints of
patients because of the position
they must maintain.
Hematocrit is monitored to assess
the amount of blood loss at arteri
ography and to complement clinical
judgement regarding bleeding com
plications. In addition, coagulation
parameters are obtained every 12
hours; fibrinogen level is particular
ly important. Although no direct
correlation has been shown between
the fibrinogen level and hemorrhag
ic complications, a level greater
than 100 mg/dL is of concern.
Finally, if no progress in lysis is
achieved after 12 hours, infusion is
discontinued. Obviously, heparin is
continued after lysis is achieved to
maintain patency while a decision is
made regarding subsequent treat
ment of the underlying lesion.
McNamara, Bomberger and Mer
chant,16 who have the most exten

sive experience with thrombolytic
therapy in this setting, have shown
that success in ATO is related to
the duration of occlusion as well as
to its location. Patients who have
an occlusion for less than 3 days do
better (100%) than patients with an
occlusion for more than 10 days. A
more proximal arterial occlusion
fares better than a distal occlusion;
for example, the lysis rate is 90% at
the iliac level versus 40% at the foot
level. In addition, the severity of
underlying ischemia, the extent of
arterial occlusive disease and the
status of the collateral circulation
determine the outcome of throm
bolytic therapy in ATO. Following
lysis of the underlying thrombus,
detailed arteriography is performed,
and treatment of the underlying
anatomic lesion or lesions is dictat
ed by the findings. Flow-limiting
lesions are found by post-lytic arte
riography in over 75% of limbs.
Balloon angioplasty, as in the coro
nary system, may be the approach
of choice in a high proportion of
limbs.
In Fig. 2, death and amputation
rates are compared among four

FIG. 2. Comparison of rates of mortality, amputation, lysis, hemorrhage and
percutaneous balloon angioplasty or surgery with thrombolytic treatment for acute
thrombotic occlusion using urokinase or streptokinase.1618-20
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major series where thrombolytic
therapy had been used for
ATO.1618'20 The mortality rates are
remarkably low; the highest level
being 3.5%. In addition, the ampu
tation rate was below that achieved
with surgical treatment alone or
with heparin therapy. The rates of
hemorrhagic complication and lysis
varied. The highest hemorrhagic
complication rate (22%) occurred in
a series18 in which streptokinase
was used; UK was employed in the
lowest (2.8%).16 The lytic rate of
45% obtained by Sicard and col
leagues19 is significantly lower than
that in the other three studies in
which it was over 75%. Finally, the
incidence of subsequent percutane
ous balloon angioplasty or surgery
in these four series emphasizes the
need to treat the underlying lesion
that produced the ATO; about 75%
of patients require subsequent cor
rective procedure.
The experience of McNamara,
Bomberger and Merchant16 with 56
instances of ATO provides impor
tant information on their manage
ment by thrombolytic therapy. On
entry into the study, all patients
were graded as to the degree of
ischemia by SV S/ISV S criteria.
Therapeutic outcome was subse
quently scored as positive or nega
tive. There was a gradual diminu
tion in positive outcome as the
pretreatment degree of ischemia ad
vanced. All limbs deemed “viable”
had a positive outcome, but only
63% categorized “irreversible” had

such an outcome. There was no
difference in the therapeutic out
come between limbs with embolic
occlusion (94%) and those with
ATO (82%). In the experience of
McNamara, Bomberger and Mer
chant, only 15% of patients had no
underlying cause for ATO; the ma
jority of patients with lesions were
treated endovascularly. Such results
suggest that thrombolytic therapy
is a reasonable choice for selected
patients with ATO.

References
1. T ennant SN, Dixon J, V enable TC et al:
Intracoronary thrombolysis in patients
with acute myocardial infarction: com
parison of the efficacy of urokinase with
streptokinase. Circulation 1984; 69:
756-760
2. Cambria RP, A bbott WM: Acute arterial
thrombosis of the lower extremity. Arch
Surg 1984; 119: 784-787
3. J ivecaard L, Holm J, S hersten T: The
outcome in arterial thrombosis misdiag
nosed as arterial embolism. Acta Chir
Scand 1986; 152: 251-256
4. B laisdell FW, S teele M, A llen RE:
Management of acute lower extremity
ischemia due to embolism and thrombo
sis. Surgery 1978; 84: 822-834
5. A bbott WM, Maloney RD, McCabe CC
et al: Arterial embolism: a 44 year
perspective. Am J Surg 1982; 143:
460-464
6. Couch NP, W heeler HB, H yatt DF et
al: Factors influencing limb survival
after femoropopliteal reconstruction.
Arch Surg 1967; 95: 163-169
7. J ivecaard L, H olm J, S hersten T: Acute
limb ischemia due to arterial embolism
or thrombosis. J Cardiovasc Surg (Tori
no) 1988; 29: 32-36
8. McP hail NV, F ratesi SJ, Barber GG et
al: Management of acute thromboembol
ic limb ischemia. Surgery 1983; 93:

381-385
9. M c N amara TO, F ischer JR: Thrombol
ysis of peripheral arterial graft occlu
sions: improved results using high-dose
urokinase. AJR 1985; 14: 769-775
10. B elkin M, O ’D onnell TF: Complica
tions of thrombolytic therapy. In B ern hard VM, T owne JB (eds): Complica
tions in Vascular Surgery, Quality Med
Pub, St Louis, 1991
11. P lecha FR, P oires WJ: Intraoperative
angiography in the immediate assess
ment o f arterial reconstruction. Arch
Surg 1972; 105: 902-907
12. W hite GH, W hite RA, K opchock GE et
al: Angioscopic thromboembolectomy:
preliminary observation with a recent
technique. J Vase Surg 1988; 7: 318325
13. Q uinones -B aldrich WJ, Z ieler E, H iatt
JC: Intraoperative fibrinolytic therapy:
an adjunct to catheter thromboembolec
tomy. J Vase Surg 1985; 2: 319-326
14. C ohen LH, K aplan M, B ernhard VM:
Intraoperative streptokinase: an adjunct
to mechanical thrombectomy in the
management of acute ischemia. Arch
Surg 1986; 121: 708-715
15. B elkin M, Valeri RC, H obson RW:
Intraarterial urokinase increases skeletal
muscle viability after acute ischemia. J
Vase Surg 1989; 9: 161-166
16. M cN amara TO, Bomberger RA, M er 
chant RF: Intraarterial urokinase as the
initial therapy for acutely ischemic lower
limbs. Circulation 1991; 83 (suppl 1):
106-119
17. Bookstein JJ, F allmeth B, R oberts A
et al: Revised spray pharmacomechanical thrombolysis; preliminary clinical re
sults. AJR 1989; 152: 1197-1100
18. H argrove WC, Barker CF, B erkowitz
HD et al: Treatment of acute peripheral
arterial and graft thromboses with lowdose streptokinase. Surgery 1982; 92:
981-983
19. S icard GA, S chier JJ, T otty WG et al:
Thrombolytic therapy for acute arterial
occlusion. J Vase Surg 1985; 2: 65-75
20- E isenbud ED, B rener BJ, S hoenfeld R
et al: Treatment of acute vascular occlu
sions with intraarterial urokinase. Am J
Surg 1990; 160: 160-165

CJS, VOL. 36, NO. 4, AUGUST 1993

353

SPECIAL SUPPLEMENT

Intraoperative Thrombolysis in Peripheral
Arterial Occlusion
Joseph A. Wasselle, MD; Dennis F. Bandyk, MD
Thromboembolic occlusion of peripheral arteries continues to be associated with
significant morbidity, mortality and loss of limbs. Surgical intervention with prompt
revascularization by clot extraction, alone or in combination with arterial bypass,
remains the standard therapy for critical ischemia with imminent tissue loss.
Mechanical thrombectomy using a balloon catheter has been the preferred technique
for distal embolus or thrombus extraction. Unfortunately, complete thrombectomy is
rare, and the procedure is associated with arterial wall injury. Intraoperative
thrombolytic therapy is an attractive adjunct to catheter thrombectomy alone and is
appropriate in the care of a significant number of patients with acute limb ischemia.
Its safety and efficacy have been confirmed in the laboratory and in a limited number
of patients. The authors review experimental and clinical data and report their
experience with 19 patients.

hromboembolic occlusion of
peripheral arteries continues to
be associated with significant mor
bidity, mortality and limb loss.1-5
The severity of limb ischemia after
arterial occlusion depends on sever
al factors: the rapidity of thrombo
sis, the presence of collateral circu
lation, the propagation or emboliza
tion of distal thrombus and the
extent of pre-existing occlusive dis
ease. Surgical intervention with
prompt revascularization by clot ex
traction, alone or accompanied by
arterial bypass, remains the stan
dard therapy for critical ischemia
with imminent tissue loss. Mechani
cal thrombectomy with a balloon
catheter has been the preferred
technique for extraction of a distal
embolus or thrombus since its in
troduction by Fogarty in 1963.6
Unfortunately, complete thrombec
tomy is rarely achieved, and the
procedure is associated with arterial
wall injury that can range from
denudation of the intima to frank
transmural wall injury with aneu
rysm formation or vessel occlu
sion.7-10

T

Intraoperative thrombolytic ther
apy to lyse residual thrombus is an
attractive adjunct to catheter
thrombectomy and is appropriate
for a significant number of patients
with acute limb ischemia. The use
of thrombolytic therapy at opera
tion is evolving. To date its safety
and efficacy have been confirmed in
the laboratory and in a limited num
ber of patients.

Experimental Observations
A number of research studies are
relevant to the clinical application
of intraoperative thrombolysis and
provide rationale for its use. Quinones-Baldrich and colleagues11
demonstrated that 85% of dogs had
angiographically demonstrable re
sidual thrombi following a best at
tempt with retrograde balloon cath
eter thromboembolectomy. In a
clinical series, White and col
leagues12 observed residual throm
bus by angioscopy within arteries
and grafts after standard balloon
thromboembolectomy in approxi

mately 80% of patients. Dunnant
and Edwards13 demonstrated that
extensive arterial thrombosis oc
curred 6 hours after acute occlu
sion of hind limb vessels in experi
mental animals. Thrombotic exten
sion into small arteries of the skin
and muscle was demonstrated by
arteriography, blood flow measure
ments and histologic evaluation.
The extent of thrombus formation
within the microcirculation indicat
ed that simple thrombectomy of
large arteries would not likely re
store adequate perfusion to impor
tant nutrient vessels.
Quinones-Baldrich and col
leagues11 used a canine hind-limb
ischemia model to study clot clear
ing with intraoperative, intra-arteri
al infusion of fibrinolytic agents
alone or in combination with bal
loon thromboembolectomy. After
autologous thrombus was embolized into the hind-limb circulation,
thrombectomy was performed, and
the distal arteries were infused with
combinations of saline and heparin
(control limbs) or streptokinase
(SK) and heparin (experimental
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limbs). Based on comparison of preand post-treatment angiograms,
thrombolytic therapy increased
clearing of clots compared with
catheter extraction alone. In addi
tion, a trend toward increased blood
flow in the limbs receiving intra
arterial SK was observed, although
differences in flow were not statisti
cally significant. The researchers
concluded that intraoperative fibri
nolytic therapy was safe and a use
ful adjunct to mechanical thromboembolectomy.
In a rigorous experimental proto
col, Belkin, Valeri and Hobson14
assessed the potential of throm
bolytic therapy to increase skeletal
muscle viability after prolonged
ischemia. In an isolated gracilis
muscle preparation in dogs, less
muscle necrosis occurred when re
perfusion included intra-arterial ad
ministration of urokinase (UK).
Compared with saline controls, UK
treatment resulted in less muscle
edema and a trend toward increased
blood flow in the muscle. These
studies confirm clinical observations
that mechanical thromboembolectomy alone is inefficient and frequent
ly leaves residual thrombus. They
also indicate that adjunctive infu
sion of a lytic agent into the distal
arterial tree and microcirculation
can restore nutrient flow and sal
vage ischemic tissue.
Based on these observations,
thrombolytic therapy is recommend
ed for patients with extensive arteri
al thrombosis, in cases in which
complete thrombectomy is not pos
sible and critical foot ischemia per
sists and when tissue loss is immi
nent despite restoration of arterial
perfusion.

are summarized in Table I.15-20 The
overall success rate after throm
bolytic therapy was about 80%. Al
though bleeding was a feared com
plication, only Cohen, Kaplan and
Bernhard15 reported a death directly
related to thrombolytic therapy,
that was bleeding from the retroperitoneum. These investigators
infused SK with inflow occlusion in
doses of 25 000 to 250 000 IU in
13 patients. The lytic drug was
administered via a repetitive bolus
technique over 30 to 150 minutes
following balloon catheter thromboembolectomy. Effective lysis, con
firmed by arteriography, pulse re
turn and increased ankle systolic
blood pressure, was achieved in 11
(85%) patients. Enthusiasm for lytic
therapy was restrained because of
the frequency of bleeding complica
tions (42%) and vessel rethrombosis
(42%).
Norem, Short and Kerstein16
demonstrated that additional throm
bus was retrievable by repeat bal

Table 1. Results Obtained in Clinical Studies of Intraoperative Regional Fibrinolytic Therapy
Drug

M axim um
dose, IU

Patients,
no.

Success
rate, %

Complications
(no. of patients)

Cohen, Kaplan and
Bernhard15

SK

250 000

13

61

R ethrom bosis (5)
Bleeding episodes
(5)
Death
(retroperitoneal
hem orrhage) (1)

Norem, Short and
Kerstein16

SK

200 000

19

100

Parent et al17

SK

150 000

28

88

UK

150 000

W ound hem atom a
(2)
W ound hem atom a
(3)
Com partm ent
syndrom e (6)
Death not related to
lytic therapy (2)

SK
UK

100 000
375 000

23

74

Bleeding (5)
R ethrom bosis (6)

SK
UK
t-PA
UK

50 000
150 000
60 mg
250 000

53

70

Bleeding (1)

19

89

Persistent fo o t
ischem ia (2)

Study

Quinones-Baldrich et
al18
Comerota and
W hite1920

C linical E xperience
Present series

The results of five clinical series
and our own experience with in
traoperative thrombolytic therapies

loon thrombectomy after throm
bolytic therapy. Angiography re
vealed residual thrombus after Fo
garty catheter thrombectomy in 19
patients. The patients were treated
with SK in bolus doses ranging
from 50 000 to 200 000 IU fol
lowed by postoperative heparin in
fusion at low doses (200 to 500
IU/h). Repeat catheter embolectomy resulted in removal of additional
clot. All of the limbs treated with
adjunctive lytic therapy showed an
giographic improvement in distal
arterial patency. Two patients had
wound hematomas.
In a comparable patient cohort,
Parent and associates17 treated 28
patients with residual thrombus
after balloon catheter thrombecto
my with either SK or UK. The
drugs were equally effective in dem
onstrating thrombolysis (88% suc
cessful lysis), but a significantly
higher rate of bleeding complica
tions was observed with SK (29%)
than with UK (5%). Compartment

SK = streptokinase, UK = urokinase, t-P A = tissue plasminogen activator, IU = international
units
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syndrome occurred in six (21%) of
these patients. Although two deaths
occurred after therapy, neither were
judged to be directly attributable to
thrombolytic therapy.
Quinones-Baldrich and col
leagues18 treated 23 patients with
continuous gravity infusion of lytic
agents. The distal arterial tree was
infused with either SK or UK mixed
with heparin, 1 to 4 units/mL over
30 minutes. Eleven patients were
continued on intravenous heparin
postoperatively and 5 (45%) had
wound hematomas. The remaining
12 patients, who were not hepari
nized, sustained no bleeding compli
cations. The researchers concluded
that preinfusion and postinfusion
arteriography has prognostic signif
icance. In the 13 (76%) of 17 limbs
in which arterial patency improved
(based on comparison of pre- and
postinfusion arteriograms), only
one reconstruction thrombosed
postoperatively. In contrast, the
treated arteries in four limbs with
out angiographic improvement re
thrombosed. Therefore, failure to
obtain angiographically observable
clearing of thrombus with intraop
erative thrombolytic therapy results
in a high likelihood of failure, and
alternative modes of revasculariza
tion should be considered.

High-Dose Lytic Therapy
The efficacy of thrombolysis de
pends on delivery of a high concen
tration of lytic agent into the site of
thrombus. Comerota, White and
Grosh19 emphasized this principle in
their report of high-dose lytic thera
py with isolated limb perfusion in
patients with discontinuous or mul
tilevel thromboemboli. This therapy
is applicable to patients in whom a
single- or double-bolus infusion
would not be effective or when any
degree of systemic fibrinolysis
would pose a significant risk. The
technique involves systemic hepa
356
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rinization, exsanguination of ve
nous blood, application of a tourni
quet for inflow and outflow arterial
occlusion, direct arterial infusion
into the affected vessel with a high
dose (1 000 000 IU or more) of UK,
and catheter drainage of the venous
effluent. Exposure to the lytic drug
of 45 to 60 minutes yielded impres
sive results in a small number of
patients suffering from extensive
multivessel distal thromboemboli.

Comparing Lytic Agents
In a recent article, Comerota and
White20 reviewed their experience
and compared available lytic agents,
including recombinant tissue plas
minogen activator (rt-PA), as ad
juncts to surgical revascularization
in 53 patients with residual distal
thrombus after proximal thrombec
tomy and revascularization (Table
II20). Inflow was restored to the site
of infusion by either bypass proce
dures or catheter thrombectomy
and lytic agents infused directly
into residual distal thrombus. Limb
salvage was achieved in 70% of
these patients, and the favourable
outcome was deemed directly attrib
utable to thrombolysis in 47%. For
the remaining 23% of patients
whose limbs were salvaged, the ben
efit of lytic therapy was indetermi
nate because it was not clear if
reperfusion was the result of lysis
alone or the combination with in
flow reconstruction or thrombecto
my or both. The only major bleed
ing complication occurred on the
3rd postoperative day in a patient

who was systemically heparinized.
It was judged not to be the result of
lytic therapy.
Wound hematoma and compart
ment syndrome are not unexpected
sequelae of treating acute limb isch
emia, particularly when patients are
maintained on systemic heparin
after operation and prolonged limb
ischemia is the presenting sign. The
reported clinical experience is the
basis for our liberal use of fasciotomy and closed-suction wound drain
age when intraoperative throm
bolytic therapy is deemed a neces
sary part of a limb-salvage proce
dure.

UK Infusion After
Thromboembolectomy
Recently Wyffells and col
leagues21 introduced the concept of
adjuvant postoperative ankle-level
infusion of lytic agents. In a care
fully selected group of 10 patients
(12 lower extremities), the research
ers used UK to clear thrombus from
limbs that remained severely isch
emic after catheter thromboem
bolectomy. Sixteen ankle-level ar
teries were directly infused with one
or two boluses of 50 000 IU, and in
14 arteries the infusion was contin
ued postoperatively through a cath
eter because patency was not re
stored. Concomitant arterial bypass
grafting was performed in four ex
tremities. Adjuvant ankle-level UK
infusion salvaged all 12 extremities.
Postoperative bleeding was com
mon (80% of patients) and due to
catheter dislodgement or microvas-

Table II. Comparison of Intraoperative Thrombolytic Agents*
Limb salvage rate, %
Agent

no.

Lysis

Indeterminate

Total

Bleeding, °/o

rt-PA
SK
UK

2
14
37

50
36
54

0
29
19

50
64
73

0
7
0

Total/mean

53

47

23

70

2

‘ Adapted from Comerota and White 20with permission

INTRAOPERATIVE THROMBOLYSIS

cular lysis of wound thrombus;
however, only four patients re
quired transfusion. One episode of
retroperitoneal bleeding occurred in
a patient with an iliofemoral inflow
graft. Rethrombosis occurred in
two patients (20%), but they were
successfully treated by repeat lysis.

Intraoperative Thrombolysis
We have used intraoperative
thrombolysis in 19 patients and
achieved successful thrombolysis of
pathogenic clot, confirmed by arte
riography, in 17 (89%) instances.
Patient selection was based on ex
tensive residual distal thrombus
after catheter thrombectomy, docu
mented by angiography. All patients
had imminent tissue loss and no
Doppler arterial signals in the foot
or at the ankle level after proximal
thrombectomy via a femoral or pop
liteal approach. Our technique was
to dissolve 250 000 IU of UK in 50
mL of heparinized saline (1
unit/mL) and to infuse slowly (5 to
10 minutes) 15 to 20 mL into the
most distal vessels containing
thrombus. It is critical that the
agent be infused at the site of
thrombotic occlusion and under
conditions of systemic hepariniza
tion. Proximal inflow arterial infu
sion was performed for 15 minutes
followed by repeat arteriography.
Repeated bolus infusions were per
formed based on the findings of the
arteriogram to a total 250 000 IU.
Repeat thrombectomy or thrombol
ysis, or both, was performed if any
thrombus remained after lytic thera
py or if flow rate was low after
restoration of inflow. Several pa
tients required inflow procedures
such as in situ saphenous vein
bypass for diffuse femoropopliteal
atherosclerotic disease or continued
ischemia. In two patients, foot isch
emia persisted and amputation was
required.
Recently, we have been impressed

by the ability of thrombolytic thera
py to lyse fibrin-platelet aggregates
that develop at sites of vein wall
trauma during in situ and reversed
saphenous vein bypass grafting.
Three patients with fibrin-platelet
aggregation at a valve site or within
a sclerotic vein segment have been
treated with intraoperative UK infu
sion in combination with graft revi
sion. Vein graft thrombectomy with
a balloon catheter was avoided, and
all grafts treated with this approach
remained patent after operation.
Platelet aggregation is best identi
fied by either pulsed Doppler spec
tral analysis or colour duplex imag
ing because angiographic features
of the lesion can be subtle on
completion arteriography.

Patient Selection
A major problem confronting the
vascular surgeon is the propagation
of thrombus into small distal arter
ies resulting in persistent ischemia
after thrombectomy or surgical by
pass. Intraoperative thrombolytic
therapy has a number of potential
benefits in this challenging patient
group (Table III). Currently, the
rationale for such therapy is the
predictable rapid lysis that occurs
following direct delivery of high
concentrations of lytic agent into
the site of pathologic thrombus.
Use of direct-acting agent such as
UK or rt-PA results in activation of
fibrin-bound plasminogen, local fi
brinolysis, and greatly accelerated
clot lysis when compared to basal
fibrinolysis. With short periods of
local infusion, minimal derange
ment of the coagulation system can

be expected, and thus wound and
remote bleeding complications are
minimized. The most common ob
served benefits are improvement in
mechanical thrombectomy efficien
cy and lysis of inaccessible clot.
Absolute contraindications to the
use of intraoperative thrombolysis
include: recent cerebrovascular acci
dent (within 3 months); active inter
nal hemorrhage and intracranial
disease. Recent intra-abdominal or
thoracic surgery and traumatic spi
nal catheterization should be con
sidered relative contraindications.
Although the type of fibrinolytic
agent, dosage and method of in
traoperative infusion varies with in
vestigators, thrombolysis success
rates are similar. UK is currently
the preferred agent used in doses of
50 000 to 100 000 IU as a slow (5
minutes) bolus injection or gravity
infusion (15 to 30 minutes) directly
into the site or sites of thrombotic
occlusion with repeat infusion every
15 to 30 minutes as necessary
according to arteriography and
Doppler ultrasonography.

Merits of Available
Thrombolytic Agents
Preference for UK is based on
extensive experience with this agent
and the reduced incidence of bleed
ing complications compared with
SK and rt-PA. In a retrospective
review of 465 patients, Graor and
associates22 showed a greater, al
though not statistically significant,
incidence of bleeding complications
with rt-PA over UK. One patient
who received rt-PA died secondary

Table III. Potential Benefits of Intraoperative Thrombolysis
•
•
•
•
•
•
•

Improves efficiency of mechanical thrombectomy
Preserves endothelium by eliminating balloon catheter trauma
Promotes clot lysis in branch and small diameter arteries
Increases perfusion to nutrient vessels
Clears residual distal thrombus after balloon catheter thrombectomy
Lyses surgically inaccessible thrombus
Lyses nonoccluding platelet-fibrin aggregates in arterial repairs

CJS, VOL. 36. NO. 4, AUGUST 1993

357

WASSELLE AND BANDYK

to an intracranial hemorrhage,
whereas no deaths occurred with
UK. One additional patient died
after developing a thigh hematoma
and multisystem organ failure after
successful lysis with rt-PA.
Although there are selected case
reports of using rt-PA for intraoper
ative thrombolysis, one cannot ig
nore the complications when this
agent is used for percutaneous
catheter-directed thrombolysis. A
direct plasminogen activator is pre
ferred for intraoperative use.
SK must first combine with plas
minogen to form an intermediate
complex that then cleaves another
plasminogen molecule into plasmin,
whereas UK directly activates fibrinbound plasminogen to form plas
min. Most important, SK is prone to
inactivation by antistreptococcal an
tibodies, which contribute to an
unpredictable lytic effect or an aller
gic reaction in up to 12% of pa
tients and anaphylaxis in 2% to 3%
of patients. Allergic reactions have
not been seen with UK or rt-PA, but
rt-PA has been shown to cause
severe thrombocytopenia in 10% of
patients.22
In vitro studies have shown that
platelet aggregation by ristocetin
(1.5 m g/m L) is inhibited in the
presence of rt-PA. These altera
tions have not been seen with UK.23

Conclusions
Postinfusion angiographic assess
ment appears to be of prognostic
value. Patients in whom thrombol
ysis is successful, as evidenced by
postinfusion arteriography, will
usually have successful reconstruc
tion and not require additional in
tervention. If no improvement is
seen on postinfusion angiograms,
the likelihood of failure is high, and
thus alternative forms of revascular
ization should be undertaken to
assure limb salvage.17 In these si
tuations, postoperative urokinase
358
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infusion as advocated by Wyffels
and colleagues21 or isolated limb
perfusion as advocated by Comerota, White and Grosh19 or both, may
be appropriate considerations.
Laboratory data and clinical ex
perience appear to provide a solid
rationale for the use of intraopera
tive thrombolytic therapy. Current
clinical experience shows that in
traoperative thrombolytic agents
can be used safely with appropriate
guidelines and can save limbs when
used as an adjunct to balloon cathe
terization or bypass. Intraoperative
lytic therapy is also useful in treat
ing platelet-fibrin aggregates that
develop on traumatized or sclerotic
vein segments following arterial by
pass procedures.
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SPECIAL SUPPLEMENT

Thrombolytic Therapy for Deep Venous
Thrombosis: a Clinical Review
Anthony J. Comerota, MD; Samuel C. Aldridge, MD
Although anticoagulation is the treatment most commonly chosen for patients
suffering from deep venous thrombosis (DVT), thrombolytic therapy offers the
promise of dissolving the thrombus within the deep venous system, restoring
patency and preserving valve function. If this is achieved, the incidence and severity
of post-thrombotic syndrome can be reduced. Data from 13 studies comparing
anticoagulant therapy with thrombolytic therapy for DVT in 591 patients have
shown that, among those treated with heparin, 4% had significant or complete lysis,
14% had partial lysis and 82% failed to improve or worsened. Of those receiving lytic
therapy, 45% had significant or complete lysis, 18% had partial lysis and 37% failed
to improve or worsened. Long-term follow-up of randomized patients has shown that
those with successful lysis had a lower incidence of post-thrombotic syndrome and
improved long-term venous function. The failure rate of systemic lytic therapy
among patients suffering iliofemoral venous thrombosis is high; therefore,
catheter-directed thrombolysis has been adopted with increasing success.
Thrombolytic therapy, delivered systemically using catheter-directed techniques,
should be considered as an important alternative in the treatment of patients with
DVT.

he use of thrombolytic agents
for the treatment of deep ve
nous thrombosis (DVT) remains
controversial. Anticoagulation con
tinues to be the therapy chosen by
most physicians who treat DVT
despite many clinical studies show
ing that lysis of venous thrombi can
be achieved and long-term postthrombotic sequelae reduced. Un
fortunately, these observations have
not been consistently confirmed,
and many physicians are unwilling
to risk potential complications as
well as the additional expense asso
ciated with thrombolytic therapy.
Accumulated data (Tables 1 and
II1-15) suggest that significantly
more patients will regain patency of
the venous system when treated
with thrombolytic therapy than
with anticoagulation; however, 50%

T

will not respond well to lytic thera
py and will be considered failures.
In light of the fact that in patients
treated with anticoagulation alone
the post-thrombotic syndrome may
take many years to develop and the
fact that many patients treated with
lytic agents may not have a good
response, it is understandable that
physicians may not appreciate the
early and long-term advantages of
thrombolytic therapy for DVT.
Those who argue against the use
of lytic agents point to the risk of
hemorrhage, the increased cost, the
limited applicability to only 15% to
20% of patients and the low report
ed success rate. However, propo
nents of lytic therapy emphasize
that current treatment is less risky
than that described in early reports.
They argue that the cost of the

post-thrombotic syndrome is high,
although it is spread over many
years. Although some patients with
DVT are not candidates for lytic
therapy (postoperative and stroke
patients), many young people are
eligible, and they are likely to gain
the greatest benefit from successful
thrombolysis.
Reports of the results of throm
bolytic therapy for DVT are poten
tially biased, because thrombolytic
therapy is usually reserved for pa
tients who have the most severe
disease (massive iliofemoral DVT
and phlegmasia cerulea dolens).
Treatment of these patients is prone
to failure, because systemic admin
istration of plasminogen activator is
unlikely to allow the drug to reach
the thrombus. In most of these
patients, the iliofemoral venous sys-
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tem contains extensive long-seg
ment occlusion, obliterating blood
flow in that region. Plasminogen
activator is unlikely to reach the
clot. Patients with less severe forms
of venous occlusion are more likely
to respond favourably to lytic thera
py, although they are usually treat
ed with anticoagulants alone.

ency of the deep venous system and
maintaining valvular function. Am
bulatory venous hypertension is the
underlying pathophysiologic feature
of the post-thrombotic syndrome
and is created by valvular incompe
tence and residual venous obstruc
tion. Therefore, one can understand
how treatment of the acute throm
botic process might influence the
long-term prognosis.
Shull and colleagues16 studied pa
tients following acute DVT. In addi
tion to physical examination, they
measured ambulatory venous pres
sures, performed ascending phle
bography and assessed the function

Rationale for Thrombolytic
Therapy
The goal of thrombolysis for
DVT is preservation of venous func
tion, which includes restoring pat

of the popliteal valve. Although
their data indicated that valvular
function had the most significant
impact on ambulatory venous pres
sures, residual venous obstruction
was associated with higher ambula
tory venous pressures for any de
gree of valvular function. As ex
pected, the combination of obstruc
tion and valvular incompetence was
associated with the most severe
ambulatory venous hypertension.
More recently, 21 patients with
acute DVT who were treated with
anticoagulation were followed up
prospectively with venous duplex
imaging.17 Valvular incompetence

T a b le 1. R e vie w o f A n tic o a g u la tio n V e rs u s L y tic T h e ra p y fo r D eep V e n o u s T h ro m b o s is

S e rie s

Y ear

In v e s tig a tio n ty p e
(to ta l no. of
p a tie n ts )

T re a tm e n t
group
(no. of
p a tie n ts )

S ig n ific a n t/
c o m p le te
resolu tion

B ro w s e , T h o m a s a n d P irn 1 1 9 6 8
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(1 0 )

SK
H ep

(5 )
(5 )
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5
1
6
2
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0
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0
9
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(5 )
(5 )
(4 )
(0 )
(1 2 )
(1 2 )

NA
NA
2 (1 0 )
2 (1 0 )
2 (8)
0 (0)
0 (0)
0 (0)

(2 6 )
(1 0 )

NA
NA
(8 )
(2 )
(2 4 )
(0 )

2 (5 )
1 (2 )*
1 (2 )
0 (0)

NA
NA

N one
1 (1 2 )*
N one
1 AD
N one
N one
N one
N one
1 (4 )*
N one

1t
N one
N one
2§
1
1

1 (8 )*
N one
N one
N one
N one
N one
N one
N one

NA
NA
NA
NA
NA
NA

N one
N one
N one
N one
None
N one

P R = p ro s p e c tiv e ra n d o m iz e d , PRB = p ro s p e c tiv e ra n d o m iz e d b lin d e d in te rp re ta tio n , P NR B = p ro s p e c tiv e n o n ra n d o m iz e d b lin d e d in te rp re ta tio n , S K =
s tre p to k in a s e , H ep = h e p a rin , rT P A = re c o m b in a n t tis s u e p la s m in o g e n a c tiv a to r, PE = p u lm o n a ry e m b o lis m , N A = n o t a va ila b le
'In tr a c r a n ia l h e m o rrh a g e
t S a m e s tu d y p o p u la tio n
fN o n fa ta l p u lm o n a ry e m b o lis m p rio r to th e ra p y
§ F a ta l p u lm o n a ry e m b o lis m d u rin g th e ra p y
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occurred in 62% of them within 271
days of the acute event. Some
valves remained competent for up
to 3 months after the acute throm
botic episode before developing in
sufficiency, and in some patients
incompetent valves developed in
vein segments that were not in
volved with the thrombotic process.
Killewich and associates17 suggest
ed that the mechanism by which
valvular incompetence occurs fol
lowing DVT might involve more
than a physical effect of the throm
bus on the valve. However, they
also observed that 38% of the pa
tients did not have valvular incom
petence during the study. For most
of the patients who maintained
long-term valve function, recanali
zation of the original thrombi was
early and complete. These observa
tions also suggest that early lysis of
the occluding thrombus preserves
valve function.
Management of patients with
DVT should include the following:
supportive patient care; prevention
of extension and embolization of
the thrombus; restoration of paten
cy of the deep venous system; and
maintenance of venous valvular
function. Eliminating the thrombus
from the deep venous system can
potentially achieve the last three of
these goals. Although thrombolytic
agents have been used in patients
with DVT to this end, several im
portant questions must be answered
to put the efficacy of lytic therapy
into proper perspective: What is the
natural history of anticoagulant

therapy? Can venous thrombi be
lysed? Is lysis of venous clot impor
tant for maintenance of long-term
venous valvular function?

Literature Review
Thirteen studies have compared
anticoagulant therapy to throm
bolytic therapy for acute DVT (Ta
ble I1-15). Patients were evaluated
with ascending phlebography before
and after therapy.1' 15 Only 4% of
the patients treated with anticoagu
lants had significant or complete
lysis, and an additional 14% had
partial lysis (Table II). The majority,
82%, had either no venographic
clearing or their thrombi were ex
tended. Only a minority of patients
experienced sufficient clearing of
thrombus to expect a return of
normal venous valvular function. Of
patients who underwent throm
bolytic therapy, 45% had significant
or complete clearing of the clot, and
18% had partial clearing.
Four other studies described the
results of thrombolytic therapy for
acute DVT but were considered un
suitable for inclusion in the collec
tive data.18-21 One group failed to
record the initial response to treat
ment and did not have an an
ticoagulation group;18 another com
pared streptokinase (SK) with uro
kinase (UK) alternating with hepa
rin and also did not use an anticoagulation cohort.19
A third study described the ve
nous hemodynamic changes follow

Table II. Phlebographic Outcome (% Lysis) of Anticoagulation Versus Thrombolytic Therapy for
Acute Deep Vein Thrombosis: Pooled Data From 13 Studies1-15
Outcome, % lysis
Treatment
(no. of patients)

None

Partial

Significant
or complete

Heparin (254)
82
14
4
Lysis (337)______________________ 37_______________ 18___________________ 45___________
•References 6 to 8 report the results of the same patient group, so for tabulation purposes they
are considered as one report.

ing treatment with either SK or
heparin.20 The patients were catego
rized according to their initial re
sponse to therapy; however, reports
were based on less than one-third of
the patients initially randomized
and treated. Thus, it would be in
correct to assume that the response
of the patients followed up for 24
months is representative of the en
tire group. Also, patients who re
main symptomatic are more likely
to seek continued care than those
who are feeling well; the poor re
sults may represent a bias due to
patient self-selection.
The fourth study21 described the
response of calf vein thrombosis to
treatment with heparin or SK. Al
though the researchers quantita
tively analysed the responses of the
two groups of patients, they did not
report individual patient response,
which precludes their inclusion in
this tabulation.

Long-Term Follow-up Studies
Two studies1122 of prospectively
randomized treatment of acute DVT
by anticoagulation or thrombolytic
therapy followed patients over the
long term (1.6 years and 6.5 years,
respectively). Protocols were similar
in the two studies, and both used
the same plasminogen activator
(SK). Long-term assessment showed
that most of the patients who were
free of post-thrombotic symptoms
had been treated with SK, whereas
most of the patients with severe
post-thrombotic symptoms had
been treated by anticoagulation
alone.
Perhaps the most critical ques
tion is: Does lysis of deep venous
thrombi preserve valvular function?
In a long-term follow-up of a pro
spective, randomized study,13 sig
nificant functional benefit was dem
onstrated 5 to 10 years after pa
tients with DVT had successfully
CJS, VOL. 36, NO. 4, AUGUST 1993
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undergone lytic therapy. The acute
response to SK therapy was similar
to that reported in Table II.
Patients were followed over the
long term for popliteal valve incom
petence and evidence of venous in
sufficiency (measured by photople
thysmography and foot volumetry).
Patients in whom lysis was initially
successful were compared with
those whose treatment did not re
sult in lysis, regardless of the thera
py they received. Patients who re
ceived lytic therapy showed no evi
dence of limb venous insufficiency
compared with those who did not
receive lytic therapy. Only 9% of the
patients in whom successful lysis
had occurred had incompetent pop
liteal valves; 75% of those without
lysis had popliteal valve incompe
tence (p > 0.001). It appears that in
patients who do not have a contra
indication to thrombolytic therapy,
thrombolysis is preferred. The issue
of whether lytic therapy for acute
DVT reduces the incidence of recur
rent DVT (by eliminating acute
thrombus thereby reducing the
thrombogenic foci over the long
term) is being studied.

Causes of Failure
of Thrombolytic Therapy
for DVT
Conditions causing the failure of
lytic therapy to re-establish patency
of the deep venous system include
the following: extensive DVT in
which the plasminogen activator
does not contact the clot; old, orga
nized thrombus; inadequate fibrino
lytic response; and premature termi
nation of lytic infusion.
In many centres, only patients
with the most extensive venous
thrombosis are treated with throm
bolytic therapy. Because these pa
tients frequently have iliofemoral
venous thrombosis, they are likely
to have the poorest long-term out
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come. This patient selection process
represents an inherent bias in evalu
ation of outcome based on therapy.
In such patients, the venous system
is frequently occluded by the throm
bus and there is no blood flowing
through the involved veins. Any
plasminogen activator infused systemically will not contact the
thrombus and cannot be expected
to restore patency.
The success of lysis is related to
the amount of fibrin bound to plas
minogen within the thrombus and,
therefore, correlates with the age of
the thrombus. Treatment of pa
tients whose thrombus is more than
1 week old is less likely to be
successful. Unfortunately, clinicians
cannot accurately determine the age
of the clot but must rely on a
patient’s symptoms. In many cases,
the symptoms and thrombus age
may not be closely correlated.
The success of systemic lytic
therapy depends on the activation
of plasminogen and the generation
of a systemic fibrinolytic response.
Even direct-acting plasminogen ac
tivators, which have high fibrin
specificity, should produce a fibri
nolytic response. To ensure that
systemic thrombolysis has been
achieved, fibrinolytic activation
must be demonstrated. Fibrinogen
level, prothrombin time, partial
thromboplastin time and fibrin deg
radation products are monitored
during infusion to document the
presence of a systemic lytic effect.
SK has been used most frequent
ly for the treatment of DVT. How
ever, circulating streptococcal anti
bodies neutralize the infused drug
and, therefore, limit fibrinolytic ac
tivity. SK has various systemic ef
fects on the coagulation system.
Circulating levels of plasminogen
and fibrinogen are markedly de
creased during SK therapy.
UK induces clotting defects simi
lar to those mentioned for SK.
However, coagulation parameters

do not deteriorate as much and
normalize more rapidly with UK
than with SK. When UK is used,
activation of fibrin-bound plasmino
gen allows fibrinolysis to occur in a
relatively inhibitor-free environ
ment. UK inhibitors have also been
demonstrated.

Duration of Thrombolytic
Therapy
In a prospective evaluation of 29
patients receiving thrombolytic
therapy for acute DVT at Temple
University, partial clearing was ob
served in 39%, and 30% failed to
improve or got worse.23 Patients
were followed up with sequential
noninvasive exam inations for
thrombus resolution every 12 to 24
hours. All patients with a positive
response demonstrated clot lysis
within 24 hours of initiation of
therapy. In 38% of the patients,
lytic therapy was terminated while
the clot was lysing. Of patients who
had a partial response, the lytic
agent was discontinued in 64%
while the clot was lysing but before
maximal resolution was achieved.
Improper duration of therapy may
be responsible for failure to clear
the clot. However, the patient may
be placed at a higher than neces
sary risk of a bleeding complication
if infusion is continued beyond the
patient's maximal response. If the
clot shows no lysis after 24 hours
or if the clot completely resolves
during that time, lytic therapy
should be discontinued. On the
other hand, if lysis occurs or is
incomplete, lytic therapy should be
continued until maximal lysis or
resolution is confirmed.

Iliofemoral Thrombosis
In our experience, systemic
thrombolytic therapy frequently
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fails in patients with iliofemoral
venous thrombosis.24 As previously
mentioned, systemically delivered
plasminogen activators may not
reach the thrombus, because no
blood is flowing over the clot. Such
patients require alternative methods
of delivery of the plasminogen acti
vator. We have used many of the
techniques employed for catheterdirected thrombolysis of arterial oc
clusion.
Based upon our current experi
ence, we recommend direct intraclot
infusion for patients with iliofemor
al venous thrombosis and those
with early phlegmasia cerulea dolens. Ipsilateral intra-arterial infu
sion with systemic doses of plas
minogen activator has been used to
treat patients with severe phleg
masia cerulea dolens who have
demonstrated signs of early venous
gangrene.
Before therapy, the extent of
thrombus must be determined. We
believe that venous duplex imaging
accurately assesses the state of the
infrainguinal veins of the leg. The
proximal extent of the thrombus
should be assessed phlebographically, accompanied by contralateral iliocavography. This knowledge is im
portant in evaluating alternatives of
therapy and in assessing whether
there is clot in the inferior vena
cava and contralateral iliac venous
system.
If the patient has nonischemic
iliofemoral thrombosis or early
phlegmasia cerulea dolens, direct
intraclot infusion is suggested. The
sheath is placed in the contralateral
femoral vein through which a guide
wire and catheter can be threaded
around the caval bifurcation into
the common and external iliac vein
thrombus. An ipsilateral catheter
can be used at the physician’s dis
cretion. Use of the contralateral
femoral vein allows placement of a
vena caval filter before infusion
through the same sheath that is

used for catheter-directed lysis. Al
though we have not used caval
filters routinely, they have been
inserted in patients presenting with
acute pulmonary emboli concurrent
with their acute venous thrombotic
episode.
Once a guide wire has been posi
tioned appropriately in the throm
bus, a catheter with multiple side
holes is used to infuse systemic
doses of lytic agent. Repeat phle
bography through the infusion
catheter is performed at 6- to
8-hour intervals. Therapy is contin
ued until maximal lysis is achieved.
Iliac vein thrombi tend to lyse
sooner than more distal thrombi
due to the direct activation of fibrinbound plasminogen. Venous duplex
imaging every 12 hours is used to
follow lysis of the more distal clot.
If the infusion catheter cannot be
positioned appropriately in the iliac
vein thrombus, a venous thrombec
tomy is performed using current
techniques.24
Patients who present with severe
phlegmasia cerulea dolens or ve
nous gangrene often demonstrate
arterial hypoperfusion. This raises
concern over the possibility of ar
terial or arteriolar thrombosis in
addition to their severe venous hy
pertension. In such cases we recom
mend intra-arterial infusion, placing
the catheter into the ipsilateral fem
oral artery from the contralateral
side. Infusing systemic doses of
lytic agents by this method ensures
that the entire dose perfuses the
leg. We have observed lysis of distal
venous thrombi and a rapid drop in
venous pressures associated with
early symptomatic improvement fol
lowing intra-arterial infusion. Al
though lysis of distal clot can be
achieved, thrombus in the iliofemor
al segment can persist. In such
cases we have performed venous
thrombectomy, although attempts
at intraclot infusion are reasonable.
This approach to the patient with

extensive iliofemoral DVT has
proved safe; no increased morbidity
occurred in six patients treated dur
ing the past 3 years. When the
thrombus was acute and did not
extend into the cava, and the guide
wire could be appropriately posi
tioned, remarkable results were
achieved.

Conclusions
Patients who present with DVT
should be thoroughly evaluated and
treated according to the severity of
their disease. Unfortunately, some
centres treat all patients with DVT
similarly. The best opportunity to
clear the venous system of throm
bus pharmacologically is early in
the course of acute DVT; the likeli
hood of successful lysis diminishes
with time. Knowing the underlying
pathophysiology of the post-thrombotic syndrome, one can appreciate
the desirability of rapidly clearing
thrombi from the deep venous sys
tem.
Pooled data from 13 studies com
paring patients treated with lytic
agents with those treated with an
ticoagulation alone revealed signifi
cantly better clearance achieved
with lytic therapy. Fewer studies
have reported follow-up data, and
the results were inconsistent. How
ever, patients treated with lytic
agents appeared to benefit, especial
ly if lysis was clearly demonstrated.
Modifying the method of delivery
of plasminogen activator for pa
tients with iliofemoral DVT ensures
high-dose infusion of the lytic agent
into the thrombus and should im
prove therapeutic outcome.
We have used intra-arterial deliv
ery of UK for massive phlegmasia
cerulea dolens or early venous gan
grene as well as direct catheter
infusion into the iliofemoral clot in
patients with less severe iliofemoral
DVT. Both techniques can be used
CJS, VOL. 36, NO. 4, AUGUST 1993

363

COMEROTA AND ALDRIDGE

with significant advantage to the
patient without compromising sub
sequent care.
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SPECIAL SUPPLEMENT

Long-Term Results of Treatment for
Axillary Subclavian Vein Thrombosis
John Malcynski, MD; Thomas F. O’Donnell Jr., MD; William C. Mackey, MD; Victor A. Millan, MD
Thrombolytic therapy is an effective method for reopening an occluded venous
segment, but little is known about the long-term results of thrombolysis via direct
intravenous route for axillary subclavian vein thrombosis (ASVT). Our experience
with 13 cases of primary ASVT illustrates the possible advantages of a protocol
consisting of lytic therapy, surgical decompression and percutaneous balloon
angioplasty if a high-grade stenosis persists. If accompanied by adjunctive therapy
to correct the underlying cause, thrombolytic therapy for ASVT results in acceptable
long-term symptom relief and vein patency.

lthough described as early as
1866,1 axillary subclavian vein
thrombosis (ASVT) is a relatively
rare condition. For example, in five
studies of surgical thrombectomy
the average number of cases of
ASVT was four per study.2 6 Fur
thermore, surgery for chronic
symptoms following ASVT is even
rarer and was described as isolated
incidents until the recent series by
Kunkel and Machleder.7 In a review
of thoracic outlet syndrome (TOS)
at the Mayo Clinic,8 only 3.5% of
nearly 100 cases had ASVT, but,
paradoxically, 80% of patients with
primary ASVT had previous symp
toms of intermittent venous com
pression due to TOS. Most cases of
primary ASVT, therefore, are relat
ed to a repetitive mechanical pro
cess exerted by the structures of
the thoracic outlet on the axillary
subclavian veins.9
This report focuses on 13 cases
of primary ASVT, reviewing the

A

possible advantages of a protocol
consisting of: direct intrathrombolytic therapy; subsequent surgical
decompression; and percutaneous
balloon angioplasty, if a high-grade
stenosis persists.

Patients and Methods
From 1986 to 1990 inclusive, 23
patients were evaluated and treated
at the New England Medical Center
Hospitals (NEMCH) for ASVT. Pa
tients presented directly to NEMCH
with upper extremity symptoms or
were referred to our institution for
treatment of previously diagnosed
ASVT. They ranged in age from 19
to 71 years (mean 40.5 years).
The ASVT was classified as pri
mary or secondary. Primary ASVT
(“effort” or compressive syndrome)
occurred in 12 patients (13 limbs as
one condition was bilateral). Eleven
patients had secondary ASVT due

to: direct trauma of an indwelling
catheter (eight patients); pre-exist
ing malignancy (two); or radiation
(one).
Primary ASVT

The 12 patients with primary
ASVT ranged in age from 19 to 52
years (mean 31 years). Criteria for
inclusion in this group were identi
fication of an “effort”-induced
cause of the thrombosis, due to a
characteristic predisposing event as
sociated with repetitive upper ex
tremity exercise, or identification of
ASVT or stenosis by ascending
phlebography, either at NEMCH or
at the referring institution. Patients
were excluded from the study if
they had: a history of malignancy;
evidence of a secondary cause for
ASVT, including the presence of an
indwelling subclavian catheter; past
or present history of a coagulopa
thy; or chronic renal failure.
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The right and left arms of one
patient were affected equally. Six of
the patients were male (including
the one with bilateral ASVT). Six
reported a history of repetitive
upper extremity exercise: three lift
ed weights, two played tennis and
one was an all-American freestyle
swimmer. Four patients could iden
tify a probable cause of the event in
their occupation or household
tasks. A precise event could not be
identified by two patients: a prison
er and a patient who sustained a
rotator cuff contusion in a motor
vehicle accident 6 weeks before the
onset of his symptoms.

Clinical Characteristics
The common, characteristic
symptom displayed by the patients
was spontaneous onset of painful
swelling of the affected extremity.
All patients sought medical atten
tion within 1 to 3 days and reported
swelling, which reached a maximum
within 1 to 3 days before admission,
except for the patient involved in
the motor vehicle accident, whose
symptoms occurred over 2 to 3
weeks. Sixty percent of the patients
observed cyanosis, half of these
patients also had rubrous skin or
mottling of the extremity on depen
dency. Concomitant neurologic
symptoms, characterized by numb
ness, occurred in four patients.
Clinical examination revealed a
swollen arm with cyanosis when the
arm was in the dependent position,
and venous engorgement may be
present.

Diagnosis
Diagnosis should be established
by phlebography after noninvasive
screening.10 Although the diagnosis
may be made noninvasively by im
pedance plethysmography (IPG),
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quantitative photoplethysmography
or duplex scanning, these methods
are limited. Collateral vessel forma
tion may obviate the resistance
changes needed to produce an ab
normal impedance plethysmogram,
particularly at rest.11 Because there
is a blind spot behind the clavicle,
which prevents venous compres
sion, duplex scanning can give false
negative results.12 The recent use of
colour-enhanced flow may improve
diagnosis of ASVT by duplex scan
ning.

and to correct a residual venous
defect, if one exists. Options for
treating the acute thrombus in
clude: intravenous heparin chang
ing to warfarin, which depends
upon the development of collateral
vessels, recanalization of the sub
clavian and axillary veins or both;
surgical thrombectomy; and throm
bolytic therapy, either by a systemic
intravenous route or by direct intra
thrombus administration by cathe
ter .
Conventional treatment of ASVT
with elevation, heat and an
ticoagulation with heparin and war
farin resulted in an appreciable inci
dence of chronic symptoms (Table
I12-15). At least one-third of the
patients experienced incapacitating
symptoms. Like iliofemoral throm-

Clinical Management
The goals in treatment for prima
ry ASVT are: to remove the throm
bus; to relieve venous compression;

Table I. Results of Conventional Treatment of Axillary Subclavian Vein Thrombosis (ASVT) With
Elevation, Heat and Anticoagulation With Heparin and Warfarin
Residual symptoms, %
Series

Year

Type (no.)

None

Mild

Disabling

Tilney, Griffiths
and Edwards13

1970

Primary (11)
Secondary (23)

27
26

18
31

Donayre and
associates14

55
43

1986

Ameli and associates15

1987

0
0
23
23

22
16
67
23

Kerr and associates12

1990

Primary (9)
Secondary (23)
Primary (6)
Secondary (13)
Primary (9)
Secondary (23)

78
0
0
0
44
30*

—

___

—

—

'Nine died.

Table II. Results of Surgery for Acute Thrombosis in Patients With ASVT
Series

Patency, %

Relief of
symptoms, %

Thrombectomy

100

100

6

Thrombectomy

100

100

Year

Number

1966

2

1971

Approach

Drapanas
and Curran2
Adams and
De Weese3
Urshel and
Razzuk4
Aziz and
associates5

1972

4

Thrombectomy/1st rib

100

100

1986

4

100

100

De Weese6

1990

6

Thrombectomy/med
clav/patch
Thrombectomy/med
clav

100

80*

'A fter 20 years
1st rib = resection of the first rib, med clav = resection of the medial portion of the clavicle,
patch = patch angioplasty
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bosis, surgical thrombectomy for
acute primary ASVT has been used
in a limited number of patients
(Table II2"6). Drapanas and Curran2
reported on two patients: following
thrombectomy, patency of the sub
clavian vein as evidenced by phle
bography was maintained and
symptoms were relieved. Adding de
compression of the subclavian vein
at the time of the thrombectomy
resulted in excellent patency rates
and relief of symptoms.34 De
Weese6 recently reported the status
after more than 20 years of six
patients who had undergone surgi
cal thrombectomy; for four of them,
treatment had included concomitant
removal of the medial clavicle. Pat
ency and long-term symptomatic
relief was achieved in five patients.
Surgical thrombectomy, however,
has two major disadvantages be
cause the operation is performed
during acute inflammation in an
area where severe blood loss and
brachial plexus injury present a
significant risk.
Ascending phlebography revealed
ASVT in nine limbs and stenosis in
four. Seven of the occluded ASVT
and two of the stenotic vessels were
treated with lytic agents adminis
tered directly into the thrombus by
catheter. Two patients presenting
with chronic incapacitating symp
toms secondary to a previous epi
sode of ASVT underwent venous
bypass; two patients with stenotic
axillary subclavian vein underwent
no lytic therapy but first-rib resec
tion.
Eight patients underwent surgi
cal decompression of their subclavi
an axillary veins. Four patients un
derwent transaxillary first-rib resec
tion by a well-described technique,16
and another four patients under
went scalenectomy. Duplex scan
ning was used in all patients to
determine patency of the axillary
subclavian veins or venous bypass
at late follow-up.

Ascending Phlebography

Of the nine limbs with occluded
subclavian veins, seven displayed
accompanying axillary vein involve
ment. Extension of thrombus into
the brachial and basilic veins oc
curred in three patients; in one
patient, both the innominate and
distal internal jugular veins were
affected. In all patients, collateral
venous flow through the innomi
nate, basilic, cephalic, internal jugu
lar was demonstrated; in one, there
was collateral flow with the superi
or vena cava. The cephalic vein was
the main outflow route for the
entire limb of one patient.
Among the four patients with
stenotic subclavian veins, venogra
phy suggested acute thrombus
overlying a chronic stenosis in two;
no evidence of acute thrombus was
found in the other two.
Thrombolytic Therapy

Nine patients were treated by
continuous direct intraluminal ther
apy using streptokinase (two pa
tients) or urokinase (seven pa
tients). A catheter was inserted into
the basilic vein on the affected arm
and advanced into the brachial vein
and, subsequently, into the axillary
vein. Contrast material was injected
to permit visualization of the par
tially or totally occluding thrombus.
The catheter was then placed within
the thrombus so that thrombolytic
agents could be administered. In
general, the patients received an
initial bolus of 250 000 units of
urokinase over 1 hour followed by
continuous infusion at the rate of
1000 IU/min. Sequential phlebog
raphy was used to determine the
rate and extent of lysis. Heparin
was administered to all patients
when thrombolytic therapy began
to achieve a partial thromboplastin
time of 1.5 to 2 times that of the
daily laboratory control. All patients

subsequently received warfarin for 3
to 6 months after the initial treat
ment. Only one patient suffered a
minor groin hematoma with throm
bolytic therapy.

Results
Of the nine limbs undergoing
thrombolysis, phlebography re
vealed complete lysis in seven. One
month later, phlebography showed
that two of the seven limbs had
rethrombosed. Subsequent assess
ment (average of 2 years later) of
the five limbs that remained patent
showed that they were still func
tioning; the two limbs that had
rethrombosed remained occluded;
and the two in which thrombolytic
therapy had failed showed recanali
zation.
A defect in the form of residual
filling was observed in patients
whose thrombus had lysed after the
initial course of thrombolytic thera
py. Two patients were treated by
percutaneous balloon angioplasty
for residual venous defects that
were thought to be hemodynamically significant (Fig. 1).

Long-Term Follow-up
The 12 patients (13 limbs) were
assessed for relief of symptoms as
well as for patency of the axillary
subclavian veins by duplex scanning
and were divided into four groups
based on their treatment. Of the
five patients who were treated by
thrombolysis and decompression,
all had patent axillary subclavian
veins and were symptom free. Of
the four patients who underwent
lysis alone, three had occluded
veins and moderate symptoms (ache
and swelling, particularly with exer
cise). The two patients who had
stenosis but no acute thrombus had
mild symptoms, principally neuroCJS, VOL. 36. NO. 4, AUGUST 1993
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logic, following their first rib resec
tion. Finally, the patients who un
derwent internal jugular to distal
axillary vein bypasses were symp
tom free and had returned to work.
Their bypasses were patent by du
plex scanning.

FIG. 1. (Top) Patency has been
achieved by direct intrathrombus infu
sion of urokinase. Some persistent
thrombus is seen just proximal to
junction of internal jugular and subcla
vian veins. Stenosis persists. (Middle)
Balloon angioplasty catheter is passed
along basilic vein into axillary subcla
vian veins to allow dilation of stenosis.
(Bottom) Result following balloon dila
tion of stenosis.
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Discussion
Management of acute primary
ASVT with direct intrathrombus
lytic therapy followed by surgical
decompression was associated with
relief of symptoms and venous pat
ency in over 75% of the patients
treated.
Should patients with primary
ASVT (“effort” thrombosis) be
treated with anything other than
heparin with conversion to warfa
rin? Swinton, Edgett and Hall17 ob
served that in 21 of 24 patients
(88%) with acute ASVT chronic
symptoms (ache in their arms and
heaviness with exercise) developed.
About half these patients were
treated with anticoagulants for their
initial episode. Three subsequent
studies12' 14 showed a relatively high
proportion of disabling symptoms:
55% of patients with primary
ASVT,13 78%14 and 44%.12 Only
Ameli and associates15 reported a
low number of disabling symptoms
among 19 patients with ASVT, of
which six conditions were due to a
primary cause (Table I). However,
four of these six patients had mild,
residual symptoms.
Chronic venous insufficiency
(CVI) of the upper extremity differs
from that in the lower extremity in
that obstruction is the major cause
of symptoms. In lower extremity
CVI, valvular incompetence is the
chief cause of symptoms. Therefore,
symptoms following acute ASVT
are related to inadequate flow
through collateral veins around the
occluded or stenotic main veins, the
axillary and subclavian veins.
Musculotendinous structures can
compress the collateral veins during
specific shoulder girdle exercises
and aggravate the underlying prob
lem.5 When this occurs with prima
ry ASVT, the vein should be re
opened.
Thrombolytic therapy for ASVT
has the possible advantage of

achieving rapid clot lysis that can
relieve acute symptoms. Thrombol
ysis can be followed by surgical
relief of vein compression and cor
rection of the underlying venous
defect, if necessary.
Results of thrombolytic therapy
in 10 series718' 25 are summarized in
Table III. Most series include fewer
than 10 patients, again illustrating
the rarity of ASVT. Immediate lysis
of thrombus in the subclavian and
axillary veins was achieved in 75%
to 100% of patients. Long-term pat
ency, however, depended on the
subsequent use of a variety of meth
ods to relieve vein compression. As
in our series, most researchers ob
served a low complication rate with
thrombolysis. We observed no
major hemorrhagic complications.
As with the treatment of acute
arterial graft occlusion, direct ad
ministration of the thrombolytic
agent into the thrombus caused
rapid thrombus dissolution, perhaps
because the lytic agent is concen
trated in the area where it must act.
The two patients who failed to
respond to thrombolysis in our se
ries both had long-standing (more
than 5 days) ASVT. Two additional
patients experienced occlusion with
in 6 weeks of treatment and both
demonstrated a high-grade narrow
ing of the vein following lysis. Per
haps percutaneous balloon angio
plasty immediately following initial
lytic therapy might have improved
the patency in these patients.
Although lytic therapy appears to
be a safe, effective means for
achieving vein patency, there is de
bate as to the best method for
surgical decompression of the sub
clavian and axillary veins. Most sur
geons wait 6 to 8 weeks after
thrombolysis to allow inflammation
to subside.7 During this time the
patient is maintained on warfarin.
In our series, we used first rib
resection and scalenectomy equally.
The anatomy of the subclavian

AXILLARY SUBCLAVIAN VEIN THROMBOSIS

and axillary veins at the thoracic
outlet differs from that of the bra
chial plexus. The subclavian vein
enters the costoclavicular space
passing anterior to the first rib, but
posterior to the clavicle. It then
passes through the “pincers” of the
posteriorly located scalenus anticus
muscle and first rib and the anteri

orly placed clavicle and subclavius
muscle. In the military position, the
clavicle and first rib may compress
the subclavian vein and the clavicle
and first rib or clavicle and scalenus
anterius muscle can compress the
subclavian vein with hyperabduc
tion and external rotation of the
arm. Resection of the first rib can

prevent potential compression of a
bony structure, as well as the scale
nus anticus and subclavius mus
cles.25 Scalenectomy, however, is a
less morbid procedure and, when
performed through a supraclavicu
lar approach, allows concomitant
treatment of any venous narrowing
by patch angioplasty. As much of

T a b le III. R e s u lts o f T h ro m b o ly tic T h e ra p y f o r A S V T

S e rie s
B e c k e r and
a s s o c ia te s 18
W e b b and
K e rs te in 19
D ru y and
a s s o c ia te s 20
T a y lo r and
c o lle a g u e s 21
S te e d and
c o lle a g u e s 22
L a n d e rc a s p e r and
a s s o c ia te s 23
S tra n g e -V o g n s e n
a n d c o lle a g u e s 25
K u n k e l and
M a c h le d e r17
W ils o n , Z a h n and
N e w m a n 24

P a te n c y , %
A d ju v a n t

R e lie f of
s y m p to m s , °/o

100

50*

100

S K , IV d ire c t

100

0

5

S K /U K , d ire c t

100

60

40

60

1985

2

S K , IV

100

100

100

100

1986

2

SK, IV

50

0

50

1987

3

S K , IV

100

100

67

100

1989

13

S K , IV

100

85

90

55

1989

24

S K /U K , d ire c t

81

100

?

1990

8

S K , IV

86

0

80

Y ear

Num ber

A g en t
an d route

1983

4

S K /U K , d ire c t

1985

1

1985

Im m e d ia te

loot

L o n g -te rm

?

'V e n o u s s u rg e ry
tW h e r e ly s is w a s ach ieve d
S K = s tre p to k in a s e , U K = u ro k in a s e , IV = in tra v e n o u s

FIG. 2. Treatment of chronic axillary subclavian vein thrombosis. (Left) Right internal jugular to axillary vein bypass. Patient’s
head is at top, chest is to right. Cephalic segment of internal jugular vein has been ligated and divided so that it may be
anastomosed to axillary vein. (Right) Postoperative phlebogram of patent internal jugular vein to axillary vein bypass with dye
coursing up arm through internal jugular vein and into innominate vein.
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the scalenus anticus muscle as pos
sible should be removed. Simple
scalenectomy will not suffice. Final
ly, resection of the medial portion
of the clavicle also permits bony
decompression and potential correc
tion of any venous stenosis, but is
cosmetically displeasing, particular
ly for women. We advocate first rib
resection as the initial approach to
decompression.
In our series, over 90% of pa
tients presenting with ASVT had a
residual defect after lysis of the
underlying thrombus (Fig. 1). When
such a defect appears hemodynamically significant it should be cor
rected. Although dilation of subcla
vian vein stenosis by percutaneous
balloon angioplasty is minimally in

vasive, it has not been associated
with acceptable long-term patency.
Glanz and associates26 observed an
initial patency rate of 76% in 19
patients; this proportion was only
35% after 1 year and at 2 years,
patency was a dismal 2%. Until such
patency rates improve, venous
patch angioplasty may be the best
approach to relieving venous steno
sis.
Two patients were referred to us
for treatment of chronic obstructive
symptoms following acute ASVT.
Results of venous bypass surgery to
relieve chronic symptoms of ASVT
are summarized in Table IV.27-30
Using Jacobson and Haimov’s30 ap
proach, we anastomosed the inter
nal jugular vein to the distal axil

lary vein (Fig. 2). More than 5 years
later, both patients have a patent
bypass, as observed by duplex scan
ning, and relief of symptoms. Al
though this is a relatively simple
venous procedure with a favourable
patency rate, its application is limit
ed by the extent of distal thrombo
sis. If the thrombus has extended
into the distal axillary or basilic
vein, then the internal jugular vein
is not long enough to be used as a
bypass. The patency rate of venous
bypass drops off sharply, if exten
sion with saphenous or other veins
is required.31
Direct intravenous lytic therapy is
a reasonable approach to treating
ASVT. Decompression by first rib
resection (preferred) or scalenecto
my should follow to remove the
mechanical cause. Less clear is the
management of chronic stenosis.
Percutaneous angioplasty could
provide early patency, but the long
term results of this approach can
not be determined from our study.
Our overall approach to ASVT is
summarized in Fig. 3.

Conclusions

FIG. 3. Recommended protocol for treatment of axillary subclavian vein thrombosis.
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Twelve patients with ASVT, 9 of
whom were treated with lytic agents
and followed up for 6 to 72 months
(mean 36 months) were studied.
Lysis of ASVT was achieved in
seven of the nine, but all seven
showed some persistent defect not
responsive to thrombolytic therapy.
Two had high-grade stenoses which
occluded at 1 month. No bleeding
or embolic complications occurred
with thrombolytic therapy. Follow
ing thrombolysis, heparin and 3 to
6 months of warfarin therapy, scale
nectomy or first rib resection were
carried out in the other five patients
with patent veins. Two patients un
derwent subsequent balloon dilation
of a high-grade venous stenosis. At
late follow-up, all five patients with

AXILLARY SUBCLAVIAN VEIN THROMBOSIS

ASVT cleared by lytic agents were
asymptomatic and noninvasive
studies showed continuing patency
o f these segments.

References
1. P aget J: Clinical Lectures and Essays,

Longmans, London, 1985
2. D rapanas T, Curran WL: Thrombecto
my in the treatment of “effort” throm
bosis of the axillary and subclavian
veins. J Trauma 1966; 6: 107-119
3. A dams JT, De W eese JA: “ Effort”
throm bosis of the axillary and subclavi
an veins. J Trauma 1971; 11: 923-930
4. U rschel HC jr, Razzuk MA: Thoracicoutlet syndrome [C]. N Engl J Med

1972; 287: 567
5. Aziz S, S traehley CJ, W helan TJ jr :
Effort-related axillosubclavian vein
thrombosis: a new theory of pathogene
sis and a plea for direct surgical inter
vention. Am J Surg 1986; 152: 57-61
6. De W eese JA: Results of surgical treat
ment for axillary-subclavian venous
thrombosis. In Beryon JJ, Yao JST
(eds): Venous Disorders, Saunders, Phil
adelphia, 1991
7. K unkel JM, Machleder HI: Treatment
of Paget-Schroetter syndrome: a
staged, multidisciplinary approach. Arch
Surg 1989; 124: 1153-1158
8. Gloviczki P, Kazmier FJ, H ollier LH:

Axillary-subclavian venous occlusion:
the morbidity of a nonlethal disease. J
Vase Surg 1986; 4: 333-337
9. Daskalakis E, Bouhoutsos J: Subclavi
an and axillary vein compression of
musculoskeletal origin. B r J Surg 1980;
67: 573-576
10. B rowse NL, Burnand KG, L eo MT:

Diseases o f the Veins, Edward, London,

1985
11. Gray B, K eifer T, Cudzillo S e t al:
Evaluation of impedance plethysm ogra
phy of th e upper extrem ity. B ru it 1981;

5: 22-25
12. K err TM, Lutter KS, Cranley RD et al:
Diagnosis of upper extremity venous
thrombosis by duplex scanning. In B ercan JJ, Y ao JST (eds): Venous Disor
ders, Saunders, Philadelphia, 1991
13. T ilney NL, Griffiths HLG, E dwards
EA: Natural history of major venous
thrombosis of the upper extremity. Arch
Surg (Chicago) 1970; 101: 792-796
14. Donayre CE, W hite GH, Mehringer SM

22.

23.

24.

25.

et al: Pathogenesis determines late mor
bidity of axillosubclavian vein thrombo
sis. Am J Surg 1986; 152: 179-184
15. A meli FM, Minas T, Weiss M e t al:
Consequences of “ conservative” conven
tional m anagem ent of axillary vein
throm bosis. Can J Surg 1987; 3: 1 6 7 169

16. Roos DB: Experience with first rib re
section for thoracic outlet syndrome.
Ann Surg 1971; 173: 429-442
17. S winton NW jr, Edcett JW, Hall RJ:
Primary subclavian-axillary vein throm
bosis. Circulation 1968; 38: 737-745
18. B ecker GJ, Holden RW, Rabe FE et al:
Local thrombolytic therapy for subclavi
an and axillary vein thrombosis: treat
ment of the thoracic outlet syndrome.
Radiology 1983; 149: 419-423
19. W ebb GL, K erstein MD: Management of
effort thrombosis with low-dose strepto
kinase. Vase Surg 1985; 19: 200-206
20. D ruy EM, T rout HH, Giordano JM et
al: Lytic therapy in the treatment of
axillary and subclavian vein thrombosis.
J Vase Surg 1985; 2: 821-827
21. T aylor LM jr, McA llister WR, Dennis
DL et al: Thrombolytic therapy followed

26.

27.

by first rib resection for spontaneous
(“effort” ) subclavian vein thrombosis.
Am J S urg 1985; 149: 644-647
S teed DL, T eodori MF, P eitzman AB et
al: Streptokinase in the treatment of
subclavian vein thrombosis. J Vase S urg
1986; 4: 28-32
L andercasper J, Gall W, F ischer M et
al: Thrombolytic therapy of axillary-sub
clavian venous thrombosis. Arch Surg
1987; 122: 1072-1075
W ilson JJ, Zahn CA, N ewman H: Fibri
nolytic therapy for idiopathic subclavian
axillary vein thrombosis. Am J Surg
1990;159:208-210
S trange-Vocnsen HH, H auch O, A nder 
sen J et al: Resection of the first rib
following deep arm vein thrombolysis in
patients with thoracic outlet syndrome.
J Cardiovasc Surg (Torino) 1989; 30:
430-433
Glanz S, Gordon DH, L ipkowitz GS et
al: Axillary and subclavian vein stenosis:
percutaneous angioplasty. Radiology
1988;168: 371-373
W itte CL, S mith CA: Single anastomo
sis vein bypass for subclavian vein ob
struction. Arch Surg 1966; 93: 664-

666
28. R abinowitz R, Goldfarb D: Surgical
treatment of axillo-subclavian venous
thrombosis: a case report. Surgery
1971; 70: 703-706
29. H ashmonai M, S chramek A, F arbstein
J: Cephalic vein cross-over bypass for
subclavian vein thrombosis: a case re
port. Surgery 1976; 80: 563-564
30. J acobson JH, H aimov M: Venous revas
cularization of the arm: report of three
cases. Surgery 1977; 81: 599-604
31. R utherford RB: Surgical management
of chronic venous insufficiency of the
upper extremities. Semin Vase Surg
1988; 1: 1 2 4 -1 3 0

CJS, VOL. 36, NO. 4, AUGUST 1993

371

SPECIAL SUPPLEMENT

Thrombolysis in Peripheral Arterial Graft
Occlusion
Dennis F. Bandyk, MD
Acute thrombosis of arterial bypass grafts in the lower extremities poses a
significant risk for limb loss. Graft salvage in patients affected by this complication
remains a challenge. The vascular surgeon must consider the spectrum of treatment
options (thrombolysis, thrombectomy, graft replacement) in managing acute graft
thrombosis. Oral anticoagulants should be considered in patients with low-flow
polytetrafluoroethylene (PTFE) grafts and after successful thrombolysis, with or
without revision. The role of thrombolytic therapy for occluded vein grafts is less
clear, but successful lysis is likely in patients who present within 48 hours of graft
thrombosis and the etiology includes a correctable graft stenosis.

he causes of graft failure are
diverse, but most will respond
to timely surgical or endovascu
lar intervention (Table I). Szilagyi
and associates1 first emphasized
“post-implantation stenosis’’ as a
major cause of graft failure. During
the 1st postoperative year, the de
velopment of stenotic lesions in the
graft and perianastomotic regions,
frequently the result of myointimal

T

Table I. Classification of the Causes of
Graft Failure
Lesions amenable to surgical or endovas
cular intervention
Technical errors
Graft entrapment
Retained valve cusps (in-situ by
pass)
Clamp injury
Platelet aggregation
Vein wall fibrosis
Acquired myointimal hyperplasia
Focal atherosclerotic disease progres
sion
Thromboembolism
Lesion amenable only to medical therapy
(anticoagulation)
Hypercoagulable states
Diffuse run-off disease

hyperplasia, are responsible for
most graft thromboses.
Progression of atherosclerosis as
a cause of graft failure occurs later,
and, after the 1st year, accounts for
an annual graft attrition rate of 2%
to 4%.2-4 Surveillance of lower ex
tremity grafts by a noninvasive vas
cular laboratory using Dopplerderived systolic pressure and duplex
scanning can identify most hemodynamically failing grafts before
thrombosis, thereby permitting
elective revision of a patent bypass.
This theory has been accepted, but
the methods and intensity of sur
veillance for optimal patient care
after arterial bypass grafting have
not been determined. For in-situ
saphenous vein bypasses followed
with duplex scanning, the subse
quent rate of occurrence of unex
pected thromboses is 1% to 2% per
year.5-7 The varied reasons for graft
failure despite surveillance include:
loss of patient to follow-up, patient
refusal to submit to graft revision,

incomplete graft surveillance and
thromboembolism.
Noninvasive graft surveillance of
prosthetic grafts has not been as
successful as for vein grafts. Unex
pected thrombosis of infrainguinal
PTFE grafts occurs despite a recent
examination reporting a normal
graft. In my experience, most PTFE
grafts have failed without premoni
tory ischemic symptoms (claudica
tion, rest pain) or vascular abnor
malities (significant interval de
crease of more than 0.15 in anklebrachial systolic pressure index).
Taylor and colleagues8 found that
surveillance of vein grafts resulted
in a higher rate of postimplantation
stenotic lesions (19%) compared
with PTFE grafts (7%) after 1 year.
Thus, depending on the intensity of
graft surveillance or the ratio of
vein to prosthetic bypasses, the fre
quency of unexpected graft throm
bosis seen by different vascular sur
geons may vary.
An important part of the manage-
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THROMBOLYSIS IN GRAFT OCCLUSION

ment of acute graft failure is the
identification and correction of the
anatomic lesion, if present, that is
responsible for the thrombotic
event. Grafts can fail for a number
of reasons, including technical er
rors in bypass construction, an em
bolic event, a hypercoagulable state
or postimplantation occlusive le
sions that develop in the graft or in
the inflow and runoff arteries.
Therefore, restoration of graft pat
ency by infusion of thrombolytic
agents is a rational first step in the
treatment of graft thrombosis. A
goal of graft thrombolysis is to
provide the surgeon with a probable
anatomic cause of thrombosis to
facilitate a decision between graft
salvage or revision versus replace
ment. An analysis of both infrainguinal vein and PTFE graft failure
has confirmed that an anatomic
lesion (vein wall fibrosis, myointimal stenosis or atherosclerotic dis
ease progression) is the culprit in
most patients.49
Conventional therapy of acute infrainguinal graft occlusion involves
graft exploration, typically at the
distal anastomosis, use of a balloon
catheter to extract thrombotic ma
terial and direct visual inspection or
arteriography to identify an under
lying anatomic abnormality. The re
sults of thrombectomy with distal
patch angioplasty or extension of
the infrainguinal reconstruction,
particularly for failed vein grafts,
have been poor. The reported pat
ency after 2 to 3 years ranges from
16% to 33%.7"12 For failed PTFE
bypasses, a new graft (preferably
autologous vein) has been recom
mended as the best surgical inter
vention.13
A review of results of salvage of
occluded vein grafts showed a
2-year patency rate of 39% and
5-year rate of only 19%.11 This and
subsequent reviews have empha
sized the superior results of vein
graft revision when performed be

fore thrombosis (5-year patency of
85%) or after restoration of patency
by thrombolysis.14 The low salvage
rate with surgical thrombectomy is
puzzling but may be due in part to
balloon catheter injury of the vein
graft itself.
Intra-arterial infusion of throm
bolytic agents delivered by percuta
neous catheters with angiographic
guidance is a suitable alternative to
the traditional approach of balloon
catheter thrombectomy.15"22 In an
extensive study of primarily (75%)
prosthetic grafts, the technical and
clinical rates of successful throm
bolysis in infrainguinal bypass
grafts was 88% and 74%, respec
tively.22 The use of lytic therapy for
graft thrombosis has a number of
potential advantages, the most obvi
ous being nonoperative restoration
of patency. Lytic therapy can also
be used to determine the anatomic
cause of thrombosis, as endovascu
lar treatment of amenable lesions,
to avoid blind exploration of scarred
operative sites, to reduce operative
time when surgical intervention is
required and as the sole treatment
when thrombosis is due to hyper
coagulable or low-flow states. Ca
theter-directed thrombolysis can be
the sole therapy, if uncovered focal
stenotic lesions are treated by per
cutaneous balloon angioplasty or
atherectomy when no anatomic le
sion is identified.

material and bypass grafting tech
nique) may influence the long-term
patency of graft thrombolysis.
When graft occlusion is associat
ed with thrombosis of runoff ves
sels, successful clot lysis produces
complete restoration of the graft
including removal of thrombus
from side branches, distal and col
lateral vessels that are inaccessible
by balloon thrombectomy; this re
sult has important implications for
treatment following either graft re
vision or replacement. Similarly, in
patients with hypercoagulable
states (antithrombin III, protein C
and S deficiencies and anticardiolipin antibody syndrome), exten
sive in-situ thrombosis distal to the
graft may preclude efficient retro
grade thrombectomy with a balloon
catheter.
Following femoropopliteal bypass
failure, when thrombosis involves
the tibial trifurcation vessels, re
moval of clot from the three tibial
arteries is seldom possible with a
balloon catheter directed from the
groin. Complete thrombectomy re
quires exploration via the popliteal
space, exposure of the tibioperoneal
trunk and cannulation of individual
tibial vessel orifices. With throm
bolytic therapy, the trauma to the
wall and endothelium that accompa
nies the use of a balloon catheter is
avoided.

Graft Thrombolysis Protocol
Graft Thrombolysis Versus
Native Artery Thrombolysis
Graft thrombolysis differs in sev
eral respects from native artery
thrombolysis. Patients with failed
grafts tend to have more advanced
atherosclerotic occlusive disease,
and many have undergone multiple
lower limb revascularizations. Thus,
the extent of collateral vessels and
other surgical factors (aneurysmal
graft degeneration, type of graft

Significant progress in the clini
cal application of thrombolytic ther
apy has occurred in the past 2
decades. Techniques for the intra
arterial delivery of lytic agents have
been refined, new infusion catheters
have been developed and initial
drug infusion rates have been modi
fied and validated in large clinical
series. Clot lysis can be predicted
with confidence using the guide
wire traversal test, and infusion
CJS, VOL. 36, NO. 4, AUG UST 1993
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times have been reduced from 2 to
5 days to less than 24 hours in
most cases.

Lytic Agents
Urokinase is the preferred agent
based on higher rates of complete
graft lysis compared with streptoki
nase (66% to 100% versus 27% to
72%, respectively), shorter infusion
time and a reduced incidence of
intracranial hemorrhage.23-25
The clinical decision to use
thrombolytic therapy depends on
the level of ischemia and a judge
ment that the limb is not at high
risk of irreversible tissue damage
during the infusion when it may
take 12 to 24 hours to restore
antegrade graft flow. Patients
whose limbs demonstrate irrevers
ible ischemia (absent sensorimotor
function, rigor, or skin marbling)
are not candidates for thrombolytic
therapy. A criterion, assessed by
angiography, for initiating throm
bolysis is the ability to access the
thrombosed graft with an infusion
catheter from a remote site, usually
the opposite groin. A proximal pa
tent segment of the graft, termed
the “ graft nipple,” must be identi
fied and a guide wire should easily
penetrate the occlusion and pass
the length of the graft (Fig. 1). A
number of investigators have con
cluded that the inability of a guide
wire to pass is associated with fail
ure of thrombolytic agents to sal
vage occluded arterial grafts. Pros
thetic aortofemoral grafts con
structed of Dacron have successful
ly undergone thrombolysis, but care
should be taken in lysis of knitted
Dacron prostheses because perigraft hemorrhage has been noted.

Diagnostic Arteriography
At my institution, diagnostic arte
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riography is carried out via the
contralateral femoral artery or aor
tofemoral graft limb. A no. 5
French catheter is manipulated
around the aortic bifurcation into
the thrombosed graft. A coaxial
catheter system is used to infuse

urokinase directly into the proximal
and distal thrombus, the dosage
evenly split between the two infu
sion ports (Table II). Intravenous
heparin is also administered at the
rate of 1000 units/h. Thrombolytic
therapy is terminated when ante-

FIG. 1. Arteriogram showing “graft nipple” (arrow) of acutely thrombosed
femoral-popliteal-dorsalis pedis composite polytetrafluoroethylene (PTFE)-saphenous vein bypass graft. Thrombolysis was successful after 16 hours of coaxial
infusion with urokinase.

Table II. Protocol for Thrombolytic Therapy for Graft Thrombosis With Coaxial Infusion
Proximal and distal ports:
1 million III of urokinase in 500 mL normal saline (2000 lll/m L )
Early morning infusion (anticipate restoration of patency in the afternoon):
250 000 III of urokinase delivered as bolus into clot or Meweissen pulse spray dosage protocol
using:
Intrathrombus infusion system
1 mL tuberculin syringe for pulse injection at a rate of 2 pulses/min, 5000 lU/m L urokinase/
pulse
Hand injection in angiography department 5000 U heparin
then,
60 mL urokinase/h at each port (total 240 000 lU/h), heparin 1000 U/h
Late afternoon infusion (anticipate restoration of patency next morning):
250 000 IU of urokinase delivered as bolus into clot
then,
30 mL urokinase/h at each port (total 120 000 lU/h), heparin 1000 U/h

THROMBOLYSIS IN GRAFT OCCLUSION

grade flow is restored, the graft and
outflow vessels are clear of throm
bus and a high-quality angiogram
can be obtained to locate the cause
of graft thrombosis.
Anatomic abnormalities identified
following graft lysis should be ma
naged on an individual basis. Ath
erosclerotic lesions involving proxi
mal or distal native arteries can be
treated effectively by either balloon
angioplasty or atherectomy. Duplex
scanning of the atherectomy site
should be performed after 1 week
to confirm that a significant residu
al stenosis does not exist. A myointimal lesion involving distal anasto
mosis or extensive progression of
disease in the outflow artery is best
treated by graft extension or re
placement (Fig. 2).

Focal Graft Stenosis
The management of focal graft
stenosis is controversial, but vein
patch angioplasty or graft segment
replacement (interposition grafting)
are more durable secondary proce
dures than balloon dilation. A per
sistent filling defect in the graft or
outflow tract at the conclusion of
an otherwise successful course of
lytic therapy should be managed by
direct thrombectomy rather than
continuing an additional 12 to 24
hours of lytic infusion.
To allow a stable fibrin plug to
form at the entry site, sheath re
moval should be delayed for 4 to 6
hours after stopping urokinase in
fusion. An assessment of limb per
fusion, by measuring the ankle-bratirnuv-7i

'

S7<

FIG. 2. Arteriogram showing stenosis (arrow) in distal segment of a femoralperoneal in-situ saphenous bypass graft after 8 hours of infusion with urokinase.
Revision consisted of interposition autologous vein graft.

chial pressure index, and graft he
modynamics, by analysis of velocity
waveform by duplex scanning, com
pletes the thrombolytic therapy pro
tocol.
In an important group of pa
tients, no significant anatomic ab
normality is seen following graft
lysis. The hemodynamic state of the
graft should be assessed by duplex
scanning, preferably using colourflow duplex imaging. The graft,
including anastomotic sites, should
be scanned for flow abnormalities,
evidence of anastomotic pseudo
aneurysm formation and residual
mural thrombus (Fig. 3). Measure
ment of peak systolic velocity in the
graft and analysis of the velocity
waveform provide an estimate of
graft flow.
Prosthetic PTFE bypasses with a
peak systolic velocity below 70 to
75 cm /s are prone to thrombosis.
In the absence of an anatomic le
sion, patients should be prescribed
oral anticoagulant (warfarin) to
maintain prothrombin time at 18 to
22 seconds. In our experience,
PTFE grafts with low flow velocity
(less than 45 cm /s) will often not
maintain patency even with an
ticoagulants. Vein graft replace
ment should be considered for these
patients if graft thrombosis recurs
(Fig. 4).
Late graft failure rates as high as
50% have emerged as a major prob
lem after apparently successful
thrombolytic therapy with and with
out revision.1922 This observation
emphasizes the importance of ap
propriate patient selection, method
of graft revision and intensity of
graft surveillance to achieve the
best results. Tabulation of outcome
following lytic therapy is not
straightforward, particularly when
urokinase infusion is used as an
adjunct before another procedure
(percutaneous balloon angioplasty,
completion thrombectomy or direct
surgical repair or bypass) rather
CVS, VOL. 36, NO. 4, AUGUST 1993
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than as sole therapy. For example,
successful thrombolysis of a femorodistal saphenous vein bypass fol
lowed by a technically flawed bal
loon dilation of an uncovered graft
stenosis might result in graft fail
ure, but should not detract from the
usefulness of thrombolytic therapy
in this application. Graft thrombol
ysis cannot salvage every graft but
should permit a more informed deci
sion regarding the potential for
graft salvage.

Treatment of PTFE Graft
Thrombosis
Success rates achieved using
thrombolysis for acute PTFE graft
occlusions have varied (Table
11115,16,18,20,21,26) Frequency of com

plete graft lysis has improved with
time, and an underlying anatomic
abnormality can be identified in
more than 50% of patients.
Over 3 years (1987 to 1990) at
the Medical College of Wisconsin,
seven patients presenting with
acute thrombosis of infrainguinal
PTFE bypass grafts underwent uro
kinase infusion on 16 occasions.
Complete lysis was achieved in 15
cases.20 The duration of infusion
ranged from 3 to 40 hours, and the
amount of urokinase infused ranged
from 300 000 to 5 800 000 IU. An
anatomic defect was identified in
nine instances and was treated by
balloon angioplasty (four cases),
graft extension (four) or vein graft
replacement (one).
Four of the seven PTFE grafts
occluded at 3 to 8 months and were

treated by thrombolysis up to four
times. Several patients with recur
rent graft thrombosis demonstrated
low flow in the graft, measured by
duplex scanning, and could not be
maintained on appropriate oral an
ticoagulants.
In general, a favourable outcome
of clot lysis can be expected if the
graft and outflow vessels are com
pletely cleared of thrombus, and
anatomic lesions are promptly cor
rected. Patency after 1 year is about
50% and emphasizes the propensity
of these conduits for rethrombosis.
Sullivan and colleagues22 reported a
1-year patency rate of 87% in pros
thetic grafts in which a lesion was
corrected compared with a 25%
patency rate in grafts in which no
lesion was identified. It is not
known whether intense surveillance

FIG. 3. Arteriogram of distal graft segment and runoff of occluded femoral-popliteal below-knee PTFE bypass (A) before and (B)
after 6 hours of infusion with high dose (1 175 000 IU) of urokinase. Duplex scanning of popliteal anastomotic site
demonstrated aneurysmal dilatation and residual mural thrombosis. Anastomotic revision was performed.
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of these high-risk grafts would im
prove patency. I have prescribed
oral anticoagulants to all patients
with PTFE thrombosis salvaged by
thrombolysis regardless of whether
an anatomic lesion was identified
and corrected. Thrombolysis of
PTFE grafts implanted for more
than 3 months tends to yield better
results than attempts to salvage a
recent prosthetic graft. In general, I
prefer vein graft replacement for
recent or repetitive PTFE failures.

Treatment of Saphenous Vein
Graft Thrombosis
The results of thrombolysis in
Prior
graft surveillance

occluded vein grafts are more con
sistent, and a number of indicators
appear to predict the likelihood of
success (Table IV19-2127). With ap
propriate patient selection, the rate
of successful lysis may be over 90%,
but restoration of patency and con
comitant percutaneous balloon an
gioplasty does not guarantee long
term patency. These observations
underscore the importance of de
tecting failure in the vein graft
before thrombosis occurs.
After successful thrombolysis, in
trinsic occlusive lesions are most
commonly found within the graft
itself or in perianastomotic seg
ments. The majority represent le
sions of intimal hyperplasia that

Thrombolysis
-►

Anatomic lesion

-►

No lesion identified

Treatment
PTA; surgery

-► Normal flow

Graft thrombosis
Anatomic lesion

-► PTA; surgery
warfarin

— ► Low flow
No lesion identified

Vein replacement

FIG . 4. A lg o r ith m for tr e a tm e n t o f failed in fr a in g u in a l e x p a n d ed P T F E g r a fts. P T A
= p e r cu ta n e o u s tr a n slu m in a l a n g io p la s ty .

T a b le III.

Success Rates of Thrombolytic Therapy for Expanded PTFE Graft Occlusions
A g en t

Study

Kakkasseril et al15
Belkin et al’6
O'Donnell et al26
Graor et al18
Seabrook et al20
Parent et al21

Streptokinase
Streptokinase
and urokinase
Streptokinase
and urokinase
Tissue plasminogen
activator
Urokinase
Urokinase

S u c ce s s rate*

3/16
5/8
7/16
10/12
15/16
12/12

'Success rate is number showing lysis over the number attempted.

T a b le IV .
Study

Belkin et al’9
Thiele27
Seabrook et al20
Parent et al21

Success Rates of Thrombolytic Therapy for Occluded Vein Grafts
A g en t

Streptokinase
and urokinase
Urokinase
Urokinase
Urokinase

S u c ce s s rate

21/35
15/19
8/8
8/9

developed at valve or anastomotic
sites or at sites of platelet aggrega
tion.28 Balloon angioplasty of these
occlusive lesions has been success
ful in less than 50% of cases.142930
A more successful approach has
been vein patch angioplasty of focal
lesions (smaller than 4 cm) or vein
interposition grafting of longer le
sions. Careful graft surveillance fol
lowing revision is mandatory as
restenosis occurs in 20% to 40% of
sites.
In a series of 11 infrainguinal
saphenous vein grafts treated with
thrombolysis and revision (surgical
revision, 8; percutaneous balloon
angioplasty, 2) or with no lesion
identified, one graft developed ste
nosis and was allowed to fail (6
months later) as the patient was no
longer ambulatory.
Parent and associates21 reported
a high initial success rate (8 of 9
grafts), but patency had decreased
to 23% after 9 months. All nonrevised grafts treated with anticoagu
lants and graft revisions treated by
balloon angioplasty occluded by 10
months. Belkin and colleagues19 re
ported 37% and 23% success rates
after 1 and 2 years, respectively; 12
of 15 failures occurred within 4
months of thrombolysis and revi
sion.
If no lesion is obvious following
vein graft lysis, duplex scanning
should be used to search for a
stenotic lesion. Mapping of the by
pass frequency will reveal a greater
than 50% reduction in diameter, an
aneurysmal graft segment or anas
tomotic pseudoaneurysm as likely
causes for the thrombotic event.
Similarly, following graft revision
by percutaneous balloon angioplas
ty, patch angioplasty or interposi
tion grafting, it is recommended
that surveillance by duplex scan
ning be carried out at 1 and 6
weeks following the secondary pro
cedure and every 3 months thereaf
ter for the 1st year.
CJS, VOL. 36. NO. 4. AUGUST 1993
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Summary
Potential candidates for graft
thrombolysis must be able to under
go angiography safely and cooper
ate with a catheter-directed throm
bolysis protocol; no contraindica
tions for clot lysis must exist; col
lateral flow must be sufficient so
that an additional 4 to 8 hours of
ischemia can be tolerated without
risk o f tissue loss; and angiography
must demonstrate that the proximal
graft origin and runoff are not
involved by diffuse atherosclerosis.
The vascular surgeon and the
interventional radiologist must com
municate effectively in selecting pa
tients who have the potential to
benefit from the use o f thrombolytic
therapy. This determination should
include objective assessment o f the
severity o f ischemia, accurate angi
ography, adequate and safe arterial
access and easy penetration of the
occluded graft by a guide wire.
Good results after clot lysis can be
expected if the morphologic fea
tures o f the graft and outflow ves
sels are adequately visualized and
anatomic defects promptly correct
ed. The hemodynamic state of
PTFE grafts should be routinely
assessed by duplex scanning be
cause low-flow grafts are prone to
thrombosis. Thrombolytic therapy
can be associated with serious com
plications and should be used only
when the benefits o f graft salvage
are weighed against the hemorrhag
ic risks o f the procedure.
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BOOK REVIEWS
continued from page 320

growth and transplantation. The practi
cal aspects of the use of bone grafts in
craniofacial and orthopedic surgery are
covered much better elsewhere.

James P. Waddell, MD, FRCSC
St. Michael’s Orthopedic Associates
Suite 800
55 Queen St. E
Toronto, ON
M5C 1R5

OSTEOARTHRITIS. DIAGNOSIS
AND MEDICAL/SURGICAL MAN
AGEMENT. 2nd edition. Roland W.
Moskowitz, David S. Howell, Victor M.
Goldberg and Henry J. Mankin. 761
pp. Illust. W.B. Saunders Company/
Harcourt Brace Jovanovich, Inc., Phil
adelphia. 1992. Price not stated. ISBN
0 -7 2 1 6 -6 5 8 1 -0

This multiauthored book is an attempt
to cover the whole field of osteoarthritis
— etiology, pathology, diagnosis and
management. An attempt has also been
made to cover individual regions such
as the hand and the foot. This is such
an immense undertaking that it it is
difficult to know where to start reading.
I made the mistake of starting on the
individual joints section. As one would
expect, these joints are covered fairly
superficially except for the chapter on
the foot by Roger Mann. Such superfi
cial coverage is only to be expected
since complete books are written about
osteoarthritis of the knee, the hip and
other joints.
Eventually, trapped on a long air
flight, I read the book as it should be
read, from start to finish.
The chapters follow in logical se

quence and are clearly written and
illustrated. The basic science chapters
are good, particularly those on the
pathologic findings in osteoarthritis by
Peter Bullough, on the biochemical
aspects by Henry Mankin and on the
biomechanics by Savio Woo.
Under general aspects of diagnosis I
found the chapter on Forrestier’s dis
ease very informative. The section on
general management includes chapters
on rehabilitation, drug therapy, intraarticular use of steroids and an excel
lent chapter by Robert Jackson on the
role of arthroscopy in the management
of osteoarthritis.
There is one absolute gem, which
justifies the cost of the whole book. It
is the chapter by Eric Radin on chon
dromalacia patellae, which is quite the
best account I have ever read.
This book is an excellent companion
for residents and fellows studying for
examinations and is worthwhile reading
for practising orthopedic surgeons.

Hugh U. Cameron, MB, ChB, FRCSC
Staff surgeon
Orthopaedic & Arthritic Hospital
43 Wellesley St. E
Toronto, ON
M4Y 1H1

PEDIATRIC SINUSITIS. Edited by
Rodney P. Lusk. 160 pp. Illust. Raven
Press Ltd., New York. 1992. $125.
(US). ISBN 0 -8 8 1 6 7 -8 9 4 -5

The authors of this book — pediatri
cians, pediatric allergists and im
munologists, family practitioners, radi
ologists and otolaryngologists — have
compiled a review of sinusitis in the

pediatric age group. Since sinusitis is
now a recognized entity in children,
conditions such as persistent purulent
rhinorrhea, cough and nasal congestion
are no longer considered variants of
normal.
The first chapter of this book deals
with the signs and symptoms of chronic
sinusitis. The data presented are based
on a survey of 45 pediatricians in the
St. Louis area. An interesting table
outlines the guidelines for diagnosing
sinusitis, and clinical judgement is con
sidered to be the most important.
One of the most valuable reference
chapters is the one in which imaging of
sinusitis in infants and children is dis
cussed in detail. The figures, including
plain radiographs, computed tomogra
phy scans and magnetic resonance im
ages, are clear and extremely well la
belled.
The chapters on the relationship of
allergy and immune deficiency to sinus
itis are brief but up to date and serve as
an excellent review for the physician.
The discussion of the surgical treat
ment of chronic sinusitis in children
makes up the longest chapter, 50 of the
160 pages in the book. The quality of
the endoscopic photographs is clear and
they are easily followed.
The book is well written. It is brief
but includes all that is necessary to
understand and treat sinusitis in the
pediatric age group. This book should
be in the library of physicians who care
for children.

Melvin D. Schloss, MD, FRCSC, FACS
Professor and chairman
Department of Otolaryngology
McGill University
The Montreal Children’s Hospital
2300 Tupper St.
Montreal, QC
H3H 1P3
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MAMMOGRAPHY SCREENING — THE BRITISH COLUMBIA EX
PERIENCE. L.J.W. Burhenne, P.M. Rebbeck. Department of Radiolo
gy, Screening Mammography of British Columbia, University of
British Columbia, Vancouver, BC

MINIMAL SURGERY FOR BREAST CANCER. E.B. Fish, J.W.
Chapman, M.A. Link. Henrietta Banting Breast Centre, Women’s
College Hospital, University of Toronto, Toronto, Ont.

To develop a mass mammography screening program based on pilot
project results, the Screening Mammography Program of British
Columbia began its operation in July 1988 with a single pilot centre and
a team of three screening radiologists. Subsequently, the program has
expanded to 13 individual centres and 29 screening radiologists. To Jan.
31, 1993, 184 267 examinations have been performed. Physical exami
nation is not provided at the screening centres, and abnormalities are
investigated in community diagnostic mammography facilities. Data are
collected directly from physicians and analysed centrally. Interval
cancers are tracked by computers through the provincial cancer
registry. Pathology review by an internationally recognized breast
pathologist is a feature of the program. Results are given at 45 months:

S c re e n in g e x a m in a tio n s

1 12 5 4 3

O v e ra ll re c a ll rate fo r a b n o rm a litie s

6 .8 %

P re v a le n t c a n c e r rate

5 .5 /1 0 0 0

In c id e n t c a n c e r rate

2 .0 /1 0 0 0

B io p s y y ie ld ra tio

3 3%

In te rv a l c a n c e r rate

0 .7 4 /1 0 0 0

S ta g e 0 -

76%

1

age 4 0 - 49
A x illa r y n o d e in v o lv e m e n t
age 4 0 - 4 9
U n it c o s t

85%
13%
8%
$ 3 3 CON

With the expansion from a pilot project to mass screening, there has
been an overall improvement in results as well as unit cost. The cancers
detected present favourable prognostic characteristics, and cancer
detection rates and interval cancer rates are sustained at levels
comparable to those of similar reports.

During the past 20 years, there has been increasing evidence that less
extensive surgery is indicated for treatment of cancer of the breast.
There is still some uncertainty about how little surgery should be done
and the role of adjuvant therapy (radiation, chemotherapy or hor
mones).
Between 1971 and 1990, 366 patients were treated by E.B. Fish with
a wide lumpectomy alone (PM; 119 patients) or a lumpectomy with
axillary dissection (PMA; 247 patients). Follow-up to 1991 was
complete for 94% of the patients; median follow-up was 2065 days and
1482 days for PM and PMA patients respectively.
Breast irradiation had a marked effect on recurrence in the same
breast (p = 0.003). There was recurrence in 20% (23 of 115) of PM
patients, 18% (13 of 71) of node-negative PMA patients and 33% (16 of
49) of node-positive PMA patients who did not receive radiation.
However, there was no recurrence in the 4 patients with PM; there was
recurrence in 3% (2 of 68) of node-negative PMA and 12% (7 of 59) of
node-positive patients who were irradiated. Control of local recurrence
was achieved by further breast surgery for all of those who were
irradiated (4 PM, 68 node-negative PMA and 59 node-positive PMA).
Local control was also achieved for 98% (44 of 45) of the patients who
received adjuvant chemotherapy; 32 of these patients received radio
therapy. The variables included in the final local recurrence model after
Cox stepwise regression were adjuvant radiation (p = 0.01), quantitative
tumour size (p = 0.01) and adjuvant hormones (p = 0.04). Regional
recurrence in the axilla occurred in 6% (7 of 119) of PM patients, 4% (5
of 139) of node-negative PMA and 6% (7 of 108) of node-positive PMA.
Distant recurrence was found in 17% (20 of 119) of the PM, 15% (21 of
139) node-negative PMA and 22% (24 of 108) of the node-positive PMA.
Death attributable to breast cancer occurred in 15% (18 of 119) of the
PM, 9% (13 of 139) of the node-negative PMA and 17% (18 of 108) of
the node-positive PMA.
Lumpectomy was followed by a low local recurrence. Adjuvant
radiation to the breast markedly decreased local recurrence in the breast
and was followed by 100% control of local breast recurrence with
further surgery. Neither radiation therapy or axillary dissection signifi
cantly altered the occurrence of distant disease or death due to breast
cancer.
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ULTRASOUND-GUIDED FINE-NEEDLE ASPIRATION BIOPSY OF
SOLID BREAST MASSES. P.B. Gordon, S.L. Goldenberg, N.H.L.
Chan. University of British Columbia, Vancouver, BC

345
The objective of this study was to evaluate the role of ultrasoundguided fine-needle aspiration biopsy in the management of solid breast
masses.
Needle biopsies were performed on 1136 breast masses known to be
solid. This report is based on 805 biopsies, 224 malignant and 581
benign, which have been confirmed by either surgical excision or
imaging follow-up.
The sensitivity of this technique in the diagnosis of solid breast
lesions was 95%, the specificity was 92% and the overall accuracy was
93%. We conclude that real-time, ultrasound-guided fine-needle aspira
tion cytology is a valuable adjunct to the clinical, mammographic and
sonographic assessment of solid breast lesions.
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WHAT FACTORS ARE IMPORTANT FOR LOCAL BREAST CAN
CER RECURRENCE FOLLOWING LUMPECTOMY ALONE? D.R.
McCready, W. Hanna, H. Kahn, B.G. Mobbs, E.B. Fish, H.L.A.
Lickley, J.W. Chapman, Women’s College Hospital, University of
Toronto, Toronto, Ont.

Although postoperative radiotherapy to the breast is considered stan
dard following breast conservation surgery, there may be subsets of
patients who are at low risk for local breast cancer recurrence and thus
may not require this treatment modality. We studied the prognostic
importance of patient-tumour characteristics and pathologic variables
on the time to first local breast recurrence in a series of 293 breast

ABSTRACTS

cancer patients to determine which factors are associated with the risk
of recurrence following lumpectomy without adjuvant radiation or
systemic therapy.
Patients were accrued between 1977 and 1986 at Women’s College
Hospital and have been followed to 1991. The prognostic variables
considered were age, estrogen and progesterone receptors (ER, PgR
respectively; positive > 10 fmol/mg protein), tumour size (mm),
histologic and nuclear grade (1 ,2 , 3), presence of in-situ component in
tumour (zero, present, comedo), amount of in-situ component in tumour
(%) and presence of lymphatic and/or vascular tumour emboli (yes/no).
The overall local breast recurrence rate was 25%. Axillary dissection
itself did not impact on breast recurrence; since the rate of local
recurrence was 23% in those undergoing this procedure and 26% in
those who did not. However, those patients who were found to have
nodal metastases had a significantly higher recurrence rate 47%, p =
0.02). Patients 65 years of age or older had significantly less local
recurrence (18%) than those younger than 65 (31%). The stepwise Cox
model of multivariate analysis included the variables: tumour emboli (p
= 0.02), ER (p = 0.01), age (p = 0.01) and the presence of in-situ
carcinoma in the tumour (p = 0.05).
The absence of tumour emboli and in-situ carcinoma along with ER
positivity and older age were significantly associated with decreased
local recurrence. Subsets of patients at low risk for local breast
recurrence can be defined.

346
THE EFFECTS OF INTRA-ABDOMINAL C02 INSUFFLATION IN
THE PIGLET. A. Graham, D. Jirsch, K. Barrington. Surgical Medical
Research Institute, University of Alberta, Edmonton, Alta.

The hemodynamic and metabolic changes associated with intra-abdomi
nal C02 insufflation (IACI) were studied in eight young, 4- to 6-kg
piglets. Cardiac index (Cl), inferior vena cava flow (IVCf) and pressure
(ICVp), femoral artery flow (Femf), blood pressure (BP) and central
venous pressure (CVP) were continuously recorded; arterial blood gases,
minute ventilation (VE) and mediastinal pressure (Mp) were recorded at
15-minute intervals. Mean values (± SD) were recorded at baseline (15
minutes), post-IACI at 15 mm Hg for 1 hour, at new baseline (15
minutes) following desufflation and hyperventilation for 30 minutes, and
post-IACI at 15 mm Hg with hyperventilation to control arterial Pc02
for 1 hour (post-IACI + V).
Baseline values were compared to values post-IACI; new baseline
values were compared with post-IACI + V.

Baseline
C! (ml/min*kg ’)
IVCf (ml/min)
Femf (ml/min)
BP (mm Hg)
CVP (mm Hg)
IVCp (mm Hg)
HR (beats/min)
Mp (mm Hg)
Pa co2 (mm Hg)
Pao, (mm Hg)
Vt(L)

136
480
35
65
6.8
14
175
48
36 85
167
0.75

i 33
:, 157
ii 620
:, 13
i 2.6
•
t 3.9
i, 32
ii 25
:, 3 29
ii 51
., 0.12

Post-IACI
158
452
31
76
8.8
27.7
184
5.25
48 26
141
0.67

,
i
i
.
,
i
r
i
.
i
:;

42194
18
123.0*
6.929
24
4 83'
540.12

New baseline
138
503
34
73
7
15
193
48
36 4
140
0.8

i
,:
,
i;
i:
,
,
.:
,:
,
,:

32
162
14
14
3
4
36
2.9
4.3
52
0.2

Post-IACI + V
138
394
25
78
11
25
195
5.5
37 4
125
11

- 38
i: 105+
i■ 11 +
i, 14+
■
, 3+
, 4+
ii 30
: 23
: 41
;i 34
, 02+

' p <- 0.05; paired /-test
+p • 0.05; paired /-test

IACI in the piglet results in significant changes in CL BP, CVP,
IVCp, Paco2 and Pao2 (p < 0.05; paired t-test). Hyperventilation with
IACI (post-IACI + V) can control Paco2 and Pa02 and alter the
hemodynamic changes associated with IACI, but significant changes in
IVCf, Femf, BP, CVP and IVCp persist (p < 0.05; paired f-test).

347
RANDOMIZED CONTROLLED TRIALS IN SURGERY. M.J. Solo
mon, R.S. McLeod, A. Laxamana, R.G. Chaytor, L. Devore, C.M.T.
Greenwood. University of Toronto, Toronto, Ont.

The object was to determine the number of randomized controlled trials
(RCTs) performed by surgeons or published in surgical journals to
determine characteristics of the trials and assess their quality.
All RCTs were retrieved by Medline for the year 1990. Medline
retrieved only 46% of surgery RCTs when compared to a manual search
of three journals. All RCTs were assessed by one surgeon using
Chalmer’s scoring system. Inter-rater reliability (r = 0.73) and validity
(r = 0.61) were tested.
Two hundred and two RCTs were retrieved including 78 (39%)
gastrointestinal, 66 (33%) oncologic, 49 (24%) breast, 35 (17%)
vascular, 26 (13%) trauma and 23 (11%) others. RCTs were performed
in one centre in 124 (62%), two to four in 42 (21%) and five or more in
34 (17%). Sixty-eight (34%) were performed in North America, 72 (36%)
in Europe and 60 (30%) elsewhere. A surgeon was the principal author
in 65 (33%). The source of funding was not stated in 124 (61%) and
only 43 (21%) were peer reviewed. In 152 (75%), two medical therapies
were compared, in 36 (18%) two surgical therapies were compared and
in 11 (5%) medical was compared to surgical therapy. One hundred and
thirty-two (65%) were published in medical journals, 60 (30%) in
surgical and 10 (5%) in other journals.
The overall mean qualitative score was 0.40 ± 0.13. The standard of
RCT differed depending on the journal (p = 0.02), principal author (p =
0.02), number of centres (p < 0.01), area of general surgery (p < 0.01)
and type of therapy (p = 0.0001). The strongest predictors of the
standard of RCT by multivariate analysis were the type of therapy
compared (p = 0.001), the journal in which the RCT was published (p =
0.006) and the area of general surgery (p = 0.007).
This study indicates that while surgeons are performing RCTs,
surgical therapies are often not tested. In addition, surgeons are more
often collaborators. Overall quality of the trial is low and varies
depending on the subject area.

348
THE ULTIMATE MODIFICATION IN THE MODIFIED NECK DIS
SECTION. G. Porter, W.J. Temple, S. Huchcroft. Division of Surgical
Oncology, Foothills Hospital, University of Calgary, Calgary, Alta.

The sacrifice of the sensory cervical plexus is a standard of a
modification of a neck dissection despite no data to demonstrate its
value in local control or the morbidity associated with the loss of the
nerve.
We have prospectively studied the operation of preserving the
sensory cervical nerves when they are free of tumour in 15 patients and
examined and compared this group with a matched group of patients
with sacrifice of the nerve. We documented function, chronic pain, local
recurrence and long-term disability.
The mean follow-up in both these groups was 26 months. The mean
area of sensory loss in patients with sacrifice of the nerves was 70.52
cm2 versus 8.2 cm2 for patients in whom it was preserved (p < 0.009).
Chronic symptoms of discomfort were 46% versus 0% (p < 0.02)
respectively. Despite involved nodes in 11 of the 15 patients with nerve
preservation, there is no regional recurrence to date. Preservation of
sensory nerves in these patients retains the majority of sensation, avoids
the significant disability of symptoms of pain and discomfort related to
the sacrifice, and is not associated with local recurrence.
These data support the conclusion that the same indications for
saving the spinal accessory nerve may also be applied to cervical plexus
with a significant improvement in function and decrease in morbidity.
CJS, VOL. 36. NO. 4. AUGUST 1993
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TONOMETRY FOR DIAGNOSIS OF SMALL-BOWEL ISCHEMIA.
B.C.D. Rudston-Brown, W. Studer. P.T. Phang. Department of
Surgery, St Paul’s Hospital, University of British Columbia, Vancou
ver, BC

ENDOLUMINAL TRANSPOUCH ULTRASOUND (TPUS) TO DIAG
NOSE AND TREAT PELVIC SEPSIS POST ILEO POUCH ANAL
ANASTOMOSIS (IPAA). M.J. Solomon, R.S. McLeod, Z. Cohen.
University of Toronto, Toronto, Ont.

It is unknown whether gastric or rectosigmoid tonometry accurately
reflects the intramucosal pH (pHi) of the small bowel. We asked: (1)
Does gastric and rectosigmoid tonometry detect small-bowel ischemia in
sepsis or mesenteric occlusion? (2) What is the relationship between
gastric, ileal and rectosigmoid tonometry and whole-body oxygen
delivery and consumption (D02-V02) and arterial lactate in the presence
of small bowel ischemia? Six pigs were given purified Escherichia coli
LPS and six animals had superior mesenteric artery (SMA) ligation.
Tonometers were placed in the stomach, ileum and sigmoid colon.
Hemodynamics, whole-body D02-V02 and pHi were measured at base
line and every 30 minutes after endotoxin or SMA ligation.

Localized sepsis after ileoanal pouch anal anastomosis (IPAA) can be
difficult to assess both clinically and with diagnostic imaging tech
niques. Transpouch ultrasound (TPUS) offers a new technique to
diagnose and aid in the treatment of patients with suspected pelvic
sepsis. The object of this review is to report our initial experience using
this modality.
Eleven patients (6 males, 5 females, mean age 32.3 years) with IPAA
who had symptoms suggestive of pelvic sepsis but with no obvious
abscess on digital examination (11), leak on pouchogram (10) nor
abscess on CT (5) were examined with TPUS. IPAA had been performed
from 1 to 72 months prior to TPUS. Symptoms included: pelvic/sacral
pain (11), fevers (9) and diarrhea (5).
On TPUS four patients had abscesses, four patients had inflammatory
phlegmons with a communicating tract to the posterior pouch anal
anastomosis, in one patient a rectovaginal fistula was confirmed and two
patients had normal examinations. Two abscess cavities (one 6 X 5 cm
and one 3 X 3 cm) were drained (150 mL and 50 mL of pus) under
ultrasonic guidance via a transischiorectal approach and a 12 French
loop drainage catheter was left in situ. In both cases sinogram and
pouchogram done a few days later revealed communication between the
cavity and the pouch that had not been demonstrated on pouchogram
before drainage of the abscess. One abscess was drained intraoperatively
prior to local revision of the IPAA. One small (2 X 2) abscess resolved
with antibiotics alone. Of the four phlegmons two responded to
antibiotics, one required abdominal revision of the pouch and one
required excision of the pouch.
Our initial experience in a small series of patients suggests that
TPUS can detect and treat pelvic sepsis after IPAA.

Septic
B a s e lin e
pHi (gastric)
pHi (ileal)
pHi (colonic)
W hole body V 0 2
( m l/m in » k g ')
W hole body 0 0 2
( m l/m in » k g ’ )
Arterial lactate

7 .05 (0.17)
7 .08 (0.18)
7 .1 5(0 .24 )
4 99 (0.65)
2 0.1 8 (3 .7 6 )
0 .6 0 (0 .1 9 )

S M A ligation
4 hours
6.80 (0.06) *
6.77 (0.11)6.75 (0.07)*

B a seline
7.01 (0.15)
7.11 (0.09)
7.02 (0.08)

4 hours
7.11 (0.18)*
6.79 (0.21)*
6.92 (0.08)*

5 .8 5(1 .86 )

3.73 (0.92)

3 .8 9(1 .52 )

12.76 (3.73)‘
0.83 (0.78)*

16.29 (3.94)
0.97 (0.51)

14.09 (3.63)
0.58 (0.18)

'p < 0.05 fo r baseline vs. 4 hours
All values are mean (SD)

We conclude that: (1) Rectosigmoid but not gastric tonometry detects
small-bowel ischemia from SMA ligation, and both gastric and rectosig
moid tonometry detect small-bowel ischemia during sepsis. (2) In sepsis
and in SMA ligation gut may be ischemic without whole-body ischemia
since whole-body V02 did not decrease. (3) Arterial lactate may indicate
gut ischemia in sepsis but not in SMA ligation. Therefore, gastric and
rectosigmoid tonometry may be important for determination of adequa
cy of resuscitation during septic shock but are limited for detection of
isolated small-bowel ischemia.
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THE USE OF FIBRIN GLUE IN THE TREATMENT OF COMPLEX
FISTULA-IN-ANO. H. MacRae, E. Wiens, W. Orrom. Royal Alexandra
Hospital, University of Alberta, Edmonton, Alta.

OUTCOME OF PATIENTS WITH ULCERATIVE COLITIS AND
POLYPOSIS MANAGED BY RESTORATIVE ILEOANAL RESER
VOIRS. P. Belliveau, R. Mehran. Department of Surgery, McGill
University, Royal Victoria Hospital, Montreal, Que.

The treatment of complicated fistula-in-ano is a challenging problem,
often requiring multiple surgical procedures with the risk of delayed
healing, anal deformity and incontinence. An ideal form of therapy for
this problem would lead to low recurrence rates with minimal morbidity
and no compromise of continence. Fibrin glue has been successfully
used as a sealant in gastrointestinal fistulae. This study assesses this
modality in the therapy of complex fistula-in-ano.
Twelve patients (6 male, 6 female) presenting with complex anal
fistulae were prospectively treated with curettage and irrigation of the
fistulous tract followed by insertion of fibrin glue. The internal opening
was managed with an internal sphincterotomy at the fistula site and
oversewing of the mucosa (four), a mucosal advancement flap (six) or no
treatment (two). Ten patients had fistulae of cryptoglandular origin and
2 were associated with Crohn’s disease. Follow-up was a mean of 7
months (range 4 to 10 months).
Six of 12 fistulae healed with the first operation. Four were
converted to simple fistulae, amenable to fistulotomy. Two failed to heal
but were successfully treated with repeat instillation of fibrin glue.
Complications were minimal, with one partial slough of a mucosal flap
and one urinary retention. There were no complaints of incontinence of
either flatus or stool associated with the therapy. Although further
follow-up is required, we conclude that injection of fibrin glue is a safe,
viable form of treatment for complex fistula-in-ano.
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During the past 11 years, we studied prospectively 150 patients (145
ulcerative colitis, 5 polyposis) undergoing colectomy and ileoanal
reservoir construction at our centre. The mean age was 33 (range 17 to
58 years). All had an S-shaped reservoir with protective ileostomy. The
early complication rate was 9%. Late complications were more numer
ous: rectal abscess 10%, anal stenosis 9%, pouchitis 8%, failure leading
to pouch excision 5% or defunction 2%. Two patients died: one from
suicide and one from AIDS from a remote transfusion prior to surgery.
Functional outcome remains stable for the majority with a stool
frequency of two to eight per day (mean four). Two patients have
persistent diarrhea responding in one to somatostatin analogue. Dynam
ic pouch-emptying studies show a mean of 71% evacuation with a
sub-group having less than 50%; these benefit from intermittent
catheterization. Schilling tests to assess B12 absorption have been
normal in all. Crohn’s disease of the ileum has developed in three
patients. In two of these, steroid response was satisfactory while in the
third it led to pouch excision for hemorrhage and deep extrasphincteric
fistula. Associated ankylosing spondylitis (three) or pyoderma gan
grenosum (three) have had poor results. Indeterminant colitis is
associated with more anorectal sepsis (abscess, fistula).
Overall outcome appears satisfactory, but continued evaluation of
anorectal function and adaptation is essential.
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LONG-TERM RESULTS OF ANTERIOR RESECTION USING THE
DOUBLE STAPLING TECHNIQUE. A. Laxamana, M. Solomon, R.S.
McLeod. H. Stern, S. Feinberg, E. Myers, Z. Cohen. University of
Toronto, Toronto, Ont.

LAPAROSCOPIC NISSEN FUNDOPLICATION: EARLY CLINICAL
EXPERIENCE. M. Anvari, M. Marcaccio, C. Allen, J. Myers. Depart
ment of Surgery and Department of Medicine, St. Joseph’s Hospital,
McMaster University, Hamilton, Ont.

The morbidity and local recurrence rates in patients with rectal
carcinomas in whom an anterior resection using the double stapling
technique was performed were reviewed.
There were 190 patients (120 males and 70 females; mean age 65 ±
12 years) operated on between 1981 and 1992. The mean level of the
carcinoma was 10.2 ± 3.5 cm (range 4 to 24 cm). The stage of the
tumour was stage I in 16, stage II in 100, stage III in 57 and stage IV in
17. Seventeen (8.9%) patients received preoperative and 27 (14.2%)
postoperative radiation. One hundred sixty-six (87%) procedures were
curative. The mean length of the resection margin was 3.0 ± 2.2 cm. At
surgery 17 (8.9%) patients had colostomies performed.
Two patients (1.1%) died. There were 12 (6.3%) intraoperative
complications of which 5 were stapler related (3 serosal tears and 2
misfirings). The postoperative complications included small-bowel ob
struction in 15, wound infection in 16, urinary retention in 12 and
intra-abdominal sepsis in 7. Clinical leaks occurred in 12 (6.3%) patients
of whom 5 required reoperation. The leak rate was significantly higher
in patients with lesions below 10 cm (13% versus 2%; p < 0.01). Stage
of tumour and preoperative radiation did not affect the leak rate.
After a mean follow-up of 32 ± 30 months, there were 14 (8.4%)
local recurrences in patients having curative resections. In comparing
patients who did or did not develop local recurrences, there were no
significant differences in the mean location of the tumour (10.7 ± 3.1
cm versus 10.1 ± 3.5 cm) nor the mean distal resection margin (2.4 ±
1.5 cm versus 3.2 ± 2.3 cm).
These results indicate that the double stapling technique for anterior
resection can be performed with an acceptable anastomotic leak rate and
with a low local recurrence rate.

From August 1992 to January 1993, 20 consecutive patients (9 males,
11 females) with a mean age of 49 years (range 23 to 73), underwent
laparoscopic Nissen fundoplication. Only patients with previous gastric
or esophageal surgery were excluded. All patients had proven reflux on
gastroscopy, 24-hour pH evaluation and esophageal manometry and
were on maintenance medical therapy.
The primary symptom was heartburn in nine patients, regurgitation
in three, dysphagia in one and respiratory complaints in six patients.
Ten patients had a hiatus hernia. Seventeen patients had biopsy-proven
esophagitis, and one patient had Barrett’s esophagus. On 24-hour pH
testing the mean percentage of time with esophageal pH < 4, was 9.4%
for the group. Twelve patients had mild and three patients had severe
esophageal dysmotility. The mean operating time was 103 ± 30
minutes and the mean hospital stay was 2.2 ± 0.4 days. There was no
conversion to open surgery. There were no mortalities, and the only
postoperative complications were: one case of mild pneumonia treated
with home antibiotics and two patients on steroids who developed
gastritis a week following omeprazole cessation after surgery. In
addition, eight patients experienced mild dysphagia for solids for the 1st
month. The median follow-up to date is 3 months. Nineteen patients
have experienced complete relief of reflux symptoms. One patient in
whom cough was the primary presenting complaint, has only experi
enced partial relief of symptoms. All patients will have repeat 24-hour
pH and esophageal manometry and symptom evaluation by an independ
ent observer, at 6, 18 and 60 months following the surgery (the
6-month results will be available by September).
Laparoscopic Nissen fundoplication is a safe procedure with minimal
discomfort and short hospital stay. It has the potential to offer
alternative therapy to patients on long-term maintenance therapy.
Further follow-up is required to establish the long-term efficacy of this
operation.

354
LAPAROSCOPIC TOTAL ESOPHAGECTOMY WITH OR WITHOUT
THORACOSCOPIC ASSISTANCE: OPERATIVE TECHNIQUE AND
PRELIMINARY REPORT. J. Mamazza, E.C. Poulin, J. Robert. Queen
Elizabeth Hospital, Hopital de Saint-Sacrement, Montreal, Que.

We present four patients who had a total esophagectomy for gastroeso
phageal junction tumours by a minimally invasive approach. Our intent
was to establish the feasibility of total esophagectomy by laparoscopy
and/or thoracoscopy. A 15 mm pneumoperitoneum is created. Five
trocars are placed in the upper abdomen (3 to 12 mm and 2 to 5 mm
ports). Using a zero or 30° laparoscope, a thorough evaluation of size,
mobility and resectability of the tumour is made after mobilizing the
gastroesophageal junction. The gastric mobilization is carried out
similar to the open technique preserving the right gastroepiploic arch.
The left gastric artery is controlled at the celiac axis with a stapling
device. The abdominal portion of the esophagus is mobilized laparascopically, and the mediastinal esophagus is dissected under direct
vision to the aortic arch. The upper esophageal dissection is carried out
through a left cervical incision and is verified from below with
laparoscopy. The specimen is extracted through the neck. If the tumour
is large or the thoracic cavity too long, the esophageal dissection may
have to be completed thoracoscopically and the tumour extracted using
a small abdominal incision. The anastomosis is made in the neck. One
patient was converted due to tumour fixation, one required a 7.5 cm
incision for specimen extraction and another had esophageal dissection
completed thorascopically. Mean operating time was 7 hours, 40
minutes. There was no mortality. Two patients developed anastomotic
leaks which drained through the neck incision. All patients did well.
Total esophagectomy is feasible by minimally invasive techniques.
Further evaluation is required to assess the short- and long-term
advantages.

356
LAPAROSCOPIC ADRENALECTOMY FOR ENDOCRINE DISOR
DERS AND INCIDENTALOMAS. M. Gagner, A. Lacroix, E. Bolte, C.
Potvin, P. Hamet, O. Kuchel, S. Querin, A. Pomp. Department of
Surgery and Medicine, Hotel-Dieu de Montreal, Universite de Montre
al, Montreal, Que.

Adrenalectomy performed by a posterior or transabdominal approach
has substantial postoperative pain. To evaluate laparoscopy as a
potential approach for adrenalectomy, we performed 18 consecutive
laparoscopic adrenalectomies on 15 patients. The 11 women and 4 men
ranged in age from 31 to 60 years (mean 45 years). Adrenal pathologies
included failed trans-sphenoidal hypophysectomy for Cushing's disease
(six), nonsecreting adenomas (four), pheochromocytoma (three), primary
aldosteronism (two) cortisol secreting adenoma (two), DHES secreting
hyperplasia (one) and myelolipoma (one). With CO2 pneumoperitoneum,
four 11 mm-trocars were inserted in the flank on the side of resection
with the patient in a hyperextended lateral decubitus position. On the
left side the splenic flexure of the colon was mobilized. On the right side
the right lobe of the liver was retracted and the triangular ligament
dissected. Adrenal vessels were secured with titanium clips. A sterile
plastic bag passed through and an 11 mm incision was used to extract
the glands in toto. Nine right and nine left adrenalectomies were
removed in a mean time of 2.6 hours. Three patients had bilateral
adrenalectomies in a mean time of 5.3 hours. Average tumour size was
4.8 cm (range 1 to 15 cm). Laparoscopic adrenalectomy was successful
in 94% of patients with one requiring a laparotomy because of
inadequate exposure. In follow-up studies, one patient had a minor
response to corticotropin-releasing factor following bilateral resection,
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although cortisol levels were below the normal range. Previous
abdominal surgery was present in 50%. Postoperative complications
were anemia in two patients with one requiring blood transfusion,
colonic pseudo obstruction (one), urinary tract infection (one) and
incisional hematoma (one). The median postoperative stay was 4 days
(range 2 to 19) with a mean of five narcotic injections. Laparoscopy can
be used successfully for adrenalectomy. It produces less postoperative
pain and rapid return to normal activity. It may be the preferred method
for removing most adrenal lesions that require operation.

357
LAPAROSCOPIC SPLENECTOMY: CLINC1AL EXPERIENCE AND
THE ROLE OF PREOPERATIVE SPLENIC ARTERY EMBOLIZA
TION. E.C. Poulin, C. Thibault, J. Mamazza, M.J. Girotti, G. Cote,
A. Renaud. Department of Surgery and Department of Radiology,
Hopital du Saint-Sacrement, Universite Laval, Quebec, Que., Depart
ment of Surgery, Queen Elizabeth Hospital, McGill University,
Montreal, Que. and Department of Surgery, Victoria Hosptial, Univer
sity of Western Ontario, London, Ont.

We describe the clinical course of 12 patients who underwent laparo
scopic splenectomy. Two patients were converted to open surgery —
the first patient because of a hemorrhagic incident and the eighth
patient, who had a 34 cm spleen, because of dissection difficulties. The
remaining patients had no mortality and perioperative morbidity was
10% (one pleural effusion). After an average postoperative stay of 3.5
days (range 2 to 9 days), most patients were able to resume normal
activities within 2 weeks. Use of preoperative splenic artery emboliza
tion was begun with the third patient and the technique involved
embolization of the spleen with coils placed proximally and contour
emboli (microspheres 355 to 500 nm), absorbable gelatin sponge and
small coils placed distally. The most effective devascularization (90% to
100%) was obtained with a combination of proximal coils in the splenic
artery and distal embolization with coils and contour emboli in the
segmental hilar branches. A good linear correlation was established
between operative blood loss and the percentage of splenic devasculari
zation by preoperative splenic artery embolization (r: -0.8084).
Laparoscopic splenectomy has become our preferred technique for
elective removal of a normal sized or moderately enlarged spleen (less
than 20 cm long) when hematologic indications are present.

358 LAPAROSCOPIC GROIN HERNIA REPAIR: PRELIMINARY
RESULTS FROM A PROSPECTIVE CLINICAL TRIAL. M. Wexler,
J. Meakins, J. Garzon, H. Sigman. Division of General Surgery, McGill
University, Montreal, Que.

This trial was designed to evaluate short- and long-term results of
laparoscopic inguinal herniorrhaphy in an 18 institution multicentre
setting. This report details our 15-month personal experience. One
hundred repairs have been performed in 82 patients. Sixteen had
simultaneous bilateral, 1 metachronous and 1 laparoscopic redo of a
laparoscopic recurrence. Fourteen were recurrent hernias. Two principal
repairs have been evaluated: (1) Transabdominal preperitoneal (TAPP)
and (2) intraperitoneal onlay mesh (IPOM) (Can J Surg 1992; 35: 441).
IPOM has been used for indirect (independent of size) or recurrences
with a well-defined sac. There were 49 direct, 44 indirect and 7 others
(mostly combined). TAPP was employed in 64 procedures and IPOM in
32. Eighty-eight percent of repairs were performed as short stay (less
than 24 hours), 5% had greater than 48 hours hospitalization. Four
were converted to open repair for technical problems or complications.
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All were remedied and discharged in 24 hours. Recurrence rate of 5%
has been documented with median follow-up of 7 months. Four
occurred in the first 21 patients; three were IPOM and two TAPP.
Technical errors have been identified. Intra- and perioperative complica
tions have been few and related to trocar or Foley catheter-induced
problems or bleeding and have been absent in the last 60 repairs.
Catheterization is no longer employed. Postoperative complications
include: hematomas (12%), usually confined, asymptomatic and predom
inantly in TAPP; early groin discomfort (13%), vague, intermittent and
related to position; deep tenderness and local bulge, often with fluid
collection which mimics recurrence, occurs principally in IPOM (25%);
lateral or medial thigh pain (3%); testicular symptoms (2%) and
hydrocele (2%). Twenty-one patients had undergone 44 previous repairs.
All favoured laparoscopic repair. Analgesic use is negligible. Only 12
patients failed to return to usual activities by 1 week. Independent
quality-of-life assessment (visual analogue scale) averages 8.5 to 9 /1 0.
These preliminary results suggest laparoscopic herniorrhaphy is safe
and effective, the learning curve is more lengthy and difficult than
laparoscopic cholecystectomy. Patient acceptance and approval is high.
Careful long-term follow-up is required before it can be recommended
over conventional repair.
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A COMPARATIVE STUDY BETWEEN LAPAROSCOPIC AND
OPEN COLORECTAL REANASTOMOSIS. E. Begin, M. Gagner, A.
Pomp, J. Heppell, C. Potvin, M. Rheault. Department of Surgery,
Hotel-Dieu de Montreal, Universite de Montreal, Montreal. Que.

The aim of the study was to compare laparoscopic (L) and open (O)
reversal of Hartmann’s procedure (RHP) under four categories: techni
cal ease, morbidity, bowel function and postoperative course and cost.
All the RHP cases in our institution over the last 36 months were
reviewed, the patients interviewed and, if consent was obtained, a
flexible sigmoidoscopy was performed. In most cases, the initial
operation was for perforated diverticulitis. Twenty-three patients under
went reanastomosis, 11 laparoscopically (2 of which were converted)
and 12 patients had open RHP. The two groups (L and O) were
comparable in terms of past medical history, weight, age and delay prior
to reanastomosis. In the L group four trocars (10 mm) were used, the
sigmoid colon and the rectum mobilized and reanastomosis was carried
out with the 25 mm (n = 4) or 28 mm (n = 5) EEA (US Surgical
Corporation) stapler.
In both the L and O groups, operative anesthesia time (mean 163.3
versus 166.3 minutes), length of colon initially resected (14.5 versus
16.8 cm) and length of colon resected at reanastomosis (5.7 versus 4.4
cm) were similar. Operative blood loss was significantly lower in the L
group (100 versus 332 mL, p = 0.03).
Perioperative morbidity was minimal in both the L group (one
postoperative bleed required two blood units, one wound hematoma)
and in the O group (two wound infections, one episode of fever of
unknown origin). There were no deaths. Long-term follow-up revealed
no recurrent diverticulitis, but there was one partial bowel obstruction
in the L group and one incisional hernia in the O group.
There was no clinical evidence of anastomotic stenosis in either
group. The Kelly-Holschneider continence index (12.7/15 versus
12.3/15) and the postoperative hospital stay (8.9 versus 9.9 days) were
again similar. However, duration of the ileus (2.7 versus 4.8 days, p =
0.0002) and resumption of activities of daily living (31.1 versus 73.3
days, p = 0.02) were significantly shorter in the L group.
The estimated hospital cost for the L patient was $3146 versus
$2610 for an O patient. In conclusion, the L approach to RHP is
associated with a shorter duration of ileus and a much faster
resumption of normal activites with similar morbidity, technical results
and ultimate functional outcome, as compared to the conventional
operation. Laparoscopic RHP is now the procedure of choice in our
institution for the majority of cases.
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LAPAROSCOPIC COLORECTAL SURGERY — THE UNIVERSITY
OF TORONTO EXPERIENCE. R.S. McLeod, H. Stern, C. Burul, R.
Reznick, Z. Cohen. University of Toronto, Toronto, Ont.

The object of this study was to review the initial experience in
laparoscopic bowel surgery at the University of Toronto. Between
November 1991 and January 1993, 46 procedures were performed (21
males, 25 females; mean age of 56 years). The diagnosis was cancer
(31), Crohn's (4) and adenomatous polyps, diverticular disease, inconti
nence and appendicitis in 2 each; familial adenomatous polyposis,
malignant melanoma and ulcerative colitis in 1 each. The attempted
procedures were: anterior resection (21), right colon resection (13),
abdominoperineal resection (APR) (4), subtotal colectomy (2), loop
ileostomy/colostomy (3), interval appendectomy (2), closure Hartmann
(1). The mean operative time was 3.5 hours.
Eight procedures were completed laparoscopically: APR (two), loop
ileostomy (three), appendectomy (two) and closure of Hartmann (one).
In 38 patients, the procedure was laparoscopically assisted. The
dissection was not completed in 13 patients because of difficulty in
mobilization (8), uncertainty of anatomy (2), dense omental adhesions
(1), Crohn’s phlegmon or intraoperative complication (1). Mobilization
of the bowel was considered adequate in the others. Major vessels were
ligated using the endovascular stapler in 20 patients (including the 2
patients who had an APR completed laparoscopically). The specimen
was removed through a small transverse or midline incision in patients,
and the anastomosis was performed extracorporeally in 23 patients.
There were two laparoscopic related complications: tear of the
sigmoid colon (one) and pre-sacral bleeding (one) which required
reoperation.
Our early results suggest that laparoscopically assisted bowel resecetions are possible. Initially, operative time is prolonged and difficulties
in exposure, mobilization and in certainty of anatomy may limit
completion of the procedure.
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LAPAROSCOPIC COLORECTAL RESECTION: PRELIMINARY
CLINICAL EXPERIENCE. J. Mamazza, S. Bouchard, E.C. Poulin, M.
Girotti, A. Nagy. Queen Elizabeth Hospital, Hopital du Saint-Sacrement, Montreal, Que., Victoria Hospital, London, Ont., and Vancouver
General Hospital, Vancouver, BC

We present 46 cases of laparoscopic colorectal resection. The mean age
of patients was 63. Twenty-three cases were for benign disease (9
diverticular disease, 7 inflammatory bowel disease, 2 rectal prolapse, 1
radiation enteritis, 1 ileal-cecal lipomatosis, 1 sigmoid volvulus, 1
angiodysplasia). Twenty-three patients were operated on for malignancy
with an average lymph-node sample of 9 (range 2 to 17). There were 18
right hemicolectomies (RH), 1 left hemicolectomy, 17 sigmoid resec
tions (SR), 3 total abdominal colectomies, 2 abdominal perineal
resections and 3 proctocolectomies (PC). Mortality and morbidity rates
were 2% and 24% respectively. Morbidity was primarily due to wound
infection (9%) and small-bowel obstruction (5%). Mean operating times
for RH. SR and PC were 131, 180 and 426 minutes respectively. Mean
time to full diet was 6 (RH), 4 (SR) and 6 days (PC). Average
postoperative stay was 9 (RH), 6 (SR) and 10 days (PC). Average time to
normal activity was 23 (RH), 15 (SR) and 19 days (PC). The conversion
rate was 7%. These preliminary results seem to indicate a potential
advantage in overall morbidity and recovery times with laparoscopic
colorectal resection. However, careful follow-up of patients treated for
malignancy is mandatory to assure that laparoscopic resection does not
compromise the existing long-term survival rates for colorectal surgery.
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THE EFFECTS OF PLEURAL OPENING DURING THE INTERNAL
MAMMARY ARTERY HARVESTING. I.M. Ali, C.E. Kinley. Victoria
General Hospital, Dalhousie University, Halifax, NS

groups. No deaths occurred. We conclude that VATS does not reduce
analgesic requirements, chest-tube-drainage time and morbidity. It
increases the operative time and cost.

Previous studies indicated that opening of the pleura during the internal
mammary artery (IMA) dissection might be an important factor in
increasing the operative morbidity. To re-evaluate this matter 280
patients who underwent coronary artery bypass grafting in which the
IMA was used were studied, 130 patients had the pleura intact, whereas
in the other 150 patients the pleura was opened. The incidences of
pleural effusion, cardiac tamponade, postoperative respiratory complica
tions and the hospital stay were compared in both groups. It was noted
that the pleural effusion occurred more when the pleura was opened
(20% versus 5%); however, none of the patients required tapping.
Postoperative bleeding with cardiac tamponade features occurred in five
patients of the closed pleural group. In the group of the opened pleura
six patients developed postoperative bleeding without tamponade. The
average postoperative hospital stay was 7 days in both groups. No
significant differences were recorded in the postoperative respiratory
complications.
This study showed that opening of the pleura during the IMA
dissection does not increase the operative morbidity. On the other hand,
opening of the pleura may have the advantages of preventing the
occurrence of cardiac tamponade when postoperative bleeding develops
so that the patient can be taken for re-exploration in a stable condition.
Also when the pleura is opened it allows the IMA to lie under the lung
away from the sternum, and therefore it prevents overstretching of the
artery by the lung and protects it from injury in case of resternotomy.
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2,3-BUTANEDIONE MONOXIME PRESERVES CORONARY AR
TERY ENDOTHELIUM-DEPENDENT RELAXATION DURING
MYOCARDIAL ISCHEMIA IN THE ISOLATED RAT HEART.
R. Cartier, F. Dagenais, M. Carrier, J. Buluran, Y. Leclerc. Montreal
Heart Institute, Montreal, Que.

64
VIDEO-ASSISTED THORACIC SURGERY VERSUS STANDARD
TREATMENT FOR COMPLICATED SPONTANEOUS PNEUMO
THORAX: A COHORT STUDY. A. Page, D. Chapleau, J. Gregoire, A.
Verdant. Departement de chirurgie, Hopital du Sacre-Coeur de
Montreal, Universite de Montreal, Montreal, Que.

2,3-butanedione monoxime (BDM) inhibits cross-bridge cycling and
calcium release from the sarcoplasmic reticulum and interferes with
myocyte activation. To evaluate the effects of BDM infusion on
myocardial function and coronary flow during myocardial ischemia,
isolated rat hearts were studied in the Langendorff apparatus for
myocardial and coronary endothelial functions. Hearts in group 1 (n =
8) were perfused for 10 min with a 37°C oxygenated Krebs-Ringer
solution (KRS) containing BDM (2.5 X 10~2 mol/L) and exposed to 30
minutes of ischemia (37°C). In group 2, a 30-minute electromechanical
arrest was induced (n = 8) by perfusing a 4°C non-oxygenated KRS
containing BDM (2.5 X 10-2 mol/L). A control group (n = 8) was
exposed to 30 minutes of ischemia (37°C). Left ventricular pressure
(LVP), dP/dt and basal coronary flow (CF) were evaluated before and
30 minutes following global ischemia. Endothelial-dependent and in
dependent coronary artery vasorelaxations were tested by measuring the
increase in CF to 5-hydroxytriptamine (5-HT, 1 X 10-6 mol/L) and
sodium nitroprusside (SNP, 1 X 10^5 mol/L) infusions respectively.
Results are expressed as percentage of recovery of the initial values.
Control ( % )
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In order to verify the claim that video-assisted thoracic surgery (VATS)
results in less morbidity than standard treatment (non-VATS), we
conducted a retrospective cohort study, the primary outcome of which
was analgesic requirement (in milligrams of morphine) in the 1st
postoperative week, and secondary outcomes were analgesic require
ment with and without chest tube, operative time, material cost,
chest-tube drainage time and hospital stay. Using strict eligibility
criteria, a convenient sample of 51 cases (14 VATS, 37 non-VATS) was
assembled. VATS cases were selected from November 1991 to Novem
ber 1992 and non-VATS from November 1987 to November 1991.
Groups did not differ with respect to age, sex or weight. The mean total
amount of morphine was 82.1 for VATS and 87.9 for non-VATS (p =
0.73). The mean daily amount was 33.7 when the chest tube was in
place and 9.7 when removed (p = 0.3E-12) and was not affected by the
exposure status. The mean chest-tube-drainage time was 2.8 days foF
VATS and 2.6 for non-VATS (p = 0.8). The operative time was longer
for VATS (196 min versus 137 min, p — 0.5E-04) because of an
increase in both anesthesia and surgical times. The mechanical stapling
device cost was higher for VATS ($362.8 versus $87.2, p = 0.1E-08).
No difference was found in postoperative morbidity and failure between

Group 1 (°/o)

LVP

*p

47 ±

6

5t

< 0 .0 5 , t p < 0 .0 1

Although no significant benefit was found in regard to LVP and
dP/dt preservation, the basal CF autoregulation and the 5-HT and SNP
relaxations were better preserved in the BDM-perfused groups. These
experiments suggest that BDM perfusion could enhance coronary
endothelium preservation during myocardial ischemia.

66
SURFACTANT SUPPLEMENTATION IN EXTENDED LUNG
GRAFT PRESERVATION FOR TRANSPLANTATION. R.J. Novick,
R. Veldhuizen, J. Lewis, F. Possmayer. University Hospital, London,
Ont.

Previous work in our laboratory has documented adverse changes in
surfactant composition after prolonged lung graft storage and trans
plantation in dogs (ARRD 1992; 145: A844). To determine whether
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surfactant supplementation is of benefit, 13 canine double-lung blocks
were pretreated with prostacyclin, flushed with 4°C Euro-Collins
solution, and stored at 4°C for 38 hours. After left single-lung
transplantation, five recipients served as nontreated controls (group I)
and eight were administered 50 m g/kg of bovine lipid extract
surfactant (bLES) directly into the left main bronchus (group II). Blood
gases, peak inspired pressures (PIP) and individual pulmonary artery
(PA) blood flows were measured every 30 minutes during 6 hours of
reperfusion, after which the native right and transplanted left lungs
were lavaged and surfactant composition was analysed.
All group I animals developed severe ischemia-reperfusion lung injury
during reperfusion. Three of eight group II dogs exhibited excellent
lung preservation (Ila), whereas five group II dogs did not respond to
surfactant treatment (lib). The results after 6 hours of reperfusion (±
SEM) were:
L e ft lu n g

P o 2/ F i o 2

G ro u p
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68
PROGNOSTIC VALUE OF DNA PLOIDY AND BIOMARKERS IN
PULMONARY CANCER. J.E. Morin, J. Sampalis, F. Halwani, R.
Michel, N.S. Wang. Department of Surgery (Division of CVT), and
Department of Pathology, Royal Victoria Hospital, McGill University,
Montreal, Que.

L e f t lu n g

la v a g e
L e ft P A
(%

These early results suggest that internal mammary dissection is
adequate and IMCAB is technically possible. Improvements in catheters,
stents and thoracoscopic instrumentation are needed. Short-term and
long-term studies will be needed to study the patency rate and sucess of
this new anastomosis.

r a tio

0 .7 3 ± 0 .1 3
0 .1 8 ± 0 .0 4
0 .4 8 ± 0 . 1 8
0 .0 6

We conclude that therapy with bLES can result in excellent
preservation of lung grafts after prolonged storage and transplantation
but that the results are not consistent. Satisfactory gas exchange in
group Ila is correlated with low surfactant small-large aggregate ratios
and the maintenance of graft PA blood flow during reperfusion. Detailed
study of the individual lobar distribution of exogenous surfactant may
be indicated to ascertain why some dogs respond and others do not
respond to surfactant replacement therapy.
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THE USE OF CORONARY METALLIC STENTS FOR THORACO
SCOPIC INTERNAL MAMMARY- CORONARY ARTERY ANASTO
MOSIS. M. Gagner, G. Soulez, L.P. Amiot, P. Ibarot. Department of
Surgery and Department of Radiology, Hotel-Dieu de Montreal,
Universite de Montreal, Montreal, Que.

Thoracoscopic surgery is rapidly expanding to all fields of conventional
cardiothoracic surgery. The internal mammary-coronary artery bypass
(IMCAB) is an established procedure for atherosclerotic coronary
disease requiring a sternotomy and extracorporeal circulation. We
experimented with the use of metallic coronary stents to establish
IMCAB thoracoscopically in a canine model.
Twenty dogs (25 to 30 kg) were anesthetized. After dissection of the
right axillary artery, a guide wire was introduced into the right internal
mammary artery under fluoroscopic guidance. The mammary artery was
dissected with thoracoscopic instruments through three trocars of 11
mm. The pericardium was opened and the descending artery dissected.
After an anterior arteriotomy, the guide wire was introduced in the
coronary artery, where the metallic stent was positioned and expanded
between the two arteries without extracorporeal circulation. The dogs
were sacrificed at the end of the surgical procedure.
Three dogs died during the procedure (two from cardiac arrhythmia,
one from anesthesia). All dogs had the internal mammary fully dissected
by thoracoscopic surgery (mean time = 35 minutes). Four dogs had a
major hemorrhage (three from the coronary arteriotomy, one from
myocardial laceration). Of the 13 anastomoses, six stents had a
malfunction (unable to expand or retrieve the catheter). Seven dogs had
a complete anastomosis (of those, one had a myocardial infarction
before the end of the procedure). The examination of these anastomoses
revealed a small gap (< 1 mm) in one half of them. The mean procedure
time was 150 minutes.

This study evaluated cell markers and DNA ploidy as prognostic
indicators in lung cancer. A cohort of 116 patients surgically treated for
lung cancer was followed prospectively. Of the 116 patients, 68 (59%)
were male, mean age was 66 years (SD = 8.0), 93% were current or past
smokers, family lung cancer was reported by 12 (10.3%) and 23 (20%)
reported family history of other cancers. Stage 1, 2, and 3 disease was
present in 71 (61%), 18 (16%) and 27 (23%) respectively at the time of
surgery. Mean follow-up duration was 22.1 months (SD = 13.7), (range
1 to 56). At the time of final follow-up a total of 43 (37%) had died, 40
(34%) from the cancer. Of the surviving patients, 14 (12%) had a
recurrence, and 59 (51%) were without cancer. Metastatic disease had
occurred in 41 (35%) of the patients. DNA was aneuploid in 54 (50%),
diploid in 47 (43%), multiploid in 8 (7%). Positive cell biomarker results
were: cytokeratin (90%), CEA (82%), chromogranin (62%), keratin
(62%), S-100 (23%) and vimentin (5%).
For metastasis, an odds ratio (OR) of 1.9, 95% confidence intervals
(Cl) = 0.82 to 4.19, was found for family lung cancer, and a significant
relative odds (OR = 4.6, 95% Cl = 1.69 to 12.69) for stage 3 disease.
Aneuploid DNA was associated with a twofold increase in the odds (OR
= 2.1, 95% Cl = 0.91 to 4.95). Among the cell markers, CEA was
associated with an increased relative odds (OR = 2.4, 95% Cl = 0.74 to
7.73).
For mortality, stage 3 disease was associated with an increased
relative odds (OR = 3.3, 95% Cl = 1.26 to 8.97). Aneuploid DNA was
also associated with increased relative odds (OR = 1.8, 95% Cl = 0.79
to 4.17). Among the cell markers a marginally significant increased
odds for mortality was found only for S-100 (OR = 2.17, 95% Cl =
0.76 to 5.98).
Conclusions: DNA ploidy and cell markers provide useful prognostic
information for lung cancer patients. This has important implications
for patient care and research.
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COMPARISON OF CLINICAL PERFORMANCE OF BIOLOGICAL
AND MECHANICAL PROSTHESES — INTERMEDIATE-TERM AS
SESSMENT. W.R.E. Jamieson, R.T. Miyagishima, G.F.O. Tyers, H.
Ling, A.I. Munro, L.H. Burr. Department of Surgery, University of
British Columbia, Vancouver, BC

Clinical performance of biological and mechanical prostheses was
assessed at 10 years with regard to structural valve deterioration (SVD)
and treatment failure freedom (freedom from valve-related [VR] mortali
ty and residual morbidity due to permanent impairment). The biological
population comprised 1210 patients with Carpentier-Edwards standard
porcine bioprostheses and 767 with mechanical prostheses (St. Jude
Medical, Bjork-Shiley Monostrut, Duromedics and Carbomedics).
The freedom from structural valve deterioration at 10 years was:
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Biological
Overall
< 35
3 6 -5 0
5 1 -6 5
> 65

76.2
54.9
62.3
77.5
92.2

±
±
±
±
±

Mechanical

1.6%
6.2%
4.2%
2.3%
2.2%

99.2 ± 0.8%
95.9 ± 4.0%
100%
100%
100%

pNS
pNS
pNS
pNS
pNS

The freedom from treatment failure at 10 years was:
Biological
Overall
< 35
3 6 -5 0
5 1 -6 5
> 65

91.5
86.0
85.9
87.1
79.4

Mechanical

± 0 .9 %
± 5.0%
± 3.2%
± 1.7%
± 2.9%

92.1
91.1
95.4
90.8
89.7

± 1.6%
± 4 .0 %
± 1 .7 %
± 3 .1 %
± 4.4%*

pNS
pNS
pNS
pNS
pNS

‘ 7 years

The freedom from other composites of VR complications was:

Reoperation
Mortality
Residual morbidity

Biological

Mechanical

71.9 ± 1.7%
88.8 ± 1.2%
95.2 ± 0.8%

88.5 ± 3.2%
84.7 ± 10.0%
96.7 ± 1.0%

pNS
pNS
pNS

Despite the increased necessity for reoperation with biological
prostheses the failure of treatment remains the same between the two
types of prostheses at the intermediate term of 10 years.

70
MANAGEMENT OF CONCOMITANT CORONARY ARTERY DIS
EASE (CAD) AND NON-SMALL CELL LUNG CANCER (NSCLC):
USE OF DECISION ANALYSIS. G.A.J. Gelfand, G. Fradet, L. Hol
lands, B. Nelems. University of British Columbia, Vancouver General
Hospital, Vancouver, BC

Concomitant non-small cell lung cancer (NSCLC) in patients with
coronary artery disease (CAD) is rare (0.3%). Management, based on
small retrospective series, is controversial. For these reasons, decision
analysis was used to determine optimal treatment strategy. For patients
with concomitant CAD and NSCLC (excluding LLL lesions) deemed
resectable by preoperative staging, a decision tree was constructed with
three alternatives: nonsurgical management, staged surgery with bypass
grafting and delayed thoracotomy, or combined surgery. Probabilities
for operative morbidity, mortality and resectability were obtained from
the literature. Outcomes incorporated estimates of utility (relative value
to the patient from 0 to 1) generated by the authors and life expectancy
calculated using the declining exponential approximation. Combined
surgery (expected utility = 2.84 quality-adjusted life years) was
favoured over staged surgery (2.61) or nonsurgical management (2.36).
One-way sensitivity analysis, which tested the stability of these findings,
found the following to have thresholds that would alter this conclusion.

Using decision analysis to incorporate estimates of risk, utility and
survival, this study supports the use of combined surgery for concomi
tant CAD and NSCLC.
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LUNG RESECTION IN THE ELDERLY POPULATION. A. Jamjoom,
C. Serrick, A. Reis, H. Shennib. The Montreal General Hospital,
Montreal, Que.

Fifty-eight octogeneric patients underwent lung resection between
January 1979 and December 1986. Fifty-three patients had primary
non-small cell lung cancer. Of these 14 (26.4%) were females and 39
(73.6%) males with a mean age of 76.3 years. Twelve (22.6%) patients
were stage I, 34 patients (64.2%) in stage II, 6 patients (11.3%) in stage
Ilia and 1 patient (1.9%) in stage Illb. Twenty-nine patients (54.7%) had
adenocarcinoma, 22 patients (41.5%) had squamous cell carcinoma, and
2 patients (3.8%) had large cell carcinoma. Fifty-nine operative proce
dures were performed in these 53 patients. All patients had pulmonary
functions correlated with safe surgical resection for a total of 5 wedge
resections (8.5%), 10 segmentectomies (16.9%), 37 lobectomies (62.7%)
and 7 pneumonectomies (11.9%). The overall 30-day operative mortality
was 9.4%. The overall 1- and 5-year survivals were 79.2% (42 patients)
and 24.5% (13 patients) respectively. However, taking into account that
at 1 year only 7 of the 11 (63.6%) deaths were cancer related and at 5
years only 29 of the 40 (72.5%) deaths were cancer related, the 1- and
5-year cancer related survivals were 86.8% and 45.3%, respectively. As
expected, patients with adenocarcinoma did worse than squamous cell
carcinoma. One-year survival for patients with adenocarcinoma was
75.8% (22 patients) and for squamous cell carcinoma was 90.9% (20
patients), which was not statistically significant. However, 5-year
survival for patients with adenocarcinoma was significantly lower than
for those with squamous cell carcinoma (13.8% [four patients] versus
40.9% [nine patients), p = 0.029). Both patients with large cell
carcinoma died within the 1st year. Tumour size also affected patient
survival. Patients with T1 tumours had a better 1-year survival than
patients with T2 and T3 tumours (100% [13 of 13] versus 72.5% [29 of
40], p = 0.033). There was no difference at 5 years. We conclude that
lung resection can be performed safely to octogeneric patients with lung
cancer. Considering the average life expectancy of this age group,
surgery appears to be an appropriate therapeutic modality.
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ENHANCED INFLAMMATORY RESPONSE FOLLOWING NORMOTHERMIC CARDIOPULMONARY BYPASS. K. Teoh, C. Bradley,
H. Burrows, J. Gauldie. McMaster University, Hamilton Civic Hospi
tal, Hamilton, Ont.

Twelve patients undergoing elective coronary artery bypass surgery
were randomized to hypothermic (COLD, n = 6, 28.8 ± 1.5 C) or
normothermic (WARM, n = 6, 34.7 ± 0.7 C) cardiopulmonary bypass
to assess the effect of temperature on the release of inflammatory
mediators. Arterial blood samples were obtained serially for 24 hours
postoperatively and assayed for interleukin-6 (IL-6, B9 proliferation).
The duration of cardiopulmonary bypass and aortic cross-clamping was
not different between the groups.
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Normothermia enhances the interleukin response to cardiopulmonary
bypass with resultant decreased vascular resistance. The inflammatory
response can be modulated by alterations in temperature.

excluded) and avoidance of usual bias in a retrospective study. We failed
to show any difference in hemodynamic parameters or inotropes
requirement following CABG between warm and cold blood cardio
plegia. Other observers have found differences in experimental studies
between the two cardioplegic solutions. However, we doubt these
results are of any clinical significance in the early outcome of the
surgery. The debate should instead be reoriented toward long-term
effects of different types of cardioplegia on the myocardial function.
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RESULTS OF CARDIAC SURGERY IN THE ELDERLY USING
NORMOTHERM1C TECHNIQUES. A.L. Panos, C.A.M. Barrozo, S.J.
Khan, T.A. Salerno. St Michael’s Hospital, Toronto, Ont,

Thirty-three patients older than 70 years of age underwent cardiac
surgery using normothermic cardiopulmonary bypass and myocardial
protective techniques. Mean age was 74 ± 3 years, and there were 21
male and 12 female patients. Procedures performed were coronary
artery surgery (ACB, 14 patients), mitral valve replacement alone (MVR,
3 patients) or with coronary artery surgery (ACB + MVR, 2 patients)
aortic valve replacement (AVR, 12 patients); Bentall procedure (1
patient) and repair of false aneurysm of the left ventricle with coronary
surgery (LVA, 1 patient).

Procedure

N

ACB

14
3
2
12
1
1

MVR
ACB +
AVR
B e n ta ll
LVA

MVR

Cross-clamp,
min
51
50
73
57
67
32

± 15
± 23
± 6
± 13

IABP

Stroke

Ml

Mortality

4
1
0
0
0
0

1
0
0
0
0
0

3
0
1
0
0
1

3
0
1
0
1
0

The preoperative [K+] was 4.1 ± 0.7 meq/L, and at the end of
surgery [K+] was 5.6 ± 0.8. The overall complication rates were:
postoperative use of intra-aortic balloon pump (IABP) 15%, stroke 3%
(recovered completely), perioperative MI rate 15%, postoperative bleed
ing requiring reoperation 9% and respiratory failure 7%. The overall
mortality was 15%. One death was due to intra-abdominal sepsis
postoperatively, leaving a cardiac mortality of 12%. The morbidity and
mortality rates for heart surgery in the elderly using normothermic
cardioplegia and normothermic cardiopulmonary bypass are comparable
to those observed when hypothermic techniques were used.
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CONTINUOUS NORMOTHERMIC BLOOD CARDIOPLEGIA IN PA
TIENTS WITH SEVERE VENTRICULAR DYSFUNCTION.
A.L. Panos, C.A.M. Barrozo, 0 . Al-Nowaiser, I.S. Ali, T.A. Salerno.
St. Michael’s Hospital, Toronto, Ont.

Left ventricular (LV) function is a predictor of operative mortality.
Patients with ejection fractions (EF) less than 20% have high mortality,
especially for emergency surgery. We report a retrospective study of 28
patients with severely impaired preoperative LV function (EF < 20%)
undergoing surgery using continuous normothermic blood cardioplegia
(CNBC) for myocardial protection. Ten patients underwent coronary
revascularization (CR), 11 valvular replacement (7 aortic, 4 mitral), 5
combined CR and valve(s) procedures, while the remaining 2 had repair
of post-myocardial infarction ventricular septal defect (1 patient) and
repair of a posterior LV wall rupture (1 patient). Mean age was 60 years,
cross-clamp time was 63 ± 28 minutes and cardiopulmonary bypass
time was 90 ± 37 minutes. The [K+] was 6.0 ± 0.9 m eq/L at the end of
the bypass and was 4.0 ± 0.7 m eq/L upon arrival in the ICU. Only 3 of
the 28 patients (10.7%) needed treatment for high [K+]. Emergency
surgery was performed on 13 patients (46.4%) (i.e., within 24 hours of
cardiac catheterization or initial in-hospital assessment). Five cases
(17.9%) were reoperations. In-hospital death occurred in 3 cases
(10.7%); 2 were reoperations and all were emergency cases with patients
more than 70 years old. Intra-aortic balloon pump assist was required in
seven cases (25%) and intraoperative defibrillation in three cases
(10.7%). Perioperative myocardial infarction occurred in four cases
(14.3%) and stroke and sternal wound infection in one case each (3.6%).
CNBC is an alternative method of myocardial protection in high-risk
patients with severely impaired LV function.
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74
WARM AND COLD BLOOD CARDIOPLEGIA: NO DIFFERENCE IN
HEMODYNAMIC PARAMETERS AND INOTROPES DURING
POSTOPERATIVE PERIOD. A.L. Lamy, G.J. Fradet, I.A. Munro.
Department of Surgery, Vancouver General Hospital, Vancouver, BC

Warm blood cardioplegia offers many theoretical advantages over cold
blood cardioplegia but has failed to show any obvious clinical superiori
ty over cold blood cardioplegia. We decided to observe the two types of
cardioplegia in a clinical situation: hemodynamic parameters and
requirement of inotropes in the postoperative period. We have analysed
all consecutive patients (81) over a 6-month period who had only
coronary artery bypass grafting (CABG). According to the surgeon,
groups were divided between warm blood cardioplegia (44) and cold
blood cardioplegia (37). There was no difference in inotropes require
ment at 0, 1, 2, 4, 12 and 24 hours after the surgery (p = ns). No
difference was found in cardiac output, systemic vascular resistance and
pulmonary vascular resistance. Mortality and morbidity were identical.
Results of this retrospective study are validated by the comparability
of the two groups, the homogeneity of their treatment (cardioplegia

A CASE ANALYSIS OF DYNAMIC CARDIOMYOPLASTY. R. Cecere,
J.N.K. Odim, R.C.-J. Chiu. The Montreal General Hospital, McGill
University, Montreal, Que.

A functional, hemodynamic and cost analysis of a case of dilated
cardiomyopathy treated by dynamic cardiomyoplasty is presented.
A 62-year-old man with a 5-year history of progressive idiopathic
dilated cardiomyopathy, New York Heart Association (NYHA) function
al class III, underwent dynamic cardiomyoplasty using the left latissimus dorsi muscle. He was previously rejected for heart transplantation
due to age. He was followed up to 2 years at regular intervals.
The patient is now NYHA functional class I, confirmed by Sickness
Impact Profile. The left ventricular ejection fraction rose from 8% to
22%. Maximal oxygen consumption improved from 0.7 L /m in (30%
predicted) to 1.4 L /m in (60% predicted). Hemodynamics showed an
overall marked improvement: pulmonary capillary wedge pressure 30
mm Hg preoperatively versus 4 mm Hg postoperatively; stroke volume
30.6 mL/beat versus 69 mL/beat; cardiac index 1.6 L/m in-m-2 versus
2.7 L/min-m-2. Plasma renin levels have fallen from 33.2 ng/m L
hourly to 1.1 n g/m L hourly. The patient had five cardiac-related
CJS, VOL. 36, NO. 4, AUGUST 1993
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hospitalizations in the year prior to admission at a cost of $10 341. In
the 2 years of follow-up, there were no cardiac-related hospitalizations.
Annual medication costs are reduced from $2500 to $1500. The costs
for cardiomyoplasty were $32 000, while heart transplant costs average
$100 000 plus $12 000 annual maintenance.
These data indicate that with proper case selection dynamic cardio
myoplasty can be highly cost effective and significantly improve the
quality of life of patients.

77
EXPERIENCE WITH CENTRIFUGAL PUMPS FOR VENTRICULAR
ASSIST DEVICE. F.B.Y. Hoy, R.C. Gomez, D.M. Geiss, J.R. Munns,
C. Stables, S. Faulkner. Downstate Heart Transplant Center, Universi
ty of Illinois College of Medicine, Peoria, 111.

Over a 6V2-year period, 43 patients aged 6 weeks to 75 years required
ventricular assist (VA) using centrifugal pumps (CP). Indications for VA
were (i) low cardiac output due to cardiotomy in 36 patients, (ii)
cardiogenic shock due to myocardial infarction in 4 patients and (iii)
bridge to transplant in 3 patients. Duration of VA ranged from 1 to 13
days. Mode of VA was BiVAD 54%, LVAD 42% and RVAD 4%. Bleeding
occurred in 29 patients, renal insufficiency in 14 patients and neurolog
ic deficits in 8 patients. Seventeen patients (40%) could not be weaned
from VA. Three patients were successfully transplanted. Twenty-three
patients (53%) were successfully weaned (of whom 16 [37%] were
discharged); 2 patients remain in hospital.
Conclusion: CP can be used for VA for up to 2 weeks with more than
half of the patients weaned and more than one-third of patients
discharged.
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INFLUENCE OF PRE-REPERFUSION MANAGEMENT WITH
“ COLD SHOT" FOR CORONARY ARTERY BYPASS SURGERY.
G. Dry, W.R.E. Jamieson, E. Germann. Vancouver General Hospital,
University of British Columbia, Vancouver, BC

The influence of “cold shot” (terminal cold, high potassium blood
cardioplegia — 400 mL) and xylocaine (200 mg) by CPB circuit was
evaluated retrospectively by comparison of two consecutive groups of
patients, group A “cold shot” (100 patients) and group B, 99 patients
with no “cold shot.”

Tests
Age
Sex - male:female
Previous M i
< 21 d
> 21 d
Angina
Stable
Unstable
Ejection fraction
> 50
3 1 -5 0
< 30
LMCS
Triple-vessel disease
Grafts
Internal mammary

G ro u p A

G ro u p B

63.9 ± 8.8 yr
76:24

64.5 ± 9.0 yr
74:25

4.0%
54.0%

1.0%
48.5%

2.0%
94.0%

2.0%
79.8%*

48.0%
35.0%
6.0%
31.0%
83.0%
3 .6 /p t
76%

52.0%
29.3%
6.1%
20.2%
75.8%
3 .3 /p t
79.8%

'p < 0.05
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The results are as follows:
G ro u p A

Mortality
Postop. cardiac arrest
Arrhythmias
SVT
Ventricular
CKMB < 24 h
CKMB > 24 h
Defibrillation
IABP
Antiarrhythmics

2.0%
3.0%
33.0%
11.0%
35.7 ± 20.6%
35.0 ± 23.8%
15%
4.0%
2.0%

G ro u p B

2.0%
3.0%
31.3%
6.1%
41.8 ± 34.2%
42.0 ± 52.1%
54%*
1.0%
5.1%

' p < 0.05

The inotropic support at completion of operation and postoperativly
at 2, 10 and 24 hours did not differentiate the groups. The groups were
similar except for a preponderance of unstable angina in group A. The
decreased need for defibrillation in group A differentiated the groups
significantly, with trends in elevation of enzymes and need for
antiarrhythmic therapy in group B. The “cold shot” does provide
clinical benefit.
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CARDIAC REINNERVATION AFTER TRANSPLANTATION: AN
ALTERNATIVE HYPOTHESIS. D.A. Murphy, S. O’Blenes, B.D.
Hanna, J.A. Armor. Dalhousie University, Halifax, NS

Norepinephrine is released from intact postganglionic efferent sympa
thetic neuron terminals in the heart. Release of this neurotransmitter
into the coronary sinus induced by tyramine is given as evidence for
reinnervation following cardiac transplantation. Previous studies have
demonstrated ganglia in the mediastinum and on the heart containing
parasympathetic neurons. Our hypothesis is that such ganglia contain
sympathetic neurons and that these ganglia are transplanted with the
heart and thus remain functional on the transplanted heart.
Methods: Eight dogs underwent cardiopulmonary autotransplanation
and acute adrenalectomy. Pre- and post-transplant electrical stimulation
of autonomic neural structures as well as chemical stimulation with
isoproterenol tyramine, nicotine was performed before and after atropine
and ^-adrenergic blockade.
Results: Central denervation was complete as shown by a total lack of
cardiac response to stellate ganglion and vagal stimulation. In the
denervated heart significant sympathetic responses were elicited with
nicotine before but not after /3-adrenergic blockade.
Conclusion: These findings demonstrate the presence of functional
adrenergic neurons on the heart, which are capable of modifying
cardiodynamics significantly. These neurons could account for norepi
nephrine release into the coronary sinus following the administration of
tyramine in post-transplant patients.
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CALCIUM CHANNEL BLOCKERS ENHANCE ENDOTHELIAL
PRESERVATION FOLLOWING GLOBAL ISCHEMIA IN THE ISO
LATED RAT HEART. R. Cartier, F. Dagenais, J. Buluran. Montreal
Heart Institute, Montreal, Que.
Myocardial ischemia affects coronary artery endothelial function. Calci
um channel blockers may protect endothelial-dependent coronary
vasoregulation during global myocardial ischemia. To verify this
hypothesis, isolated rat hearts were studied in the Langendorff appara
tus for coronary endothelial function. Group I (n = 6) was exposed to a
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30-minute warm ischemia (37°C) and used as a control. Groups II, III
and IV (n = 24) were exposed to similar ischemia but respectively
pretreated for 10 minutes with increasing doses (10~9 mol/L to 10~6
mol/L) of verapamil (VL), nifedipine (NE) and diltiazem (DM). Endo
thelium-dependent coronary flow increase was tested by infusing
5-hydroxytriptamine (5-HT, 1 X 10-6 mol/L) before and 30 minutes
following global ischemia. Results are expressed as a percentage of
recovery of the initial values.
1 0 9 mol/L
VL

61 ± 1 6 *
57 ± 11*
NE
3 ± 16
DM
C o n tro l 3 ± 11

1 0 8 mol/L

1 0 7 mol/L

1 0 6 mol/L

68 ± 6*
2 4 ± 11
56 ± 8*

82 ± 11*
2 2 ± 17
62 ± 7*

42 ± 3
19 ± 2 0
66 ± 4 *

*p < 0 .0 5 D u n n e t v a ria n c e a n a ly s is co m p a rin g tre a te d g ro u p s to c o n tro l

In comparison to the control group, all calcium channel blockers
were efficient in preserving endothelial-dependent coronary artery
relaxation during global warm ischemia but differed in a dose-related
fashion.
81
PENTASTARCH HIGH VISCOSITY IS NOT RESPONSIBLE FOR
CORONARY ARTERY ENDOTHELIAL DAMAGE DURING UW
SOLUTION PERFUSION IN ISOLATED RAT HEARTS. F. Dagenais, R. Cartier, J. Buluran. Montreal Heart Institute, Montreal, Que.

Pentastarch (PT) high viscosity may account for coronary artery
endothelial damage by increasing shear stress during University, of
Wisconsin (UW) solution perfusion. To verify this, rat hearts were
studied in the Langendorff apparatus for endothelial function. Hearts in
group 1 (n = 6) were perfused for 10 minutes with UW (4°C) and group
2 (n = 6) with PT 5% (4°C) containing 100 meq/L KC1 (360 mOsm/L).
Baseline coronary blood flow (BCF) and endolethium-dependent and
independent coronary artery relaxations, measured by the coronary flow
increase to 5-hydroxytriptamine (5-HT, 1 X 10~6 mol/L and sodium
nitroprusside (SNP, 1 X 10-5 mol/L) infusions respectively, were
recorded before and after perfusion. Changes in coronary flow during
perfusion (PCF) were also recorded. Results are expressed as percentage
recovery of the initial values.

Acute myocardial injury in pediatric congenital heart surgery still
remains at elevated ranges. This study evaluated the role of oxygen
saturation and platelet activating factor (PAF) in ischemia-reperfusion
injury. Twenty-one female swine at 4 weeks of age were subjected to
limited left thoracotomy and a right to left shunt between the
pulmonary artery and left atrial appendage. In addition, a pulmonary
artery band was placed distal to the shunt. When a chronic hypoxemic
state (saturation 80%) developed, animals were prepared for open-heart
surgery, and their hearts were subjected to 90 minutes of global
hypothermic ischemia, and the abnormalities were corrected. At this
stage animals were divided into three groups. Group A (n = 7)
introduction of 95% to 100% oxygen saturation following the comple
tion of cardiopulmonary bypass (CPB). This group was treated as a
clinical conventional method and used as the control group. Group B (n
— 7) introduction of 80% saturation after CPB gradually increasing to
100%. Group C (n = 7) use of PAF-antagonist CV-3988, a phospholipid
analogue of PAF that has PAF-antagonistic properties (10 m g /k g IV
slow infusion 1 hour before the cross-clamp).
Myocardial functional parameters assessed by hemodynamics and
echocardiography included myocardial performance, systolic function,
diastolic compliance, diastolic work and left ventricular wall stress.
Results of this experimental protocol demonstrated significantly (p <
0.05) better myocardial performance, contractile capacity (left ventricu
lar wall stress), diastolic compliance, systolic and diastolic function for
group C compared to groups A and B.
This investigation revealed that myocardial injury in presence of
chronic cyanosis may not be due to introduction of 100% oxygen.
Mediators of inflammation such as PAF play a greater role in the
pathophysiology of myocardial ischemic-reperfusion injury in chronic
hypoxemic state. Interventional therapy with PAF-atagonists such as
CV-3988 may prevent myocardial ischemia-reperfusion injury in patients
undergoing open-heart surgery for correction of congenital heart
disease.

83
CARDIAC TROPONIN T AND CKMB MEASUREMENTS AS CLINI
CAL MARKERS OF HEART PRESERVATION. M. Carrier, B.C.
Solymoss, R. Cartier, L.C. Pelletier. Montreal Heart Institute and
University of Montreal, Montreal, Que.

PCF drop was comparable in both groups suggesting similar but
increased shear stress during perfusion whereas BCF autoregulation
was not affected. However, UW-perfused hearts presented impairment of
the coronary endothelial-dependent and independent relaxations, indi
cating that the increase in shear stress induced by PT was not
responsible for endothelial and smooth muscle damage during UW
perfusion.

Safe periods of ischemic preservation of less than 4 hours have been
recommended in heart transplantation. To determine the severity of
myocardial cell damage during that period, we have measured serial
CKMB activity, CKMB mass and Troponin T in 10 patients during the
first 48 hours after cardiac transplantation. All donors have had normal
cardiac function by echocardiographic evaluation. Hearts were arrested
with cold crystalloid cardioplegia and preserved in hypothermic solu
tion. All patients survived the 1st week after transplantation. Total
ischemic time averaged 130 ± 1 1 minutes (range 88 to 195). Maximal
CKMB activity, CKMB mass and Troponin T after transplantation were
140 ± 15 IU/L, 168 ± 43 n g /L and 3.89 ± 0.37 ng/m L respectively.
There was no significant correlation between ischemic time and maximal
elevation of CKMB activity (r = 0.18), CKMB mass (r = 0.39) and
Troponin T (r = 0.01). There was no significant correlation between
ischemic time and the slope of excretion of CKMB activity (r = 0.14)
and CKMB mass (r = —0.38). A moderate negative correlation between
ischemic time and the slope of excretion of Troponin T (r = —0.47) was
observed. In conclusion, myocardial cell damage during a short period
of ischemic preservation appears to be mild, and it is best reflected by
the elevation and the pattern of excretion of cardiac Troponin T.
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PATHOPHYSIOLOGY OF ISCHEMIA-REPERFUSION INJURY IN A
MODEL OF CHRONIC CYANOSIS. A.K. Oayuhi, W.R.E. Jamieson,
J.G. LeBlanc, E. Feeley, A. Poostizadeh, M. Nikbakut-Sanjer. Depart
ment of Surgery, University of British Columbia, Vancouver, BC

84
PULMONARY NEUTROPHIL SEQUESTRATION IN ASSOCIATION
WITH CARDIOPULMONARY BYPASS. M.L. Myers, J.E. Powe,
G. Morrissey, D. Laidley. Victoria Hospital, University of Western
Ontario, London, Ont.

UW (% )

BCF
5-HT
SNP
PCF

90
29
74
48

±
±
±
±

10
12
10
8

PT (% )

98 ± 4
104 ±8*
100 ± 8 f
54 ± 7

' p < 0.01, f p < 0.05
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Complement and neutrophil activation have been clearly demonstrated
in association with cardiopulmonary bypass (CPB). Previous studies
have also shown pulmonary artery (PA) to left atrial neutrophil (LA)
gradients indicative of pulmonary neutrophil sequestration. The purpose
of this study was to scintigraphically characterize this neutrophil
sequestration in patients following cardiopulmonary bypass using
autologous technetium-99m (Tc99nl)-labelled neutrophils. Ten patients
undergoing elective coronary artery bypass surgery were studied.
T c"m-labelled autologous neutrophils were injected 10 minutes prior to
CPB. Postoperative imaging with a mobile gamma camera was carried
out immediately as well as 24 hours postoperatively. Control images
were obtained in outpatients undergoing neutrophil imaging for chronic
infectious problems. Image intensity was graded on a scale of 0 to 3+.
All images were independently graded by two experienced observers.
Patients underwent an average of 3.0 ± 0.2 distal anastomoses with a
mean CPB time of 88.8 ± 6.0 minutes. There were no postoperative
complications, and patients were discharged 7.8 ± 0.2 days after
surgery. A significant mean PA to LA gradient developed intraoperatively but had resolved in the initial postoperative hour. Initial images
showed four patients with 2+ activity, three patients with 1+ activity
and three patients with no excess activity. Two patients had persistent
1+ activity at 24 hours. Nine patients in the control group showed no
activity while one had 0 to 1+ activity. This study demonstrates that
pulmonary neutrophil sequestration occurs in most patients with CPB
but is not necessarily associated with clinical sequelae.
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ALTERNATIVE APPROACH TO THE CABROL TECHNIQUE OF
AORTIC ROOT REPLACEMENT. E.A. Pascoe, B.W. Rusnak. St.
Boniface General Hospital, University of Manitoba, Winnipeg, Man.

Composite valve graft replacement is a widely applied approach to the
surgical treatment of annuloaortic ectasia and dissection involving the
aortic root. The Cabrol technique of coronary artery reattachment
employs a separate Dacron tube to deliver blood from the aortic graft to
the coronary arteries. As currently promoted by Cabrol and other
authors, the coronary tube occupies a location posterior and to the
right of the aortic graft. This alignment, in some patients, can allow
excessive angulation of the coronary tube at its anastomosis with the
right coronary ostium. Thrombosis of the right limb of the coronary
tube, ascribed to this excessive angulation, has been reported by the
Baylor group.
In three patients we have employed an alternative approach to the
Cabrol technique by passing the coronary tube from its anastomosis
with the left coronary ostium, then anterior and to the left of the aortic
graft, to its anastomosis with the right coronary ostium. A coronary
tube in this location is decidedly shorter than its counterpart on the
other side and. in the appropriately selected aortic root, allows optimal
alignment with both coronary ostia. All patients have enjoyed excellent
clinical outcomes and have exhibited favourable appearances of the
coronary tube and coronary artery flow at postoperative angiography.
Only when he first reported his novel technique of aortic root
replacement did Cabrol describe a left-anterior location of the coronary
tube in relation to the aortic graft. We have shown that this largely
abandoned technical approach can obviate the problem of excessive
angulation and should be considered in selected patients undergoing
aortic root replacement.
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REDUCED POSTOPERATIVE BLEEDING FOLLOWING USE
OF TISSEEL IN 300 OPEN-HEART SURGERY PATIENTS.
T.M. Kieser, A. Maitland, L. Parsons, R.C. Woodman. Department of
Surgery, Foothills Hospital, University of Calgary, Calgary, Alta.

Tisseel fibrin sealant was used consecutively in all cardiac surgical
392
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patients from Feb. 27, 1989, until September 1990. One hundred
patients prior to the use of Tisseel (group I), 100 cases immediately
following initial use of Tisseel (group II) and 1 year later 100 patients
also with Tisseel (group III) were studied retrospectively for age, sex,
type of surgery, category of urgency, degree of hypothermia, pump
time, cross-clamp time, numbers of total and individual blood products
transfused, need for reoperation for bleeding and other related parame
ters. There was a significant increase in the number of patients
requiring no blood products; (group I 10.41%, group II 33.33%, group
III 38.18%), a significant decrease in total number of blood products
used in patients with Tisseel; (group I 23.69, group II 10.34, group III
13.18), and reoperation for bleeding was greatly reduced in Tisseel
groups (group I 21.8%, group II 7.29%, group III 5.15%) despite an
increased trend toward urgent/emergent surgery in group III (group I
51.1%, group II 48%, group III 79.4%). From this study, it appears that
Tisseel is very effective in reducing bleeding in cardiac surgery.
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WOUND INFECTION IN CARDIAC SURGERY. A. Softah, P. Bedard,
M.P. Brais, W. Goldstein, P.J. Hendry, R.G. Masters, W.J. Keon.
University of Ottawa Heart Institute, Ottawa, Ont.

A prospective study for wound infection in 3200 consecutive patients
undergoing cardiac surgery with cardiopulmonary bypass at the Univer
sity of Ottawa Heart Institute was performed from April 1990 to
December 1992. Wound infection occurred in 136 patients (4.25%).
Superficial sternal wound infection (skin and subcutaneous tissue)
occurred in 79 patients (2.4%). Staphylococcus epidermidis occurred in
37 patients and Staphylococcus aureus in 22. Of these 79 patients, the
internal mammary artery (IMA) was used in 45 (56%). Deep sternal
wound infection (bone and mediastinum) occurred in 13 patients (0.4%).
Staphylococcus aureus was the causative organism in 10 patients (77%).
All of the 13 deep sternal infections occurred in patients having
coronary artery bypass (CAB), and the IMA was used in 9 patients
(69%). Leg wound infection developed in 46 of 2462 patients who
underwent CAB (1.9%), with the Staphylococcus implicated in 15 (33%).
Overall, Staphylococcus was the infecting organism in 63.9% (87 of
136) of wound infections. There was a 3.7% mortality for patients with
wound infection (5 of 136). In four patients wound infection was a
major contributor, all of whom had deep sternal infection with
Staphylococcus aureus. We conclude that our incidence of wound
infection following cardiac surgery is acceptably low. Special attention
has to be directed to Staphylococcus infections with appropriate
prophylactic antibiotics. Where there is evidence of infection we
recommend aggressive treatment with antibiotics, irrigation and
debridement as required.
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STANDARD PORCINE BIOPROSTHESES — HANCOCK AND CARPENTIER-EDWARDS. COMPARISON TO VALVE-RELATED COM
PLICATIONS TO 15 YEARS. W.R.E. Jamieson, A.I. Munro,
R.T. Miyagishima, P. Allen, L.H. Burr, G.F.O. Tyers. University of
British Columbia, Vancouver, BC

From 1975 to 1982 the Carpentier-Edwards standard (CE-S) and
Hancock standard (H-S) bioprostheses were implanted in 1194 and 177
patients in 1213 and 179 operations, respectively. The mean age of the
CE-S group was 57.2 years (range 8 to 85 years) and the H-S group
was 51.4 years (range 12 to 83 years). The early mortality of the CE-S
was 7.6% (91 patients) and the H-S group, 6.2% (11 patients). The late
mortality was 4.7% and 5.6% per patient-year for the CE-S and H-S
groups, respectively. The mean follow-up was 7.4 years for the CE-S
prosthesis and 8.1 years for the H-S prosthesis. The linearized rate of
structural valve deterioration (SVD) was 1.6% per patient-year and 3.9%
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December 1992. There were 6 males and 19 females with age
distribution between 15 to 71 years. In 22 patients the tumour was
located in the left atrium, in 2 in the right atrium and in 1 in the left
ventricle. The final diagnosis was never established on clinical grounds
alone. The most common presenting features were fatigue, dyspnea and
C E -S
H -S
“unusual” heart murmur. Chest pain was a relatively rare feature, but
embolization of the tumour occurred in almost 54% of our patients.
TE and ATH (overall)
7 6 .6 ± 2 . 1 %
7 8 .5 ± 4 .2 %
pNS
Two patients had concomitant coronary artery stenoses and one patient
PVE (overall)
9 3 .2 ± 1.1%
9 1 .5 ± 3 . 3 %
pNS
had left ventricular aneurysm. One patient with right atrial myxoma had
SVD
a distal pulmonary embolization, three patients had embolization to the
(A V R )
7 0 .7 ± 6.8%
7 4 .7 ± 7 . 1 %
pNS
peripheral vascular system and one to the mesenteric artery presenting
(M V R )
3 4 .7 ± 8 .0 %
4 0 .9 ± 6.8%
pNS
with acute abdomen. All patients required multiple diagnostic proce
V R m ortality
8 5 .0 ± 2 .1 %
8 5 .2 ± 3 .8 %
pNS
dures including heart catheterization, two dimensional cardiac ultra
V R residual m ortality
9 4 .4 ± 0.9 %
8 9 .3 ± 3 .3 %
pNS
sound, CT scan and MRI of the heart. All adult patients had coronary
T re atm e n t failure
8 0 .3 ± 2.3%
7 5 .3 ± 4 .6 %
pNS
angiograms. Cardiac ultrasound was the most reliable, expeditious and
cost-effective procedure. Two patients had demonstrable vascular pedi
The Hancock and Carpentier-Edwards standard porcine biopros- cle and contrast opacification of the tumour during coronary angio
theses show no significant difference between clinical performance, as grams. All patients underwent successful resection of the tumour.
measured by freedom from valve-related complications, including struc During the 1960s the tumours were resected only with underlying
endocardium of the atrial septum. Thereafter, all patients were treated
tural valve deterioration and composites of valve-related complications.
by removal of the tumour with resection of the underlying atrial
septum. There were three hospital deaths; all these patients had tumour
embolization prior to surgery. Surgical treatment was instituted prompt
ly and without delay in all patients once the diagnosis was established.
89
complications related to the conducting system occurred
PREDICTING OUTCOME FOLLOWING MITRAL VALVULOPLAS Postoperative
in 18 patients; none were fatal. All lesions were histologically benign.
TY. L. Perrault, R. Cossette, D. Chapleau. Departement de chirurgie, There
three late deaths, non-tumour related. In long-term
Hopital du Sacre-Coeur de Montreal, Universite de Montreal, Montre survivorswere
followed
up to 30 years, there was no evidence of tumour
al, Que.
recurrence.
per patient-year for aortic valve replacement (AVR) and mitral valve
replacement (MVR), respectively, for both prostheses. The freedom from
valve-related complications and composites, at 15 years, is as follows:

Survival and freedom from reoperation following mitral valvuloplasty
(MV) was evaluated in 54 patients between October 1973 and December
1992, Ages of 35 men and 19 women averaged 49 years (± 18 years).
NYHA class was II or III in 48 patients (89%) and class IV in 6 patients.
At surgery degenerative disease was present in 43 patients (80%),
rheumatic in 8 patients (15%) and developmental in 3 patients (6%).
Annuloplasty (Carpentier 18, Duran 27, others 3) was completed in 48
patients and was the sole procedure in 6 patients. MV consisted of
quadrangular resection of the posterior leaflet in 24 patients, transloca
tion of posterior chordae in 9 patients, chordal shortening in 10
patients, commissural suturing in 2 patients and commissurotomy in 3
patients. In six patients posterior leaflet resection (three patients),
plication (one patient) and anterior leaflet suturing (one patient) were
performed. Associated procedures included CABG (10) aortic valve
replacement (2), tricuspid annuloplasty (3), atrial septal defect closure
(2) and resection of left ventricular aneurysm (1). Operative mortality
was 6% (three patients). Follow-up ranged from 1 to 164 months with a
mean of 39 months (± 42 months). Actuarial survival at 5 years was 89
± 8% and freedom from reoperation was 85 ± 9%. Reintervention was
required in eight patients (15%) at a mean interval of 39 months (range 1
to 133 months). Operative complications and unfavourable postopera
tive NYHA status were significantly predictive of death (p < 0.05).
Reoperation at the time of MV and unfavourable postoperative NYHA
status were associated with increased incidence of reintervention (p <
0.05). We conclude that postoperative NYHA status is predictive of
survival and freedom from reoperation following mitral valve repair.
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PREEMPTIVE THORACIC EPIDURAL ANALGESIA (PTEA) FOR
THORACOTOMY: FENTANYL (F) VERSUS BUPIVACAINE (B).
H. Unruh, T. Yeh, T. Koran, B. Ong. Department of Surgery and
Department of Anesthesia, University of Manitoba, Winnipeg, Man.
There are conflicting reports concerning the beneficial effects of
preemptive analgesia. We set out to deterimine if preemptive thoracic
epidural analgesia (PTEA) was superior to standard postoperative
epidural fentanyl (F) and evaluated the role of opiate receptor blockade.
Forty-six patients undergoing posterolateral thoracotomy were random
ized to receive either PTEA with bupivacaine (B) or F via a T6-7
catheter. General anesthesia was induced intravenously and maintained
with inhalational agents and the epidural study drug (0.5% B at 5 mL/h
or F at 50 /u.g/h). At skin closure, the study drug was replaced with F.
The patients’ pain was assessed by visual analogue scores (VAS) with a
VAS greater than 4 indicating moderate pain requiring intervention.
Side effects were treated by dose reduction or naloxone. There was no
difference in the ages, gender distribution, weight, height and preopera
tive spirometry.
B
T im e , h
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CARDIAC MYXOMA. J. Barwinsky, M. Cohen, E.A. Pascoe, K.
Warrian, S. Kim, J. Teskey, K. Duncan, S. Bhattacharya. St. Boniface
General Hospital, Health Sciences Centre, University of Manitoba,
Winnipeg, Man.
The incidence of primary cardiac tumours varies from 0.001 to 0.28% of
large autopsy series; over 50% are cardiac myxomas. We reviewed 25
cases admitted to our service for treatment between 1962 and December
1992. Eight of these patients were admitted between January 1991 and

1
4
24
48
72

D ose
67
70
62
55
54

± 30
±21
± 18
±22
±22

F
VAS
4 .3
2 .5
0 .9
1 .2
1 .3

± 0 .5
± 0 .5
± 0 .5
± 1 .6
± 0 .6

D ose
81
77
68
61
59

±
±
±
±
±

32
28
27
25
26

VAS
4 .0
4 .7
0 .9
0 .8
0 .3

±
±
±
±
±

0 .5
0 .5
0 .5
0 .5
0 .5

Intraoperative hypotension (13 of 19 in B and 10 of 21 in F) and
other side effects were frequent and equally common. PTEA with B or F
is effective in reducing postthoracotomy pain and is associated with
similar side effects. With PTEA less F is required by 1 hour compared to
postoperative infusion.
CJS, VOL. 36. NO. 4. AUGUST 1993
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92
LARYNGOPHARYNGOESOPHAGECTOMY FOR CARCINOMA OF
THE HYPOPHARYNX AND CERVICAL ESOPHAGUS. K. Gehman,
R. Inculet, A.C. Casson, R.J. Finley, H. Heeneman. University of
Western Ontario, Victoria Hospital, London, Ont.

Between 1981 and 1992, 18 patients underwent laryngopharyngoesophagectomy (LPE) for carcinoma of the hypopharynx and cervical
esophagus. There were 16 males and 2 females with ages ranging from
45 to 76 years (mean 59 years). The specific indications for the surgery
were primary carcinoma of the hypopharynx or cervical esophagus (n —
13), recent resection of hypopharyngeal carcinoma with positive
resection margins (n = 2), persistent pharyngocutaneous fistula after
partial pharyngectomy (n = 1) and synchronous pharyngeal and
esophageal carcinomas (n = 2). All patients were approached and
resected through combined cervical and abdominal incisions (no thora
cotomy). Sixteen patients were reconstructed with a gastric interposi
tion. Two patients, who additionally required gastrectomy, were recon
structed with colon interposition. Thirty-day operative mortality was 2
of 18 (9%). Postoperative complications occurred in eight patients.
Anastomotic leaks developed in two patients, both of whom received
prior remote neck radiation. Overall survival at 24 months was 30%
with 20% of the patients disease free (median survival, 9 months). Two
of four patients receiving preoperative adjuvant chemotherapy and/or
radiotherapy had no residual tumour at resection and three of these
four patients are presently disease free.
LPE can be performed with acceptable mortality rates and provide
good relief of dysphagia. Previous radical radiotherapy to the neck
predisposes to pharyngogastric anastomotic failure. Induction therapy
for carcinoma of the hypopharynx and cervical esophagus is promising
and warrants further study.

93
CYSTIC HYDATID LUNG DISEASE IN NORTHWEST CANADA.
R.D. Moore, J.D. Urschel, R.E. Fraser, S.S. Nakai, A.J. Geeraert.
Department of Surgery, University of Alberta Hospitals, Edmonton,
Alta.

A retrospective survey of patients hospitalized with Sylvatic, cystic
(Ecchinococcus granulosus) lung disease over a 20-year period was
undertaken to determine optimal treatment.
Fourteen patients with a mean age of 32 years were admitted with a
diagnosis of cystic pulmonary hydatid disease. Three patients were
initially managed by observation; 12 patients ultimately underwent 13
procedures. Eight enucleations, three wedge resections and two lobecto
mies were performed with no mortality. Major morbidity was limited to
one postoperative pneumatocele requiring reoperation. No bronchopleu
ral fistulae occurred. Despite five cases of intraoperative cyst rupture,
there were no cases of anaphylaxis or seeding. Surgery successfully
eradicated pulmonary hydatid disease in all 12 operated patients.
Sylvatic cystic hydatid lung disease is a more benign disease than
classic (pastoral) hydatid disease. Asymptomatic cysts should be ob
served. Surgery is indicated for symptomatic, enlarging or infected
cysts, and occasionally for diagnostic uncertainty. Conservative surgical
resection, by endocyst enucleation or wedge resection is recommended.
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94
THORACIC FENESTRATION (THORACOSTOMA) FOR MAJOR
UNCONTROLLED SEPSIS: A STUDY OF 62 PATIENTS. A.A.
Conlan, J. Schultz, M. Chan, M. Scoccianti, L. Baptista, P. Delikaris.
Divisions of CT Surgery, Queen’s University, Kingston, Ont. and
University of the Witwatersrand, Johannesburg, S. Africa

This two-centre study was completed to define the indications for
thoracostoma, its mortality and morbidity and the closure methods
required. Sixty-two patients underwent thoracostoma for uncontrolled
pleural or pleuropneumonectomy sepsis. Thirty-four patients had post
pneumonectomy empyema after resection for inflammatory disease (28),
lung cancer (5) and lung necrosis (1). Seventeen others had uncon
trolled pleuropulmonary sepsis vith chronic empyema. Eleven further
patients had chronic pleural sepsis following complicated thoracic
trauma. Preceding surgical procedures were pneumonectomy (34),
lobectomy (8), decortication (9), excision of empyema (4), pleural
drainage (21), diaphragm repair (2), colostomy (2), excision of bullae
(1), oesophagogastrectomy (1). Eleven patients had major bronchopleu
ral fistulae while 3 patients had esophagopleural fistulae. Hospital
mortality was 11.3%. One post-thoracostoma, six bronchopleural and
one esophagopleural fistula closed. Space closure methods were thora
coplasty (16), muscle flap transposition (5), spontaneous closure (6),
local closure (3) and open or accepted stomas (25). Thoracostoma gave
control and clearance of sepsis, allowed nutritional recovery and marked
space shrinkage. Definitive space closure was often delayed (range 3 to
18 minutes).

95
SURGICAL TREATMENT OF METASTATIC LUNG CANCER.
M. Fallahnejad, K. Haas, U. Seinige, A. Staddon, P. Epstein. Graduate
Hospital and the University of Pennsylvania, Philadelphia, Penn.

This study emphasizes the role of curative surgery in treatment of
metastatic lung lesions. Between January 1980 and January 1993, 42
patients, ages ranging from 16 to 86, were treated for curative resection
of metastatic lung lesions by 61 thoracotomies. Primary sites were lung
cancer in 13, breast 9, colonic tumour 2, bone and soft-tissue sarcoma
9, genitourinary 7 and upper airway 2. Patients were selected based on
control of primary, minimal 12 weeks free interval and absence of any
other metastatic lesion. Twenty-three patients had lobectomy, 23
multiple lung resection, 2 pneumonectomy, 4 thoracotomy with biopsy
only, 6 had mediastinotomy and 3 median sternotomy with multiple
synchronous resection in both lungs. There was one postoperative
death due to massive pulmonary embolus. There were 11 complications:
4 atelectasis, 3 prolonged air leaks, 1 infection and 3 cardiac
arrhythmia, which all responded to conservative therapy. Overall
survival from primary disease ranged between 6 months and 21 years.
Three patients died in less than 6 months, four died during the 1st year,
three died after 3 years, one died 4 years postoperatively and one patient
is lost to follow-up. Thirty remaining patients are alive at the time of
this report. Better diagnostic methods, advancement in chemotherapy
and relative safety of surgery make thoracotomies and lung resections,
even by repeated intervention, the treatment of choice for appropriate
metastic lung cancer.
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A HISTOLOGIC STUDY OF GRAFT INFECTION AND THROMBO
SIS. K.J. Lachapelle, A.M. Graham, J.F. Symes. Department of
Surgery, Royal Victoria Hospital, Montreal, Que.

There appears to be an association between vascular graft infection and
thrombosis, but the mechanism involved is poorly understood. Thirtytwo piglets were separated into two groups following infrarenal aortic
replacement with a 6 mm porous Dacron graft. Group I (n = 16) had
intraoperative contamination of the graft with 106 Staphylococcus
aureus while group II (n — 16) served as controls. At 1 and 3 weeks
postoperatively, eight animals from each group were sacrificed at
random and grafts assessed for infection, patency and stained for light
microscopy using hematoxylin and eosin, Masson's trichrome and alcian
blue (for sulfated polysaccharides). Selected grafts were studied with
transmission electron microscopy. At 1 week, all grafts from group I
were culture positive, but no grafts from either group were thrombosed.
All grafts had a thin acellular fibrin lining. At 3 weeks, all grafts from
group I were grossly infected and six of eight were thrombosed versus
zero of eight in the noninfected group (x2 — 6.6; p = 0.01). All
nonthrombosed grafts were lined by a cellular pseudointima composed
of collagen and secretory cells with features of both endothelial and
smooth muscle cells. The outermost lining was covered with fibrin as
well as an alcian blue-positive substance. Thrombosed grafts lacked this
cellular collagen lining and were occluded with thrombus.
Graft infection appears to cause thrombosis in a time-dependent
fashion by preventing the formation of an antithrombotic pseudointima.

915
AORTIC ANEURYSM REPAIR FOLLOWING PREVIOUS AORTIC
GRAFTING. G. DeRose, K.A. Harris, W.G. Jamieson. Division of
Vascular Surgery, Victoria Hospital, University of Western Ontario,
London, Ont.

Between June 1990 and January 1993, 11 patients had aneurysm repair
at or above the proximal anastomosis of a previous infrarenal aortic
graft. Patients with infected grafts and known suprarenal aneurysms at
the time of the original surgery were excluded. Original indication for
surgery was aneurysm in six patients (three ruptured) and occlusive
disease in five patients. The mean interval from initial surgery to
presentation was 19 years (range 6 to 20 years).
All patients had true aneurysms beginning in the proximal juxtaanastomotic aorta. Three patients presented with thoracoabdominal
aneurysms, four with suprarenal aneurysm and four with infrarenal
aneurysm. Repair was accomplished by thoracoabdominal approach in
three patients, retroperitoneal approach in four patients (three supraceliac and one infrarenal clamp) and transperitoneal approach in four
patients (one supraceliac and three infrarenal clamps). All patients
survived aneurysm repair and remain alive and well (mean follow-up of
13.5 months). True aneurysmal degeneration proximal to an infrarenal
aortic graft does occur. Routine surveillance of patients after aortic
grafting is recommended, particularly as the time interval from the
original operation increases. Thorough assessment and surgical plan
ning make successful repair of such complicated aneurysms possible,
providing excellent long-term results for those high-risk patients.

916
THE SELECTION OF A POLYESTER ARTERIAL PROSTHESIS
FOR ANEURYSECTOMY: RECOMMENDATIONS AFTER 10
YEARS’ EXPERIENCE. R. Guidoin, H.P. Noel, R. Labbe, Y. Douville,
L. Lessard, M.W. King, M. Lortie. Departement de chirurgie, Univer
sity Laval, Institut des biomateriaux du Quebec, l’Hopital Saint
Francois d’Assise et l’Hopital du Saint Sacrement, Quebec, Que.

Between 1983 and 1992 our case load included 520 patients with
aneurysectomy (412 elective cases and 108 ruptured aneurysms). The
arterial prostheses implanted during these interventions were located at
the following sites: aorto-bi-iliac 220 (42%), aorto-aortic 200 (39%),
aorto-bifemoral 84 (16%) and aorto-iliofemoral 16 (3%). Aorto-aortic
bypasses were preferred in 50% of the cases of ruptured aneurysms,
whereas aorto-bi-iliac bypasses were selected in 45% of the elective
cases. Ninety-four percent of patients with ruptured aneurysms received
woven grafts, while for elective surgery this proportion fell to 67%. A
variety of different knitted and impregnated polyester grafts were also
employed.
The success of this surgical approach with only a few minor
complications leads us to make the following recommendations: (a) for
ruptured aneurysms, a compact, regular woven or low-porosity polyes
ter graft should be selected so as to ensure rapid hemostasis. The
alternatives, such as woven velour grafts, are problematic because
hemostasis is not immediate. Likewise, hemostasis of impregnated
knitted prostheses can be unpredictable in cases of massive transfu
sions, and weft-knitted grafts are not recommended because of their
lack of dimensional stability and tendency to dilate, (b) For elective
aneurysms, woven grafts make an appropriate choice in the aorto-aortic
position, but warp knitted prostheses, with or without impregnation, are
recommended for bifurcations.
Our experience has demonstrated that high patient survival rates can
be achieved by making the appropriate choice of graft. It is therefore
important to always keep a variety of different types of polyester grafts
on hand.

917
ENDARTERECTOMY VERSUS ANGIOPLASTY IN THE TREAT
MENT OF LOCALIZED STENOSIS OF THE ABDOMINAL AORTA.
O. Steinmetz, N.V. McPhail, G. Hajjar, G.G. Barber, C.W. Cole.
Ottawa Civic Hospital, University of Ottawa, Ottawa, Ont.

During the past 5 years we have treated 16 female patients with
localized stenosis of the lower abdominal aorta. All were young or
middle aged (mean 50.3 years, range 37 to 68) and presented with
intermittent claudication. Three were hypertensive, four had associated
coronary artery disease, two were diabetic and all were smokers.
Angiography revealed aortic hypoplasia in nine. All had localized
stenosis of the abdominal aorta, seven had associated common iliac
stenosis and one had a unilateral superficial femoral stenosis. Runoff
was normal in the remainder.
Eight were managed by aortoiliac endarterectomy. This was confined
to the aorta in one and extended to one or both common iliac arteries in
seven. There were no perioperative deaths and no complications. All
were free of claudication after a mean follow-up of 29 months and had
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durable improvement in ankle pressure indices (mean ankle-brachial
index [ABI] preoperatively 0.69, postoperatively 1.06).
During the past 2Vi years an additional eight patients have been
treated by percutaneous balloon angioplasty of the aorta, combined with
common iliac percutaneous transluminal angioplasty (PTA) where
necessary. Only partial dilation was achieved in one case, and another
had a subintimal tear with no improvement requiring surgery within a
year. The remaining six are symptom free after a mean follow-up of
13.4 months with sustained improvement of pressure indices (mean ABI
0.71 pre-PTA, 0.95 post-PTA).
Endarterectomy is an effective method of treating this type of lesion.
In our small experience PTA appears to be less reliable but is much less
invasive, and longer follow-up is needed to define its role.

918
INFERIOR VENA CAVA INTERRUPTION. C. Comeau, H. Fong, I.
Morrow. Department of Surgery and Department of Radiology,
University of Manitoba, Winnipeg, Man.

in 220 lower extremities clinically suspected of acute deep venous
thrombosis (DVT).
One hundred and twenty-two (55.5%) of the 220 CV studies were
negative for acute DVT. In 67 (68.4%) of the 98 positive CV studies the
thrombus involved both the BK and AK segments. In 21 (21.4%) of the
positive CV studies the thrombus was limited to the BK segment, and in
the remaining 10 positive studies only the AK segment was involved.
Because of technical inadequacy, 18 DS studies were excluded from
analysis at BK level, and 2 others were similarly excluded at AK level.
The overall sensitivity of DS when compared to CV was 96.8%. The
overall specificity, positive predictive value (PPV) and negative predic
tive value (NPV) of DS were 99.1%, 98.9% and 97.4% respectively. For
isolated BK thrombosis, the sensitivity, PPV and NPV of DS were
88.9%, 94.1% and 96.1% respectively. These values reached 98.7%,
100% and 99.3% for the AK level.
We conclude that in the hands of expert technicians DS is a very
reliable means of diagnosing acute DVT in the lower extremities and
will avoid CV in over 90% of cases.

920
From 1983 to 1992, 54 patients (28 males and 26 females, mean age
65) had inferior vena cava (IVC) interruption in prevention of pulmonary
embolism.
Indications for IVC interruption were: contraindication to an
ticoagulation therapy 33 patients (61%), recurrent pulmonary embolism
on anticoagulation therapy 12 patients (22%) and for prophylaxis alone
9 patients (17%). Documented iliofemoral thrombosis and pulmonary
embolism occurred in 46 of 54 patients and 18 of 54 patients
respectively, of whom 17 patients had both.
Six patients had major operative procedures performed concurrently
with IVC interruption. Methods of IVC interruption were: Greenfield
filter 39, Vena Tech filter 6, IVC ligation 4, DeWeese clips 2, Mobin
Uddin umbrella 1 and unsuccessful attempts in insertion of filter 2.
With the exception of those procedures done concurrently with a major
operative procedure, all were done under local anesthetic with fluoros
copy.
At follow-up there were two patients with documented pulmonary
embolus postoperatively, including one death from pulmonary embolus.
The patency of IVC was maintained in 36 of 39 patients with Greenfield
filters and 5 of 6 patients with Vena Tech filters. All other patients had
IVC thrombosis postinterruption associated with prolonged severe leg
edema.
There were 17 deaths postoperatively. Eleven deaths (mortality 20%)
were within 30 days of IVC interruption (carcinoma 3, multiorgan
failure 2, respiratory failure 2, adult respiratory distress syndrome 1,
cardiogenic shock 1, cerebrovascular accident 1 and cardiac arrest on
operating room table prior to procedure 1). None of these patients
benefitted from IVC interruption.
Complications included: patients with persistent vagus nerve paralysis
one, laceration of IVC two, laceration of internal jugular vein one,
misplaced filter one and retroperitoneal hematoma one.
We concluded that insertion of filter devices is an acceptable means
of preventing massive pulmonary emboli. However, it is not a procedure
without significant complications, and careful selection of patients for
these procedures is necessary.

919
A COMPARISON OF DUPLEX SCANNING AND CONTRAST VE
NOGRAPHY IN THE DIAGNOSIS OF DEEP VEIN THROMBOSIS
OF THE LOWER EXTREMITIES. A PROSPECTIVE STUDY. N.
Miller, R. Satin, L. Tousignant, N.M. Sheiner. Sir Mortimer B. Davis
Jewish General Hospital, McGill University, Montreal, Que.
Duplex scanning (DS) was prospectively compared to contrast venogra
phy (CV) both at the tibioperoneal (BK) and femoropopliteal (AK) levels
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SURVEILLANCE AFTER VASCULAR RECONSTRUCTION: RATIO
NALE AND COSTS. D.L. Wooster, St. Joseph’s Health Centre,
University of Toronto, Toronto, Ont.

Models of clinical and vascular laboratory surveillance of patients after
vascular repair of aneurysmal, infrainguinal and carotid disease were
identified. Defined “Levels of Evidence” were applied to the available
literature to assay the rationale for surveillance in high-risk and all such
patients. Costs were ascertained from the Hospital Medical Records
Institute and scheduled benefits to identify the cost per outcome over 5
years.
The study showed class I (recommended) status for “high-risk”
carotid and “all” infrainguinal and class III (insufficient data to support
or reject) for “all” carotids and “all” or “high-risk” aneurysm patients.
Cost per outcome for postoperative surveillance was $2800 to $3700
for infrainguinal bypasses, $9980 to $12 900 for carotid endarterecto
my and $22 000 to $37 000 for aneurysm repairs.
This assessment indicates that specific recommendations and antici
pated costs can be justified in some but not all surveillance programs.
More detailed data and consensus recommendations are needed before
definitive policies can be set.

922
SIBLINGS ARE NOT A HIGH-RISK GROUP FOR UNDETECTED
ABDOMINAL AORTIC ANEURYSM: A CASE-CONTROL STUDY.
C.W. Cole, A.G. Bouchard, G.B. Hill, D. Lacasse, D. Moher, K. Rody,
B. Shea, P. White. Ottawa Civic Hospital, University of Ottawa,
Ottawa, Ont.

Introduction: Siblings of patients with abdominal aortic aneurysms
(AAA) have been suggested as a possible high-risk group who might
benefit from screening.
Methods: To test this hypothesis a case-control study was carried
out. Siblings of AAA patients and a control group (patients with
cataracts) were given a 10-minute questionnaire and an ultrasound
assessment of the abdominal aorta. SVS/ISCVS criteria were used to
determine when an AAA was present.
Results: A total of 1257 subjects were approached of whom 596
(47%) participated. Thirty-four AAAs were detected; only 2 were found
in women. Further analysis was therefore restricted to male subjects (84
cases and 220 controls). The crude odds ratio for siblings with respect
to the presence of undetected AAA was 1.4 (95% Cl, 0.7 to 3.1).
Younger age, smoking and limited education were significant potential
confounding factors. Using logistic regression analysis, the adjusted
odds ratio for siblings remained 1.4 (95% Cl, 0.6 to 3.0). Age and
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education remained significant predictors in the multivariate analysis,
but smoking did not.

extremity revascularization. We are impressed with the high patient
acceptance and low morbidity of arm vein harvest.

Conclusions:

(1) Siblings are not a high-risk group for undetected AAA.
(2) Age less than 70 and less formal education are significant
predictors for the presence of undetected AAA.
(3) Screening programs for AAA should be directed at men in the 7th
decade of life, especially those with less formal education.

926
FRESH VEIN ALLOGRAFTING FOR ARTERIAL RECONSTRUC
TION IN DOGS: ROLE OF DONOR-SPECIFIC IMMUNE REAC
TIONS. E. Wagner, Y. Marois, R. Roy, Y. Douville, R. Guidoin.
Centre de Recherche en Inflammation, Immunologie et Rhumatologie,
Le Centre Hospitalier de l’Universite Laval and Departement de
chirurgie, Universite Laval, Quebec, Que.

923
SPINAL CORD ISCHEMIA FOLLOWING ABDOMINAL AORTIC
OPERATIONS: REPORT OF EIGHT CASES OVER A 14-YEAR
PERIOD. R.P. Guzman, A.R. Downs, N. Pillay. Department of
Surgery and Department of Medicine, Health Sciences Centre, Winni
peg, Man.

Spinal cord ischemia is a rare but well-recognized complication
following abdominal aortic surgery. Eight cases (four males and four
females with an age range of 51 to 81 years) of postoperative spinal
cord ischemia were identified among 1248 abdominal aortic operations
(0.6%) performed over a 14-year period. Four cases occurred following
abdominal aortic aneurysm repair (three ruptured, one elective), two
cases following removal of infected aorto-bifemoral grafts, one case
following aortoiliac endarterectomy and one case following mesenteric
bypass for intestinal ischemia. The level of ischemia occurred between
T10 and L4 and generally at the L l-2 levels. Five of the eight (63%)
patients died in the immediate postoperative period. The three patients
who survived the immediate postoperative period had either near-total
or total recovery. Although rare and unpredictable, the diagnosis and
prognostic implications of this devastating complication should be
appreciated in the setting of postoperative neurologic deficits which
may occur in a variety of clinical settings following abdominal aortic
reconstruction.

925
PATIENT ACCEPTANCE OF ARM VEIN AS A DURABLE LOWER
EXTREMITY BYPASS CONDUIT. D. Gray, K.A. Harris, G. DeRose,
W.G. Jamieson. Division of Vascular Surgery, Victoria Hospital,
University of Western Ontario, London, Ont.

Technically more demanding operations in the field of vascular surgery
and the realization that the premier conduit is autogenous vein has led
to the search for alternatives for previously used or inadequate long
saphenous veins. In the past 36 months, 18 patients had portions of the
basilic, cephalic or both arm veins harvested and used as the major
portion of a lower extremity revascularization procedure for limb
salvage (mean length of follow-up 18.6 months). Two patients died and
the remaining 16 patients were interviewed. Eight grafts had inflow
arteries distal to the common femoral and 16 had outflow arteries distal
to the popliteal. There were two early graft occlusions attributed to
poor outflow tracts, and both resulted in amputation. By life-table
analysis the 2-year patency rate was 89%. Measurements from standard
points of the arm and leg revealed the following lengths: arm 58.9 ±
2.7 cm, leg 82.8 ± 5.0 cm, indicating that careful selection of inflow
and outflow arteries was necessary. Duplex scanning revealed no
aneurysmal degeneration of the grafts in follow-up. Patients assessed
discomfort on a visual analogue scale out of 10 (arm 2.7 ± 2.5, leg 5.2
± 2.8). There were several patients with early postoperative dysesthesia
in the donor arm, but only three were left with long-term sensory loss
and no functional disability. With the exception of the early graft
failures, all patients stated they would undergo the same operation
again.
We conclude that arm vein is a useful and durable conduit for lower

In the absence of the long autologous saphenous vein, synthetic
prostheses and bioprostheses perform very poorly in small calibre
arterial reconstruction. This study was undertaken to evaluate the
importance of immune reactions to the venous allograft used as a
substitute to small-diameter arteries. Five pairs of histoincompatible
mongrel dogs were subjected to femoral arterial replacement using a 10
cm looped femoral vein allograft. A control autograft was also
performed. Eight dogs out of 10 were considered in this study and
cultured vascular endothelial cells (VEC) were obtained from each one.
Serum samples were collected at 0, 0.5, 1 and 2 months after
transplantation to determine antibody development by flow cytometry,
complement-dependent cytotoxicity and Western blotting. Graft-infiltrat
ing lymphocytes were cultured from biopsies performed at 0.5 and 1
month in order to assess their cytolytic activity by a 51Cr release assay.
All autografts were patent at retrieval but one. Four allografts
thrombosed at 1 month, two did so at 2 months and two others were
occluded at 3 months. Donor VEC-specific antibody formation was
observed at 1 month in seven dogs and at 2 months in one case, which
occurred prior to or at the time of graft occlusion. Reactive sera
contained donor VEC-specific cytotoxic antibodies in most of the dogs
(six of eight). Moreover, these antibodies were shown to be directed
against major histocompatibility complex (MHC) antigens, their reactivi
ty being lost following absorption on donor splenocytes. In addition, as
demonstrated by Western blotting, donor-specific antibodies were
reactive with proteins of 22, 30 and 40 kDa on VEC and of 40 kDa on
spleen cells. Graft-infiltrating lymphocytes were successfully cultured
from all allograft biopsies in six animals, but not from autografts, and
exhibited a donor VEC-specific cytotolytic activity. These results
suggest that donor-specific immune reactions could be directly related
to venous allograft occlusion and that MHC antigens could be the major
targets of immune rejection reactions.

927
IS THROMBOLYSIS EFFECTIVE IN THE MANAGEMENT OF THE
ACUTELY ISCHEMIC LOWER LIMB? J.M. Hunter, P.D. Fry, S.C.
Cunningham, L.S. Machan. University Hospital, Vancouver, BC

The authors analyse the results of 25 sequential patients presenting
with an ischemic lower extremity and treated by local infusion of
urokinase over 4 to 24 hours.
Graft occlusions numbered 67%, native artery occlusions 33%.
Complete or significant thrombolysis was achieved in 79% of grafts and
86% of native vessels. However, 80% of graft occlusions ultimately
required surgery to correct the underlying problem, whereas 86% of
patients with arterial occlusions could be treated either by endovascular
techniques or anticoagulation with shortened hospital stay. The mortali
ty was 0%, but morbidity requiring surgery occurred in 8% of patients.
Though effective in many patients and improving the information
regarding distal runoff, urokinase prolonged hospital stay significantly
and cost an average $4000 per patient. We conclude that thrombolysis
is an effective treatment combined with endovascular techniques for
native artery occlusions but fails to benefit significantly patients with
previous bypass grafts and is associated with increased cost and
morbidity.
CJS, VOL. 36, NO. 4. AU G U ST 1993
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A NOVEL METHOD OF EVALUATING CELLULAR VIABILITY IN
SKELETAL MUSCLE. G.M. Peters, R.F. Potter, K.A. Harris, C.G.
Ellis, W.G. Jamieson, G. DeRose. Division of Vascular Surgery,
Victoria Hospital and the Robarts Research Institute, University of
Western Ontario, London, Ont.
Our aim was to study the changes in tissue viability following
ischemia-reperfusion in skeletal muscle. We believe application of
intravital videomicroscopy, a method of viewing living tissue in situ,
combined with fluorescent nuclear dyes would provide the unique
opportunity to quantify not only the temporal changes in cellular
viability, but correlate such changes with microvascular perfusion. To
test this method, the reflected extensor digitorum longus (EDL) muscle
in four male Wistar rats (195 g), anesthetized with sodium pentobarbital
(Somnatol, 65 mg/kg; IP), was bathed in Krebs solution containing the
fluorescent nuclear dyes bisbenzimide (Hoechst 3342, 5 jig/mL) and
ethidium bromide (5 Mg/mL). Bisbenzimide stains the nuclei of all cells,
while ethidium bromide stains only the nuclei of cells with damaged
(i.e., permeable) membranes. Images of the EDL muscle were videotaped
every 30 minutes for 5 hours, from which the ratio of the number of
permeabilized cells to the total number of cells was measured. In
addition, the number of perfused capillaries per millimetre (Nc/mm) was
measured to determine if prolonged exposure to the dyes altered
microvascular perfusion. Although the number of perfused capillaries
remained stable (26.5 ± 1.7 [SEM]), the index of cellular damage
increased from 0.31 ± 0.06 to 0.50 ± 0.08. Regression analysis showed
the temporal change in permeability began after 60 minutes of
exposure. This increased permeability appeared to be due to prolonged
exposure to the dye mixture, as a single application of the dyes, 4 hours
following exposure of the EDL muscle in three additional rats, revealed
a mean ratio of 0.20 ± 0.03. This study established fluorescence
intravital videomicroscopy as a novel technique for quantifying the
temporal changes in cellular viability in skeletal muscle.

929
COMPARISON OF PERMCATH, ARTERIOVENOUS FISTULA AND
ePTFE GRAFT SURVIVAL IN HEMODIALYSIS PATIENTS.
S. Seneshen, B. Ulmer, G. Pylypchuk, R. Walker, D. McFadden, B.
Lawlor, M. Baltzan, R. Baltzan, J. Kappel. St. Paul’s Hospital,
Saskatoon, Sask.
We compared actuarial survival and complication rates of all double
lumen, silicone central venous line (Permcath) (n = 92), Cimino-Brescia
fistulas (AVF) (n = 134) and reinforced expanded polytetrafluoro-
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ethylene (ePTFE) grafts (n = 30) inserted for hemodialysis access
between October 1981 and June 1992.
Data were collected from the hospital charts on catheter insertion
site, indication for insertion, surgeon, presence of concomitant diabetes
mellitus, complications and survival of the access and reason for
termination. The three groups were comparable in age and sex.
Actuarial survival for the Permcaths, AVF and PTFE grafts were
84.7%, 79.8% and 85.7% at 6 months, 78.4%, 76.0% and 75.0% at 12
months and 65.3%, 63.6% and 69.2% at 24 months respectively.
Thrombosis or infection resulted in only 14% of Permcath failures,
whereas 20% of AVF and 37% of PTFE grafts failed because of
thrombosis. There was no significant difference between diabetics and
nondiabetics with regard to access survival or complication rates. There
were no episodes of sepsis syndrome in association with Permcath
infections.
We conclude that Permcaths provided reliable and long-lasting
hemodialysis access with low complication rates. They compare favoura
bly to the “'gold standard” method of vascular access (AVF) and can be
used for much longer periods of time than previously thought.

930
ACUTE ON CHRONIC MESENTERIC ISCHEMIA. S.G. Hurst, G.
DeRose, K.A. Harris, W.G. Jamieson. Division of Vascular Surgery,
Victoria Hospital, University of Western Ontario, London, Ont.
Despite classic symptoms of postprandial abdominal pain and weight
loss, chronic mesenteric ischemia is often undiagnosed until a patient
presents with acute exacerbation and/or peritonitis. This potentially
lethal combination of acute on chronic mesenteric ischemia presents
special challenges. In the past year, six patients (five female, one male)
presented with worsening abdominal pain and peritoneal signs. Chronic
symptoms were present for an average of 15.4 months with average
weight loss of 14.5 kg. Angiography revealed occlusive disease of the
celiac and superior mesenteric artery (SMA) in four patients and of the
SMA alone in two. All six patients had mesenteric revascularization with
no mortality. All had Dacron bypasses; four from the supraceliac aorta,
one from a previous aortofemoral graft and one from an aortic graft
used to repair a concomitant aortic aneurysm. Simultaneous bowel
resection was required in two patients and cholecystectomy for ischemic
cholecystitis in two patients. There were no septic complications. At a
mean follow-up of 8.5 months, all patients were able to eat without pain
and had regained their weight.
Prompt revascularization and resection of nonviable bowel to avoid
perforation provides good long-term results for acute on chronic
mesenteric ischemia.
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General Surgeon
Woodstock General Hospital and its medical staff are
searching for a surgeon to complement its current
surgical team.
A general surgeon with broad-based training and
experience and a subspecialty in thoracic or vascular
surgery would be desirable.
Woodstock General Hospital is a 150-bed acute,
chronic and psychiatric hospital. The city of
Woodstock is a pleasant family-oriented town located
the same distance from London, Kitchener/Waterloo
and Hamilton.
Interested candidates with appropriate FRCSC creden
tials (or eligibility) should send their curriculum vitae
to:
Vice President
Human Resources
Woodstock General Hospital
270 Riddell Street
Woodstock, Ontario
N4S 6N6

— S93-159

CHAIRMAN, DEPARTMENT OF SURGERY
ST. PAUL’S HOSPITAL
VANCOUVER, BRITISH COLUM BIA
St. Paul’s Hospital and the University of British Columbia are seek
ing an outstanding academic surgeon to serve as Chairman of the
Department of Surgery at St. Paul’s Hospital.
The St. Paul’s Hospital Department of Surgery is an integral part of
the University of British Columbia Department of Surgery and its
teaching and research programs. St. Paul’s Hospital is an active 560bed tertiary care teaching hospital located in downtown Vancouver,
British Columbia. The Department of Surgery has about 32 full-time
members representing most subspecialties, all of whom participate in
undergraduate and postgraduate teaching programs. Clinical pro
grams, both local and provincial, provide about 18 000 surgical pro
cedures annually. In addition to excellence in clinical teaching pro
grams, a strong thrust in the areas of cardiac sciences, colorectal
surgery, minimally invasive surgery and outcome studies form the
foundation of an integrated research program.
The individual we seek for this senior position is to be dynamic, inno
vative and energetic with a strong academic background as well as
experienced in administration and cross-professional collaboration.
Salary will be commensurate with experience and qualifications.
Anticipated starting date will be Jan. 1, 1994.
UBC welcomes all qualified applicants, especially women, aboriginal
people, visible minorities and persons with disabilities. In accordance
with Canadian immigration requirements, priority will be given to
Canadian citizens and permanent residents.
Please submit a letter of application, a CV and the names of three ref
erees, no later than Oct. 1, 1993 to:
Dr. C. B. Warriner
Chair, Department of Surgery Search Committee
St. Paul’s Hospital
Room 333, Comox Bldg.
1081 Burrard Street
Vancouver, BC
V6Z 1Y6, Canada
_S93-158
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CLASSIFIED ADVERTISING
PROFESSOR and HEAD
Department of Surgery
Queen's University Health Sciences Centre
COMMUNITY SURGERY TRAINING PROGRAM:
ON — Queen's University, its affiliated teaching
hospitals and community hospitals welcome
applications from qualified candidates to enrol
in the Community Surgery Training Program.
This program is conducted by members of the
Departm ents of Surgery, Obstetrics and
Gynaecology, Urology, Otolaryngology and the
Intensive Care Unit. Trainees must be qualified
general surgeons holding or eligible to sit for
certification of the Royal College of Physicians
and Surgeons of Canada or an equivalent quali
fication. Trainees must have a general licence
to practise in Ontario or have an educational
licence from the College of Physicians and
Surgeons of Ontario. Trainees must provide a
Certificate of Professional Conduct from the
College of Physicians and Surgeons of Ontario.
Trainees holding an educational licence must
be financially self-supporting. Trainees who
have a general licence to practise may bill for
services as a clinical assistant. All trainees
must provide evidence of CMPA or equivalent
lia b ility insurance coverage at the general
surgery category. Applicants should submit a
curriculum vitae and evidence of good standing
by a letter of reference from their training pro
gram director or from a licensed medial practi
tioner. Should the applicant be currently on the
active medical staff of one or more hospitals,
the hospital(s) must provide a letter of good
standing. Enquiries should be directed to either
the Postgraduate Medical Education Office,
Faculty of Medicine, Queen’s University,
Kingston, ON K7L 3N6, tel (613) 545-2544: or
Program D irector - Community Surgery,
Department of Surgery, Queen's University,
Kingston, ON K7L 3N6, tel (613) 545-2660, fax
(613) 544-9174.
—S93-161

SURGEON: BC - Required for 44-bed hospi
tal with cooperative medical community serv
ing a large retirement population in scenic
mountain valley in British Columbia close to
the Idaho border. Hospital equipped for Gl
endoscopy and laparoscopic surgery. Moder
ate workload would permit enjoyment of the
area recreational facilities which include golf,
fishing, hiking, skiing, etc. Contact: Dr. H.G.
Harding, PO Box 130, Creston, BC VOB
1 GO: tel (604) 4 2 8 -7 0 2 1 , fax (604)
4 2 8 -3 5 8 1 .
-S 93-154

VASCULAR
SURGEON
W anted: certified peripheral vascular
surgeon to join tw o other surgeons at
a regional referral centre in Kentville,
NS.
For information contact:

Bruce W . Palmer, MD, FRCSC
Head, Department of Surgery
Valley Regional Hospital
150 Exhibition Street
Kentville, NS
B 4N 5 E 3

-S 9 3-1 56

GENERAL SURGEON: ON — Well-estab
lished group practice is looking to replace a
retiring partner/surgeon to serve a communi
ty of 30 000 + located 25 minutes west of
London. Town population 10 0 0 0 + . Fully
computerized, modern clinic adjacent to a
fully accredited, well-equipped hospital using
116 acute care beds. Busy emergency de
partment. Preference will be given to orthopedics/gynecology. Essentials include la
paroscopy skills and fellowship status. Onein-three on-call schedule for this pleasant
community. Large referral base guaranteed.
Associate to full partnership attainable.
Please contact or send CV to: Steven Wong,
c/o Strathroy Medical Clinic, 3 76 Carrie
St., Strathroy, ON N7G 3E3; tel (519)
2 4 5 -0 4 3 0 .
-S 92-128

GENERAL SURGEON: SK - Associate re
quired in a busy referral private practice.
Laparoscopic surgery forms a significant and
increasing portion of the practice. Moving to
new facility within 12 months. University city
of 180 000+ with many amenities. FRCS
required. Contact and send CV to: Dr. Len F.
Rivers, 4 0 6 -7 5 0 Spadina Cres. E, Saska
toon, SK S7K 3H3: tel (306) 6 5 2-4754,
fax (306) 2 4 4 -6 0 0 1 .
-S93-157

Applications are invited for the position of
Professor and Head, D e pa rtm e nt of
Surgery, Faculty of M edicine, Q ueen's
University, We are searching for an out
standing academic surgeon with proven
administrative experience who, as Head,
will foster excellence in tea chin g and
patient care, while strongly supporting the
d e v e lo p m e n t of research w ithin the
department,
The Department of Surgery has 42 full-time
faculty representing a wide range of sub
specialties. The head of the department
also functions as Surgeon-in-Chief within
th e Hotel Dieu and Kingston G eneral
Hospitals, the two tertiary care teaching
hospitals w ithin the Health Sciences
Centre. The department contributes to the
educational programs of undergraduate
medical students and postgraduate surgi
cal interns and residents in approved train
ing programs.
This appointment will be at the rank of pro
fessor with salary com m ensurate with
qualifications and experience.
In accordance with Canadian immigra
tion regulations, this ad vertisem ent is
directed to Canadian citizens and perma
nent residents. Queen's University has an
employment equity program and encour
ages applications from all qualified candi
dates, including women, aboriginal peo
ples, people with disabilities and visible
minorities. Letters of application, together
with a curriculum vitae and the names of
three referees, should be d irected , by
September 15,1993, to:
Dr. R. F. Maudsley
Vice-Dean, Faculty of Medicine
Queen's University, Kingston, ON

K7L3N6

—S93-162

B/C ORTHOPEDIC SURGEONS AND
OTHER SPECIALTIES: NEW YORK, US Needed for non-treatment disability evaluation
centres in Buffalo, Watertown, Malone and
Plattsburg, New York. For further information
please reply with CV to: Sam H. Stedman,
620 Erie Blvd. W , Ste, 208, Syracuse, NY,
USA 13204; or tel (315) 4 7 5 -3 9 2 6 .
—S93-155

ADVERTISERS’ INDEX

SURGEON-IN-CHIEF
OTTAWA GENERAL HOSPITAL
Applications are invited from surgeons with excellent clinical skills
and administrative experience. Qualities of leadership and ability to
foster research in the department will be necessary attributes.
Priority will be given to candidates who are bilingual and are Canadian
citizens. The position is a conjoint appointment by the hospital and
university, and is governed by a G.F.T. contract.
Please forward a curriculum vitae and names of three referees by
October 30, 1993 to:
Dr. J.A. Maroun
Chief of Staff
Ottawa General Hospital
501 Smyth Road
Ottawa, Ontario
K1H 8L6
—S93-160
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T h e Illustrated History
of Medicine
/ rom paleomedicine to contempo
rary laboratory medicine, from
Mesopotamia to Greece and Europe,
through China, India and the Ameri
cas, this history of medicine, or rather
the history of different kinds of
medicine, is found here in illustrated
form — a rigorous and elegant syn
thesis and chronology in 13 chapters.
Professor Jean-Charles Sournia
explores medicine’s theories, diag
noses and therapies, public health
and hygiene. But he also contrasts
themes such as the continuity and
breakdown of medical practices, or
different forms of medicine based in
belief and reason.

that truly bring this new study to life;
The Illustrated History of Medicine
gives pride of place to pictures and
their commentaries. More than 700
paintings and photographs from
around the world enrich the history;
300 of these fascinating images are in
colour.
T he Canadian Medical Associa
tion is proud to be the exclusive
agent in Canada for Harold Starke
by Jean-Charles Sournia
Publishers’ The Illustrated History of
Medicine. Distinctively different
medical masters, from ethnomed- from other published histories, this
icine to technomedicine, from Sum beautiful volume will be a treasured
erian concepts linking illness with addition to your library.
sin to today’s Hippocratic tradition.
T he volume charts the distances and
differences in more than 50 chrono
The Illustrated History o f Medicine
logical tables, a glossary of terms, an
Professor Jean-Charles Sournia
index of names and a bibliography.
ISBN 1-872457-05-3

This history of medicine is also
the history of physicians through the
ages, of their philosophies, living
conditions, social status, tensions
But it is the beautifully repro
and differences, from the unknown
duced
paintings and photographs
healers of prehistory to modern

© Harold Starke Publishers Limited, 1992
Size: 246mm x 326mm,
hardbound and jacketed

Acs, please send m e ______ copies ot The Illustrated History of Medicine today!
C M A members: $199 (includes shipping by Priority Post and handling). O thers: $220 plus $24 shipping and
handling. Please add 7% GST to total. All orders must be prepaid.
□ Cheque or money order enclosed (payable to the Canadian Medical Association)
□ Credit card

O VISA

O MasterCard

O American Express
Expiry date

Card number____
Name (pleaseprint)
Address_________
City____________

Province________________ __

Postal code______

Telephone (

Signature _______

Total amount (including GST)

Mail to:

Membership Services
Canadian Medical Association
1867 Alta Vista Drive
Ottawa, ON K1G3Y6

GST registration #121 765 705

) ___________

Credit card payments may be made by
phone:
731-9331, ext. 2307 (Ottawa and area)
toll free:
1-800-267-9703, ext. 2307 (outside Ottawa area)
fax:
1-613-523-0937
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The benefits continue
long after Valtrac
has disappeared.
Introducing the Valtrac*
biofragmentable anastomosis ring,
a major breakthrough in bowel
anastomosis technology that’s both
surgeon friendly and patient friendly.

Valtrac is patient friendly because it
biofragments and passes harmlessly and
painlessly out of the body, leaving no foreign
matter to hinder postoperative imaging. It
provides the added benefit during healing
of supplying intraluminal support, which
reduces the incidence of stricture, stenosis
or obstruction1.
To attend a Valtrac clinic and get the full
Valtrac story, please call: (416)470-3600
and ask for the Valtrac line.

—

Already surgeons have proved Valtrac’s
procedural superiority over sutures and
staples in thousands of patients. Valtrac
provides uniform application
regardless of location and
disparate bowel end sizes. It
also performs consistently in
end-to-end, end-to-side and
VALTRAC side-to-side procedures.

And, finally, Valtrac closes under direct
visualization. So you know it’s closed.

DAVIS+GECK
Cyanamid Canada Inc.
‘ Trademark of American Cyanamid Company 1Data on file with Davis + Geek

